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Obesity is a global public health problem, arising from the interaction between behavioural, 
environmental and genetic factors. The implications of obesity on orthodontic treatment 
included orthodontic treatment plan, less cooperation, longer duration and more health-
related problems. However no data exists in relation to orthodontic tooth movement (OTM) 
in obese patients, from either a clinical or biochemical perspective. 
The aim of this project was to study the influence of obesity on OTM by measuring 
(1) The rate of tooth movement and the time taken to achieve completion of tooth 
alignment using fixed orthodontic appliances in normal weight and obese patients; (2) The 
effect of obesity on orofacial pain response during the early stages of orthodontic treatment 
with fixed-appliances; and (3) The effect of obesity on the biochemical changes in 
unstimulated whole mouth saliva (UWMS), gingival crevicular fluid (GCF) and serum with 
and without orthodontic treatment. 
Different biomarkers were detected, including (1) Obesity-related biomarkers such 
as adiponectin, leptin and resistin; (2) Tissue remodelling biomarkers such as Matrix 
metalloproteinase-8 (MMP8), Matrix metalloproteinase-9 (MMP9) and their inhibitor 
(TIMP-1); (3) Bone remodelling biomarker such as Receptor Activator of Nuclear Factor 
Kappa B Ligand (RANKL); and (4) Inflammation biomarker such as Myeloperoxidase 
(MPO) and C-reactive protein (CRP). 
Two main studies were conducted in this thesis: 
The first study is a cross sectional study in which UWMS, GCF and serum were 
collected from normal weight and obese adults (18-45 years) without orthodontic treatment. 
Same samples were collected from a matched number, age and gender of normal weight 
and obese patients have fixed orthodontic appliance with 0.019 x 0.025 – inch stainless 
steel archwire in upper and lower arches. The rationale behind this study is to detect the 
effect of obesity and/or orthodontic treatment on the levels of the selected biomarkers in 
different bio-fluids. 
The second study is a prospective cohort study in which data were collected from 
12-18 years old normal weight and obese patients at 4 time-points: (T1) prior to treatment 
at the normal records appointment; (T2) 1 hour following placement of the fixed appliance; 
(T3) 1 week following placement of the fixed appliance; and (T4) at the end of alignment 
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stage (0.019 x 0.025 – inch stainless steel archwire in the lower arch). The responses to 
orthodontic treatment were assessed in different ways: (1) Rate of tooth movement using 
dental study casts (T1, T3, T4); (2) Pain and discomfort using a self-reporting questionnaire 
(1st week); and (3) Biochemical assay of markers in UWMS, GCF and peripheral serum 
(T1, T2, T3, T4). 
The data of this study presented that the rate of OTM was significantly higher in 
obese patients compared to normal weight, and obese patients needed less time to achieve 
tooth alignment compared to normal weight, but this was non-significant. Obese patients 
experience higher mean pain than normal weight patients accompanied by higher 
consumption of analgesics. Alongside, GCF was more likely to express biochemical 
changes during OTM compared to UWMS and serum, with GCF-levels of leptin; resistin, 
MPO and RANKL were significantly different between obese and normal weight patients 
and associated with observed rates of OTM. 
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LDS:  lithium dodecyl sulphate 
LMW:  low molecular weight 
m:  meter 
mA:   milliamp 
mg:  milligram 




mm:  millimeter 
mM:  millimolar 
MMP8: matrix metalloproteinase-8 
MMP9: matrix metalloproteinase-9 
MMW: medium molecular weight 
MPO:  myeloperoxidase 
mRNA: messenger ribonucleic acid 
Nm:  nanometer 
NSAID: non-steroidal anti-inflammatory drug 
OECD: Organisation for Economic Co-operation and Development 
OPG:  osteoprotegerin 
OTM:  orthodontic tooth movement 
PAR:  peer assessment rating 
PAS:   Periodate Schiff Stain 
PBS:  phosphate buffered saline 
PDL:  periodontal ligament 
pg:  pictogram 
PG:  prostaglandin 
PMN:  polymorphonuclear 
PRAPg: peroxisome proliferator-activated receptor gamma 
qRT-PCR: quantitative reverse transcription polymerase chain reaction 
RANK: receptor activator of nuclear factor kappa B 
RANKL: receptor activator of nuclear factor kappa B ligand 
RCPCH: Royal College of Paediatrics and Child Health 
RP-HPLC: Reversed-Phase High Performance liquid chromatography 
SA-PE: streptavidin-phycoerythrin conjugate 
SD:  standard deviation 
SDS-PAGE:  sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SEM:  standard error of mean 
S-HMW: super high molecular weight 
sIg:  secretory immunoglobulin 
SWB:   Standard Western blot 




TBST:  Tris Buffered Saline with Tween 
TGF:  transforming growth factor 
TIMP1: tissue inhibitor of metalloproteinase 
TNF:  tumor necrosis factor 
UWMS: unstimulated whole mouth saliva 
VAS:  visual analog scale 
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Chapter 1 Introduction 
1.1 Obesity 
Obesity is a specific disease state characterized by chronic subclinical inflammation 
mediated through excess adipose accumulation and the concomitant production of systemic 
pro-inflammatory factors (Deng et al., 2016). There has been a steady rise in obesity during 
the last few decades (Ng et al., 2014). This trend represents a major healthcare challenge 
over both the short and long-term because of the significant associations between obesity 
and multiple chronic diseases (Whitlock et al., 2009). It is widely believed to be a key risk 
factor for various conditions, including type 2 diabetes (Lean et al., 1998), cardiovascular 
disorders such as congestive heart failure, hypertension and coronary artery disease, and 
both obstructive sleep apnoea and cardiac arrhythmias (Kopelman, 2000, Willett et al., 
1995) and overall increased risk of all-cause mortality (Aune et al., 2016); however, the 
causal mechanisms behind these relations remain uncertain. Although these risks are more 
widespread in adults, they are growing in obese adolescents, with sleep apnoea in particular 
causing increased concern (Neeley II and Gonzales, 2007). Obesity is also known to 
influence systemic bone metabolism through complex mechanical, hormonal, and 
inflammatory interactions (López-Gómez et al., 2016) with associations between obesity 
and reduced bone remodelling (Ivaska et al., 2016) and increased bone mineral density 
(Salamat et al., 2016). Although there is little data relating obesity to changes in alveolar 
bone composition within the healthy periodontium, longitudinal data has shown a 
significant association with increased rates of tooth eruption (Must et al., 2012). 
Numerous studies have shown that obesity is not exclusive to the adult population 
in developed countries; a large proportion of children and adolescents are now showing 
significant levels of fat accumulation (Kopelman, 2000, Fadel et al., 2013). One of the 
greatest concerns with childhood obesity is that an obese child tends to develop into an 
obese adult who will exhibit all the associated co-morbidities (Pietrobelli et al., 2005). 
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1.1.1 Prevalence of obesity 
In 2011, the Organisation for Economic Co-operation and Development (OECD) published 
data regarding both overweight and obese populations and did so for varying countries. 
Based on a series of up-to-date health surveys in the OECD, 50.3% of the adult population 
reported that they were overweight or obese. India (2.1%), Indonesia (2.4%) and China 
(2.9%) were revealed to be the least obese countries, and the United States (33.8%), 
Mexico (30.0%) and New Zealand (26.5%) the most obese. Being overweight and obese 
has a prevalence of over 50% among adults in no fewer than 19 of 34 OECD countries. In 
Australia and New Zealand alone, the prevalence of obesity has more than doubled 
throughout the last 20 years, while it has increased by half in the United Kingdom and the 
United States (The NHS Information Centre, 2012). 
Since 1995, England has seen a significant rise in childhood obesity, where 11% of 
boys and 12% of girls were obese. Obesity levels increased steadily up until approximately 
2004 and 2005, when they peaked at 19% among boys and girls. Levels have been slightly 
reduced in recent years, implying a flattening trend or gradual downward shift. In 2014, the 
percentage of obese children was not statistically significant in relation to the previous 
years. However, in the same year, obesity among boys (19%) reached the same peak level 
as in 2004 (Fat, 2014) (Figure 1.1). 
 
 
Figure 1.1 Three-year moving averages from 1995 to 2014 for children aged 2-15 who were obese, and 
overweight including obese. Acknowledgments to (Fat, 2014). 
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Globally, it is assumed that 287 million school-age children can be classed as 
severely overweight (Von Bremen et al., 2012) and that this global tendency is on the 
increase. The International Obesity Task Force has stated that in 2004 approximately 14 
million school children in the European Union were overweight, with 3 million of these 
being classed as obese (Lobstein et al., 2004). The same pattern is clear when looking at the 
United States data collected in the National Health and Nutrition Examination Survey. 
While only 4.6% of American adolescents were overweight from 1963 to 1965, this 
number had risen to 15.5% by 2000 (Ogden et al., 2002). It then continued to increase to 
17.1% in 2004, before reaching 18.1% in 2008 (Ogden et al., 2010). Indeed, other authors 
report much higher values, with data collected from the United State or Brazil indicating 
that almost 30% of children and adolescents are overweight or obese (Flores et al., 2013). 
1.1.2 Causes of obesity 
A wide range of risk factors have been associated with obesity, including single gene 
mutations (Farooqi et al., 2003), gene-environment interactions (Qi et al., 2014). 
Environmental factors also play a significant role in causality, including a sedentary 
lifestyle, the intake of high-energy foods (Kopelman, 2000, Baur and O'Connor, 2004), 
sugary soft drinks (Ludwig et al., 2001) and a lack of physical activity (Robinson, 2001) 
among many other factors. Collectively, these may affect leptin sensitivity, which plays a 
role in the pathogenesis of obesity (Friedman, 2000). Indeed, these adverse lifestyle 
patterns are often established from early childhood (Reilly et al., 2005). 
Although the mechanisms that underpin obesity remain unclear, it is understood that 
genetic and environmental factors, as well as socioeconomic and behavioural influences, 
lead to increased caloric intake and reduced physical activity. Furthermore, such factors 
prompt metabolic and endocrine abnormalities, both of which represent important causative 
elements. Other studies reported that obesity may be influenced by the pathology caused by 
oral bacteria that increase metabolic efficiency and appetite, and redirect the metabolism of 
energy through increasing levels of TNF-α or decreasing adiponectin levels (Goodson et 
al., 2009). 
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1.1.3 Assessment of obesity 
The term ―overweight‖ denotes an excess of body weight, whereas ―obesity‖ indicates an 
excess of fat. Direct measures of body fat are not available clinically, meaning that obesity 
is assessed by anthropometrics that indirectly estimate body fat (Flodmark et al., 2004). 
Assortments of methods have been described to assess obesity for both research and 
clinical purposes. First, the triceps skinfold uses a measurement obtained by grasping the 
skinfold at the triceps or subscapular area (Goran, 1998), it provides information about 
overweight children more effectively than it does for the presence of fat (Freedman and 
Sherry, 2009). Second, waist circumference measures obesity at the narrowest area, 
between the iliac crest and the rib cage, using a measuring tape (Roche et al., 1996), it 
correlates predominantly with cardiac disorders and an adverse lipid profile (Ramachandran 
et al., 2002). The third and most commonly used method in the assessment of obesity is 
Body Mass Index (BMI). This constitutes a numerical index that classifies the weight of an 
individual via the formula: BMI=weight in kilograms/squared height in meters (Kopelman, 
2000, Ogden et al., 2006). Body weight is then classified using a range from underweight to 
obese, making the BMI a standard method for the evaluation of the body weight of an 
individual and its subsequent comparison with that of other individuals. 
According to the World Health Organization (WHO), an adult person is considered 
underweight if their BMI is <18.5; healthy (normal weight) if the BMI is 18.5-24.9; 
overweight if the BMI is 25-29.9; obese if the BMI is 30-39.9; and morbidly obese if the 
BMI is ≥ 40. BMI should take into consideration age and gender for individuals of 2-20 
years and express the results in a percentile. This means that for children, specific cut off 
points for the BMI are absent and instead a percentile is relied upon (Pietrobelli et al., 
2005). The validity of the BMI has been investigated extensively and presents limitations in 
terms of overestimating body fat in people with unusually large muscle mass, as is 
frequently the case for trained athletes or body builders (Deurenberg et al., 1999). 
1.1.4  Obesity and inflammation 
Obesity has been shown to increase susceptibility to infection via the modulation of 
immune responses (Falagas and Kompoti, 2006). Diverse inflammatory mediators are 
released by adipocytes, provoking a systemic inflammatory state that may negatively affect 
the healing of wounds (Maury and Brichard, 2010, Ouchi et al., 2011). 
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Adipose connective tissue exhibits a predominance of adipose cells (adipocytes), 
which are found either in clusters or in isolation within connective tissue. Due to the 
majority of these cells being present in large aggregates, they constitute a major constituent 
of adipose tissue throughout the body and can be split into two categories: unilocular 
(common or yellow) and multilocular (brown). Unilocular adipose tissue comprises cells 
containing one large central droplet of yellow fat in their cytoplasm. Multilocular adipose 
tissue comprises cells that contain numerous lipid droplets and abundant brown 
mitochondria, which are chiefly involved in thermogenesis in the neonate (Unqueira and 
Carneiro, 2005). 
Adipose tissue acts as an endocrine organ by secreting numerous adipokines that 
can cause a range of diseases due to dysregulated immune responses (Ouchi et al., 2003, 
Ouchi et al., 2011). Adipokines are soluble proteins that bind to specific receptors on target 
cells – usually cells that surround their producing cells – and induce the production of 
intracellular signals. This leads to changes in the cells as a result of alterations in their gene 
expression and regulation. Adipokines are effective even at low concentration and play an 
essential role in inflammatory disorders, such as periodontal disease (Ouchi et al., 2011). 
Similar to cytokines, they influence the secretion of other adipokines within networks. To 
take an example, IL-1β and TNF-α are able to act in unison to stimulate the production of 
IL-6 by human gingival fibroblasts (Ouchi et al., 2011). Also IL-8 and TNF-α can prompt 
the accumulation of neutrophils within the tissues of periodontitis (Liu et al., 2001). 
The relationship between obesity and adipokines has been studied extensively. 
Leptin is secreted by adipocytes, regulating appetite and metabolism through hypothalamic 
mediators (Zhang et al., 1994). Moreover, inflammatory cytokines such as TNF and IL-1 
are produced by adipocytes and lead to the pro-inflammatory state associated with obesity 
(Fantuzzi, 2005). Conversely, a significant reduction of IL-6 and TNF-α, coupled by an 
increase in IL-8 levels in the plasma, has been identified with weight loss (Bruun et al., 
2003). A study of young subjects shows a positive correlation between TNF-α in GCF and 
a BMI ≥ 40, as well as with non-pathological periodontal pockets. This indicates that 
increases in TNF-α are due to a systemic effect, rather than being a result of the monocytes 
found in inflammatory periodontal conditions (Lundin et al., 2004). An alternative study 
evaluated the volume of adipocytes and the relation that this has with TNF-α, IL-6, 
adiponectin and high sensitivity C-reactive protein (hs-CRP) in obese and lean patients 
both with and without type 2 diabetes. The study revealed that adipocyte volume is 
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positively correlated with TNF-α, hs-CRP and IL-6 levels, yet negatively correlated with 
adiponectin levels. Furthermore, it is important to emphasize that this correlation was not 
only related to type 2 diabetes but also to obesity when analyzed alone (Bahceci et al., 
2007). 
1.1.5 Obesity and bone metabolism 
Obesity and bone metabolism are also interrelated, with obesity affecting bone metabolism 
through a range of mechanisms. Since adipocytes and osteoblasts are derived from a 
common mesenchymal stem cell (Gregoire et al., 1998), with the agents that inhibit 
adipogenesis stimulating osteoblast differentiation (Gimble et al., 1996, David et al., 2007b, 
Sen et al., 2008) and those that inhibit osteoblastogenesis increasing adipogenesis 
(Beresford et al., 1992); obesity may decrease osteoblastogenesis, while increasing 
adipogenesis. Mechanical loading promotes osteoblast differentiation and inhibits 
adipogenesis through the down-regulation of the peroxisome proliferator-activated receptor 
gamma (PPARg) or the stimulation of a durable beta-catemin signal (David et al., 2007b, 
Sen et al., 2008). The activation of PPARg by thiazolidinediones decreases osteoblast 
differentiation, bone mineral density and trabecular bone mass, while increasing adipocyte 
differentiation and bone marrow adipose tissue volume (Gimble et al., 1996, Tornvig et al., 
2001, Lazarenko et al., 2006). 
Furthermore, bone resorption may be increased by obesity by way of up-regulation 
of pro-inflammatory cytokines, such as IL-6 and TNF-α. Both of these have been shown to 
be capable of stimulating osteoclast activity through regulation of the 
RANKL/RANK/OPG pathway (Khosla, 2001, Pfeilschifter et al., 2002) (Figure 1.2). 




Figure 1.2 Bone resorption upregulated by adipocytes. Adipocytes secret TNF-α, IL-1β, IL-6, adiponectin, 
resistin, and leptin are capable of modulating osteoclastogenesis through RANKL/RANK/OPG pathway 
(grey-green arrows). Osteoblasts, fibroblasts and adipocytes are derived from mesenchymal stem cell. 
Osteoclasts are differentiated from monocyte/macrophage precursors of hematopoietic stem cells origin. IL, 
interleukin; OPG, osteoprotegerin; RANK, receptor activator of nuclear factor kappa B; RANKL, receptor 
activator of nuclear factor kappa B ligand; TNF-α, tumor necrosis factor alpha; MMP, matrix 
metalloproteinase; ECM, extracellular matrix. Adapted from (Cao, 2011). 
 
Obesity may have an effect on bone metabolism, either directly or indirectly, due to 
adipocyte-derived adipokines, such as leptin and adiponectin. Both an increase in serum 
leptin (Canavan et al., 2005, Van Dielen et al., 2001) and a decrease in serum adiponectin 
(Ouchi et al., 1999) have been linked to obesity that may stimulate the transportation of 
macrophages to adipose tissue (Sierra-Honigmann et al., 1998), thus promoting their 
adhesion to endothelial cells (Maeda et al., 2002) (Figure 1.3). 




Figure 1.3 The implication of leptin and adiponectin in the pathogenesis of the metabolic syndrome in 
obesity. Acknowledgments to (Ricci and Bevilacqua, 2012). 
 
Finally, it has been shown that a high-fat diet, which is often a cause of obesity, 
interferes with the absorption of calcium in the intestines. Free fatty acids have the potential 
to form insoluble calcium soaps that cannot be absorbed, thus encouraging low calcium 
absorption (Carnielli et al., 1996, Nelson et al., 1998). 
In general terms, body weight is positively correlated with bone mass (Felson et al., 
1993, Reid, 2002) and low body weight presents a risk factor in terms of depleted bone 
mass and increased bone loss in humans (Ravn et al., 1999). However, decreased bone 
mass as a result of obesity may be due to increased marrow adipogenesis at the expense of 
osteoblastogenesis, and/or increased osteoclastogenesis due to an increase in the production 
of pro-inflammatory cytokines. Excessive leptin secretion, or reduced adiponectin 
production, and/or reduced calcium absorption associated with a high fat intake also present 
possible triggers for obesity-related decreased bone mass. 
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1.1.6 Obesity and periodontal diseases 
Adipose tissue can influence the intensity and resolution of inflammatory responses in 
multiple tissues (Issa and Griffin, 2012, Pierpont et al., 2014). Indeed, there is evidence of 
an increased risk of chronic periodontitis (Keller et al., 2015, Suvan et al., 2011) and 
variation in inflammatory and metabolic markers in obese subjects affected by periodontal 
disease when compared to normal weight (Papageorgiou et al., 2015a). The systemic 
induction of inflammatory markers may provide a link between obesity and periodontitis, 
(Pradeep et al., 2012). 
Studies into the association between obesity and periodontitis as a chronic problem 
in health are frequently cited in the literature (Al-Zahrani et al., 2003, Sarlati et al., 2008, 
Ylöstalo et al., 2008). First observed in 1977 in rats, bone resorption and periodontal 
inflammation have been shown to be more severe in obese populations (Perlstein and 
Bissada, 1977). These early findings were supported by further studies (Khader et al., 2009, 
Ritchie, 2007) that show obesity is a predictive factor for periodontal disease regardless of 
age, gender, race, ethnicity or the effects of smoking. It is possible that this can be 
explained by the hyper-inflammatory nature of obesity, which may lead to a resistance to 
insulin and eventually prompts both a greater susceptibility to diabetes and an increased 
risk of periodontitis (Lakkis et al., 2012). 
Longitudinal studies have found a direct association between obesity and 
overweight individuals at the baseline with subsequent advances in periodontitis (Jimenez 
et al., 2012, Gorman et al., 2012). The results of one particular review into the association 
between periodontal disease and overweight and obese individuals suggests that being 
overweight, obesity, weight gain and increased waist circumference may all constitute risk 
factors for the development or worsening of periodontal measures, such as probing depth, 
alveolar bone loss, attachment loss and plaque index (Keller et al., 2015). 
The risk of periodontal disease and obesity is increased by diabetes, smoking, 
osteoporosis, alcohol consumption, psychological stress and age (Genco, 1996, Genco and 
Borgnakke, 2013). It has also been reported that people with a high BMI suffer from 
periodontitis, with significant clinical attachment loss in adults (Suvan et al., 2011, Chaffee 
and Weston, 2010) and similarly in children (Ekuni et al., 2008, Modéer et al., 2011). These 
findings have been linked to the exacerbated pro-inflammatory changes that take place with 
periodontal disease. 
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The underlying biological mechanisms behind any association between obesity and 
periodontitis are not well known. Oxidative stress is thought to link periodontitis and a 
range of metabolic disorders, including high blood pressure and impaired glucose 
regulation, which is predominantly related to a chronic pro-inflammatory state (Eckel et al., 
2005). Additionally, it has been hypothesized that an association between obesity and 
periodontal disease may result in a host defence alteration, an impairment of glucose 
tolerance, an increase in the psychological stress response and pro-inflammatory response 
secretion (Range et al., 2013). 
A more recent study estimates the local and systemic concentrations of resistin, 
adiponectin, leptin, TNF-α, IL-6 in serum and GCF in obese and normal weight people, 
both with and without chronic periodontitis. This specific study demonstrated that levels of 
resistin increase with periodontitis whereas adiponectin levels decrease. In addition, higher 
levels of TNF-α were noted in obese patients with the presence or absence of periodontitis 
(Zimmermann et al., 2013). These results are further confirmed by research that establishes 
an association between TNF-α and BMI (Lundin et al., 2004). 
Obese and normal weight males were compared in further investigations into the 
field, with this particular study concluding that leptin levels were affected by both 
periodontitis and obesity, with marked differences seen in IL-6 levels among the tested 
groups (Khosravi et al., 2009). These outcomes were confirmed by other studies which 
stated that the secretion of TNF-α and IL-6 is a result of the pro-inflammatory effect of 
resistin and consequent impairment effect of adiponectin (Bokarewa et al., 2005). Since 
TNF-α plays a role in both bone matrix degradation and bone resorption (Kurtis et al., 
2005), periodontal breakdown can indeed be expected, even where clinical signs remain 
absent, in obese patients both with or without periodontitis (Rossomando et al., 1990). 
In addition, periodontitis has been found to be 1.8 and 2.3 times more frequent in 
obese and overweight/obese individuals than individuals of normal weight, respectively. 
The related mechanism is enhanced by additional inflammatory responses and an increase 
in the quality and quantity of dental plaque in obese persons (Suvan et al., 2014). 
Consequently, host response to the antigens derived from bacterial plaque may be altered 
by obesity, prompting instabilities in the inflammatory response throughout the duration of 
periodontal disease (Słotwińska and Słotwiński, 2015). As an inflammatory disease then, 
periodontitis may be influenced by local and systemic factors, including diabetes, immune 
disorders, smoking and obesity. 
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1.1.7 Obesity and orthodontics 
In light of the results outlined above and further studies detailed in the literature below, 
obesity may significantly affect orthodontic therapy via its effect on bone metabolism, 
growth and development, which consequently affects puberty and potentially the movement 
of teeth during orthodontic therapy in obese persons (Neeley II and Gonzales, 2007). 
Furthermore, obesity can have a significant and negative psychological effect on children. 
Obese children tend to be socially isolated, a factor that may explain their tendency to fail 
to comply with orthodontic therapy (Must and Strauss, 1999). Perhaps more drastically, the 
facial aesthetics of obese individuals differ from those of people with normal weight, which 
is a factor that should be taken into consideration when planning orthodontic treatment. For 
instance, cephalometric and facial analyses should be altered during the examinations of 
obese or overweight patients. Such patients tend to exhibit larger mandibles and shorter 
distance in the upper face that have the potential to alter treatments. Obese patients also 
tend to have flatter or more concave profiles as a result of increased mandibular length and 
increased tissue thickness. The average or normal values for this group should be viewed in 
light of the knowledge that they were originally acquired through the measuring of persons 
of normal weight and that therefore they might not apply to obese populations. In light of 
this information, such patients should be treated individually with careful attention being 
paid to their psychosocial status (Neeley II and Gonzales, 2007). 
An alternative research paper studied the impact of BMI on oral health and patient 
cooperation during orthodontic treatment. It found that an increased BMI seems to be a risk 
factor for reduced cooperation, longer treatment duration, and an increased number of oral 
health-related problems during multiple bracket treatment. This indeed indicates that such 
patients need special attention during orthodontic therapy (von Bremen et al., 2015). 
Another study in the field has been undertaken to quantify the association between BMI 
and the wear time of removable orthodontic appliances, as well as assess alterations in BMI 
during orthodontic treatment. This particular study failed to find statistically significant or 
clinically relevant differences for usage or adherence in normal-weight and overweight / 
obese patients. This suggests that orthodontic treatment in young patients with removable 
devices does not require BMI-dependent changes to be taken into account in the treatment 
strategy. However, the study does state that the use of removable appliances during meal 
times raises the likelihood of a reduction in food intake, meaning that the orthodontist may 
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play an active role in weight reduction (Schott and Ludwig, 2014). Another study related to 
this theme has been undertaken into the relationship between BMI percentile and skeletal 
maturation, using the cervical vertebral method, and dental maturity, using the Demirjian 
assessment method, in adolescent orthodontic patients. This particular work found the 
cervical vertebral stage and dental age to be more advanced in subjects with increased BMI 
percentiles. As a result, the recommendation is that orthodontists consider weight when 
evaluating growing children and adolescents (Mack et al., 2013). 
Periodontal-orthodontic therapy is usually aimed at the correction of a periodontal 
condition, aesthetic and functional improvement. Although some believe that orthodontic 
treatment may worsen the periodontal status of a patient (Zetu et al., 2010), a selection of 
other researchers assert that osteogenetic variations between periodontitis and non-
periodontitis patients may result in differences in orthodontic treatment (Dersot, 2012). 
1.2 Biomarkers 
A biomarker is a substance that is objectively measured and evaluated as an indicator of 
physiologic, pathogenic conditions or outcome to a therapeutic treatment (Taba et al., 
2005). 
1.2.1 Cytokines 
Cytokines are low-molecular weight proteins released by specific cells that prove to be 
effective in very low concentrations. Their actions may play out locally or systemically, 
either on the very cell that secretes the cytokine (autocrine) or on a nearby cell (paracrine) 
(Okada and Murakami, 1998). Cytokines are produced through a cascade process in which, 
one cytokine stimulates its target cells to make additional cytokines. Cytokines are also able 
to act in a synergistic (two or more cytokines acting together) or antagonistic manner 
(cytokine causes opposing activities) (Fuhlbrigge et al., 1997). Multiple cytokines operate 
as a network in a pleiotropic (that is, the ability of one cytokine to act on different cell 
types) and redundant (refers to the property of multiple cytokines having the same 
functional effectors) (Fuhlbrigge et al., 1997, Prlic and Bevan, 2006). Cytokines are known 
to have a short half-life that ranges from a few hours to a few days, with a low 
concentration of plasma ensuring that it acts for a limited period of time only and thus 
across short distances (Kindt et al., 2007). 
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Immune system cells produce several types of cytokine, including lymphokines, 
monokines and interleukin cytokines, which are made by lymphocytes, monocytes and a 
certain form of leukocyte, respectively. The chemokines cytokine is responsible for a range 
of chemotactic activities within the human body (David et al., 2007a). 
Cytokines act directly or indirectly in the enabling of bone and periodontal ligament 
(PDL) cell differentiation, activation and apoptosis and are involved in the bone 
remodelling and inflammatory processes during OTM (Krishnan and Davidovitch, 2006a, 
Meikle, 2006). Various researchers have demonstrated elevated levels of cytokines in tooth 
movement (Alhashimi et al., 2001); more specifically, cytokines are most commonly 
present in the PDL during the early stages of OTM (12-24 hours). Extended investigations 
into the mechanisms through which they have identified both their effector (pro-
inflammatory) and suppressive (anti-inflammatory) functions during OTM (Lynch et al., 
1988). Due to sequential reactions and released substances, several of these biologically 
active molecules have been proposed as suitable biomarkers that may aid in developing a 
better understanding of the biological processes involved in OTM, improving treatment and 
reducing adverse side effects (Zainal Ariffin et al., 2011). 
The trend of obesity has sharply risen and became an increasing concern. This 
accompanied by an interest in the immunomodulatory cytokines as potential mediators 
and/or targets for prevention and treatment of obesity and metabolic syndromes (Pasquin et 
al., 2016), especially there is evidence of markedly increase of TNF-α, IL-6, and IL-8 
release by adipose tissue of obese subjects (Fain, 2006). 
1.2.2 Adiponectin 
Adiponectin is a protein released by adipocytes that exhibits various functions in the 
targeting of different types of cells. To be more specific, it has been shown to potentially 
influence insulin resistance, inflammation and cardiovascular systems (Funahashi et al., 
1999), and may even harbour various beneficial effects for obesity and obesity-related 
diseases (Turer and Scherer, 2012). AdipoR1 and ApidoR2 are the names of the two 
adiponectin receptors that have been discovered and they are expressed in skeletal muscles 
and the liver, respectively (Yamauchi et al., 2003). Both of these receptors exert anti-
inflammatory effects and are also expressed in the fibroblasts of gingiva and PDL 
(Iwayama et al., 2012). A third receptor, known as T-cadherin and mainly associated with 
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middle- and high-molecular weight adiponectin, is expressed on vascular endothelial cells 
and smooth muscle (Hug et al., 2004). When AdipoR1 and R2 are activated, an increase in 
the oxidation of fatty acid in skeletal and hepatic muscle results, as well as increased lactate 
production by skeletal muscle, reduced hepatic gluconeogenesis, increased glucose uptake 
and the suppression of inflammatory and oxidative stress (Yamauchi et al., 2002, Yoon et 
al., 2006). Moreover, when T-cadherin is activated, the vascular endothelial cells are 
protected against apoptosis induced by oxidative stress (Joshi et al., 2005). 
Adiponectin produced and secreted mainly by adipocytes (Scherer et al., 1995). It 
has N-terminal collagen-like region and a C-terminal complement factor C1q-like globular 
domain (Shapiro and Scherer, 1998, Kishore et al., 2004, Wong et al., 2004). Thus, it exists 
as a full-length protein and/or globular adiponectin. This cleavage is mediated by a 
leukocyte elastase, secreted by activated monocytes and/or neutrophils (Tilg and Moschen, 
2006). Serum adiponectin is produced as a monomer of 28 kDa. By way of a number of 
post-translational modifications, self-assembly then occurs as oligomers of differing 
molecular weights: high molecular weight (HMW), medium molecular weight (MMW), 
and low molecular weight (LMW) (Kadowaki and Yamauchi, 2005, Daniele et al., 2008a, 
Liu and Liu, 2014) (Figure 1.4). The oligomeric state of adiponectin is particularly 
important due to the fact that it has a significant influence on biological activity (Schapher 
et al., 2009). More specifically, various in vitro studies reveal HMW to be the most 
biologically active of oligomers. These are, in turn, associated with metabolic disorders and 
thus provide us with an indispensible diagnostic marker (Hirose et al., 2010). 
Evidence suggests that salivary gland epithelial cells are responsible for producing 
adiponectin and may indeed be involved in local immune response regulation. Salivary 
adiponectin measurement is easy and non-invasive, and would be useful if it were to be 
included in a range of clinical studies. The occurrence of adiponectin and very high 
molecular weight oligomers in saliva has been mentioned in at least one study (Kadowaki 
and Yamauchi, 2005). Alternative studies have measured salivary adiponectin levels in 
saliva samples collected using two different methods for each participant, namely the test 
tube and the Salivette systems (cotton wads). The results were then correlated with serum 
adiponectin, the researchers found a significant correlation between adiponectin levels in 
plasma and test-tube saliva, while a correlation between adiponectin levels in plasma and 
the Salivette-sampled saliva remained absent (Toda and Morimoto, 2008). A further 
research paper and investigation found an increase in measurable levels of adiponectin in 
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saliva upon the dilution of the sample. This specific paper goes on to explain that due to 
inhibitor(s) of adiponectin/anti-adiponectin binding in the saliva, after dilution the 
inhibitory effect becomes clear (Akuailou et al., 2013). Further research has observed 
adiponectin in both human serum and saliva via a process of Western blotting under non-
reducing conditions. This revealed a detection rate of serum adiponectin of 150 kDa 
(hexamer) and 250 kDa (high molecular weight multimer), with only one band having been 
detected in saliva that sits above the higher molecular band found in serum and referred to 
as the super higher molecular band (Lin et al., 2014). A number of studies have found very 
low adiponectin levels in human saliva when studied in relation to plasma (Toda et al., 
2007, Toda and Morimoto, 2008, Akuailou et al., 2013). 
With regard to BMI, a series of studies have shown that serum adiponectin levels 
and the amount of oligomers are inversely correlated with BMI, as well as being very 
closely related to obesity and related diseases (Daniele et al., 2008b, De Rosa et al., 2013). 
A further study has analyzed total adiponectin expression and its oligomeric profile in 
samples of saliva for both obese subjects and controls. The same study also compared 
adiponectin oligomerization between samples of serum and saliva. The paper’s analysis of 
the different adiponectin oligomers reveals a slightly higher expression of total, HMW and 
LMW salivary adiponectin in obese patients compared to the controls. Additionally, HMW 
oligomers found in saliva have a higher molecular weight than those found in serum, which 
confirms that more complex oligomers can be found in saliva, known as super HMW (S-
HMW) (Nigro et al., 2015). 
Obesity may trigger a decrease in both plasma adiponectin and its receptors 
(AdipoR1 and AdipoR2), thus leading to adiponectin resistance and subsequent insulin 
resistance (Kadowaki and Yamauchi, 2005). Alternative studies reveal that patients with 
diabetes type 2, obesity and coronary artery disease may exhibit hypo-adiponectinemia 
(Ouchi et al., 1999, Joseph et al., 2002). 
In periodontitis, adiponectin may not work effectively, since a reduced number of 
adiponectin receptors may in turn worsen periodontal disease (Yamaguchi et al., 2010). 
This is confirmed by other studies that have found a reduced number of adiponectin 
receptors in patients with severe periodontitis when compared to their healthy counterparts 
(Saito et al., 2008, Yamaguchi et al., 2010). Moreover, since adiponectin and its receptors 
are expressed in osteoblast cells, it is believed to be linked to both anti-inflammatory 
functions and bone metabolism (Berner et al., 2004, Oshima et al., 2005). It may affect the 
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function of PDL cells, which may be differentiated between as osteoblasts and 
cementoblasts (Seo et al., 2004). Additionally, one particular study has revealed that 
adiponectin has anti-inflammatory properties for human and mouse gingival fibroblasts, 
while also improving the osteoblastogensis of PDL cells in humans. It also helps to 
maintain the homeostasis of periodontal health, improve periodontal lesions, and promote 
wound healing and tissue regeneration (Iwayama et al., 2012). A selection of other studies 
shows that the serum concentration of adiponectin is reduced in patients with periodontitis 
in comparison to healthy individuals (Saito et al., 2008, Furugen et al., 2008). These levels 
increase following periodontal treatment (Furugen et al., 2008). 
Finally, research suggests that adiponectin may suppress TNF-α and stimulate 
inflammatory responses in macrophage and endothetial cells (Ouchi et al., 2011). It also has 
the potential to enhance the migration of endothetial cells and stimulate their differentiation 
into capillary-like structures (Ouchi et al., 2004). 
 
 
Figure 1.4 Structure of adiponectin. Full-length adiponectin is composed of 244 amino acids, including a 
collagen-like fibrous domain at the N-terminus and a C1q-like globular domain at the C-terminus. In plasma, 
full-length adiponectin combines via collagen domain and forms multimer complexes, such as trimers and 
hexamers, and a high-molecular-mass (HMW) form. A smaller form of adiponectin that consists of globular 
domain also exists in plasma in very small amounts. Acknowledgments to (Okamoto et al., 2006). 




Leptin is an adipose-derived hormone secreted in proportion to the size and number of 
adipocytes present. As a result, plasma leptin levels are higher for obese individuals and 
decreased after weight loss is achieved (Considine et al., 1996). While leptin is mainly 
synthesized by adipose tissue it is also produced at low levels in other tissues. Leptin has a 
range of effects, including appetite inhibition, energy expenditure stimulation, and the 
modulation of lipid and bone metabolisms, coagulation, hematopoiesis, pancreatic beta-
cells function and insulin sensitivity (Krysiak et al., 2012, Carbone et al., 2012) (Figure 
1.5). Moreover, leptin is known to regulate the immune system and inflammatory responses 
via chiefly pro-inflammatory actions (Krysiak et al., 2012, Carbone et al., 2012, Procaccini 
et al., 2012). Leptin mediates its effects by binding to the full-length leptin receptor and, in 
addition to the brain; this receptor is also expressed in a wide range of peripheral tissues. 
Upon binding, various intracellular pathways and transcription factors are triggered 
(Carbone et al., 2012, Zhou and Rui, 2013). 
A polypeptide hormone, leptin is also categorized as a cytokine (Zhang et al., 1994), 
and its receptor shares structural and functional likenesses with various long-chain helical 
cytokines: IL-6, IL-11, IL-12, leukaemia inhibitory factor, granulocyte-colony–stimulating 
factor, and oncostatin M (Ahima and Flier, 2000). Leptin is said to orchestrate the host 
reaction to both inflammatory and infectious stimuli, since it stimulates the immune system 
by boosting cytokine production and phagocytosis by macrophages (Fantuzzi and Faggioni, 
2000). Accordingly, an overall upsurge in leptin during inflammation and infection 
suggests that leptin is a component of the mechanisms of both immune response and host 
defense. 
Earlier studies signal a relationship between periodontal disease and leptin levels 
due to successful demonstrations of the presence of leptin in healthy and slightly inflamed 
gingivae (Johnson and Serio, 2001). Numerous investigations show that levels of GCF 
leptin activity may shape the development of periodontal disease, with its level decreasing 
progressively in GCF as periodontal disease progresses (Karthikeyan and Pradeep, 2007b). 
It has also been suggested that leptin contributes to bone formation due to its direct 
effect on osteoblast proliferation and differentiation, as well as its prolonging of the life 
span of human primary osteoblasts by inhibiting apoptosis (Bozkurt et al., 2006). Leptin is 
also involved in antiosteogenic effects since it acts centrally on the hypothalamus 
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(Włodarski and Włodarski, 2008). Overall, at high local concentrations leptin protects the 
host from inflammation and infection, while also maintaining bone levels. 
A significant number of studies have investigated leptin in relation to orthodontic 
treatment. One such study tested whether leptin is detectable in GCF found around moving 
teeth. In order to determine whether any changes occur during OTM, a split mouth design 
study was undertaken during the distalisation of the canine at the baseline, after 1, 24 and 
168 hours. Here, leptin concentrations of the test teeth were found to decrease in a time-
dependent manner when compared to the baseline measurement, with the decrease 
becoming significant at 168 hours (Dilsiz et al., 2010). 
 
 
Figure 1.5 The biology of leptin with different body weight. A loss of body fat causes a decrease in leptin, 
which leads to a state of positive energy balance where in food intake exceeds energy expenditure. An 
increase in body fat enhances the levels of leptin and a state of negative energy balance, with energy 
expenditure exceeding food intake. Obesity could result from insufficient or absence of sensitivity to leptin at 
its site of action that would increase circulating leptin. 




The biomarker resistin is a polypeptide derived from adipocytes and is named after its 
apparent ability to resist insulin. Rich in cysteine, this molecule belongs to the set of 
adipokines (which also includes leptin, adiponutrin and adiponectin) whose protein was 
first found in mouse adipose tissue. Also known as an adipocyte-specific secretory factor, 
only a very small amount of resistin is expressed in adipocytes in humans, and this chiefly 
takes place in the neutrophils, macrophages, and monocytes (Patel et al., 2003). Human 
resistin is also known to operate as a pro-inflammatory molecule, since it induces the 
synthesis and secretion of the following pro-inflammatory cytokines: TNF-α, IL-6, IL-12 
and monocyte chemo-attractant protein (MCP)-1 (Silswal et al., 2005). 
The link between periodontitis and resistin has been researched to a considerable 
extent in the field (Furugen et al., 2008). Resistin has also been studied in GCF in terms of 
its function as an inflammatory mediator in both the induction and resolution of human 
experimental gingivitis (Offenbacher et al., 2010). Rheumatoid arthritis, (Bokarewa et al., 
2005), inflammatory bowel disease (Kaser and Tilg, 2008) and asthma (LaRochelle et al., 
2007) (along with other chronic inflammatory conditions), also show a direct correlation 
with resistin concentration, and various studies indicate a positive correlation between 
resistin and pro-inflammatory factors in adults with patho-physiological conditions; these 
include, type 2 diabetes mellitus, atherosclerosis, inflammation of the respiratory tracts and 
renal disease (Brownlee, 1992, D’Aiuto et al., 2004). 
One particular study detected the levels of resistin in the saliva and serum of 
diabetic type 2 and non-diabetic subjects using ELISA. Their results indicate the presence 
of resistin in the saliva of both groups, with a significantly higher level being registered for 
that of the diabetic patients. For type 2 diabetes mellitus, both salivary and serum resistin 
correlate positively with BMI and insulin resistance (Yin et al., 2012). A clinical study 
conducted to estimate the levels of resistin in GCF in health, chronic periodontitis and type 
2 diabetes mellitus individuals suggests that resistin is found in GCF in all groups with a 
significant increase in periodontitis among diabetes mellitus groups (Gokhale et al., 2014). 
Another study compared resistin levels in GCF and serum in obese and non-obese subjects, 
both with and without periodontitis, found that the highest levels of resistin were observed 
in the obese group with periodontitis in both GCF and serum (Patel and Raju, 2014). 
Similarly, a more recent study measured the levels of resistin in obese and non-obese 
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subjects with and without periodontal disease, reported that resistin were elevated in GCF 
with obesity and periodontal diseases, therefore they recommended to consider resisitin as 
inflammatory marker as it was associated with both obesity and periodontitis (Suresh et al., 
2016). 
1.2.5 C-reactive protein 
C-Reactive Protein (CRP) is present in the serum of individuals in the presence of illness 
and was first purified in 1941 (Burtis et al., 2012). It is produced in the liver as an 
inflammatory reactant during the acute inflammation phase. In biological terms, it exhibits 
pro-inflammatory effects and serves to intensify both the activation and infiltration of 
macrophages around necrotic tissue (Takahashi et al., 2010). 
When acute inflammation and tissue destruction occurs, concentration levels for 
CRP rise within 6 to 24 hours up to levels of 1000 fold (Salonen et al., 1984). In the 
presence of chronic inflammation its presence is also known to increase, with its levels 
rapidly falling with the cessation of the stimulus (Håheim et al., 2009). The effects of 
cytokines such as IL-1, IL-6 and TNF-α are responsible for this elevation and are produced 
at the sites of inflammation before being carried to the liver via systemic circulation; this 
ultimately results in increased secretion of acute inflammatory reactants such as CRP (Ide 
et al., 2004, Gabay, 2006, Nibali et al., 2007). 
CRP acts as a diagnostic marker for acute inflammation, tissue damage and low-
grade systemic inflammation, with its values being used to supervise the progression of 
disease and the outcome of any treatment (Ridker and Silvertown, 2008, Paraskevas et al., 
2008). Furthermore, CRP could be adopted as a predictive biomarker for both 
cardiovascular diseases and systemic inflammation (Danesh et al., 1998), which leads to the 
hypothesis that elevated levels in periodontitis could be related, at least in part, to a link 
between periodontitis and cardiovascular disorders (Paraskevas et al., 2008). More 
specifically, periodontal bacteria may be released into the blood stream through 
mastication, tooth brushing and dental treatments. These would then lead to a risk of 
bacteraemia, which is connected to the severity of gingival inflammation (Silver et al., 
1977). Additionally, the cells present in the connective tissue that lies beneath periodontal 
pockets may discharge inflammatory biomarkers such as CRP, and even plasminogen 
activator 1 and fibrinogen (Blake and Ridker, 2002), leading as a result, to problems of a 
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systemic nature (Beck et al., 1996). The risk of cardiovascular disorder is considered low 
when the CRP serum level is less than 1 mg/l, intermediate at 1-3 mg/l, and high at above 3 
mg/l (Ridker, 2003). 
A positive link between CRP and oral disease has been identified in studies 
investigating the serum of systemically healthy persons experiencing oral inflammation 
(Boucher et al., 1967). Later research also notes that CRP levels in the entire saliva 
(Pederson et al., 1995) and GCF (Fitzsimmons et al., 2009, Fitzsimmons et al., 2010) of 
healthy subjects is correlated to a great extent with the severity of their periodontal 
parameters, namely plaque index, pocket depth and gingival index. However, it must be 
noted that GCF is a transudate of serum and thus contains both locally produced 
components and serum. As a result, the CRP level increase in GCF for periodontitis could 
be the result, in part, of local production within the gingival sulcus or production related to 
systemic origin (Black et al., 2004). One particular study dedicated to a specific comparison 
of the CRP in GCF and gingivae of subjects both with and without periodontitis shows that 
CRP in GCF and periodontal tissue is not of local origin. Instead, it is of a systemic origin 
that could result from periodontitis or a number of alternative systemic diseases. CRP 
production in tissue promoted from periodontium may provide an explanation for this, 
since it may occur as the result of locally produced biomarkers such as IL-1β (Marcaccini 
et al., 2010). Periodontitis can therefore be understood as a chronic disease characterized by 
bidirectional influences. Here, inflammation may occur due to a local increase in IL-1β 
production, which in turn may lead to a more systemic inflammatory response in remote 
organs such as the liver, to cite an example. The overall result of this would be an increase 
in CRP level in the serum. On the whole then, in a complex disease such as periodontitis 
both local and systemic factors may act both synergistically and independently 
(Fitzsimmons et al., 2010). 
Since it induces both MMP1 and MMP9 in human endothelial cells, it may also 
have an important role in the connective tissue destruction in periodontitis (Caliskan et al., 
2007). Additionally, the bacteria associated with periodontal disease that invade gingival 
tissues may interact in a direct manner with human arterial endothelial cells, which would 
lead to a higher local CRP level (Rautemaa et al., 2004, Jandik et al., 2008). However, this 
does not constitute the main source for a systemic elevation since here the levels are much 
lower than those seen in the blood. A clear and undisputed mechanism for the increase of 
CRP in patients with periodontitis has not been found. However, a variety of studies note 
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that IL-6 synthesis in the liver increases when sever periodontitis is present, which leads to 
the production of CRP (Slade et al., 2000, Noack et al., 2001). In such a case, the IL-6 
source in cases of severe periodontitis could be either Kupfer cells in the liver and/or 
adipocytes (Yamaguchi et al., 2005). 
In relation to this, one particular study was conducted in order to determine if the 
CRP detected in GCF is the product of local fabrication within the gingival tissue. The 
method used involved the collection of GCF and gingivae from non-periodontitis and 
periodontitis sites. The findings showed that CRP in the GCF appears to be of systemic 
origin, and therefore may be a sign of systemic inflammation due to periodontal infection 
or the presence of inflammatory disease elsewhere (Megson et al., 2010). A further study 
related to this field evaluated the effects of orthodontic treatment on systemic levels of 
CRP. To do so, the researchers compared CRP levels before treatment and then at 3 more 
time points, each set 2 months apart, during treatment using ELISA assay. The results 
showed no significant elevation of CRP or other inflammatory markers at any time point. 
This suggests that conventional orthodontic treatment is not associated with a systemic 
immune response (MacLaine et al., 2010). 
Several clinical and biochemical investigations were also conducted to determine 
the relationship of inflammatory marker (CRP) levels with obesity. Some studied the 
association of circulating hs-CRP levels in the presence of obesity with diabetes mellitus in 
non-obese/nondiabetic, obese/nondiabetic, non-obese/diabetic and obese/diabetic groups. 
They reported a significant association of serum hs-CRP levels with waist circumference 
and fasting blood sugar levels (Ebrahimi et al., 2016). In another study the serum 
concentrations of CRP in obese, overweight and normal weight breast cancer women, 
higher levels of circulating CRP were observed in obese patients in comparison to normal 
weight and levels were significantly correlated with BMI and waist-to-hip ratio (Babaei et 
al., 2015). Additionally, Rose and co-workers evaluated the concentrations of CRP in blood 
after weight loss in morbidly obese patients (BMI values of >40 kg/m
2
) exposed to 
intensive weight reduction. Initially blood showed significantly high levels of CRP 
compared with the healthy individuals; however, with about 9.4% reduction in body 
weight, a significant reduction in the concentration of CRP was observed (Rosc et al., 
2015). 




The recruitment and activation of polymorphonuclear neutrophils (PMN) constitute key 
events in inflammation and are characterized by the liberation of intracellular granules 
(Bogaard et al., 2010). Azurophilic granules of PMNs contain the enzyme myeloperoxidase 
(MPO), which is included in the host-derived group of compounds that are important for 
the tissue defence promoted by PMNs (Bernabé et al., 2005). 
MPO activity is directly correlated to the number of tissue PMNs (Cao and Smith, 
1989) meaning that MPO activity, not its quantity, is used in inflammation studies to 
determine the number of PMNs (Lamster et al., 1985). In patients with coronary artery 
disease, acute myocardial infarction and unstable angina it is possible to identify increased 
levels of circulating MPO (Baldus et al., 2003, Brennan and Hazen, 2003), which indicates 
a potentially adverse outcome (Tang et al., 2011). MPO plasma levels are also predictive of 
the outcome for patients in the early stages of the onset of chest pain (Rudolph et al., 2011, 
Nicholls et al., 2011) and present a correlation with impaired left-ventricular function 
(Rudolph et al., 2007). 
A useful method for the monitoring of periodontal inflammation is the analysis of 
MPO enzymatic activity in saliva or GCF (Cao and Smith, 1989, Yamalik et al., 2000, 
Marcaccini et al., 2010). This is particularly interesting because sample collection is not 
invasive, and the determination method is simple and accessible for standard laboratories 
(Marcaccini et al., 2010). Various dental studies of the use of MPO in GCF show that MPO 
is greater in the GCF collected from inflamed sites (Cao and Smith, 1989, Kaner et al., 
2006). 
Since MPO levels found in the GCF represent the extent of PMN infiltration, 
determining MPO might prove a valuable technique in assessments of the degree of tissue 
inflammation; a particularly interesting development for the application of orthodontic 
force, among other areas. Following the application of this force, PMNs migrate into the 
tissue to then extravagate in increased numbers into the GCF (Lowney et al., 1995). 
Changes in the periodontium occur during orthodontic movements, depending on the 
magnitude, duration and direction of the applied force (Karacay et al., 2007). A further 
study was conducted in order to establish MPO activity in the GCF and saliva, specifically 
whole stimulated saliva, of orthodontic patients. Measurements were taken at the baseline, 
and then 2 hours, and 7 and 14 days following the application of orthodontic force. The 
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results showed that 2 hours following application, mean MPO activity increased in both the 
GCF and saliva of orthodontic patients, before then returning to the baseline level at the 7 
and 14-day measurement points in both saliva and GCF (Marcaccini et al., 2010). In 
relation to the degree of dental crowding, MPO activity was measured in GCF and whole 
saliva during orthodontic alignment phase of patients have severe and minimal crowding, at 
baseline, 2 hours, 7 and 14 days after activation of orthodontic appliance. The results 
showed that the MPO activity was not influenced by the amount of dental crowding, 
therefore the two groups of moderate and severe crowding showed increases in salivary and 
GCF levels of MPO after 2 hours in comparison to baseline and remained elevated till the 
seventh day to return back to the baseline levels after 14 days (Navarro-Palacios et al., 
2014). 
There is evidence of association of MPO with obesity. Several studies were 
conducted in this field; the circulating concentrations of MPO were significantly increased 
in severely obese compared to controls, which remain elevated even after bariatric surgery 
and weight loss (Nijhuis et al., 2009). Similarly, circulating MPO in obese individuals, with 
or without systemic inflammation and potential cardiovascular risk, increased in obese 
subjects with hs-CRP above 3 mg/l (a biomarker for inflammation and cardiovascular risk) 
(Borato et al., 2016). More recently higher levels of MPO were remarkably observed in 
obese children in comparison to controls (Varma et al., 2016, Marcovecchio et al., 2016). 
1.2.7 Matrix metalloproteinase 
Matrix Metalloproteinases (MMPs) are a family of endopeptideases that are zinc-dependent 
and contain more than 25 enzymes. These play a key role in regulating various biological 
processes and are key to PDL remodelling in terms of both physiological and pathological 
conditions (Stamenkovic, 2003). These 25 enzymes can be divided into subfamilies 
according to their primary structures; cell localization and substrate specificity, including 
collagenases (MMP1, MMP8 and MMP13) disintegrate native fibrillar collagens. 
Gelatinases MMP2 and MMP9 are known to cleave denatured collagen (gelatin), meaning 
that they complement collagenases where the degradation of fibrillar collagens occurs 
(Pilcher et al., 1999, Quasnichka et al., 2005); the same can be said for stromelysins 
(MMP3, MMP10 and MMP11), membrane-type MMPs (MMP14, MMP15, MMP16 and 
MMP17), and a selection of miscellaneous MMPs (Jabłońska-Trypuć et al., 2016). 
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Collagenases cleave interstitial collagens I, II, and III at a specific site and also 
cleave other extra cellular matrix (ECM) and non-ECM molecules. Fragments of collagen 
are then degraded by gelatinases (Raffetto and Khalil, 2008). MMP8 is mainly produced by 
the polymorphonuclear leucocytes, but the epithelial cells and fibroblasts also have a role to 
play in its production (Mäntylä et al., 2003, Ingman et al., 2005). 
Gelatinases (MMP2 and MMP9) are responsible for type IV collagen degradation, 
vasculature remodelling, angiogenesis, inflammation and atherosclerotic plaque rupture 
(Jaiswal et al., 2011). They are secreted by several vascular cell types, including endothelial 
cells, fibroblasts and myofibroblasts, monocyte derived macrophages and local tissue 
macrophages (Bourboulia and Stetler-Stevenson, 2010). MMP2 is constitutively expressed 
on cell surface, while MMP9 is stored in secretory granules in different cell types and it is 
inducible by exogenous stimuli, such as cytokines, growth factors or altered cell–matrix 
contacts (Amălinei et al., 2007, Bourboulia and Stetler-Stevenson, 2010). 
MMPs are secreted as inactive proenzymes, and these can later be activated by 
proteolytic processing in the ECM (Snoek and Von den Hoff, 2005). Their activity is 
coordinated by the tissue inhibitors of metalloproteinases (TIMPs) (Verstappen and Von 
den Hoff, 2006). MMPs and TIMPs are crucial for the physiological remodelling of the 
periodontium and responses to forces of mechanical stimuli during orthodontic procedures 
(Ingman et al., 2005). The use of synthetic MMP inhibitors has, in a number of studies, 
been shown to diminish OTM (Holliday et al., 2003, Bildt et al., 2007). 
A variety of research studies focus on both in vivo and in vitro levels of MMPs in 
gingiva (Redlich et al., 2001), gingival and periodontal fibroblasts, as well as in GCF 
(Miyoshi et al., 2001, Apajalahti et al., 2003) in relation to orthodontic forces. Within the 
periodontium, a careful alteration process of the ECM is essential during orthodontic 
treatment. This allows for both tooth movement and the preservation of periodontium 
functional integrity (Junior et al., 2011). 
Levels of MMP8 in GCF have been studied for treatment with fixed orthodontic 
appliances, identifying a relationship between levels and stages of the treatment under the 
condition of a good control of the bacterial plaque (Apajalahti et al., 2003). A relationship 
is also present with the pain reported by numerous patients within the first hours of the 
insertion of the orthodontic device (Avellan et al., 2005). Both of these links can be 
explained by way of the participation of MMP8 in the generation of PDL remodelling 
during dental movement. Other authors engaged in comparable research sustain that MMPs 
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are involved in the regulation of bone remodelling in the marginal periodontium, during 
which ECM components (including collagen) are broken down and removed, before new 
components are then synthesized and deposited (Holliday et al., 2003). 
Experiments on laboratory rats concerning MMP production in the PDL during 
orthodontic movement reveal that MMP8 is produced first, by cells at the cemental surface 
and, second by osteocytes in alveolar bone (Takahashi et al., 2003). However, MMP8 is not 
produced in other PDL cells. Furthermore, it has been shown that hypertrophied gingiva 
during orthodontic treatment may be triggered by MMP8 accumulation in GCF; this can 
even occur in the absence of plaque accumulation or gingivitis. This can be observed in a 
study that measured the levels of MMP8 in GCF in relation to gingival overgrowth (GO) 
during orthodontic treatment. GO is a common result of mechanical stress and periodontal 
remodelling. Periodontal examination and GCF collection took place 1 hour before 
treatment and then 1, 4 and 8 hours and weekly after treatment throughout a period of 8 
weeks. Researchers found that for patients who did not develop GO MMP8 levels increased 
during the first 4-8 hours following orthodontic appliance activation, before then returning 
to their original level. Conversely, in patients with GO, the level of MMP8 in GCF 
continued to rise. For those cases of GO with inflammation, MMP8 levels were 
significantly higher than those without, meaning that MMP8 values in GCF show potential 
as a marker of GO (Surlin et al., 2010). However, another study examined the levels of 
MMP 1, 2, 3, 7, 8, 12 and 13 in GCF of periodontally compromised teeth 1 week before 
orthodontic activation and then 1 hour, 24 hours, 7 days, 14 days and 21 days following 
orthodontic appliance activation. They found that the orthodontic movement of 
periodontally compromised teeth without active pockets did not result in significant 
changes in the GCF levels of MMPs. The only significant change was found between the 
two groups occurred in the MMP 12 levels at 24 hours after orthodontic activation 
(Almeida et al., 2015). 
One specific in vitro study suggests that MMP9 is important for the degradation of 
collagen matrices since it enables the migration of osteoclast precursors to sites of bone 
resorption (Ishibashi et al., 2006). As a result, MMP9 may also act as a biomarker for the 
monitoring of remodelling in periodontal tissue during tooth movement. Mostly, MMP9 is 
derived from monocytes and macrophages, with its levels in GCF being greater for patients 
with periodontitis. Consequently, it may act as a biomarker of periodontal disease and help 
with the early detection of periodontitis (Ingman et al., 1996). Human gingival tissue, GCF 
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and saliva all exhibit a marked increase in MMP9 activities from PMNs sources (Ingman et 
al., 1996). A further study measured the influence of orthodontic retainers on periodontal 
health status biomarkers in GCF and found no relationship between fixed retainers and 
periodontal disease (Rody Jr et al., 2011). This finding has been confirmed by a series of 
other studies (Pandis et al., 2007, Booth et al., 2008). However, MMP9 exhibits a 
significant level of elevation for a higher percentage of sites with visible plaque in the 
incisor region of the fixed retainer, indicating that a dental plaque may induce the release of 
MMPs in GCF, regardless of clinical inflammation. Measurements of the levels of MMP3, 
MMP9 and MMP13 in canine retraction during OTM at different time intervals have found 
statistically significant fluctuations of MMP3, MMP9 and MMP13 at the compression side 
during OTM, with levels rising within the first hour of orthodontic force application before 
decreasing significantly during the following 24 hours; after this period of time, levels 
increased at a gradual pace (Junior et al., 2011). Finally, in humans MMP levels change in 
the GCF as a result of the application of orthodontic forces (Apajalahti et al., 2003). 
The tissue inhibitors, TIMPs are characterized as slow and tight-binding inhibitors. 
Mammalian TIMPs are two-domain molecules with N-terminal domains of about 125 
amino acids. They also have a smaller C-terminal domain of about 65 residues and each 
domain is stabilized by three disulfide bonds (Williamson et al., 1990). In isolation, N-
terminal domains are capable of establishing a stable native molecule that exhibits 
inhibitory activity against MMPs (Willenbrock et al., 1993). However, while different 
TIMPs are known to bind tightly to the majority of MMPs (Liu et al., 1997), reports exist 
of various dissimilarities in inhibitory properties among different TIMPs. As a result, 
TIMP2 binds tightly to the zymogen of MMP2 (proMMP-2) to form an important complex 
for the cell-surface activation of proMMP2 (Nagase, 1998). By comparison, TIMP1 forms 
a specific complex with proMMP9 (Goldberg et al., 1992), while TIMP4 also binds to the 
C-terminal domain of proMMP2 (Bigg et al., 1997). TIMP3 is extremely challenging to 
extract from tissues and studies show that it seems to bind strongly to ECM components 
(Yang and Hawkes, 1992), making the actions of TIMP3 limited to areas near to the point 
of synthesis. 
In terms of tissue remodelling, TIMPs are able to inhibit MMPs by developing 1:1 
enzyme-inhibitor complexes. Numerous studies indicate that TIMPs inhibit cellular 
invasion, metastasis, tumorigenesis and angiogenesis (Gomez et al., 1997), which can be 
partially attributed to the inhibition of matrixins. However, TIMPs exhibit a variety of 
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cellular activities. Additionally, TIMPs have a twofold effect on bone resorption in bone 
metabolism. They are known to stimulate bone resorption at low concentrations by directly 
stimulating osteoclasts (Sobue et al., 2001), and reduce bone resorption by inhibiting MMP 
activity at higher concentrations (Geoffroy et al., 2004). 
A longitudinal study investigated changes in cytokines and biomarkers for bone and 
tissue metabolism in GCF for patients of orthodontic treatment. GCF was collected from 
tension and compression sites at the baseline before tooth extraction and appliance 
placement, followed by intervals during orthodontic treatment of 4 hours, 7 days and 42 
days after the application of distalising forces to the maxillary canine teeth. Tension sites 
adjacent to the canines exhibited significant increases in MMP9 and TIMPs 1 and 2 across 
all of the time points used in the study following force application, while increases in 
MMP9 were seen at compression sites after a period of 7 days (Grant et al., 2013). Another 
study compared the circulating levels of MMP8, proMMP2, proMMP9 and total MMP9, 
the tissue inhibitors TIMP1 and TIMP2, as well as the MMP8/TIMP1, MMP9/TIMP1 and 
MMP2/TIMP2 ratios in obese and non-obese children and adolescents. The results showed 
higher circulating levels for MMP8 in obese children and adolescents, but not for MMP9 or 
MMP2. Lower TIMP1 and higher TIMP2 inhibitors were found in obese groups when 
compared to non-obese groups (Belo et al., 2009). The same study found no gender 
differences in the levels of MMP2, MMP8, pro-MMP9, MMP9, TIMP1 and TIMP2 
between obese and normal children and adolescents, in line with another study reported no 
influence of gender differences on the levels of MMPs in healthy adults subjects (Tayebjee 
et al., 2005). 
1.2.8 Receptor activator of the nuclear factor kappa-B ligand 
The Receptor Activator Nuclear Factor Kappa-B Ligand (RANKL) constitutes a crucial 
factor in osteoclast formation, fusion, activation and survival (Schoppet et al., 2002), and is 
produced by osteoblasts, stromal and activated T-cells (Udagawa et al., 1999). It has been 
shown in the literature to prompt bone resorption and bone loss. Alternate splicing is used 
to produce two isoforms: first, a type II membrane protein (mRANKL) and second, a 
soluble molecule (sRANKL) that lacks both cytoplasmic and trans-membrane domains. 
The membrane-bound protein appears to be the homeostatic form – even though both forms 
are bioactive. Additionally, sRANKL production indicates the presence of both pathologic 
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and non-physiological conditions (Nakashima et al., 2000). As articulated in the research, 
RANKL is mRANKL when expressed by cells of osteoblastic lineage. Alternatively, it 
forms sRANKL when expressed by activated T-cells (Schoppet et al., 2002). RANKL 
triggers its specific RANK receptor (situated on the osteoclast and dendritic cells) and its 
signalling cascade (Yasuda et al., 1999). 
When RANKL binds to an osteoclast RANK site, the result is an intracellular 
expression of various factors associated with the TNF receptor (TRAFs). Additionally, 
mature osteoclast survival depends on the presence of RANKL, although alternative 
factors, such as IL-1, have also been shown to promote survival. Where this is absent, 
osteoclasts are subjected to apoptosis (Wise and King, 2008, Eriksen, 2010). 
In contrast to the above, osteoprotegerin (OPG) is a secreted member of the tumor 
necrosis factor receptor superfamily and is known to negatively control osteoclastogenesis. 
The binding of OPG to the RANKL competitively constrains the binding of RANKL to 
RANK preosteoclast sites, prompting the termination of the differentiation process that 
leads to mature osteoclasts. OPG is also known as an osteoclast inhibitory factor, or more 
specifically, a soluble decoy receptor produced by osteoblastic cells and the cells of the 
PDL. It then binds to RANKL and inhibits RANK/RANKL interaction, a process that 
represents the mainstay of osteoclastogenesis (Kanzaki et al., 2004, Vitovski et al., 2007, 
Boyce and Xing, 2008) (Figure 1.6). Research shows that osteoclast activity is influenced 
by the osteoblast through the production of RANKL and OPG. Hence, the RANKL/OPG 
balancing system is crucial in the regulation of osteoclastogenesis (Trouvin and Goeb, 
2010, Bae et al., 2011) (Figure 1.7). 
Various in vivo and in vitro studies of PDL cells corroborate the role of the RANK, 
RANKL and OPG system in osteoclastogenesis (Oshiro et al., 2002, Nakao et al., 2007). 
When compressive orthodontic force is applied, RANKL upregulation is present and thus 
prompts the stimulation of a PGE2 pathway. Finally, the initiation of osteoclastic activity 
takes place, thus prompting bone resorption (Wise and King, 2008). An improved 
understanding of the RANKL/OPG balancing system could lead to new clinical techniques 
for the identification of optimal forces in tooth movement (Lin et al., 2007, Meikle, 2007). 
A randomized clinical pilot study evaluated the expression of RANKL and OPG after the 
application of elastic separators in a split mouth design study. The study found that 
RANKL increased while OPG decreased in both the short term (24 hours) and long term (7 
days) when compared to the baseline (Barbieri et al., 2012). 
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Levels of RANKL and OPG were also compared in the GCF of adults and juvenile 
orthodontic patients in an alternative study. This research found that the levels of RANKL 
increased after 24 hours while those of OPG decreased in both groups. However, the 
RANKL/OPG ratio was higher for the juvenile patients and this led to a greater amount of 
tooth movement in juveniles in comparison to the adults in the study (Kawasaki et al., 
2006). Further related research has ascertained the levels of RANKL and OPG in the GCF 
during OTM at intervals of 0, 1, 24, and 168 hours following the application of a retracting 
force. It also investigated the effect of compression force on RANKL and OPG production 
from human PDL cells following a compression force (0, 0.5, 1.0, 2.0, or 3.0 g/cm
2
 for 48 
hours). The results showed significantly higher GCF levels of RANKL, and significantly 
lower levels of OPG, in the experimental teeth than in the control group at the 24-hour 
mark. Significant differences also remained absent at the 0, 1 and 168-hour marks 
(Nishijima et al., 2006). 
The expression and concentration of RANKL and OPG in human PDL with 
orthodontic forces of different magnitudes for 7 days is the subject of another related study. 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to 
measure OPG and RANKL mRNA expressions, while ELISA was used in order to assess 
the concentrations of OPG and RANKL protein in the compression and tension sides of 
PDL. The results demonstrated that RANKL expression and concentration increase at the 
compression side due to the application of orthodontic force. The RANKL/OPG ratio was 
also significantly higher for the experimental rather than the control teeth. It would seem 
that these finds thus suggest that RANKL contributes to bone modelling as a response to 
the placement of orthodontic force in its initial stage (Otero et al., 2016). 
A review study showed that OPG levels fall immediately after the application of 
orthodontic force. This signals the beginning of bone resorption – a key process in the 
induction of tooth movement. The same review showed that juveniles who exhibit an 
increased RANKL/OPG ratio in GCF display a faster OTM rate than adults (Kapoor et al., 
2014). An alternative study was conducted to establish OPG and sRANKL levels in serum 
and GCF in relation to root resorption in a rat model. Force was applied using an 
orthodontic coil spring, before the teeth were then extracted and analysed using micro-
computed tomography scanning. The results showed a positive linear correlation in serum 
between RANKL and degree of root resorption, with OPG concentrations decreasing 
significantly in severe root resorption. It is possible to state then that the OPG/RANKL 
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ratio might prove a reliable prognostic factor for degree of root resorption following 
orthodontic treatment. In GCF, RANKL concentration exhibited a negative correlation with 
RANKL concentration in serum, while the OPG/RANKL ratio suggests whether the dental 
root will be protected against external root resorption or not (Tyrovola et al., 2010). A 
different research paper studied the correlation of salivary levels of sRANKL and OPG 
with the phases of OTM, namely initial, lag and post lag. Here the findings showed that a 
significant increase in RANKL and decrease in OPG leads to, overall, an increase in the 
RANKL/OPG ratio in time following the activation visit. The findings thus indicate that 
changes in salivary sRANKL and OPG, as well as in their ratios, may be linked to the 
varying phases evident in OTM (Flórez-Moreno et al., 2013a). 
Changes in the cytokines and biomarkers of bone and tissue metabolism in GCF 
among patients partaking in orthodontic treatment have been successfully examined in one 
particular longitudinal study. Here GCF was collected from the tension and compression 
sites at the baseline. This was done before tooth extraction and the placement of the 
relevant appliance, and following this at intervals during the orthodontic treatment: 4 hours, 
7 days, and 42 days after the application of distalising forces to the maxillary canine teeth. 
The results found that after 42 days the compression sites exhibited increases in RANKL 
levels (Grant et al., 2013). 
The roles played by RANK, RANKL and OPG in periodontal tissue reactions, in 
response to orthodontic forces, have been investigated in another study. The results showed 
that RANKL concentrations in GCF increased during OTM, and the ratio of RANKL to 
OPG concentrations in the GCF was significantly greater than at the control sites. A 
number of in vivo studies have confirmed the presence of RANKL and RANK in 
periodontal tissues during the experimental tooth movement of rat molars. They have also 
shown that when placed under mechanical stress PDL cells may induce osteoclastogenesis 
via the upregulation of RANKL expression during OTM. As a consequence, it is reasonable 
to assume that the RANKL⁄RANK⁄OPG system has a key role to play in OTM (Yamaguchi, 
2009). 




Figure 1.6 Role of RANKL/RANK/OPG pathway in bone remodelling. Osteoblasts are derived from 
mesenchymal stem cell. Preosteoclasts are differentiated from hematopoietic stem cells. RANKL-receptor 
activator of nuclear factor kappa B ligand-produced by osteoblasts binds to RANK-receptor activator of 
nuclear factor kappa B-on preosteoclasts forming mature osteoclasts; OPG-osteoprotegerin- produced by 
osteoblasts binds to RANKL and inhibits RANK/RANKL interaction. 
 
 
Figure 1.7 RANKL/OPG ratios. RANKL, receptor activator of nuclear factor kappa B ligand; RANK, 
receptor activator of nuclear factor kappa B; OPG, osteoprotegerin. Acknowledgments to (Kajiya et al., 
2010). 
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1.3 Orthodontic tooth movement 
OTM represents the movement of a tooth through alveolar bone due to the application of an 
appropriate external orthodontic force. This results in strain within the biological system, 
which forces cellular components to adapt to their new and modified conditions (Henneman 
et al., 2008). OTM differs from physiological tooth movement, which refers to tooth 
eruption or drift characterized by the abrupt generation of both compression and tension 
regions within the PDL (Reitan, 1960). OTM is therefore considered as exaggerated 
physiological movement may occur at speed or slowly, with this being determined by the 
physical characteristics of the force being applied, as well as the size and biological 
response of the PDL (Rygh and Brudvik, 1995). Conversely, physiological tooth movement 
is consistently a slow process and occurs mainly in the buccal route into the cancellous 
bone, aiming at growth in the cortical bone. 
Two interconnected OTM processes, namely deflection or bending of alveolar bone 
and remodelling of the PDL, alveolar bone, dental pulp and gingival tissue, on which the 
applied force causes a compression on one side with an equivalent stretching force on the 
opposite side of the alveolar bone with the PDL (Dolce et al., 1996). Mechanical loading is 
also known to modify the vascularity of periodontal tissue and its blood flow. This in turn, 
leads to the local synthesis and release of numerous neurotransmitter molecules, cytokines, 
growth factors, and colony-stimulating factors; all of which are involved in the maturation 
of immune cells and arachidonic acid metabolites. For a range of cell types, cellular 
responses are prompted both in and around the teeth by the liberated molecules, thus 
generating a constructive microenvironment for the deposition or resorption of tissue 
(Sandy et al., 1993). Thus, OTM unlike other inflammatory conditions of PDL, such as 
periodontitis, in which the inflammatory condition is characterised by alveolar bone 
destruction and loss of marginal PDL result from imbalance between pro- and anti-
inflammatory signals in response to the accumulation of dental plaque adjacent to the 
gingival margin (Socransky et al., 1984). 
Numerous factors influence the success of orthodontic treatment, such as 
periodontal health, oral hygiene and orthodontic forces. New methods for the quickening of 
OTM have been pursued by clinicians for a number of reasons: shorten treatment times, 
reduce adverse effects, such as pain, discomfort, dental caries, periodontal disease, and 
minimize iatrogenic damage, such as root resorption (Dolce et al., 2002, Krishnan and 
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Davidovitch, 2006a, Cardaropoli and Gaveglio, 2007, Zainal Ariffin et al., 2011, Andrade 
et al., 2012). 
1.3.1 Phases of OTM 
Three phases of tooth movement have been identified by Burstone (1962) (Figure 1.8). The 
first initial phase occurs when an orthodontic force is applied to the tooth, resulting in tooth 
displacement and evidence of rapid movement in the space of the PDL. This phase 
comprises both cellular and tissue reactions, and includes the recruitment of osteoclasts and 
osteoblasts on the compression and tension sides. 
The second lag phase involves hyalinization at the compression site of the PDL, 
which takes place due to the distortion of PDL fibres. This in turn affects blood flow, 
leading to little or no tooth movement until the complete removal of necrotic tissue has 
been accomplished. On the tension side, pre-osteoblast cells proliferate and migrate 
towards the alveolar bone surface to produce new bone matrix (osteoid). 
In the final postlag phase tooth movement resumes. Here the pressure side exhibits 
indirect bone resorption by the removal of the ischematic bone close to the hyalinization, 
followed by direct bone resorption in the remodelling process, while bone deposition 
occurs simultaneously on the tension side (Melsen, 1999). 
 
 
Figure 1.8 Rate of tooth movement plotted against number of days following application of continuous force. 
Acknowledgments to (Burstone, 1962). 
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1.3.2 Cellular and molecular changes in OTM 
During OTM regions of compression and tension develop within the PDL. The 
compression region is pressed by the orthodontic appliance in the direction of the force, 
which leads to the deformation of blood vessels and disruption in the arrangement of the 
tissue surrounding the teeth. PDL cells undergo metabolic changes due to hypoxia and 
decreased nutrient levels, with cells coming to rely on anaerobic glycolysis in hypoxic 
conditions. Many of the enzymes involved in anaerobic metabolism can act as potential 
markers; for example, the lactate dehydrogenase molecule accumulates during anaerobic 
metabolism (Passarella et al., 2008). Hyalinization is frequently triggered by mechanical 
force, often leading to PDL necrosis and subsequent bone resorption. Hyalinization occurs 
in cell-free areas of the PDL, at these sites the normal tissue architecture and staining 
characteristics of the collagen have been lost in the processed histological material. A 
selection of studies report distortions in the arrangement of normal periodontal fibres, 
numerous cell fragments (debris), areas of degraded matrix interspersed between intact 
collagen fibrils, and, in some cases, the presence of pyknotic nuclei in the hyalinization 
areas (Bonafe‐Oliveira et al., 2003, von Böhl et al., 2004, Kitase et al., 2009). Following 
OTM, a response is prompted from the tissue, yet bone repair only occurs at the 
compression region when the magnitude of the force decreases. During the early stages of 
OTM, the markers for bone remodelling can be analyzed through the measurement of both 
osteoclastic and osteoblastic activities at the compression regions (Faltin et al., 2001, 
Bonafe‐Oliveira et al., 2003, Casa et al., 2006, Andrade et al., 2012). 
In the tension region, the forces applied by braces during orthodontic treatment lead 
to the formation of new bone. Local precursor cells, or mesenchymal stem cells, are 
differentiated from osteoblasts, while mature osteoblasts move on to form osteoids and a 
process of mineralization ensues. In addition to this, endothelial nitric oxide synthase 
(eNOS) has been shown to mediate bone formation in the area of tension, which thus 
suggests that eNOS could provide a useful marker for osteoblastic activity (Sprogar et al., 
2008, Tan et al., 2009, Andrade et al., 2012). A number of research papers and studies have 
investigated the link between enzyme profiles and alveolar bone formation at the sites of 
tension, while alkaline phosphatase has been identified as another biochemical marker that 
has been proven to be valuable and reliable during osteoblastic activity (Ariffin et al., 2010, 
Yazid et al., 2010). 
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1.3.3. How do teeth move under orthodontic force? 
OTM can cause successive responses in both the periodontal tissue and alveolar bone. At 
the start of orthodontic treatment, acute inflammation takes place and is characterized by 
the dilatation of blood vessels in the supporting periodontal tissue. Plasma and leucocytes 
travel out to produce various local and systemic biochemical signal molecules that evoke 
the synthesis and secretion of various substances, such as prostaglandin, growth factors and 
cytokines. Acute inflammation lasts for 1-2 days before chronic inflammation begins. 
During this phase fibroblasts, endothelial cells, osteoblasts, and alveolar bone marrow cells 
proliferate and this continues until the next orthodontic treatment appointment, after which 
acute inflammation returns due to activation by tooth-moving orthodontic appliances 
(Krishnan and Davidovitch, 2006a). The orthodontic forces bend the alveolar bone that 
compress and stretch the PDL, leading to alterations in the electrical neutrality of the 
alveolar bone. The compressed PDL then becomes the site of intense bone resorption, while 
stretched PDL areas interface with active osteogenesis sites (Krishnan and Davidovitch, 
2009). 
In biochemical terms, the forces used in OTM lead to an initial increase in levels of 
bone-resorptive mediators and the associated receptors, namely IL-1β, IL-8, RANKL, and 
TNF-α; this occurs as early as 1 minute (Dudic et al., 2006) or 1 hour into the procedure 
(Karacay et al., 2007), and peaks after 24 hours (Sari and Uçar, 2007, Luppanapornlarp et 
al., 2010, Kaya et al., 2011, Alikhani et al., 2013, Kuroki et al., 2014). These mediators 
slowly decrease to the baseline at the following observation point: 48 hours, 168 hours, 14 
days and 21 days (Karacay et al., 2007, Sari and Uçar, 2007). Conversely, bone-forming 
mediators, such as OPG, exhibit an immediate decline on the application of orthodontic 
force on the site of retraction after 1 hour (Toygar et al., 2008, Tuncer et al., 2013), and at 
24 hours (Toygar et al., 2008, Barbieri et al., 2012). Furthermore, during the acute 
inflammatory phase, pain can be noted due to an increased concentration of inflammatory 
mediators. In particular, these include cytokines and prostaglandins in the GCF of the 
moving teeth (Krishnan and Davidovitch, 2015). 
Various studies compare the compression and tension sites show a decrease in OPG 
by 24 hours at the compression side (Barbieri et al., 2012), as well as an increase in RANK 
and TGF-β1 after 7 days (Nishijima et al., 2006, Barbieri et al., 2012). Various other 
mediators show temporal variations on the compression side, with IL-1β increasing as soon 
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as 1 minute (Dudic et al., 2006) or after 4 hours (Grant et al., 2013); RANKL increasing 
after 24 hours in both juveniles and adults (Kawasaki et al., 2006) or after 42 days (Grant et 
al., 2013); and IL-8 after 4 hours (Grant et al., 2013) or after 10 days (Tuncer et al., 2005). 
In contrast, the tension site has been shown in various studies to demonstrate an appreciable 
increase in TNF-α (Grant et al., 2013) and other bone-resorbing mediators, such as IL- 1β, 
PGE2 and IL-8. However, this rise is shown to have occurred earlier than for compression 
and, across all of the observation points, with levels higher than those seen at the 
compression side (Tuncer et al., 2005, Grant et al., 2013). 
1.3.4 Bone remodelling with OTM 
Bone growth, adaptation and turnover occur by way of two key mechanisms: modelling and 
remodelling. Bone modelling is characterized by independent processes of bone resorption 
by osteoclastic activity and bone formation by osteoblastic activity result in changes in the 
size and/or shape of bone. Bone remodelling is characterized by a constant balance of 
osteoclast induced bone resorption and osteoblast induced bone formation, which goes on 
to replace the existed bone at the same site (Graber et al., 2011). This process occurs across 
several stages: the initiation of osteoclast formation; bone resorption mediated by the same 
cells; reversal period which encompasses bone formation mediated by osteoblasts; and 
finally, matrix mineralization (Nanda and Kapila, 2010) (Figure 1.9). 
In the process of bone remodelling the early steps, namely the initiation of 
osteoclast formation, require the differentiation and activation of osteoclast forerunners to 
form osteoclasts. The latter of these are then responsible for the beginning of bone 
resorption process. This resorption is later followed by bone formation and the number of 
sites that enter into the bone formation phase, merged with the rate of resorption, will prove 
decisive in overall turnover (Eriksen et al., 1986, Charles et al., 1987). 
Bone resorption constitutes the second step in this process and this occurs when the 
bone surface is prepared. This preparation stage involves the removal of the surface’s un-
mineralized osteoid, which then lines it and produce various proteolytic enzymes, including 
MMPs, collagenase and gelatinase. Osteoclasts are known to recognize extracellular bone 
matrix proteins through cell surface integrin adhesion molecules: examples of such proteins 
include osteopontin. The osteoclast is then stimulated at the surface of the mineralized bone 
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and it is believed that this process is mediated through the osteoblast via local factors or 
cell-to-cell contacts (Fuller et al., 1991). 
Osteoclasts are able to resorb the surface of the bone via the production of hydrogen 
ions – these change the pH balance and dissolve any inorganic elements. Proteolytic 
enzymes then come into play by degrading the organic components. The organic matrix 
largely comprises collagen type I (90% of the protein in bone) and is degraded by the 
lysosomal cysteine proteinases cathepsin B, L, and K, which work in conjunction with the 
MMPs, collagenase and gelatinase B. Osteoclast activity stops due to apoptosis, also known 
as programmed cell death, and this implies that the process by which the osteoclast life 
span is regulated may represent another important determinant in bone metabolism. 
Approximately 9 days after resorption beings to take place – at which point the 
osteoclast has resorbed the bone surface to its maximum depth – a reversal process begins. 
While, as stated above, osteoclastic activity is reduced by apoptosis, it is also known that 
increased calcium levels present in the sub-cellular space also impede resorption. Various 
substances released from the bone matrix during resorption have also been shown to 
prompt osteoclast deactivation. 
Bone formation is thus the final point in a long process and series of events, 
including the proliferation of primitive mesenchymal cells, the formation of preosteoblasts, 
matrix formation and mineralization. Osteoblasts meet on the base of the resorption cavity 
in order to produce osteoid. Local factors such as the transforming growth factor (TGF) and 
the exposed type I collagen attract cells towards the resorptive defect. The local 
proliferation of osteoblast precursors is then influenced by TGF, as well as the insulin-like 
growth factors (IGF) I and II, fibroblast growth factor (FGF) and platelet derived growth 
factor (PDGF). 
Osteoid mineralisation begins 13 days later at a rate of approximately 1 µm per day. 
Over the course of 120 to 180 days the bone formation process then takes place and only 
finishes once the cavity is filled (Eriksen et al., 1986). 
Overall by virtue of being acutely sensitive and responsive to applied mechanical 
loads, osteocyte cells are key participants in this process. Their network of cellular 
projections facilitates communication with neighbouring osteocytes, alveolar bone surface-
lining cells, and bone marrow cavity cells. Osteoblasts maintain direct contact with 
osteocytes and respond to these signals to initiate appositional changes. Activated 
osteoblasts send signals to the approaching osteoclasts that encourage these cells to begin 
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resorption of the alveolar bone. Furthermore, the osteoblasts notify the osteoclasts when to 
stop this process (Xie et al., 2008). 
Growth factors released from the bone through a genetic mechanism for osteoclast 
activation and suppression regulate the remodelling process, making RANK, RANKL and 
OPG gene products that control both bone resorption and formation sequences (Nanda and 
Kapila, 2010). In addition, the local hormones prostaglandins, a product of arachidonic acid 
metabolism, are chemical agents produced by mammalian cells after cell injury, osteoblasts 
included. These constitute 20-carbon essential fatty acid molecules and are seen to play a 
key role in the mediation of the inflammatory response that enables tooth movement 
(Yamaguchi and Kasai, 2005). A variety of other agents have been identified as affecting 
bone remodelling and tooth movement, including growth factors (platelet-derived growth 
factors), the parathyroid hormone (PTH), and interleukins or other cytokines through their 
stimulation of the production of prostaglandin E2 (Kale et al., 2004). 
 
 
Figure 1.9 Bone remodelling cycle (initiation of osteoclast formation, bone resorption, reversal process, bone 
formation and mineralisation). PTH: parathyroid hormone. Acknowledgments to (Garg, 2009). 
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1.3.5 Tissue remodelling with OTM 
The area of compression of the periodontium leads to both a narrowing of the PDL and 
vascular restriction; which can in turn; cause ischaemia, necrosis and vessel degeneration. 
If the force is strong enough, it may even result in hyalinisation or sterile necrosis. 
However, if it is possible that the PDL be maintained despite a reduction in the blood 
supply, cellular activity increases and monocytes are differentiated into fibroblasts and 
osteoclasts. These fibroblasts and osteoclasts are responsible for the remodelling of both 
soft and hard tissues. Areas of hyalinisation are lacking blood supply and as a result the 
host is incapable of recruiting a cellular inflammatory response and, consequently, 
resorption cannot take place. However, where orthodontic force is distributed in an 
irregular manner in the PDL adjoining areas of normal periodontium are present. Such 
areas contribute to a remodelling of the hyalinised areas. In this process, both osteocytes 
and vascular elements penetrate the hyalinised tissue, and the alveolar bone found in this 
particular region is removed by underlying resorption (Rygh, 1973). 
The tension sites show stretching of the PDL fibres, vascular dilatation and a rise in 
local vascular activity (Rygh et al., 1986). In the same areas, the first three days see a 
reduction in the volume of collagen, while vascularisation increases (Crumley, 1964). 
Collagenase enzymes are produced by mechanical stress, prompting the development of 
macrophages and fibroblasts (Sandy, 1992). Collagen fibres within the PDL exist in coiled 
forms. When tooth movement exceeds intrinsic fibre length, new fibres need to be 
synthesized and incorporated into the ligament proper. Progenitor cells generate osteoblasts 
via local production within the periodontium (EugeneRoberts and Chase, 1981). After 
vascular dilatation increased vascular activity can be seen in a particular area. Sheets of 
densely packed cells are formed on the bone by osteoblasts and the extracellular organic 
matrix of bone is secreted. Here the components include type I collagen, osteocalcin, 
osteoponin and osteonectins. Cytokines, proteoglycans and growth regulating factors are 
also released. (Rygh et al., 1986). 
Furthermore, blood vessels are crucial in mediating OTM, with angiogenesis and 
remodelling of existing blood vessels aiding in adjustments to the new environment created 
by mechanical forces. It has been reported that orthodontic force application is followed by 
a preliminary reduction and subsequent increase in the number of PDL blood vessels 
(Anastasi et al., 2008, Ren et al., 2008). These blood vessels execute a key role in 
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mechanical force-induced aseptic inflammation, in which they operate as sources for both 
cytokines and chemokines. Demonstrating a confirmation of the presence of aseptic 
inflammation, increased expressions of IL-1β, IL-1 receptor, IL-6, IL-6 receptor, IL-8 
receptor, IL-11, and TNF-α have been demonstrated in the compressed PDL (Koyama et 
al., 2008). 
1.3.6 Rate of tooth movement 
The displacement of a tooth per unit time is used to describe the rate of tooth movement 
and is typically measured in mm per hour, day, week or month. As little as one millimetre 
per month counts as an acceptable rate of tooth movement (Walther et al., 1994, Graber et 
al., 2011). 
It is normal for all of the teeth involved in a fixed orthodontic appliance to move 
differently or independently, rendering a quantification of this distance difficult without the 
use of reference points. Different methods have been used to measure the rate of OTM. One 
particularly notable method was developed by Little (1975) to measure the linear 
displacement of anatomical contact points. OTM rate was measured during the alignment 
stage, with displacement being reduced with time. This method can thus be employed as an 
indicator for the rate of the alignment achieved and lower incisor stability following 
orthodontic treatment. 
Fixed-appliances orthodontic treatment of moderate to severe malocclusion usually 
lasts for a year and a half (Tsichlaki et al., 2016), with some variation according to the 
associated factors (Fisher et al., 2010, Mavreas and Athanasiou, 2008). Recently, both 
orthodontists and patients have become interested to accelerate tooth movement (Uribe et 
al., 2014), particularly adult patients who prefer to finish the treatment with the shortest 
time for social and aesthetic concerns (Rosvall et al., 2009). Additionally, reduced 
orthodontic treatment duration has significant advantages to decrease the side effects of 
orthodontic treatment, such as pain, caries, gingival recession and root resorption (Talic, 
2011, Segal et al., 2004). 
More recently, numerous surgical and nonsurgical adjuncts to orthodontic treatment 
have been outlined to reduce treatment duration. Surgical techniques include alveolar 
corticotomy (with or without local augmentation) and various forms of distraction (Uzuner 
and Darendeliler, 2013). There is some evidence that surgical intervention can increase 
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rates of tooth movement in the short term (Gkantidis et al., 2014, Hoogeveen et al., 2014); 
however, discomfort, morbidity, and inconvenience for the patient are likely to be 
associated with surgery. Among nonsurgical methods, a low-intensity laser irradiation was 
used in humans during the retraction of upper canines in a 2-month split mouth design 
study, using mechanical activation in control side and the same mechanical activation with 
irradiation by a diode laser emitting light on 4 days of each month on the other side. A 
significant acceleration in the canine retraction by 34% more in lasered side compared to 
the control was observed, with no evidence of damage to the surrounding bone and tissues 
(Cruz et al., 2004). One clinical trial was also performed to determine if 
photobiomodulation reduces the orthodontic alignment time by using a near-infrared light 
device to irradiate the surface of the cheek 20 or 30 minutes per day or 60 minutes per week 
with traditional fixed orthodontic appliance. They found that the rate of change in the 
irregularity was 0.49 and 1.12 mm/week for the control and test groups, respectively, 
suggesting that photobiomodulation produced remarkable clinical changes in the OTM 
(Kau et al., 2013). The other non-surgical methods to accelerate OTM include pulsed 
electromagnetic field, which was investigated using a split mouth design study during 
canine retraction. The results showed that canines exposed to pulsed electromagnetic fields 
retraction was 1.57 ± 0.83 mm more than control canines (Showkatbakhsh et al., 2010). 
Pharmacological approaches to accelerate tooth movement have also investigated. 
One study measured the rate of tooth movement with and without submucosal injection of 
PGE1 during distal movement of canine. The results showed that the rate of canine 
retraction was almost 1.6-fold on the side of PGE1 injections in comparison to the control 
side (Yamasaki et al., 1984). Conversely, another study conducted to assess the effect of 
relaxin -soft tissues remodelling hormone- on the tooth movement and stability in humans. 
They found that there were no significant differences in the OTM between relaxin and 
placebo groups (0.08 mm and 0.09 mm, respectively) over the 8-week treatment; and in 
relapse from week 8-12 (0.07 for relaxin and 0.08 for the placebo) (McGorray et al., 2012). 
Although numerous innovations in the design and construction of fixed appliances 
have been advocated, there is little high-quality evidence to suggest that bracket design or 
arch wire sequence can significantly influence the speed of tooth movement (Papageorgiou 
et al., 2014b, Papageorgiou et al., 2014a, Jian et al., 2013). One particular study conducted 
to compare mandibular teeth alignment using self-ligating and a conventional edgewise 
orthodontic bracket system, found no difference in the initial rate of mandibular incisor 
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alignment rate (0.119 mm/day and 0.135 mm/day) respectively, between them (Scott et al., 
2008a). Another randomized trial investigated the influence of supplemental vibrational 
force on the rate of orthodontic tooth alignment with fixed appliances in three groups of 
patients (1: using removable intraoral vibrational device, 2: using an identical non-
functional device, 3: fixed appliance only). No evidence was found to indicate that 
supplemental vibrational force might significantly increase the rate of initial tooth 
movement. Similarly, no evidence was found that it might reduce the amount of time 
needed to achieve final alignment in the three tested groups (210.2, 217.5, 200.7 days), 
respectively (Woodhouse et al., 2015a). A double blind randomized clinical trial study 
investigated the effects of low diode laser on the rate of canine retraction on days 1, 3, 7, 
30, 33, 37, 60, 63 and 67 using sectional closing coil and found comparable rate of tooth 
movement in both irradiated and non-irradiated sides at each time point (Dalaie et al., 
2015). 
The duration of treatment and number of visits were compared using two different 
fixed orthodontic appliances (self-ligating and conventional brackets). They found that the 
bracket type did not significantly influence the duration of treatment (21.4 vs. 18.3 
months), the number of visits required (17.8 vs. 15.7) and the percentages of PAR score 
reductions (68.5% vs. 74.3%) (Fleming et al., 2010). This confirmed by the outcomes of 
another study used same appliances, showed the overall treatment duration (24.5 vs. 23.0 
months), number of visits (14.2 vs. 14.5), or overall percentage of reduction in PAR scores 
(85.2% vs. 83.4%) in the treatment of patients need teeth extraction to fix the crowding  
(DiBiase et al., 2011). 
One in vivo study investigated the effects of caffeine intake on OTM in rats. After a 
static compressive force was applied for a period of 3 weeks, the degree of tooth movement 
and its effect on the periodontium were assessed in vitro for groups both with and without 
caffeine groups. The results showed that in vivo, the caffeine group exhibited a 
significantly greater rate of tooth movement than the control group. In vitro, caffeine at 
0.01 mM significantly heightened the compression-induced expression of RANKL and 
COX-2, and prostaglandin E2 production in the PDL. They have thus suggested that a daily 
caffeine intake of a yet-to-be specified dosage may enhance OTM by increasing 
osteoclastogenesis (Yi et al., 2016). 
The rate of orthodontic movement is primarily affected by: 
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Force Magnitude: Tooth movement increases proportionally with force, yet only up to a 
point. Forces that go beyond this point prompt unnecessary trauma to biological tissues and 
can prove stressful for the anchorage. The force magnitude applied to an individual tooth 
depends upon two elements: first, its root surface area and second, the type of tooth 
movement planned. With regard to this topic, research can be found that specifically cites 
the optimum force for tooth movement at being around 20-25 g/cm
2
 of root surface area 
(Proffit et al., 2014). 
Force Duration: In general terms, orthodontic force is applied in either an intermittent 
(removable appliances), interrupted or continuous (fixed appliances) manner. The blood 
stream begins to show chemical indicates for OTM within a few hours of the force 
application and then clinical tooth movement takes place. Yet a light continuous force is 
superior to intermittent force for optimal tooth movement due to the nature of cell biology, 
that is, a system that remains in a persistently responsive state as opposed to a shifting state 
(Samuels et al., 1998). 
Age: Both tooth movement and biologic responses to orthodontic treatment are slower in 
adults than in adolescents and children. This can be attributed to the fact that adult PDL is 
much less cellular and the density of their alveolar bone much greater (Walther et al., 
1994). A higher RANKL/OPG ratio in GCF for juveniles can be used to explain the greater 
velocity and amount of OTM in juveniles compared to that for adults (Kawasaki et al., 
2006). 
Occlusal interlock: Normal occlusion in orthodontics has developed as the result of a 
particular concept that requires teeth have a specific arrangement: an intra-arch relationship 
and inter-arch to opposing arches. Well-aligned dental arches with normal labial and buccal 
over jet, overbite and have a normal antero-posterior relationship between maxillary and 
mandibular arches constitute normal occlusion. A good buccal occlusion may act to resist 
tooth movement (Gray, 2004). 
Individual variation: A series of factors may be responsible for the variations that occur in 
the rate of tooth movement, including rate of body growth, metabolism, bone density and 
PDL turnover (Kusy and Tulloch, 1986, Pilon et al., 1996). 
Drugs and chemical agents: Extensive research has been conducted into the accelerative 
or preventive effects of various drugs and chemical agents on OTM, and it has been shown 
that the rate of tooth movement can be altered by the application of certain agents either 
locally or systemically. Prostaglandin, vitamin D and corticosteroids constitute promoter 
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agents and they are responsible for the acceleration of the required tooth movement via the 
augmentation of the bone resorption process. Suppressor agents, such as nonsteroidal anti-
inflammatory drugs, and bisphosphonates lessen tooth movement by either reducing bone 
resorption or enhancing bone formation (Valiathan and Dhar, 2006, Bartzela et al., 2009). 
1.4 Human body fluids as a source of biomarkers 
The human body comprises a wide variety of fluids such as blood, urine, saliva, GCF, tears 
and sweat, all of which possess an expansive selection of proteins. These fluids fill organs 
or body cavities after circulating through the body, before being secreted or excreted. Not 
only are they key to overall health and well-being, but they also offer clues to the body’s 
biological processes and its functions. For example, blood, urine, and cerebrospinal fluid, 
are applied clinically in the examining of human health and the diagnosis of diseases (Loo 
et al., 2010). Serum and plasma, which are found in the blood, are particularly popular in 
clinical testing since they surround all tissues and organs, possible gathering the byproducts 
of disease. Varying concentrations of specific plasma have been linked to certain diseases. 
In terms of whole saliva, this is recognized as a potential disease biomarker for both 
discovery and diagnosis. It is readily available from most individuals, can be easily 
collected, stored and processed, and requires a simple and non-invasive collection process. 
A compare and contrast exercise for the protein compositions of salivary and plasma fluids 
are thus worthwhile. Significant overlaps in protein content between saliva and plasma may 
present saliva as a diagnostic and an alternative to blood tests (Loo et al., 2010). This area 
has made great progress since the mid-2000s, when advancements began to take place in 
salivary testing for health and disease in both oral and systemic terms (Schipper et al., 
2007, Genco, 2012, Wong, 2012). 
Applied force causes local inflammation and greater capillary permeability in 
paradental tissues during orthodontic treatment. Since GCF occurs closer to the sites of 
these activities and is less likely to be diluted, it has a better diagnostic potential than saliva 
for the markers of these activities (Rody Jr et al., 2011). The first studies undertaken into 
GCF were aimed at bettering clinical judgment, and the prevention and treatment of 
periodontitis. It was only when our understanding of humeral immune responses, genomics 
and proteomics improved that the potential applications of GCF and saliva analyses began 
to be discussed. If the immune and inflammatory responses of an individual to certain 
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stimuli can be measured through studies of oral fluids, then the results may allow for an 
assessment of the risk of the individual both orally, and in terms of other systemic 
conditions (Genco, 2012, Giannobile, 2012). 
1.4.1 Gingival crevicular fluid 
GCF is an exudate found in the gingival sulcus, between the tooth and marginal gingiva. In 
the healthy sulcus it is a transudate of interstitial fluid and is present in minute amounts. 
GCF is released into the crevicular sulcus at a flow rate of close to 3 µl/hour (Perinetti et 
al., 2013), and under stimulated or inflamed conditions reflects the concentration of 
metabolites in the serum, increasing in volume with the severity of the inflammation up to 
44 µl/hour. 
The result of increased capillary fluid filtration in comparison to lymphatic uptake 
leads to fluid accumulation as oedema and/or leaves the area as GCF. It largely comprises 
serum components, inflammatory cells, connective tissue, epithelium and microbial flora 
established in the gingival sulcus and exhibits defence activities by flushing carbon 
particles and bacteria from the sulcus, while its antimicrobial properties and antibodies 
improve inflammation resistance (Goodson, 2003, Griffiths, 2003). 
1.4.1.1 Composition of GCF 
The main origin of the aqueous portion of GCF is serum, yet its composition can be 
modified to a great extent by the products and microorganisms present in its pathway from 
the gingival tissue through to the sulcus. In general, it comprises cellular components that 
include bacteria, desquamated epithelial cells and leukocytes that pass through sulcular 
epithelium, such as PMNs, lymphocytes, monocytes and erythrocytes. These cells originate 
from blood vessels in the gingival connective tissues as a result of the stimulation of cells 
and metabolic products in plaque close to the gingival sulcus (Kavadia-Tsatala et al., 2001). 
Granulocytes form about 70-80% of GCF cells, while monocytes and macrophages 
account for around 10-20% and 5% each for mast cells and T-lymphocytes. Together with 
organic compounds such as carbohydrates, lipids and protein, electrolytes like calcium, 
sodium, potassium, fluoride and magnesium are also present. Certain levels may be higher 
in GCF; with glucose concentration 3-4 time that of serum, for example; while protein 
levels are much lower than in serum. Metabolic and bacterial products such as lactic acid, 
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hydroxyl proline, urea, endotoxins, cytotoxic substances, prostaglandins, antibacterial 
factor and hydrogen sulphide have also been shown to be present (Zia et al., 2011). 
Other components of GCF are enzyme and enzyme inhibitors such as acid 
phosphatase, pyrophosphatase, alkaline phosphatase, lysozyme, B-glucoronidase, 
hyaluronidase and proteolytic enzymes like mammalian proteinases that includes cathepsin 
D, cathepsin G, elastase, plasminogen activators, bacterial proteinases (endo and 
exopeptidases, collagenase and lactic dehydrogenase serum proteinase inhibitors like alpha 
2- macroglobulin, alpha 1- antichymotrypsin, alpha 1- antitrypsin (Zia et al., 2011). 
1.4.1.2 Rationale for the study of GCF 
The study of GCF was first introduced and pursued in the hope of improving clinical 
diagnosis, prevention and treatment for gingivitis and periodontal disease. Early studies 
focused on the amount of GCF and its correlation with clinical and histological measures of 
inflammation. To summarize, cross-sectional and longitudinal studies find that the amount 
of GCF is positively correlated to clinical indices of gingival inflammation, while 
correlation between amount of GCF and histological evidence of inflammation prove 
weaker and at times discordant (Cimasoni, 1982). 
Early efforts evaluate the differences among GCF constituents linked to healthy 
versus periodontal-compromised teeth or sites, and various studies indicate that levels of 
GCF constituents reflect both local events and a donor’s overall systemic response 
(Champagne et al., 2003). More recently, improved knowledge of humoral immune 
responses, genomics and proteomics has broadened the prospective applications of GCF 
analysis. It has been suggested that if an individual’s immune and inflammatory responses 
to stimuli can be measured and assessed to calculate periodontitis, then via careful analysis 
an assessment of the relative risks for an individual of developing other conditions could 
also be made, including diabetes mellitus, cardiovascular disease, HIV and hepatitis 
(Ebersole, 2003, Lamster and Ahlo, 2007). 
1.4.1.3 Collection of GCF 
GCF can be collected using various techniques, such as gingival washing, immune-
magnetic beads, micropipettes or capillary tubing, pre-weighed twisted threads, and 
absorbent strips of filter paper. The last of these methods is considered less traumatic when 
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correctly performed and can be applied to the specific site both easily and quickly 
(Tzannetou et al., 1999). 
Intra-crevicular application can be employed, where the strip is inserted into the 
base of the pocket or extra-crevicular application, where the strip is placed over the crevice 
region or at its entrance to prevent traumatic irritation and the subsequent simulation of 
GCF secretion (Newman et al., 2006). No significant differences were found in GCF 
collected from either site (Griffiths, 2003). 
1.4.1.4 GCF collection difficulties 
Major sources of GCF contamination constitute blood, plaque and saliva, and hence precise 
steps should be taken before GCF collection. These include isolation of the teeth with 
cotton rolls, followed by the gentle removal of the supra gingival plaque and, finally, 
complete drying of the teeth’s surface with an air stream (Griffiths et al., 1992). 
In the case of GCF contamination with blood the sample should be discarded, while 
plaque contamination may affect the determination of the volume. The avoidance of saliva 
contamination requires sure isolation and alpha-amylase could be used to confirm or 
disprove contamination by saliva in a sample (Griffiths et al., 1997). 
1.4.1.5 Volume of GCF 
GCF volume is measured according to the surface area of the strip dampened by the fluid. 
For a more accurate measurement a staining of the strip can be done, either with ninhydrin, 
which gives a purple colour as an indicator, or by the systemic administration of 2 g 
fluorescein 2 hours before GCF collection, followed by a UV-light examination of the 
stained strip; the latter of these methods is more sensitive to protein staining. The volume 
of collected GCF can be measured by comparing the strip weight before and after sample 
collection. However, this is quite a sensitive process due to the small amount of fluid 
secreted from a healthy crevice. Periotron provides a more reliable method and involves an 
instrument that measures the volume and composition of the collected sample using an 
electrical current that is passed through the dampened strip (Golub and Kleinberg, 1976). 
This ultimate technique is fast and leaves no marked effects on the sample. 
Sample evaporation presents the main problem in GCF volume measurement, 
especially for volumes of less than 1 µl. Since such samples require further investigation, 
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care should be taken to store each strip in a sealed container to avoid any fluid evaporation 
that may affect volume measurement. Recovery of the collected GCF is essential, with 
centrifugal elution demonstrating approximately 100% protein recovery (Cimasoni, 1982). 
One microliter is the maximum strip capacity and a longer collecting time may lead to the 
collection of more fluid than allowed for by the maximum capacity limit (Goodson, 2003). 
Previous evidence shows that GCF volume might prove a better indicator of 
gingival inflammation than standard clinical assessments (Griffiths et al., 1992). Given that 
tissue remodelling incident to OTM is elicited by an inflammatory process (Krishnan and 
Davidovitch, 2006b), it is hypothesized that the volume of GCF production will reflect 
these tissue changes (Griffiths, 2003). Additionally, the clinical recording of periodontal 
conditions may exclude the idea that, due to plaque accumulation, gingival inflammation is 
responsible for an increase in GCF production rather than tooth movement. However, 
conflicting results are reported in the literature, with studies showing both increased and 
unchanged GCF volumes incident to OTM (Perinetti et al., 2013). 
Across numerous studies, very little or no statistically significant changes in GCF 
volume incident to OTM has been recorded. The changes that are seen are generally 
ascribed to clinical or subclinical inflammation following the placement of a fixed 
orthodontic appliance. Some such studies have compared the volume of GCF during 
distalisation of the maxillary canine in split-mouth designs in adult and juvenile groups 
across 4 time points. They found no significant difference between moved and non-moved 
teeth at each time point or over time within the test and control teeth for both the adult and 
juvenile groups (Kawasaki et al., 2006, Dilsiz et al., 2010). Comparable results are cited by 
further study that measure GCF volume at different time points using varying orthodontic 
force (Luppanapornlarp et al., 2010). A final study notes that GCF volume increase mainly 
results from subclinical periodontal inflammation following fixed appliance placement, 
rather than from OTM (Drummond et al., 2011). 
1.4.1.6 Flow rate and constituents of GCF 
Flow rate describes the movement of fluid from or into the gingival pocket and occurs at 
approximately a few microliters per hour. It can be measured by monitoring the volume of 
fluid that crosses a defined boundary at a given time. Its rate and composition can be 
altered through inflammation induced by OTM or periodontitis. Both a flushing action and 
an isolation effect are the result of GCF flow, with the substances present in the gingival 
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sulcus being easily rinsed out by the flushing action. Furthermore, the outward flow of 
GCF would not allow for saliva to retrograde to the gingival sulcus, resulting in the 
isolation of the gingival sulcus from the oral cavity (Kavadia-Tsatala et al., 2001). 
Under healthy conditions GCF flow rate remains stable over time, while it has been 
shown to increase with inflammation and decrease with therapy (Goodson, 2003). GCF 
flow rate was also reported to be increased (Baldwin et al., 1999) or remained with no 
significant changes (Uematsu et al., 1996a, Miyajima et al., 1990) during orthodontic 
treatment. A greater quantity of GCF can be collected from adolescents in comparison to 
adults, regardless of the presence of any stimuli (Ren et al., 2002). Smokers provide a 
smaller amount of GCF than non-smokers (Hedin et al., 1981). 
GCF sampling sequences may affect volume and for healthy sites the fourth and 
fifth samples have been shown to yield higher volumes of GCF than previous samples due 
to increased trauma (Chapple et al., 1996). By comparison, protein concentrations remain 
stable at healthy sites yet increase at inflamed sites with repeated sampling (Curtis et al., 
1988). 
At this point, it is important to emphasize that GCF constituents are affected by both 
local and systemic conditions (Ebersole, 2003). Periodontitis is an obvious example of a 
heterogeneous disease in which both the environment and genes affect severity (Kinane et 
al., 2005). 
1.4.1.7 GCF and orthodontic therapy 
Studies concerning GCF and orthodontic therapy have both followed and reflected 
periodontal research, with the mechanical stimuli applied to teeth during orthodontic 
treatment being expected to affect the amount and constituents of GCF. Histological studies 
conducted in a guinea pig model demonstrate that orthodontic forces cause localized 
increased vascular permeability. This increased vascular permeability is similar to that seen 
in the inflammatory process (Storey, 1973) and appears to support the aforementioned 
expectation that the mechanical stimuli applied to teeth during orthodontic treatment affect 
the amount and constituents of GCF. 
Numerous studies have examined the relationship between tooth movement and 
physical, cellular or molecular changes in paradental tissues and modifications in GCF 
constituents during OTM (Krishnan and Davidovitch, 2009). The results indicate noticeable 
effects on the quantity and constituents of GCF, together alterations in the haemostatic 
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condition of the periodontal space – an effect that led to biochemical and cellular changes 
that re-shape the contour of the alveolar bone (Toms et al., 2002). Less significant changes 
in GCF were observed in children with good oral hygiene undergoing orthodontic treatment 
when compared to the control group (Tersin, 1978). Meanwhile, GCF does not constitute 
an indication for tissue remodelling in orthodontic treatment (Perinetti et al., 2013). 
In vitro and in vivo research began to report studies of the measurement of GCF 
constituents in relation to orthodontic force, with many of these studies being concerned 
with the identification of GCF markers linked to orthodontic stimuli. Some such studies 
compare markers at both the experimental and control sites using a split-mouth design 
study across various time points. Here GCF samples are collected before the application of 
mechanical stimulus to provide a baseline, and further samples are gathered at a variety of 
time points after fixed appliance application. The results reveal that, on average, peak levels 
occur in the markers 1-2 days after the application of force, before returning to the baseline 
level after 1 week (Giannopoulou et al., 2006, Kawasaki et al., 2006, Karacay et al., 2007). 
Similar results have been observed for inflammatory biomarkers during the retraction of 
maxillary canines (Alikhani et al., 2013), while other studies to have compared GCF 
biomarker levels before, during and after orthodontic treatment reveal no differences 
between untreated teeth, treated teeth, and teeth with retention (Pender et al., 1994, 
Griffiths et al., 1998). Others have employed GCF analysis in the testing of the 
effectiveness of preventive measures against plaque accumulation during OTM (Sköld-
Larsson et al., 2003, Paschos et al., 2008), and a selection of alternative studies have 
measured the levels of ECM proteins in GCF to analyse the presence and levels of root 
resorption (no resorption, mild and marked) (Mah and Prasad, 2004, Balducci et al., 2007). 
For instance, a study reported that RANKL/OPG has been significantly increase with root 
resorption more than 2 mm in comparison to the control samples (George and Evans, 
2009). Additionally, age and growth status influence cytokines levels in GCF, which is 
shown to have an effect on the rate and amount of tooth movement. In one particular study, 
different mediators were found to increase in different age groups, with IL-6, GM-CSF 
increasing in juveniles alone and PGE2 increasing in both juveniles and adults (Ren et al., 
2002). 




A principal natural media in the oral cavity is saliva, a unique body fluid that continually 
bathes the area to maintain the healthy tissues of the oral cavity, oropharynx and larynx 
(Humphrey and Williamson, 2001). Saliva is formed by three pairs of major salivary 
glands, namely parotid, submandibular and sublingual, and hundreds of minor salivary 
glands, with some of the GCF being secreted from the gingival sulcus (Welton, 2012). The 
presence of saliva in the oral cavity is vital for the maintenance of healthy teeth and oral 
tissues. Its secretion is mediated by the parasympathetic and sympathetic nerve supply, and 
its type and volume are controlled by the autonomic nervous system (Proctor and 
Carpenter, 2007). The easy and non-invasive collection and diagnosis of saliva has 
facilitated extensive research into carrier susceptibility, physiological and pathological 
changes, and the monitoring levels of hormones, drugs, ions, antibodies and 
microorganisms. 
1.4.2.1 Salivary glands 
Salivary gland tissue comprises secretory end pieces (acini) and the ductal tree system, with 
secretion taking place in two stages. First, the acinar cells secrete isotonic primary saliva 
rich in NaCl. Second, the saliva passes through the striated duct cells where most of NaCl 
is reabsorbed and K+ is secreted in order to render the saliva more hypotonic as it passes 
from the ducts towards the mouth (A Catalán et al., 2009, Welton, 2012) (Figure 1.10). 
The first major salivary gland is the parotid gland, of which there are two in 
humans. The largest of the salivary glands, each is located in front of the ear and behind the 
mandibular ramus. Shaped like a wedge, its base is superficially directed and apex deeply 
directed, and its secretion is serous or watery in consistency. Second, the submandibular 
glands are around half the size of the parotid gland, with the superficial part situated 
between the mandibular body and mylohyoid muscle and its smaller deeper part resting 
above the mylohyoid muscle in the floor of the mouth. The submandibular glands secrete a 
mixture of mucous and serous fluids. Finally, the much smaller sublingual glands are about 
one fifth of the submandibular glands and located in the floor of the mouth, where they 
produce a predominantly mucous secretion. The minor salivary glands comprise the small 
buccal, labial, palatal, plalatoglossal and lingual glands found in the oral cavity and they 
chiefly comprise mucous components. Their viscous secretion is due to a high 
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concentration of mucin and very low levels of phosphate, with an absence of bicarbonate. 
Their main ions are sodium, potassium and chloride and they exhibit a fluoride 
concentration several times that of the major salivary glands (Welton, 2012). 
 
 
Figure 1.10 Molecular mechanisms of saliva secretion. Acinar cells secrete a large volume of isotonic-like 
fluid rich in NaCl. The generation of a trans-epithelial osmotic gradient drives water flow through apical 
Aquaporin 5 (a small integral membrane protein) and possibly paracellular pathways. Ductal cells, relatively 
impermeable to water, re-absorb most of the NaCl and secrete K[+] and HCO3[−]. Acknowledgments to 
(Delporte, 2013). 
 
1.4.2.2 Saliva composition 
Water forms around 99% of saliva, in addition to various inorganic components such as 
sodium, chloride, potassium, magnesium, calcium, phosphate and bicarbonate. It also 
contains organic components such as proteins, including immunoglobulin, enzymes and 
antimicrobial factors, glycoproteins, albumin, polypeptides and oligopeptides. Glucose and 
nitrogenous products such as urea and ammonia are also present in saliva (Humphrey and 
Williamson, 2001, Welton, 2012) (Figure1.11). 
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Both the type of secreting gland and salivary flow rates can affect saliva 
composition. For instance, with an increased salivary flow rate the pH and the 
concentration of proteins, sodium, chloride and bicarbonate increase, whereas levels of 
magnesium and phosphate decrease. Moreover, saliva composition is affected by duration 
of stimulation. For instance, with an increase in stimulus duration the concentration of 
bicarbonate increases and chloride levels decrease. In addition, saliva composition is not 
affected by the nature of the stimulus, although the stimulus does affect the flow rate, 
which in turn affects composition. Circadian rhythms are also known to influence 
composition; for example, sodium and chloride peak in the early morning, while the protein 
concentration peaks in the late afternoon. In light of these changes, time for saliva 
collection should be fixed to allow for the standardization of studies. Phosphate 
concentration in unstimulated saliva is approximately 5-6 mmol/l, which is higher than that 
of 1 mmol/l in plasma. In contrast, protein concentration in saliva is much lower at only one 
thirtieth of that in plasma. Urea concentration is about 4 mmol/l, which is slightly lower 
than that in plasma, and saliva has been shown to contain less calcium (2.5 mmol/l) than in 
plasma (Dowes, 2012). 
 
 
Figure 1.11 Components of whole saliva. Adapted from (Kaufman and Lamster, 2000). 
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1.4.2.3 Function of saliva 
The complexity of saliva reflects the multiplicity of its functions. In addition to its 
lubricating mechanism, it provides extensive protection from chemical, mechanical and 
thermal irritation to both soft and hard oral tissues; acts as an ion reservoir to enhance tooth 
remineralisation; reduces tooth demineralization by way of a buffering mechanism that 
neutralizes the pH of plaque; stimulates antimicrobial activity to help control the oral micro 
flora with a presence of antibodies, molecules and various enzymes; aids digestive action 
through its alpha amylase enzyme in order to breakdown starchy foods; facilitates food 
tasting through dissolving activities that allow for interaction between food particles and 
taste buds; produces salivary proteins to assist in the formation of a pellicle and protein 
matrix for the plaque, forming an acquired enamel protection barrier; and finally, saliva 
facilitates air flow, speech and swallowing (Welton, 2012) (Figure 1.12). 
 
 
Figure 1.12 Overview of the main functions of saliva in relation to its organic and inorganic constituents. 
Acknowledgments to (Amerongen and Veerman, 2002). 
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1.4.2.4 Salivary flow 
Daily salivary flow rate is approximately 0.5-0.6 litres/day, with a value below 0.1 ml/min 
being considered hyposalivation and a value above 0.4 ml/min being considered 
hypersalivation (Flink et al., 2005). This flow rate differs for stimulated and unstimulated 
saliva (Dowes, 2012). 
The flow rate for unstimulated saliva normally averages 0.3-0.4 ml/min (Flink et al., 
2005), with the parotid generating around 25% of this, the submandibular forming 60%, 7-
8% coming from sublingual glands, and a further 7-8% accumulating from the minor 
salivary glands (De Almeida et al., 2008). For stimulated saliva, an average flow rate of 
1.5-2.0 ml/min comprises 50% from the parotid glands, 35% from the submandibular 
glands, 7-8% from the sublingual glands, and the same percentage from the minor salivary 
glands (Dowes, 2012). 
Salivary flow rate and its composition can be influenced by a wide range of factors, 
such as systemic medical conditions (depression, allergies and hypertension), individual 
hydration, body posture, lighting, smoking, the circadian and circannual cycles, thinking 
about food, visual stimulation, and medication. Stimulated salivary flow rate is also 
affected by the regular stimulation of the salivary flow, size of salivary glands and body 
weight (De Almeida et al., 2008). Although many elderly people suffer from a dry mouth, it 
has been reported that this does not result from low salivary flow but is more likely to be 
due to the effects of medication and some systemic illnesses. A higher saliva flow rate is 
more effective for the reduction of demineralization and the promotion of re-mineralization 
of the teeth, leading to an increased chance of calculus formation (Dowes, 2012). 
1.4.2.5 Saliva as a diagnostic tool 
Saliva is seen as an ideal diagnostic bio-medium and provides an excellent alternative to 
other body fluids for the purposes of investigation. It is easily collected, stored and 
transported, while also being safe to handle in comparison to other biological media. 
Furthermore, sample collection can be repeated frequently throughout the day without the 
need for skilful personnel, therefore it is anticipated that salivary diagnosis will be 
particularly useful in cases where repeated samples of body fluid are required and the 
drawing of blood impractical and/or unethical (Pfaffe et al., 2011). 
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It is a well-known fact that saliva contains a wide range of proteins, peptides, 
electrolytes, nucleic acids and hormones. These originate from various sources, with its 
biochemical and immunological components, for example, coming from a salivary gland 
itself or through the passive or active diffusion of blood (Aps and Martens, 2005, Chiappin 
et al., 2007). 
Accordingly, saliva has been discussed not only as an important biological material 
for diagnostic tests, but also for the explanation of the pathogenesis of numerous systemic 
diseases, such as leukemia, Sjogren’s syndrome, AIDS, systemic lupus erythematosus, and 
diabetes mellitus. As demonstrated by the increasing use of this biological fluid for 
diagnostic purposes in oral pathologies, salivary analysis may aid in the identification of 
many diseases, especially those affecting the oral cavity (Mandel, 1990, Streckfus and 
Bigler, 2002). Non-invasive salivary testing may prove an effective modality for the 
diagnosis and prognosis of oral cancer, and the monitoring of a patient’s post-therapy status 
(Nagler et al., 2003). 
The pathogenesis factor and salivary components appear to be closely associated, as 
confirmed by studies into salivary biochemical and antioxidants systems in several 
pathological conditions (Nagler et al., 2003; Aizenbud et al., 2008). Various enzymes can 
be found among the important components of saliva that are proposed as disease markers. 
The damaged cells of periodontal tissue increasingly release intracellular enzymes into the 
GCF and saliva. Further studies suggest that saliva analysis may provide a cost-effective 
approach for the assessment of periodontal diseases in populations (Kaufman and Lamster, 
2000). However, a range of studies present conflicting results regarding various individual 
salivary agents and the link that they might have with oral health, in particular for dental 
caries (Numabe et al., 2004). 
It was also shown that different salivary components can be used for the diagnosis 
of oral conditions and monitoring the course of treatment, such as enzymes and 
immunoglobulins, hormones of host origin, bacteria and bacterial products, ions, and 
volatile compounds. However, to date no one chemical agent is more important than any 
other. A significant number of the defence factors show additive or synergistic interactions 
against oral pathogens (Mandel, 1990, Kinney et al., 2007). A lack of saliva or saliva 
deficiency results in negative implications for both oral health and general body health 
(Pinka et al., 2009). 
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1.4.2.6 Saliva collection methods 
Saliva can be collected and measured as unstimulated whole saliva or stimulated saliva. 
Unstimulated whole saliva covers, moisturizes and lubricates oral tissues and provides the 
normal baseline present in oral cavity during a 24-hour period. It often correlates with 
systemic clinical conditions more accurately than stimulated saliva does due to the fact that 
the materials used to stimulate flow may change the composition of saliva (Munro et al., 
2006). 
Whole-mouth resting saliva is collected using one of the following methods: 
draining, drooling, spitting, swabbing or suction (Navazesh, 1993). More recently, the 
alternative technique of using filter paper placed in the sublingual pocket for unstimulated 
saliva collection has shown numerous potential advantages over other known procedures 
(Neu et al., 2007). 
Mechanical, olfactory, gustatory or pharmacological stimuli are used to stimulate 
saliva, which is collected either by having the patient chew on a piece of paraffin and/or by 
applying 0.1– 0.2 ml/l (approximately 1 drop) of citric acid to the tongue (Navazesh, 1993). 
Saliva can also be probed from specific glands via cannulation of the glandular ducts, or 
through the use of certain collecting devices at the site where the glandular ducts emerge 
(Edgar et al., 2004). 
1.4.2.7 Salivary changes with periodontal diseases 
Periodontal disease is the most noteworthy condition that can be diagnosed via saliva 
analysis since various enzymes, cytokines and biomarkers of bone turnover are present in 
saliva in cases of periodontitis in comparison to saliva pertaining to healthy periodontal 
status (Teles et al., 2009, Kinney et al., 2011). In addition, while both locally and 
systemically derived biomarkers of host origin are contained in saliva, further microbial 
markers for periodontal disease are also present (Kaufman and Lamster, 2000, Koh and 
Koh, 2007). Nevertheless, it must be noted that the detection of the active disease site is 
difficult in saliva analysis and, furthermore, such an analysis is affected by factors such as 
salivary flow rate, medications and smoking (Gursoy et al., 2010). 
Several studies have been conducted to investigate certain biomarkers in saliva for 
the early detection and management of periodontitis, the earliest biomarker investigated 
was IL-1β. Many studies concluded significantly higher levels of IL-1β in the periodontitis 
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group comparing to the healthy ones (Tobón-Arroyave et al., 2008, Gursoy et al., 2009, 
Ebersole et al., 2013), others found same level of IL-1β with and without periodontitis 
(Christodoulides et al., 2007, Teles et al., 2009). Alternative studies showed same levels of 
salivary TNF-α in patients with periodontitis and healthy subjects (Gursoy et al., 2009, 
Mirrielees et al., 2010). In addition to the cytokines, significantly higher levels of 
adipokines such as visfatin and chemerin have been observed in saliva of patients with 
periodontitis comparing to periodontal health subjects (Tabari et al., 2014, Özcan et al., 
2015). Salivary RANK and OPG were measured in patients with periodontitis, some 
studies showed same levels of OPG in diseased and healthy groups (Miller et al., 2006, 
Costa et al., 2010), others mentioned that OPG levels declined following periodontal 
treatment (Kinney et al., 2011, Sexton et al., 2011). Another study mentioned that the 
salivary levels of RANKL were the same in periodontitis and healthy groups (Frodge et al., 
2008), however other studies reported that salivary RANKL was significantly higher in 
periodontitis group in comparison to the healthy one (Tobón‐Arroyave et al., 2012, Tabari 
et al., 2013). Further research demonstrated significantly higher levels of growth factors in 
saliva with periodontitis (Wilczynska-Borawska et al., 2006, Rudrakshi et al., 2011, 
Wilczyńska-Borawska et al., 2012). 
1.4.2..8 Salivary changes with orthodontic treatment 
OTM takes place through bone remodelling that is used primarily to enable bones to 
respond and adapt to mechanical stress during orthodontic treatment (Van Nieuw 
Amerongen et al., 2004, Ariffin et al., 2010). Due to such treatment, lactate dehydrogenase 
levels increase in saliva during bone remodelling. For the time being, clinical and 
radiographic follow-up examinations comprise the main method for patient evaluation. 
However, saliva analysis may provide a foundation for phase-specific screening in OTM 
(Flórez-Moreno et al., 2013b). 
During orthodontic treatment, salivary flow rates have been shown to increase 1-3 
months after the delivery of fixed appliances in comparison to the baseline measured both 
before starting treatment and at the control levels (Li et al., 2009). It has also been shown 
that 90-180 days after the completion of orthodontic treatment, the salivary flow rate 
moved closer to the baseline and control levels. Research into the cariogenic bacterial 
counts in whole saliva have found that 3 months after the delivery of the fixed appliance, 
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bacterial counts increased significantly before returns to baseline levels (Peros et al., 2011). 
Other studies illustrate associations between specific genotypes and susceptibility to root 
resorption (Al-Qawasmi et al., 2003), speed of OTM (Iwasaki et al., 2009), and primary 
eruption failure (Frazier-Bowers et al., 2010). More recently, saliva, collected in sufficient 
volume, has been employed to identify genotyping instead of blood and buccal swabs 
(Pulford et al., 2013). 
The biocompatibility of orthodontic appliances was investigated by analysing the 
metal ion released from the materials of the appliances into saliva; the results showed that 
most of ions were released during the initial stage of the treatment (Mikulewicz and 
Chojnacka, 2010). Salivary alpha-amylase activity was measured as a possible indicator for 
pain during orthodontic treatment, the results showed no correlation between pain intensity 
during orthodontic treatment and salivary levels of alpha-amylase (Campos et al., 2011). 
An alternative study examined the salivary concentration of bone remodelling biomarkers 
such as deoxypyridinoline and bone-specific alkaline phosphatase during orthodontic 
treatment, the outcomes of this prospective follow up study indicated that although both of 
these biomarkers may indicate increased bone remodelling. It appears that only 
deoxypyridinoline increased in the earlier phases of OTM, whereas bone-specific alkaline 
phosphatase might act as an indicator of bone formation at the end of tooth movement 
(Flórez-Moreno et al., 2013b). 
A different research paper linked the salivary levels of soluble RANKL, OPG and 
RANKL/OPG ratio to the phases of orthodontic treatment and reported that their levels 
might assist clinically in the monitoring of orthodontic treatment (Flórez-Moreno et al., 
2013a). IL-1β, TNF-α, malondialdehyde, nitric oxide, and 8-hydroxydeoxyguanosine were 
investigated in saliva of patients with fixed orthodontic appliances before treatment, at 1st 
month and at 6th month of treatment. The findings showed that there were no significant 
changes in the levels of these analytes at any time point indicating that changes with OTM 
do not exceed the physiological limits of these analytes in saliva (Atuğ Özcan et al., 2014). 
The level of inflammation during orthodontic treatment was assessed by measuring MPO 
activity in saliva and GCF at baseline, 2 hours, 7 days and 14 days after the activation of 
orthodontic appliances. MPO activity increased until day seven with the highest activity 
was at 2 hours and values were reduced to baseline level at day 14 in the both GCF and 
saliva samples (Navarro-Palacios et al., 2014). 
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1.4.2.9 Salivary changes with obesity 
In recent years, it has been suggested that the determination of salivary adipokines may 
contribute to the elucidation of the physiology and role of adipokines not only in the 
development of obesity and insulin resistance, but also in inflammation, lack of energy 
balance or the stress response. For instance, a study mentioned a positive correlation 
between the salivary adiponectin concentrations with its circulating concentration of 
healthy individuals. However, the levels of salivary visfatin did not correlate with the 
concentration in serum (Mamali et al., 2012). Some reports indicated a significant increase 
in the concentration of salivary CRP  (a sensitive marker of systemic inflammation) in 
obese children than in children of normal weight (Naidoo et al., 2012, Goodson et al., 
2014). Similarly, correlation was also observed between serum and salivary uric acid, 
systolic and diastolic blood pressure, waist circumference, BMI, blood glucose, 
triglycerides, high-density lipoprotein and the number of cardiometabolic risk factors 
(Soukup et al., 2012). A reduced level of antioxidants was also observed in obese 
individuals not only in serum but also in saliva (Bhardwaj et al., 2008). 
Three times more bacterial cells were observed in the subgingival biofilm with six 
more bacterial species in the saliva of obese adolescents in comparison to normal weight 
(Zeigler et al., 2012). In the same field, another study evaluated the salivary conditions of 
morbidly obese patients prior and 6 months after bariatric surgery, finding that obese 
patients undergoing bariatric surgery presented with a higher microbiological level of 
mutans streptococci in saliva after 6 months (Hashizume et al., 2015). 
Some salivary parameters have been examined in stimulated saliva in relation to 
BMI such as pH, flow rate, buffer capacity, proteins concentration, phosphate, calcium, 
sialic acid and peroxidase activity. The authors suggested that overweight and obesity lead 
to increase in concentrations of sialic acid, protein, and reduce phosphorus as well as 
peroxidase activity which may promote dental caries (Pannunzio et al., 2010). 
In more elaborated investigations salivary flow rate has also been measured in 
relation to obesity. A low salivary flow rate was observed with childhood obesity (Modéer 
et al., 2010), with BMI>25 in adults less than 50 years old (Flink et al., 2008) and in 
morbidly obese (BMI>40) (Knaś et al., 2015) which further strengthens the negative 
influence of obesity on oral health. Conversely, other study reported comparable salivary 
pattern in obese and normal-weight individuals (Epstein et al., 1996). 
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1.5 Thesis aims and objectives 
Obesity is recognised as a low-grade systemic inflammatory disease, which modifies the 
host immune response, resulting in an increased risk of infections and a systemic pro-
inflammatory state. In oral health, there is a close relationship between obesity and 
periodontitis due to the exacerbated pro-inflammatory changes that take place in 
periodontal disease. Since orthodontic treatment mainly depends on tissue and bone 
remodelling within the periodontium, obesity can potentially affect orthodontic therapy; in 
particular, through pro-inflammatory changes within the PDL space that could have an 
impact on tissue remodelling within the PDL. 
During OTM teeth are exposed to mechanical stimuli that alter the vascularity of 
periodontal tissue and blood flow, leading to local synthesis and release of different 
biological molecules (biomarkers). The sequence of biological mechanisms that control the 
shift from stimulus (orthodontic force) to reaction (tooth movement) can be monitored and 
evaluated in relation to higher or lower levels of relevant biomarkers. Therefore, 
biochemical analysis is a useful and promising method to monitor the changes during a 
certain period and to investigate the response of dental and paradental tissues to OTM. 
There is some evidence of variation in the levels of biomarkers in obese and 
normal-weight individuals with periodontal disease; however, data relating to biomarkers 
within this population during OTM is sparse. Although some retrospective studies have 
found that obesity can affect orthodontic therapy potentially through its effect on bone 
metabolism, growth and development, currently no study exists to investigate OTM in 
obese patients, from either a clinical or biochemical perspective. 
In humans, different biological samples have been used to monitor periodontal 
disease progression such as saliva, GCF, plaque biofilm and blood. Biomarker analyses 
during initial OTM needs to be investigated in GCF samples, as it is non-invasive and 
closely positioned to the periodontium where tissue and bone remodelling takes place. 
However, the components of GCF consequently pass to saliva, which is easier, less 
invasive and less expensive to collect and analyse. We are interested in studying OTM in 
association with obesity, and therefore serum samples also need to be analysed. The 
rationale behind this is that adipokines, are mainly produced by adipocytes and secreted in 
blood as the first transporter. Therefore in this study, three different samples, namely 
UWMS, GCF and serum, were used to assess the levels of the selected biomarkers. 
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The main aim of this investigation was to examine the influence of obesity on OTM 
in adolescent subjects at both the clinical and biochemical levels. 
In order to achieve this aim the following objectives were undertaken: 
1- Measure the effects of obesity on biochemical changes in UWMS, GCF and serum 
of humans with and without orthodontic treatment; 
2- Measure rate of OTM and time taken to achieve completion of tooth alignment 
using fixed orthodontic appliances in a cohort of normal weight and obese patients; 
3- Biochemical analysis of inflammation, tissue remodelling, bone metabolism and 
obesity-related biomarkers in different bio-fluids (UWMS, GCF and serum) of 
normal weight and obese subjects to assess which fluid is more representative for 
biological changes seen during OTM; and 
4- Measure pain experience and analgesic intake during initial alignment with fixed 
orthodontic appliances in normal weight and obese patients. 
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Chapter 2 Participants and methods 
2.1 Ethical approval 
This study was approved by the Human Research Ethics Committee of King's College 
London (BDM/14/15-8, November 2014), and the United Kingdom National Research 
Ethics Service, NRES Committee foundation (14/LO/0769, October 2014). Informed 
written consent was obtained from all participants. 
2.2 Body mass index measurement 
In order to classify the participants into normal weight and obese, BMI was measured as 
follow: 
2.2.1 Body mass index for adults 
Height and weight of participants were measured to calculate BMI as weight in kilogram 
divided by square height in meter (kg/m
2
). The body weight of subjects was measured to 
the nearest 0.1 kilogram (kg) using a calibrated scale and height was measured to the 
nearest centimetre (cm) using a wall-mounted ruler. According to WHO, BMI classified as 
<18.5 underweight, 18.5-24.9 healthy (normal weight), 25-29.9 overweight, 30-39.9 obese, 
≥40 morbidly obese. Participants who were classified as underweight and overweight were 
excluded from the study. 
2.2.2 Body mass index for growing subjects 
Height and weight of participants were measured to calculate BMI (kg/m
2
) similar to adults 
by measuring the body weight to the nearest 0.1 kilogram (kg), using a calibrated scale and 
the height to the nearest centimetre (cm) using a wall-mounted ruler. The Royal College of 
Paediatrics and Child Health (RCPCH) UK WHO growth charts (2013) were used to 
calculate and classify BMI centile in relation to age and sex (Appendices 1 and 2). 
Accordingly, subjects were classified as underweight (BMI centile <2), normal weight 
(BMI centile 2-91), overweight (BMI centile 91-98) and obese or morbidly obese (BMI 
Chapter Two  Materials and method 
87 
 
centile >98). Subjects who were classified as underweight and overweight were excluded 
from the study. 
2.3 Periodontal health 
In order to adjust the possible interactions of bacterial plaque and gingival inflammation on 
the concentrations of biomarkers, the periodontal health was measured using established 
and validated gingival (Löe and Silness, 1963) and plaque (Silness and Löe, 1964) indices, 
which are characterised as follow: 
2.3.1 Dental plaque 
Dental plaque thickness adjacent to gingival margin was assessed following the criteria of 
(Silness and Löe, 1964), while Ramfjörd index teeth were examined to represent the whole 
dentition (Ramfjord, 1959). In this study, four surfaces of each tooth were examined and 
these included mesial, buccal, distal and lingual surfaces according to the criteria for plaque 
index as: 
0: No plaque 
1: A film of plaque adheres to the free gingival margin and adjacent area of the tooth. The 
plaque may be seen in situ only after application of disclosing solution or by using probe on 
the tooth surface. 
2: Moderate accumulation of soft despites within the gingival pocket, or the tooth and the 
gingival margin, which can be seen with the naked eye. 
3: An abundance of soft matter within the gingival pocket and/or the tooth and gingival 
margin. 
2.3.2 Gingival health 
For the diagnosis and assessment of gingival health a validated gingival index has been 
described (Löe and Silness, 1963). The four surfaces of Ramfjörd index teeth were 
examined to represent the whole mouth as that done for dental plaque measurement 
(Ramfjord, 1959). The criteria for gingival index as: 
0: Absence of inflammation / normal gingiva. 
1: Mild inflammation: slight change in colour, slight oedema, no bleeding on probing. 
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2: Moderate inflammation: moderate glazing, redness, oedema, and hyperatrophy, bleeding 
on probing. 
3: Severe inflammation: marked redness and hyperatrophic ulceration, tendency to 
spontaneous bleeding. 
2.4 Participants and sample collection 
Three groups of participants were recruited as follows: 
1) Normal weight (BMI = 18.5-25) and obese (BMI ≥ 30) adult participants without 
orthodontic treatment (control cohort), with a minimum age of 18 years and a maximum 
age of 45 years were purposively recruited with a matched age and gender from 
students and researchers from King’s College London Dental Institute (Guy’s Hospital). 
They have clinically acceptable gingival health, no artificial prosthesis or orthodontic 
appliance or retainers, no history of illness or the taking of medication within the 
previous 3 months, were not pregnant and non- smokers; 
2) Normal weight (BMI = 18.5-25) and obese (BMI ≥ 30) adult patients undergoing fixed 
appliance orthodontic treatment with 0.019 x 0.025-inch stainless steel rectangular 
archwires in the upper and lower arches with a minimum age of 18 years and a 
maximum age of 45 years were purposively recruited with a matched age and gender 
from patients attending for routine fixed-appliance treatment at King’s College London 
Dental Institute (Guy’s Hospital). They have no history of illness or the taking of 
medication within the previous 3 months, were not pregnant and non- smokers; and 
3) Normal weight (BMI centile= 2-91) and obese (BMI centile ≥ 98) adolescent patients 
with a minimum age of 12 years and a maximum age of 18 years were purposively 
recruited with a matched age and gender from patients attending for routine fixed-
appliance treatment at King’s College London Dental Institute (Guy’s Hospital). They 
have permanent dentition; mandibular arch incisor irregularity index of 4-12 mm, need 
fixed orthodontic appliance treatment with or without teeth extraction, no medical 
contraindications or regular medication (including antibiotic-therapy in previous 3 
months); and non-smokers. 
From each individual the following samples were collected during the day between the 
hours 9:30 am to 3:30 pm: 
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1) UWMS was collected by asking the subject to passively drool in a pre-weighed sterile 
plastic tube for 5 minutes. The sample was put in an icebox containing ice after 
collection and carried to the laboratory where it processed and stored. The processing 
procedure of the collected saliva started with weighing the tubes with the sample again 
(to get the net saliva volume), vortexing them for 20-30 seconds and centrifuging the 
samples at 9200 g for 5 minutes. The processed saliva was aliquoted into small 
Eppendorf Tubes® (1000 μl capacity), labelled and stored at – 80 °C in freezers until 
the time for analysis. 
2) Samples of GCF were collected using Periostrip (OraFlow Inc. New York, USA), from 
the distal side of the lower incisors and canines because the rate of alignment of these 
teeth was measured using Little’s Irregularity Index. Plaque was removed gently by a 
strip of cotton held in tweezers, the teeth were dried and the surrounding area isolated 
with cotton-wool rolls. Periostrip was placed 1 mm sub-gingivally into the gingival 
crevice for 30 seconds (Figure 2.1). If there was any contamination of the strip with 
saliva or blood it was discarded. Each strip was placed in an individual Eppendorf 
Tubes® (500 μl capacity, Alpha Laboratories, UK) and immediately transferred to an 
icebox containing ice. Then the collected samples were carried to the laboratory where 
they were processed and stored. The processing procedure of GCF started with 
measuring the volume of the collected GCF by placing the strip between the upper and 
lower counterparts of the Periotron 8000 electronic micro-moisture meter (OraFlow 
Inc. New York, USA) (Figure 2.2), with readings converted to an actual volume by 
reference to the standard curve and measured the diluting factors of the collected GCF. 
Proteins in the Periopaper were eluted with 20 µl phosphate buffered saline (PBS) for 
each strip, centrifuged at 9200 g for 5 minutes while the handle of the strip was secured 
under the lid. Then the eluted GCF was aspirated from all Eppendorf tubes, pooled, 
aliquoted into small Eppendorf Tubes® (500 μl capacity, Alpha Laboratories, UK), 
labelled and stored at – 80 °C in freezers until the time for analysis. 
3) Peripheral blood was collected by finger pinprick using a disposable sterile needle 
(ACCU-CHEK, Safe-pro, Germany). A few droplets of blood were collected with a 3-
4 sterile Sialostrips (OraFlow Inc. New York, USA). Each strip placed in individual 
Eppendorf Tube® (500 μl capacity, Alpha Laboratories, UK) and transferred to icebox 
containing ice immediately. The samples were carried to the laboratory, processed and 
the volume and diluting factor were measured in the same way mentioned for GCF, but 
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each strip was eluted using 100 µl PBS and centrifuged at 5900 g for 5 minutes to 
separate the blood.Then, the supernatant serum was aspirated from all Eppendorf tubes, 
pooled, aliquoted into small Eppendorf Tubes® (500 μl capacity, Alpha Laboratories, 
UK), labelled and stored at – 80 °C in freezers until the time for analysis. 
 
 
Figure 2.1 Gingival crevicular fluid collections. 
 
 
Figure 2.2 Periotron 8000 used for the measurement of GCF and blood volume. Periotron was cleaned and 
dried after each sample. 
 
2.5 Stimulated parotid saliva collection 
Stimulated parotid saliva was collected using a parotid saliva collector (lashley cup, King’s 
Medical Science, UK), Tygon tubing (10.2 cm for the collecting tube from the inner circle 
of the parotid saliva collector, and 30.5 - 40.6 cm to connect the parotid collector to 
syringe) and 3 ml Luer-lock syringe attached to a blunt cannula. 
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The orifice of the parotid duct is located on the buccal mucosa opposite the upper 
second molar tooth. The area was dried and the parotid collector was placed on the mucosa 
so that the inner ring surrounded the duct orifice. The collector is held on the mucosa by 
suction from the outer ring, created by pulling back on the syringe and allowing the 
pressure to come to equilibrium. A medium binder clip is attached to the Tygon tubing 
going from the collector to the syringe to ―lock-in‖ the air in the tubing. 
The suction created should be sufficient enough to hold the cup in its place without 
occluding the inner chamber of the parotid collector with tissue (not too much suction). 
Stimulation is performed by applying 2% citric acid solution to the posterior lateral 
surfaces of the tongue, bilaterally, using 2 drops every 30 seconds to stimulate secretion. 
Saliva from the parotid gland then flows passively into the inner ring and through the 
attached tubing. The flowing saliva then collected into an ice-cooled pre-weighed and pre-
labelled container. 
2.6 Flow rate 
As the salivary and GCF flow rate can be influenced by the inflammation and mechanical 
stimulation, the UWMS and GCF flow rates were measured to adjust the possible 
interaction with the concentration of biomarkers. 
2.6.1 UWMS flow rate 
The measurement of UWMS flow rate was performed by weighing the tubes with the 
sample and subscribed from the original weight of tubes before sample collection to get the 
net saliva weight in gram. Then the net weight divided by the duration of sample collection 
(5 minutes) to measure the salivary flow rate per minute (ml/min). 
2.6.2 GCF flow rate 
GCF flow rate calculation was started by measuring the volume of the collected GCF from 
all strips using the Periotron, with readings converted to an actual volume by reference to 
the standard curve. 
 Since GCF was collected for 30 seconds, the total volume multiplied by 2 to get the 
volume per minute, and then divided by the number of the selected teeth in order to 
calculate the GCF flow rate for a tooth per minute. 
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2.7 Total protein concentration 
Total protein concentration of sample was measured in UWMS, eluted GCF and eluted 
serum using the NanoDrop (software V3.5.2, Thermo Fisher Scientific, UK). The 
Nanodrop was calibrated with 2 µl of nuclease free water. Then 2 µl from each sample was 
applied to the Nanodrop and protein concentration was measured at 280 nm with setting 1 
Abs=1 mg/ml. Triplicate measurements were made for each sample and the mean average 
was calculated. 
2.8 Sample preparation and electrophoresis 
All samples were prepared under reducing conditions with 5% NuPage lithium dodecyl 
sulphate sample buffer (LDS, Invitrogen, Thermo Fisher Scientific, UK), 10% 0.5 M 
dithiothreitol (DTT) and heated for 3 minutes at 100 °C. The samples were either stored at - 
20 °C or used for analysis immediately. 
Samples were analysed for protein content using sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE). 10 µl of samples and 5 µl of SeeBlue 
Plus Pre-stained marker (Invitrogen, Thermo Fisher Scientific, UK) were loaded into pre-
cast NuPage Novex, 4-12% Bis Tris gel (Novex, Life Technologies, UK). 
These gels were set up in an Xcell vertical electrophoresis unit (Invitrogen, Thermo 
Fisher Scientific, UK) with 25 ml NuPage MES SDS running buffer (Invitrogen, Thermo 
Fisher Scientific, UK) and 475 ml distilled water and electrophoresed for 35 minutes at 125 
mA and 200 volts constant. 
In order to detect proteins in the loaded samples, gels were stained once using Silver 
stain, Coomassie Brilliant Blue stain and Periodate Schiff stain (PAS). 
2.9 Immuno-detection of proteins 
Electrophoretic transfer of protein (Western blot) from SDS-PAGE gels to nitrocellulose 
membranes (Whatman Protan; Dassel, Germany) was carried out for the detection of 
specific proteins. 
For Western blotting, a nitrocellulose membrane was placed on top of the SDS-
PAGE gel and sandwiched between filter paper and sponge saturated and packed with 
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NuPage Transfer Buffer of 25 ml NuPage transfer buffer (Invitrogen, Thermo Fisher 
Scientific, UK), 50 ml methanol and 425 ml double distilled water. 
The sandwich was secured in an Xcell vertical electrophoresis unit (Invitrogen, 
Thermo Fisher Scientific, UK) and filled with the remaining transfer buffer. Transfer was 
carried out at 30 volts constant and 150 mA for 60 minutes. At the end of the transfer, the 
gel was discarded and the membrane placed (contact side up) in a clean disposable tray for 
protein detection. 
For immunoblotting, the membrane was blocked with Tris Buffered Saline with 
Tween (TBST) solution for 1 hour with gentile agitation on a rocker. The primary antibody, 
with specific dilution, was added to the membrane in the TBST for 1 hour with gentle 
agitation. The membrane was washed with TBST 3 times, 5 minutes each, then incubated 
with a secondary antibody diluted 1:2000 with TBST for 1 hour with gentle agitation. The 
solution discarded and the membrane washed as previously described. Antibody signal was 
detected using chemiluminescent substrates (Immun-Star Western C, Bio-Rad Laboratories, 
Inc, UK). The detection signal was visualized using the chemi Doc 
TM
 Imaging system 
(BioRad) laboratories ltd, Herts, UK. 
2.10 Zymography 
For more specific detection of MMPs, samples were also analysed for gelatinase using 10% 
zymogram gelatin gels electrophoresis of Novex, Life Technologies, UK. Using X-cell 
vertical electrophoresis unit with 1X Tris-Glycine SDS running buffer (Novex, Life 
Technologies, UK) (100 ml 10X Tris-Glycine SDS running buffer to 900 ml deionized 
water). 5 µl of samples and 5 µl of Tris-Glycine SDS sample buffer (2X) (Novex, Life 
Technologies, UK) was loaded per well and electrophoresed for 90 minutes at 30 - 40 mA 
and 125 volts constant. 
Samples were denatured in SDS buffer under non-reducing conditions and without 
heating, run on a Novex®Zymogram gel (Novex, Life Technologies, UK) using Tris-
Glycine SDS Running Buffer (2X). After electrophoresis, the enzyme was re-natured by 
incubating the gel in (1X) zymogram re-naturing buffer (Novex, Life Technologies, UK), 
for 30 minutes. The gels were then equilibrated in (1X) zymogram developing buffer 
(Novex, Life Technologies, UK) for another 30 minutes. 
Chapter Two  Materials and method 
94 
 
The equilibrated gel was incubated in fresh zymogram developing buffer overnight 
for maximum sensitivity and then stained with Coomassie blue stain, and de-stained. 
Regions of gelatinase activity appeared as clear bands against a dark blue background 
where the gelatinase has digested the substrate. 
2.11 Mass spectrometry identification of proteins 
(proteomics) 
In order to identify the positively detected proteins in the gel, mass spectrometry was 
performed. 
Under heating and reducing conditions, purified adiponectin standard (Recombinant 
human adiponectin (NSO-derived)/Acrop30, CF, R&D systems-Bio-Techne, UK), UWMS, 
eluted GCF and eluted serum were loaded in the same gel twice. After electrophoresis, 
proteins in one half of gel were transferred to nitrocellulose membrane by Western blot for 
detection of adiponectin by immunoblotting. Proteins of interest were identified by 
immunoblotting then cut from the second half and sent for proteomic analysis at the Centre 
of Excellence for Mass Spectrometry, King's College London, to detect the proteins by a 
specialist technician. 
The desired sections were then reduced, alkylated and subsequently digested with 
trypsin (Promega, Madison,WI, USA) at 37 
o
C for 2 hours then overnight at room 
temperature. The reaction was stopped by formic acid. Digests (peptides) were extracted, 
desalted and cleaned up then separated, eluted and ionised using Reverse phase- High-
Performance Liquid Chromatography RP-HPLC. Ionised molecules (precursors and 
fragmented) were measured (scanned) using MS detector (scan). All LC-MS/MS data were 
searched using the MASCOT database search engine (Matrix Science, London, UK) 
against human Swis-sprot protein database (uniprot sprot 130220 database) to obtain 
peptide and protein identifications. MASCOT results were imported into Scaffold version 4 
(Proteome Software, Portland, OR, USA) and viewed. 
2.12 Enzyme-linked-immuno-sorbant assay 
In order to measure the concentration of specific protein (adiponectin), enzyme-linked-
immuno-sorbant assay (ELISA) was performed. The wells of 96-well microtitre plate 
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(Thermo Scientific, UK) were coated overnight at 4 
o
C with 100 µl of unconjugated capture 
antibody (mouse monoclonal IgG purified, R&D systems-Bio-Techne, UK) diluted to 
1:2000 in pH 9.6 sodium carbonate buffer (0.1 M). The wells were washed 3 times with 
phosphate buffer saline and 0.1% Tween 20 (PBS-T).  200 µl of the standard (1 µg/ml of 
recombinant human adiponectin (NSO-derived)/Acrop30, CF, R&D systems-Bio-Techne, 
UK) was added in duplicates of 2-fold serial dilutions. 100 µl of UWMS, GCF and the 
serum of 20 volunteers was added in duplicates. 
After 1 hour incubation at 37 
o
C, the plate was washed 3 times with PBS-T. A 1:500 
dilution of the detecting antibody (biotinylated mouse monoclonal IgG, R&D systems-Bio-
Techne, UK) was incubated on the plate for 1 hour at 37 
o
C. Following a third wash with 
PBS-T, 100 µl of horseradish peroxidase streptavidin (Vector laboratories, USA) was 
added for all wells and incubated at 37 
o
C for 1 hour followed by 3 times washing with 
PBS-T. 100 µl of substrate solution contained 250 µl of 3, 3’, 5, 5’ tetramethylbenzidene 
stock solution (3 mg/ml in DMSO) and 3 µl hydrogen peroxide in 20 mls of sodium acetate 
buffer (100 mM, pH 5.5) was added. The reaction was stopped after colour changing by the 
addition of 50 µl of 2 M sulphuric acid and the absorbance at 450 nm read in a microplate 
reader (Bio-Rad, iMark, UK). The data were exported to an Excel spreadsheet and 
multiplied by a diluting factor to get the final values for statistical analysis. 
2.13 Detection and quantification of biomarkers by 
magnetic Luminex multiplex assay 
In order to measure the concentrations of many proteins in the same small volume of 
sample, especially GCF because of its limited volume, magnetic Luminex screening assays 
(R&D systems-Bio-Techne, Abingdon, UK) were carried out for 3 types of sample 
according to the manufacturer’s instructions. Specific antibodies are pre-coated onto 
colour-coded magnetic microparticles. The microparticles, standards and samples were all 
pipetted into wells and the immobilized antibodies bind the protein of interest. The plate 
was washed to remove any unbound substance and a biotinylated antibody cocktail specific 
to the protein of interest was added. After another wash, streptavidin-phycoerythrin 
conjugate (SA-PE) was added to each well, which bound to the biotinylated antibody. 
Measurements were made using Bio-Plex Manager 
TM
 6.1 software of a Luminex machine 
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(Bio-Plex 200 system with HTF, Bio-Rad Laboratories Ltd, UK). The magnitude of the 
phycoerythrin-derived signal, which is proportional to the amount of the analyte bound, 
was analyzed using Bioplex Manager 6.0. Table 2.1 demonstrates the upper and lower 
detection values for the selected biomarkers. The data were exported to an Excel 
spreadsheet and multiplied by diluting factor to get the final values for statistical analysis 
(Figure 2.3). 
 
Table 2.1 Limits of detection for biomarker Luminex analysis. 
Biomarker * Lower limit of 
detection (pg/ml) 
Upper limit of 
detection (pg/ml) 
Coefficient of variation 
† (%) 
Adiponectin 193.74 432390.10 2.4 
Leptin 55.15 111251.22 3.0 
Resistin 4.83 9709.28 1.8 
MMP8 25.45 53522.68 2.3 
MMP9 20.03 41870.79 2.8 
TIMP1 7.91 17479.14 2.1 
MPO 16.31 34627.04 2.8 
CRP 17.29 38785.30 2.4 
RANKL 5.14 10509.81 2.3 
* all manufactured by R&D Systems. MMP8, matrix metalloproteinase-8; MMP9, matrix metalloproteinase-
9; TIMP1, tissue inhibitor of metalloproteinase 1; MPO, myeloperoxidase; CRP, C reactive protein; RANKL, 
receptor activator of nuclear factor kappa-B ligand 
† mean coefficient of variation was calculated by measuring the same standard on 10 plates and dividing the 
standard deviation by the average value (*100) 
 
 
Figure 2.3 Principle of Luminex multiplex assay. Adapted from (Fuerstenberg et al., 2014). 
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Chapter 3 Biomarker detection in different 
bio-fluids 
3.1 Introduction 
Earlier trials have been conducted to investigate biochemical markers of periodontal 
disease using combined saliva biomarkers and periodontal biofilm pathogens for the 
prediction and diagnosis of periodontal diseases (Ramseier et al., 2009, Kinney et al., 
2011). More recently, it has been reported that saliva biomarkers are best for disease 
sensitivity, whereas the greatest disease specificity is found with GCF biomarkers. 
In contrast, serum biomarkers do not show a significant role (Kinney et al., 2014). 
These findings were confirmed by Becerik et al. (2012) who reported that plasma cytokines 
unlike GCF cytokines are not related to inflammatory levels of periodontal disease. 
It has been suggested that biomarker analysis throughout OTM and its association 
with obesity may need to be investigated in serum and GCF. The rationale behind the 
former is that some hormones, such as adiponectin and leptin are mainly produced by 
adipocytes and secreted in blood as the first transporter and investigated in serum (Saito et 
al., 2008, Furugen et al., 2008, Yamaguchi et al., 2010). Whilst the justification for GCF is 
that during OTM the supra-crestal gingival fibres are not totally destroyed, they are 
compressed or retracted to maintain PDL health during OTM (Redlich et al., 1996) and this 
will restrict the immediate movement of mediators through the gingival margin into the oral 
cavity (Junior et al., 2011). However, the components of GCF consequently pass to saliva, 
which is easier, less invasive and less expensive to collect and analyse. From the above 
information, in this study, the three different samples namely UWMS, GCF and serum, will 
be used to assess the levels of biomarkers. 
3.1.1 Aims of the study 
The specific aims of this preliminary study were: 
1- Optimising the collection and processing of UWMS, GCF and serum; and 
2-  Detection of some biomarkers in the collected sample. 
Chapter Three  Biomarker detection in different bio-fluids 
98 
 
3.2 Optimisation of biomarker investigating techniques 
3.2.1 Sample preparation 
Sample collection including UWMS, GCF and serum was performed as described in 
Section 2.4. Total protein concentration was measured in UWMS, GCF and serum using 
NanoDrop (software V3.5.2) as described in Section 2.7. Sample preparation, 
electrophoresis and immuno-detection of proteins were performed as described in Sections 
2.8 and 2.9. 
3.2.2 Standard curve calibration 
The reliability of the Periotron 8000 was tested using a known volume of nuclease free 
water applied to Periopapers and Sialostrips used for GCF and blood collection, 
respectively. This calibration was repeated twice and the Periotron readings were calculated 
and used to generate a calibration curves using polynomial regression formula Y= 
0.0001X
2
 – 0.0053X for Periopapers (Figure 3.1) and Y= 0.0001X2 – 0.0006X for 
Sialostrips, where X is the Periotron reading and Y is the volume in microliters (µl) (Figure 
3.2). 




Figure 3.1 The standard curve for Periotron 8000 using Periopaper. 
X = Periotron readings; Y = Volume in microliters (µl) 
 
 
Figure 3.2 The standard curve for Periotron 8000 using Sialostrip. 
X = Periotron readings; Y = Volume in microliters (µl) 
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3.2.3 Centrifuging speed and time 
The Periopapers and Sialostrips used to collect GCF and blood respectively were subjected 
to breakdown with centrifuging. Different centrifuge speeds and times were performed to 
optimise sample recovery. 
GCF was eluted from Periopaper with 20 µl PBS, 1 µl was added to 60 Periopapers 
placed individually in the tubes, and divided into 4 groups of 15 according to the speed 
used (16300, 9200, 5900, 2300) g. Each group was subdivided into 3 subgroups according 
to the time used (5, 10, 15) minutes, as shown in Table 3.1. Some of the Periopapers were 
destroyed at 16300g at 3 tested times (5, 10 and 15) minutes. However, papers remained 
intact and were dry, when centrifuging at 9200 g for 5 and 10 minutes. Some papers broke 
down at 15 minutes. Moreover, intact Periopapers were obtained at 5 and 10 minutes 
centrifuging with 5900 g and at all times with 2300 g centrifuging, but these strips 
remained wet suggesting the sample may not have been fully eluted. Therefore, the optimal 
elution condition for Periopapers was centrifuging at 9200 g for 5 minutes. 
The Sialostrips used to collect blood were also tested under the same conditions. 
Blood collected on the strip was eluted with 100µl PBS. The results in Table 3.2 show 
strips remained intact and almost dry when centrifuging for 5 minutes at 5900g. Higher 
speeds resulted in breaking down at all-time points. The strips remained wet at lower speed. 
Therefore, the optimal elution condition for Sialostrips was centrifugation at 5900g for 5 
minutes. 
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Table 3.1 Optimising centrifuging time and speed for the collected GCF using Periopaper. Each strip was 
eluted with 20µl PBS. 
No Centrifuging Speed (g) 
Centrifuging time 
(minutes) 
Number of broken 
papers 
(out of 5 papers used) 
1 16300 5 1 
2 16300 10 1 
3 16300 15 2 
4 9200 5 0 
5 9200 10 0 
6 9200 15 2 
7 5900 5 0 * 
8 5900 10 0 * 
9 5900 15 1 
10 2300 5 0 * 
11 2300 10 0 * 
12 2300 15 0 * 
*Wet strip 
 
Table 3.2 Optimising centrifuging time and speed for blood collection using Sialostrip. Each strip was eluted 
with 100µl PBS. 
No Centrifuging Speed (g) 
Centrifuging time 
(minutes) 
Number of broken 
strips 
(out of 5 strips used) 
1 16300 5 1 
2 16300 10 2 
3 16300 15 3 
4 9200 5 1 
5 9200 10 1 
6 9200 15 2 
7 5900 5 0 
8 5900 10 1 
9 5900 15 1 
10 2300 5 0 * 
11 2300 5 0 * 
12 2300 10 0 * 
*Wet strip 
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3.2.4 Identification of proteins 
After loading 10 µl of UWMS, eluted GCF and eluted serum with equal amounts of total 
protein (3.9 µg) to SDS-PAGE gel electrophoresis, different stains such as Silver Stain, 
Coomassie Blue Stain and Periodate Schiff Stain (PAS) were used to identify different 
proteins in the samples. Some proteins are specifically noticed in one fluid, others are 
clearly diffused from serum to saliva (Figure 3.3). 
 
 
Figure 3.3 SDS-PAGE gels represent the total protein in different bio-fluids. 10 µl of Unstimulated whole 
mouth saliva (S), gingival crevicular fluid (G) and serum (B) with different stains; PAS, Periodate Schiff stain 
M, molecular weight marker. 
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3.2.2 Detection of biomarkers 
Certain biomarkers have been selected to optimise the proper collection of GCF, such as 
amylase; the diffusion of protein from serum to saliva via GCF, such as albumin; and the 
origin of others such as MMP9 and adiponectin. 
3.2.2.1 Amylase enzyme 
Saliva alpha amylase enzyme is entirely of salivary gland origin; around 80% of it is 
secreted by the parotid glands and the remainder by submandibular glands (Helmerhorst, 
2012). Therefore, in the current study, it was used as a control to check the validity of GCF 
sample collection without saliva contamination. A total of 10 µl of UWMS and eluted 
GCF, with an equal amount of total protein (2.25 µg) was applied to SDS–PAGE gel. 
Proteins were transferred onto a nitrocellulose membrane by Western blot and 
immunoblotting. A sheep polyclonal amylase antibody (Abcam, UK) was used at a dilution 
of 1:1000 and 1:2000. Amylase was present in UWMS at both antibody dilutions and 




Figure 3.4 Immunodetection of amylase different bio-fluid. Unstimulated whole mouth saliva (S) and 
gingival crevicular fluid (G); 1:1000, 1:2000: The dilutions of primary antibody; M, molecular weight marker. 




Albumin is abundant in serum; its level increases in GCF during inflammation as a result of 
increased vascular permeability (Giannopoulou et al., 1990) and to lesser extent due to an 
increased number of macrophages (White et al., 1980) and lymphocytes (Tunstall and 
James, 1974) during inflammation. 10 µl of UWMS, eluted GCF and eluted serum with an 
equal amount of total protein (4.8 µg) were loaded to SDS-PAGE gel. Proteins were 
transferred onto a nitrocellulose membrane by Western blot and immunoblotting. Primary 
monoclonal anti-albumin antibody produced in mouse, 1:1000 dilution, was used and 
showed an intensive binding. More dilution of primary antibody to (1:10000) showed less 
bands in comparison to (1:1000) but multiple bands have also been seen. Further dilution of 
samples by loading 3 µl of UWMS (0.007 µg) to 7 µl distilled water, 2 µl of eluted GCF 
(0.003 µg) to 8 µl distilled water and 1 µl eluted serum (0.0014 µg) to 9 µl distilled water. 
Half amount (5 µl) of each sample was loaded in the SDS-PAGE gel and showed single 
albumin band at the same molecular weight indicated that blood is the origin of salivary 
albumin through GCF (Figure 3.5). 
 
 
Figure 3.5 Immunodetection of albumin in different bio-fluids. Unstimulated whole mouth saliva (S), 
gingival crevicular fluid (G) and serum (B); 1:1000, 1:10000: The dilutions of primary antibody; M, 
molecular weight marker. 
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3.2.2.3 Marix Metalloproteinase 9 (MMP9) 
MMPs are a family of enzymes which play a vital role in PDL remodelling (Stamenkovic, 
2003). A number of studies have reported an alteration of MMP quantity in human GCF as 
a consequence of applied orthodontic forces (Apajalahti et al., 2003, Cantarella et al., 
2006). Others stated that the alteration in their GCF levels resulted either from biological 
changes within the gingival tissue (Junior et al., 2011) or in deeper periodontal tissues 
(Mogi et al., 2004). MMP9 is a member of this family, 10 µl of UWMS, eluted GCF and 
eluted serum samples at 3.0 µg total protein, were loaded in SDS-PAGE gel. Antihuman 
MMP9 primary antibody from goat (R&D Systems, Bio-Techne, UK) was used at 1:1000 
dilutions. MMP9 was seen in GCF sample only. This has been confirmed by using (0.005, 
0.01, 0.02 µg) standard Western blot. Control experiment also has been performed using 
only anti-goat secondary antibody (AbD Serotec), 1:2000 dilution, showed no MMP9 in all 
samples. In the conducted experiment, the immunoblotting of MMP9 showed a single band 
in GCF, but not in saliva or serum samples which recommend the local origin of MMP9 in 
the gingival sulcus (Figure 3.6). 
 
 
Figure 3.6 Immunodetecion of MMP9 in different bio-fluids. Unstimulated whole mouth saliva (S), gingival 
crevicular fluid (G) and serum (B); 1:1000: Dilution of primary antibody; M, molecular weight marker; SWB: 
standard western blot purified protein (0.02 µg, 0.01 µg, 0.005 µg). Control means only secondary antibody 
was used without primary antibody. 




Adiponectin is an abundant serum protein, produced by adipocytes and demonstrates 
multiple functions by targeting different types of cells. It may exert many effects on obesity 
and related diseases (Turer and Scherer, 2012), therefore it is speculated that it can be 
affected by orthodontic treatment of obese patients.10 µl of UWMS, eluted GCF and eluted 
serum with an equal amount of total protein (4.0 µg) were applied to a SDS-PAGE gel. 
Proteins were transferred onto a nitrocellulose membrane by Western blot and 
immunoblotting. Anti-adiponectin primary antibody produced in rabbit (sigma, UK) at 
dilution 1:2000 was applied. Adiponectin present in serum sample around 30 kDa, smaller 
adiponectin protein band was also found at higher molecular weight. In UWMS band was 
seen at molecular weight 49-62 kDa. However, it was absent in GCF. Moreover, no 
adiponectin protein was found in control blots using only anti rabbit secondary antibody at 
dilution 1:2000 (Dako, UK) (Figure 3.7). 
A single band in UWMS was seen at a different molecular weight than those in 
serum. Thus further investigation is required to explore this protein and its activity. 
 
 
Figure 3.7 Immunodetection of adiponectin in different bio-fluids. Unstimulated whole mouth saliva (S), 
gingival crevicular fluid (G) and serum (B). Control means only secondary antibody was used without 
primary antibody; M, molecular weight marker. 
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3.3 The origin of salivary adiponectin 
3.3.1 Background 
Adiponectin is a protein produced and secreted mainly by adipocytes; it exists as a full-
length protein and/or globular adiponectin. This cleavage is mediated by a leukocyte 
elastase, secreted by activated monocytes and/or neutrophils (Tilg and Moschen, 2006). It 
has multiple biological activities that are mediated by its three receptors, AdipoR1, 
AdipoR2 and T-cadherin. 
Currently, adiponectin is predominantly detected in blood samples. A few studies 
have investigated adiponectin levels in saliva as an easier and non-invasive sampling route 
that would be useful for assessing adiponectin in many clinical studies; however the results 
of these studies are confusing. One study found increases in saliva levels of adiponectin 
when samples were diluted. The authors explained these findings by suggesting that there 
are potentially assay inhibitory factors in saliva that may be prone to greater dilution effects 
than the adiponectin protein. Thus, dilution of saliva results in an apparent increase in 
adiponectin as the inhibitory factors cease to be effective at a greater rate (Akuailou et al., 
2013). 
Another study observed the band pattern of adiponectin in human serum and saliva 
by Western immunoblotting under non-reducing conditions. They found two bands in 
serum (medium molecular band at 150 kDa and higher molecular weight band at 250 kDa), 
whereas, only one band in saliva which was detected - above the higher molecular band that 
seen in serum - called super higher molecular band (Lin et al., 2014). Furthermore, most of 
the conducted studies mentioned a very low level of adiponectin in human saliva relative to 
plasma (Toda et al., 2007, Toda and Morimoto, 2008, Akuailou et al., 2013); however, the 
nature and precise forms of adiponectin in human saliva are not well understood. 
3.3.1.1 Aims and objectives 
The main aim of the present study was to verify the origin of adiponectin in saliva. 
In order to address this aim the following steps were undertaken: 
1- Detection of adiponectin using different assays such as Western blot and 
immunoblotting, ELISA and magnetic Luminex multiplex array assay; and 
2- Mass spectrometry (proteomics) to identify the proteins.  
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This study hypothesized that adiponectin can be detected in saliva and this is derived 
from the circulation. 
3.3.2 Methods 
The study was approved by the Human Research Ethics Committee of King's College 
London (BDM/14/15-8, November 2014). Informed written consent was obtained from all 
participants. 
3.3.2.1 Participants and sampling 
The participants in this study were recruited as mentioned in Section 2.4 number 1, 
including 20 normal body weight (BMI = 18.5-25) healthy adult volunteers (10 males and 
10 females) with a mean age of 29 years (SD=7.1) ranged between 19-44 years. 
From each participant UWMS, GCF and serum were collected as described in 
Section 2.4. 
3.3.2.2 Samples analyses 
Detection and quantification of adiponectin were undertaken by Western blot and 
immunoblotting as described in Section 2.9. Samples were loaded with reducing and 
heating conditions using 5% NuPage lithium dodecyl sulphate sample buffer (LDS, 
Invitrogen), 10% 0.5 M dithiothreitol (DTT) and heated for 3 minutes at 100 °C. In 
addition, samples were loaded under non-reducing and non-heating conditions in which 
additional 2 µl distilled water was added instead of DTT without heating the samples. 
In order to confirm the effect of heat denaturation and reducing conditions on the 
detected protein in saliva, UWMS samples from randomly selected 5 participants were 
similarly loaded in another gel for electrophoresis with and without heating and reducing 
conditions. The protein was transferred to nitrocellulose membrane by Western blot and 
immunoblotting for adiponectin detection, as described in Section 2.9. 
Then purified adiponectin and UWMS from the 20 participants were loaded under 
reducing and heating conditions in other gels for Western immunoblotting to detect the 
protein in UWMS of all subjects, as described in Section 2.9. 
Additionally, ELISA as described in Section 2.12, and magnetic Luminex screening 
assay as described in Section 2.13 were undertaken to quantify adiponectin in UWMS, 
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GCF and serum of 20 healthy adults by the first and 19 healthy adults by the second assay 
because of limited room in Luminex plate. 
Under heating and reducing conditions, purified adiponectin standard (Recombinant 
human adiponectin (NSO-derived)/Acrop30, CF, R&D Systems, Bio-Techne, UK), 
UWMS, eluted GCF and eluted serum were loaded in the same gel twice, as described in 
Section 2.8. After electrophoresis, proteins in one half of gel were transferred to 
nitrocellulose membrane by Western blot for detection of adiponectin by immunoblotting, 
as described in Section 2.9. Proteins of interest were identified by immunoblotting then cut 
from the second half and sent for proteomic analysis to detect the proteins, as described in 
Section 2.11. 
3.3.2.3 Tissue culture 
Tissue culture was performed to assess the biological activity of the existing protein 
(pseudo-adiponectin) in parotid saliva. 
The human gingival fibroblast cell lines (HGF-1 ATCC CRL-2014
TM 
Homo 
sapiens, human gingival biopsy, normal, UK) expressing adiponectin receptors were grown 
in Dulbecco’s modified eagles medium (DMEM) (Sigma, UK) containing 4500 mg/l 
glucose with 10% fetal bovine serum (FBS), 1% L-glutamin and 1% penicillin-
streptomycin (P/S) (Sigma-Aldrich, Dorset, UK). Cells were seeded into 12-well plates at a 
density of 1.8 x 10
5
 cells in each well from a 75 cm four flasks which was split when 
approximately 85-90% confluent. 
Following 18 hr of pre-incubation without or with either 1 ml adiponectin (10 
µg/ml) or 1 ml of parotid saliva, cells were treated with either 1 ml of IL-1β (0.5 ng/ml) or 
of 1 ml of suspended salivary bacteria for 12 hr. At the end of the incubation periods, the 
supernatants were collected and the concentrations of IL-6 and IL-8 cytokines were 
measured in triplicate using magnetic Luminex performance assay kits for cytokines (R&D 
Systems, Bio-Techne; Abingdon, UK) according to the manufacturer’s instructions. 
Parotid saliva for tissue culture assay was prepared as mentioned in Section 2.5; 250 
µl of parotid saliva added to 750 µl of DMEM. Salivary bacteria suspension was prepared 
by collecting UWMS for 5 minutes, centrifuged at 500 rpm for 10 minutes. The supernatant 
was aliquoted as 1 ml in each 1.5 ml Eppendorf (Alpha Laboratories, UK) and centrifuged 
at 9200 g for 10 minutes. The supernatants were discarded leaving salivary bacteria pellets 
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which were suspended in 1 ml of DMEM, then 500 µl of the suspended salivary bacteria 
added to 500 µl of DMEM to treat the cells. 
3.3.2.4 Study size 
A previous study investigated the levels of the GCF biomarkers MMP8, MMP9, IL-1β, 
OPG and CRP as a predictor of periodontal disease progression (Kinney et al., 2014). They 
found differences in the levels of GCF biomarkers between participants with stable 
periodontitis and those with progressing periodontitis and the mean effect size was 2.77. 
Using this effect size (assuming a significance level of 0.05 and power of 0.80) it was 
calculated (Gpower 3.1.2) that a sample size of 8 would be sufficient to detect a significant 
difference in the biomarkers between the obese and the normal weight  groups. However, to 
allow for dropouts and a weaker effect size for biomarkers in saliva, a total sample size of 
40 (20 in each group) was recruited. 
In this study one group of 20 normal weight participants was included to identify 
the origin of adiponectin in saliva, whereas 20 normal weight and 20 obese participants 
were included in Chapter 4 to compare the levels of the selected biomarkers between 
normal weight and obese subjects. 
3.3.2.5 Statistical analysis 
Descriptive statistics were used to summarise the outcome variables. Parametric and non-
parametric analyses were carried out after checking for the normality assumptions using the 
Shapiro-Wilk test of normality. 
The non-normally distributed data of adiponectin concentrations in UWMS, GCF 
and serum groups were analysed using Kruskal –Wallis test. One-way analysis of variance 
(ANOVA) was used to analyse the normally distributed data of the IL-6 and IL-8 
concentrations in the supernatants of human gingival fibroblast. If the overall significance 
was achieved, Post Hoc analysis was carried out with Bonferroni step-down correction. A 
p-value of <0.05 was considered statistically significant. All statistical analyses were done 
using SPSS (BM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 23; 
Armonk; New York; IBM;Corp). 




The clinical parameters of the subjects enrolled in the present study are shown in Table 3.3. 




Age (years): Mean (SD) 29 (7.1) 
Gender: male / female 10 / 10 
UWMS flow rate (ml/min): Mean (SD) 0.56 (0.21) 
GCF flow rate (µl/min): Mean (SD) 0.6 (0.1) 
UWMS, unstimulated whole mouth saliva; GCF, gingival crevicular fluid. 
 
Under non-reducing and non-heat denaturing conditions, purified adiponectin 
resolved to around 55 kDa, whereas several different molecular weights variants of 
adiponectin were seen in serum as 67 kDa, 56 kDa and 28 kDa. In GCF no adiponectin 
band was detected. However, in UWMS an immuno-reactive band was found at molecular 
weight, around 50 kDa. Under reduced conditions, purified adiponectin reduced to around 
30 kDa, whereas the single band seen in UWMS remained at 50 kDa. The 2 distinct bands 
in serum possibly corresponding to the trimer (67 kDa) and the monomer band resolved to 
a single band (30 kDa) (Figure 3.8). 
 
 
Figure 3.8 Immunodetection of adiponectin in different bio-fluids. Standard purified adiponectin (st), 
unstimulated whole mouth saliva (S), gingival crevicular fluid (G), serum (B); M, molecular weight marker; 
DTT: dithiothreitol. 
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UWMS of 5 subjects were investigated with and without heating and reducing 
conditions showed positive bands at around 50 kDa, which are not related to any of 
multimer adiponectin in serum. Generally these bands showed no change in their molecular 
weight after reducing and heating conditions but they appeared stronger (Figure 3.9). The 
same bands have been seen (50 kDa) in UWMS of 20 participants, under reducing and heat 
denaturation conditions, which are away from purified adiponectin bands (30 kDa) with 
0.47 µg/ml band intensity (Figure 3.10). 
 
 
Figure 3.9 Immunodetection of adiponectin in unstimulated whole mouth saliva of 5 subjects. (A) Without 
heating and reducing conditions. (B) With heating and reducing conditions. 
 
 
Figure 3.10 Immunodetection of adiponectin in unstimulated whole mouth saliva of 20 subjects with heating 
and reducing conditions. (A) Immunoblotting (St, standard purified adiponectin). (B), Scatterplot showing 
band intensity relative to purified adiponectin (median with 95%CI). 
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ELISA was used to assess the levels of adiponectin in UWMS, GCF and serum of 
20 healthy subjects. As shown in Figure 3.11, the highest level of adiponectin was found in 
serum with a mean of 475 µg/ml (SD, 181), less in GCF with a mean of 59 µg/ml (SD, 71) 




Figure 3.11 Scatterplots showing the levels of adiponectin (median with 95%CI) in different bio-fluids by 
ELISA. Unstimulated whole mouth saliva (UWMS), gingival crevicular fluid (GCF) and serum of 20 healthy 
adults; ***, significant difference (p<0.001). 
 
Magnetic Luminex screening assay has been carried out to measure the level of 
adiponectin in UWMS, GCF and serum of 19 normal healthy subjects. The highest level of 
adiponectin found in serum with a mean of 66.3 µg/ml (SD, 49.4), less in GCF with a mean 
of 3.8 µg/ml (SD, 2.3) and the least in UWMS with a mean of 0.05 µg/ml (SD, 0.02) with 
high significant difference (p<0.001) (Figure 3.12). 
 
 
Figure 3.12 Scatterplots showing the levels of adiponectin (median with 95%CI) in different bio-fluids by 
Luminex. Unstimulated whole mouth saliva (UWMS), gingival crevicular fluid (GCF) and serum of 19 
healthy adults; ***, significant difference p<0.000. 
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Proteomic analysis for the positive bands seen in purified adiponectin, UWMS and 
serum showed that adiponectin was detected in the purified adiponectin at very low 
numbers of detected peptides, and with a low probability in serum and no adiponectin in 
UWMS (Appendix 3 and 4). 
To test the biological activities of the salivary pseudo adiponectin protein in 
comparison to purified adiponectin, we measured the effect of adiponectin and parotid 
saliva on the levels of IL-6 and IL-8 expressed by a human gingival fibroblast cell line 
(HGF-1) stimulated by salivary bacteria and pro-inflammatory cytokine IL-1β. Adiponectin 
and parotid saliva significantly reduced the levels of IL-6 and IL-8 induced by IL-1β and 
salivary bacteria. Furthermore, adiponectin and parotid saliva showed comparable 
reduction in the levels of IL-6 and IL-8 induced by salivary bacteria; however, the anti-
inflammatory effect of parotid saliva was significantly greater than adiponectin on IL-6 and 
IL-8 induced by IL-1β (Figures 3.13 and 3.14). 
 
 
Figure 3.13 Box plots showing the effect of adiponectin and parotid saliva on the levels of IL-6 expressed by 
human gingival fibroblast cell line (HGF-1) stimulated by salivary bacteria and IL-1β; *, significant 
differences p<0.01; **, significant differences p<0.001; #, significant differences comparing to none and 








































































































































Figure 3.14 Box plots showing the effect of adiponectin and parotid saliva on the levels of IL-8 expressed by 
human gingival fibroblast cell line (HGF-1) stimulated by salivary bacteria and IL-1β; *, significant 
differences p<0.01; **, significant differences p<0.001; #, significant differences comparing to none and 
adiponectin p<0.001, vertical whiskers indicate minimum to maximum values. 
 
3.3.4 Discussion 
The main aim of this study was to verify the source of salivary adiponectin. Adiponectin, is 
mainly produced by adipocytes and secreted into blood, to date this has mostly been 
investigated in blood (Furugen et al., 2008, Saito et al., 2008, Yamaguchi et al., 2010). 
GCF composition often reflects the concentration of metabolites in blood and its collection 
is less invasive than blood. However, the components of GCF consequently pass to saliva, 
which is easier, less invasive and less expensive to collect and analyse. One study found 
that adiponectin could be produced by salivary gland epithelial cells (Katsiougiannis et al., 
2006) and might play a protective role during inflammation of the salivary gland 
(Katsiougiannis et al., 2010). From the above information, in this study the three different 
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The results of the immunoblotting confirmed by previous studies showed that SDS-
PAGE under non-reducing and non-heat denaturing conditions shows several different 
molecular weights of human serum adiponectin, designed as low molecular weight 
including monomer, dimer and trimer (Waki et al., 2003). The same study showed that with 
a reducing agent adiponectin converted into a trimer of 67 kDa, whereas with 10 minutes 
heat at 95 °C it was converted into a dimer of 56 kDa and a monomer of 28 kDa, with both 
heat denaturing and reducing conditions all adiponectin forms were converted into 
monomer. In this study, not all adiponectin structures were broken down into monomer, 
which could be related to different type and concentration of reducing agent used. For 
instance, Waki et al. (2003) utilized both beta mercaptoethanol and DTT as a reducing 
agent. Moreover, adiponectin monomers and trimers can bind with albumin showing 
fractions at 90-100 kDa (Hada et al., 2007). 
A single band that has been seen in UWMS at molecular weight of around 50 kDa 
and this is similar to the bands seen in immunoblotting assays of adiponectin in saliva 
(Akuailou et al., 2013). However, this band is not necessarily adiponectin, as in the present 
study, the band in UWMS occurred at different molecular weight than that of serum and 
purified adiponectin with and without heating and reducing conditions. Moreover, it did not 
show any change in molecular weight after heating and reducing conditions as purified 
adiponectin and adiponectin in serum did, that confirmed by immunoblotting of UWMS 
from other 5 subjects. Additionally, under heating and reducing conditions, same bands (50 
kDa) were seen in UWMS of all participants, which are at different molecular weight of 
purified adiponectin and may indicate that this protein is unlikely to be adiponectin. 
Although previous study showed adiponectin receptors R1 and R2 expressed in 
human PDL cells and gingival fibroblasts (Iwayama et al., 2012), under reducing and heat 
denaturation conditions, no clear band could be found by immunoblotting the GCF sample 
in this study. 
Both ELISA and Luminex multiplex assays showed the highest concentration of 
adiponectin in serum and the lowest in UWMS, this is well matched with the outcome of 
other studies, which stated that human salivary adiponectin level is very low (0.37-6.42 
ng/ml) in comparison to that of plasma (0.58-12.40 µg/ml) (Toda et al., 2007). In addition, 
Toda and Morimoto (2008) reported that adiponectin level in plasma (8.94-13.68 µg/ml) is 
higher than its level in saliva collected in test tube and in salivette (0.69-1.41 ng/ml, 0.71-
0.86 ng/ml) respectively . In the present study, the value of the detected protein in UWMS 
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by ELISA is more or less approximate to values of pseudo adiponectin protein detected by 
immunoblotting, which is 7-8 folds the levels of adiponectin measured in UWMS by 
Luminex. 
Furthermore, proteomic analysis showed adiponectin was detected in the purified 
adiponectin (standard) at very low numbers of detected peptides, and with a low probability 
in serum but not in UWMS. These findings indicate that the positive results of adiponectin 
in saliva might come from other proteins, which have the same anti-inflammatory effect as 
adiponectin, as confirmed by our tissue culture experiments when both purified adiponectin 
and parotid saliva reduced the levels of IL-6 and IL-8 expressed by human gingival 
fibroblast as a result of inflammation induced either by IL-1β or salivary bacteria. These 
findings agree with a previous study showing that adiponectin reduced the production of 
IL-6 and IL-8 expressed by human gingival fibroblasts (Iwayama et al., 2012). Further 
study is required to identify this specific protein. 
3.3.5 Conclusion 
Salivary adiponectin has a small contribution from serum via the GCF but there also 
appears to be a contaminating protein, which reacts with several antibodies in Western blots 
and ELISA, which is unlikely to be adiponectin. 
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Chapter 4 Effects of obesity on biochemical 
changes in saliva, GCF and serum with and 
without orthodontic treatment: a cross 
sectional study 
This chapter includes two main cohorts; the first cohort is the control group which has 
normal weight and obese adults without orthodontic treatment; and the second cohort has 
normal weight and obese adults underlying fixed-appliance orthodontic treatment with 
0.019 x 0.025-inch stainless steel archwires in upper and lower arches. 
4.1 Control cohort 
4.1.1 Introduction 
The accumulation of fat in obesity results in serious health complications, increasing the 
risk of significant disease and morbidity. Adipose tissue does not only represent the region 
of fat storage in the body but also acts as an endocrine organ that is able to secrete multiple 
immunomodulatory proteins known as adipokines (Exley et al., 2014). Adipokines such as 
adiponectin, leptin, resistin and omentin can be defined as molecules secreted by adipose 
tissues that participate in the regulation of appetite and glucose homeostasis as well as 
modulating the immune response (Tilg and Moschen, 2006). Physiologically, adipose tissue 
can secrete constitutive levels of adipokines, which have been shown to have both anti-
inflammatory properties, such as adiponectin; and pro-inflammatory activities, such as 
leptin, resistin, as well as pro-inflammatory cytokines such as TNF-α and IL-6. In obese 
subjects, adipocytes and associated immune cells are known to increase the expression of 
pro-inflammatory molecules and reduce anti-inflammatory, resulting in a chronic low-grade 
inflammatory state (Nakamura et al., 2014, Fantuzzi, 2005). The increased circulatory level 
of inflammatory mediators, particularly IL-6 has been associated with hepatocyte 
stimulation to synthesize and produce a low-grade systemic inflammation marker CRP 
(Zhang et al., 2009), which has been classified as an essential cause of many illness 
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conditions including metabolic syndrome (Bassuk et al., 2004), atherosclerosis and 
coagulation (Adar et al., 2015), coronary heart disease (Danesh et al., 2008), cancers and 
metastases (Zhou et al., 2012), and other health conditions like depression (Musselman et 
al., 2001). 
A number of biomarkers for obesity have been studied in the bloodstream. Amongst 
these, leptin exerts a role in both immunity and inflammation, stimulating the secretion of 
pro-inflammatory mediators (Procaccini et al., 2012) as well as controlling appetite. 
Resistin, which has pro-inflammatory effects, involved in several inflammatory diseases 
(Park and Ahima, 2013); whilst other cytokines, such as TNF-α and IL-6, are produced by 
monocytes and macrophages, but are up-regulated by adipose tissue (Nakamura et al., 
2014). In contrast, adipokines with anti-inflammatory activity such as adiponectin can 
strongly induce the production of anti-inflammatory cytokines and down-regulate the 
activity of pro-inflammatory mediators (Nigro et al., 2014, Fantuzzi, 2005). In addition to 
the blood, these and other biomarkers have also been measured using alternative biological 
media. Saliva is a good diagnostic tool offering an excellent alternative to other body fluids 
for investigative purposes (Pfaffe et al., 2011). GCF is a transudate of the interstitial fluid, 
since serum is the main origin of the aqueous portion of GCF, its composition is highly 
modified by both local and systemic conditions (Kavadia-Tsatala et al., 2001). The 
composition of GCF can therefore reflect the systemic as well as local conditions in 
humans. Venous blood is generally considered to be the best body fluid for the evaluation 
of systemic processes. However, the collection of blood involves potential risks to subjects, 
such as bruising, transient discomfort and infection at the venepuncture site. Moreover 
blood collection needs a trained professional to collect it, as well as specific handling and 
collection vessels. It is less favourable in research involving children, as well as in other 
research subjects for whom venous access is difficult (elderly or critically ill) (Williamson 
et al., 2012). The substitution of other body fluids, such as saliva and GCF would greatly 
improve ease of sample collection. However, analysis of biomarkers in these fluids from 
humans has not been widely researched. 
4.1.1.1 Aims and objectives 
The specific aims of this study were to investigate the effect of obesity on selected 
biomarkers and to measure these biomarker levels in UWMS, GCF and serum. 
To address these aims the following steps were undertaken: 
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1. Comparing the levels of biomarkers in obese and normal weight subjects; and 
2. Measuring the levels of biomarkers in UWMS, GCF and serum. 
The hypothesis was that obesity does not change the levels of the selected biomarkers. 
4.1.2 Methods 
The study was approved by the Human Research Ethics Committee of King's College 
London (BDM/14/15-8, November 2014). Informed written consent was obtained from all 
participants. 
4.1.2.1 Participants and sampling 
The 48 healthy adult volunteers (20 males and 28 females) were recruited as described in 
Section 2.4, number 1. For all participants, plaque levels and gingival health were 
considered clinically acceptable. Height and weight were measured to calculate BMI as 
described in Section 2.2.1. According to BMI, 6 females were classified as overweight 
(BMI = 25 - 30) and 2 were underweight (BMI<18.5) and were excluded from the study. 
The sample consisted of 20 normal weight (BMI =18.5 - 25) (10 males and 10 females) 
with a mean age of 29 years (range 19-44 years) and 20 obese (BMI ≥30) (10 males and 10 
females) with a mean age of 30.95 years (range 18-45 years) (Figure 4.1). 




Figure 4.1 Diagram for sample distribution of control cohort. 
 
From each individual UWMS, GCF and serum were collected, as described in 
Section 2.4. UWMS and GCF flow rate were measured as mentioned in Section 2.6. 
UWMS were analysed for albumin and secretory immunoglobulin A (sIgA) contents using 
Western blot and immunoblotting as described in Section 2.9. 
In addition, UWMS was analysed for gelatinase using 10% zymogram gelatin gels 
electrophoresis as described in Section 2.10. The levels of selected biomarkers were 
determined using a magnetic Luminex screening assay (R&D Systems, Bio-Techne; 
Abingdon, UK) for only 19 participants from each group because of the limited room in the 
Luminex plate, as described in Section 2.13. 
4.1.2.2 Study size 
The sample size calculation was based upon a previous study (Kinney et al., 2014) as 
described in Section 3.3.2.4. 
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4.1.2.3 Statistical analysis 
Descriptive statistics were used to summarise outcome variables. Parametric and non-
parametric analyses were carried out after checking for the normality distribution using 
Shapiro-Wilk test of normality. Kruskal-Wallis test was used to analyse the not normally 
distributed data of the three gelatinase bands measured. Mann Whitney U test was used to 
compare the not normally distributed data of biomarkers’ concentrations and sIgA 
concentrations between the normal weight and obese groups. Independent t-test was used to 
compare the normally distributed data of albumin concentration, age, BMI and UWMS and 
GCF flow rates in both groups. All statistical analyses were done using SPSS (BM Corp. 
Released 2013. IBM SPSS Statistics for Windows, Version 23; Armonk; New York; 
IBM;Corp). 
4.1.3 Results 
The clinical parameters of the subjects enrolled in the present study are shown in Table 4.1. 
Age did not significantly differ between obese and normal weight groups (p=0.380). 
 
Table 4.1 Clinical characteristics of participants in control cohort study. 
Parameters Normal weight Obese 
Number 20 20 
Age (years): Mean (SD) 29 (7.1) 30.9 (6.9) 
Gender: male / female 10 / 10 10 / 10 
BMI (kg/m
2
): Mean (SD) 21.5 (1.6) 32.2 (2.5)* 
SD, standard deviation; BMI, body mass index; *, significantly higher (p<0.0001) using independent t-test. 
 
4.1.3.1 UWMS and GCF flow rate 
The flow rate of saliva is frequently altered in different disease states. Additionally, 
periodontal health status and mechanical stimuli can modify GCF flow rate. We therefore 
measured the flow rate of UWMS and GCF in our normal weight and obese groups. 
The UWMS flow rate was comparable for both obese and normal weight groups 
(p=0.146), whereas the GCF flow rate was significantly higher in the obese group 
compared to normal weight (p=0.0001) (Table 4.2). 
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Table 4.2 UWMS and GCF flow rate of 20 obese and 20 normal weight adults of control cohort study. 










Number 20 20 20 20 
Mean 0.56 0.68 0.6 0.8 
SD 0.21 0.29 0.1 0.2 
SEM 0.05 0.06 0.02 0.03 
p value 0.146 0.0001 
UWMS, unstimulated whole mouth saliva; GCF, gingival crevicular fluid; SD, standard deviation; SEM, 
standard error of mean. 
 
4.1.3.2 Comparison of obesity biomarkers between normal weight and 
obese groups 
Adiponectin was significantly reduced in GCF (p=0.025) and serum (p=0.032) of the obese 
subjects compared to normal weight, whilst levels were similar in UWMS (p=0.223). 
Leptin was significantly reduced in UWMS of the obese group (p=0.00004); however, in 
GCF and serum levels were comparable in both groups (p=0.103, p=0.977), respectively. 
No differences in resistin levels were observed between obese and normal weight groups in 
UWMS, GCF and serum (p=0.234, p=0.297, p=0.075), respectively (Figure 4.2, Table 4.4). 




Figure 4.2 Scatterplots showing the concentrations of obesity biomarkers in unstimulated whole mouth saliva 
(UWMS), gingival crevicular fluid (GCF) and serum of 19 obese and 19 normal weight subjects in control 
cohort (median with 95%CI); *, significant difference (p<0.05); ***, significant difference (p<0.001). 
 
4.1.3.3 Comparison of tissue remodelling biomarkers between normal 
weight and obese groups 
MMPs such as MMP8 and MMP9 are crucial for PDL remodelling in both physiological 
and pathological conditions, with their actions regulated by inhibitors, such as TIMP1. 
The levels of MMP8 were comparable in UWMS and GCF (p=0.234, p=0.284), 
respectively, and significantly higher in serum of the obese group compared to normal 
weight (p=0.001). MMP9 showed comparable levels in UWMS, GCF and serum (p=0.977, 
p=0.138, p=0.686), respectively. The levels of the inhibitor, TIMP1, were comparable in 
UWMS and GCF (p=0.644, P=0.863); however, in serum the levels were significantly 
higher in the obese group (p=0.0138) (Figure 4.3, Table 4.4). 
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Expressing the ratio of MMPs to TIMP levels provides a measure of the balance 
between the ECM damage done by MMPs and the inhibition of these effects by TIMPs 
during remodelling. UWMS, GCF and serum showed comparable levels of MMP8/TIMP1 
ratio (p=0.191, p=0.751, p=0.470) and MMP9/TIMP1 ratio (p=0.708, p=0.234, p=0.370), 
respectively in both obese and normal weight groups (Figure 4.4, Table 4.4). 
 
 
Figure 4.3 Scatterplots showing the concentrations of tissue remodelling biomarkers in unstimulated whole 
mouth saliva (UWMS), gingival crevicular fluid (GCF) and serum of 19 obese and 19 normal weight subjects 
in control cohort (median with 95%CI); MMP8, matrix metalloproteinase-8; MMP9, matrix 
metalloproteinase-9; TIMP1, tissue inhibitor of metalloproteinase 1  *, significant difference (p<0.05); **, 
significant difference (p<0.01). 

















n o rm a l w e ig h t o b e s e
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0













































n o rm a l w e ig h t o b e s e
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0














































































Figure 4.4 Scatterplots showing the levels of MMPs/inhibitor ratios in unstimulated whole mouth saliva 
(UWMS), gingival crevicular fluid (GCF) and serum of 19 obese and 19 normal weight subjects in control 
cohort (median with 95%CI). MMP8, matrix metalloproteinase-8; MMP9, matrix metalloproteinase-9; 
TIMP1, tissue inhibitor of metalloproteinase 1. 
 
In addition, zymography was used to detect the gelatinases (MMP2 and MMP9) in 
UWMS of 20 obese and 20 normal weight adults. Bands were seen as bright bands within 
the stained gel at 72 kDa for MMP2, 92 kDa and 120 kDa for MMP9. The results showed 
the highest band intensity at 120 kDa, then 92 kDa and the least at 72 kDa in both obese 
and normal weight groups. However, Kruskal-Wallis test showed no statistical difference 
between the three detected bands in both normal weight and obese groups (p=0.984, 
p=0.778), respectively (Table 4.3, Figure 4.5). 
 
Table 4.3 Mean of gelatinase bands intensity in UWMS of 20 obese and 20 normal weight subjects in control 
cohort. 
 Normal weight Obese 
MW 120 kDa 92 kDa 72kDa 120 kDa 92 kDa 72kDa 
mean 12149302 2541689 710033.3 16888026 4578699 3615717 
SD 21753688 3481653 631489.3 42732128 8348219 10095393 
SEM 4864273 778521.2 141205.3 9555194 1866719 2257399 
P value 0.984 0.778 
MW, molecular weight of gelatinase; SD, standard deviation; SEM, standard error of mean. 
 




































































































Figure 4.5 Bands intensity of gelatinase in unstimulated whole mouth saliva of 20 obese and 20 normal 
weight subjects in control cohort detected by zymography using the ChemiDoc Imaging system (BioRad) 
laboratories ltd, Herts, UK. 
 
4.1.3.4 Comparison of bone remodelling biomarker between normal 
weight and obese groups 
The wide range of pro-inflammatory mediators produced by adipocytes of obese subjects 
stimulates the RANKL/RANK pathway, which in turn enhances osteoclastogensis and bone 
resorption. 
The levels of RANKL were significantly higher in GCF (p=0.001) and serum 
(p=0.007) and significantly lower in UWMS (p=0.0001) of the obese group compared to 
normal weight (Figure 4.6, Table 4.4). 





Figure 4.6 Scatterplots showing the concentrations of bone remodelling biomarker in unstimulated whole 
mouth saliva (UWMS), gingival crevicular fluid (GCF) and serum of 19 obese and 19 normal weight adults in 
control cohort (median with 95%CI); RANKL, receptor activator of nuclear factor kappa-B ligand; **, 
significant difference (p<0.01); ***, significant difference (p<0.001). 
 
4.1.3.5 Comparison of inflammation biomarkers between normal weight 
and obese groups 
Diverse inflammatory mediators are released by adipocytes, provoking a systemic 
inflammatory state that may negatively affect the general health status. Certain biomarkers 
such as CRP and MPO were used for the diagnosis and prediction of acute inflammation 
and tissue damage. 
The levels of MPO were higher in obese group compared to normal weight in 
UWMS, GCF and serum (p=0.002, p=0.0001, p=0.006), respectively. However, the levels 
of CRP were significantly higher only in serum of obese group (p=0.003) and comparable 
in UWMS and GCF (p=0.103, p=0.091), respectively of the two groups (Figure 4.7, Table 
4.4). 
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Figure 4.7 Scatterplots showing the concentrations of inflammation biomarkers in unstimulated whole mouth 
saliva (UWMS), gingival crevicular fluid (GCF) and serum of 19 obese and 19 normal weight subjects in 
control cohort (median with 95%CI); MPO, myeloperoxidase; CRP, C reactive protein; *, significant 
difference (p<0.05); **, significant difference (p<0.01); ***, significant difference (p<0.001). 
4.1.3.6 Comparison of biomarkers between saliva, GCF and serum 
The levels of the selected biomarkers were varied in different bio-fluids; the highest levels 
of some biomarkers were observed in serum followed by GCF and the least in UWMS such 
as adiponectin, leptin and CRP. However, the highest levels of the other biomarkers were 
observed in GCF followed by serum and then UWMS such as resistin, MMP8, MMP9, 
TIMP1, MPO and RANKL. These sequences were almost the same in both normal weight 
and obese groups (Table 4.4). 
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Table 4.4 Mean and standard deviations of biomarkers’ levels in UWMS, GCF and serum of 19 normal 
weight and 19 obese subjects without orthodontic treatment. 
Biomarkers Sample 
Normal weight Obese 
Mean SD Mean SD 
Adiponectin 
(ng/ml) 
UWMS 55.86 26.81 65.85 27.80 
GCF 3763.81 2343.09 2980.59 3731.01 
serum 66255.87 49389.97 27428.94 12973.52 
Leptin 
(pg/ml) 
UWMS 224.49 176.27 67.09 68.82 
GCF 2374.33 1667.91 1606.38 823.15 
serum 4172.15 2289.91 8913.44 11357.47 
Resistin 
(ng/ml) 
UWMS 3.20 3.59 3.72 2.67 
GCF 301.30 184.55 344.41 144.83 
serum 9.91 9.85 18.28 22.97 
MMP8 
(ng/ml) 
UWMS 16.30 13.30 21.32 29.37 
GCF 2261.78 1308.11 3026.44 2344.71 
serum 37.11 26.05 63.22 12.50 
MMP9 
(ng/ml) 
UWMS 11.49 12.27 23.52 29.91 
GCF 2326.18 1151.66 3282.47 2100.75 
serum 235.81 180.49 336.02 280.92 
TIMP1 
(ng/ml) 
UWMS 16.81 6.13 16.23 3.65 
GCF 152.37 83.83 146.80 99.83 
serum 40.54 18.69 69.08 49.48 
MMP8/ 
TIMP1 
UWMS 0.49 0.44 0.62 0.83 
GCF 8.42 6.90 14.56 22.49 
serum 0.46 0.42 1.32 2.64 
MMP9/ 
TIMP1 
UWMS 0.16 0.14 0.41 0.53 
GCF 4.66 2.39 8.83 10.92 
serum 1.62 0.97 1.60 1.80 
MPO 
(ng/ml) 
UWMS 4.68 2.20 8.56 4.78 
GCF 201.51 124.10 467.10 254.00 
serum 139.12 84.45 221.29 100.55 
CRP 
(ng/ml) 
UWMS 0.52 0.67 0.13 0.10 
GCF 11.82 27.84 283.49 651.35 
serum 208.45 201.72 2348.35 2343.88 
RANKL 
(pg/ml) 
UWMS 231.71 179.96 41.81 21.57 
GCF 2485.61 1809.75 3347.43 911.43 
serum 204.51 302.52 408.27 312.59 
SD: standard deviation; UWMS: unstimulated whole mouth saliva; GCF: gingival crevicular fluid; MPO, 
myeloperoxidase; CRP, C reactive protein; MMP8, matrix metalloproteinase-8; MMP9, matrix 
metalloproteinase-9; TIMP1, tissue inhibitor of metalloproteinase 1; RANKL, receptor activator of nuclear 
factor kappa-B ligand. 
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4.1.3.7 Comparison of albumin and sIgA in UWMS of normal weight and 
obese subjects by immunoblotting 
Western immunoblotting was used to detect other biomarkers in 20 obese and 20 normal 
weight adults. Unfortunately, because of the limited amount of the collected GCF, these 
proteins were detected only in UWMS by Western blot and immunoblotting. Band intensity 
of albumin and sIgA in UWMS of 20 normal weight and 20 obese subjects were quantified 
by scanning image analysis as shown in Figure 4.8 and, Figure 4.9 respectively, with no 
statistical significant differences for both albumin (p=0.484), and sIgA (p=0.314) were 
observed between normal weight and obese groups. 
 
 
Figure 4.8 Albumin in unstimulated whole mouth saliva (UWMS) of 20 obese and 20 normal weight` adults 
in control cohort. (A) Scatterplots (median with 95%CI), (B) Immunoblotting images. Stand: standard. 




Figure 4.9 Secretory IgA in unstimulated whole mouth saliva (UWMS) of 20 obese and 20 normal weight 
adults in control cohort. (A) Scatterplots (median with 95%CI), (B) Immunoblotting images, stand: standard. 
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4.2 Orthodontic treatment cohort 
4.2.1 Introduction 
When an orthodontist applies pressure and forces to a tooth, the patient will experience 
some local inflammation around the tooth, and this in turn increases capillary permeability 
in the paradental tissues and leads to the production of compounds that allow connective 
tissues and the surrounding bone to remodel (Storey, 1973). The compounds that are 
produced include cytokines and hormones, which are vital for repair (Teitelbaum, 2000, 
Sandy et al., 1993). 
In those who are obese, it has been found that adipocytes and associated immune 
cells increase the production of pro-inflammatory proteins; such as leptin, resistin, TNF-α 
and IL-6, whilst at the same time, they cause a reduction in anti-inflammatory proteins, 
such as adiponectin, and this causes a degenerative low-grade inflammatory state (Fantuzzi, 
2005, Nakamura et al., 2014), which can heighten the risk of obese individuals contracting 
periodontitis. Thus, it is argued that obesity can affect orthodontic treatment, namely pro-
inflammatory changes in the PDL space, which can have a negative effect on the 
remodelling of tissue in the PDL. 
It has been widely argued that venous blood is the best body fluid in terms of 
assessing the systemic process. Nevertheless, biochemical analysis of GCF is also an 
insightful method in terms of assessing the changes at one single site within a specific 
timeframe, in addition to determining the reaction of the dental and periodontal tissues to 
fixed orthodontic forces (Lee et al., 2004, Tuncer et al., 2005). It is likely that the same 
principle can also be applied to the use of whole saliva, and this is due to the fact that it is 
made up of the same components in GCF (Akalιn et al., 2007). 
The current literature reveals that obesity has an effect on the remodelling of bone 
metabolism, via various mechanisms, and these may have a significant effect on OTM 
(Cao, 2011). Conversely, forces applied by orthodontic appliance give rise to complicated 
mechanical and biological events such as matrix strain and fluid flow, cell strain, cell 
activation and differentiation, and remodelling which result in OTM (Henneman et al., 
2008). Therefore, it can be argued both obesity and OTM pervert the standard physiological 
mechanisms of tissue and bone metabolism. Nevertheless, the potential changes of 
biomarkers during OTM in obese humans have not yet been characterised. 
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4.2.1.1 Aims and objectives 
The specific aims of this study were to investigate the effect of obesity on selected 
biomarkers during orthodontic treatment and to measure biomarker levels in saliva, GCF 
and serum. 
To address these aims the following steps were undertaken: 
1- Comparing the levels of biomarkers in obese and normal weight patients with 
fixed orthodontic appliances; and 
2- Measuring the levels of the biomarkers in UWMS, GCF and serum. 
The hypothesis was that obesity does not change the levels of selected biomarkers 
in patients undergoing fixed appliance orthodontic treatment. 
4.2.2 Methods 
The study was approved by the United Kingdom National Research Ethics Service, NRES 
Committee foundation (REC reference: 14/LO/0769, October 2014). Informed written 
consent was obtained from all participants. 
4.2.2.1 Participants and sampling 
A total of 47 adult orthodontic patients (23 males and 24 females) under treatment with 
fixed orthodontic appliance (precoated 3M Victory 0.022-inch bracket, MBT prescription, 
3M Unitek, Monrovia, USA) with 0.019 x 0.025-inch stainless steel rectangular archwires 
in the upper and lower arches were recruited as described in Section 2.4, number 2. Height 
and weight were measured for all participants to calculate BMI as shown in Section 2.2.1. 
According to the BMI 9 patients (4 males and 5 females) were classified as overweight 
(BMI = 25 - 30), and were excluded from the study. The sample therefore consisted of 19 
normal weight (BMI= 18.5 - 25) (9 males and 10 females) with a mean age of 24.6 years 
(range 18-35 years) and 19 obese (BMI ≥30) (9 males and 10 females) with a mean age of 
26.6 years (range 18-42 years) (Figure 4.10). 




Figure 4.10 Diagram for sample distribution of patients with orthodontic treatment. 
 
For all participants, plaque levels and gingival health were measured as described in 
Section 2.3. UWMS, GCF and peripheral blood were collected as described in Section 2.4. 
UWMS and GCF flow rate were measured as mentioned in Section 2.6. The levels of the 
selected biomarkers were determined using a magnetic Luminex screening assay (R&D 
Systems, Bio-Techne; Abingdon, UK) as described in Section 2.13. 
The study size and statistical analysis were the same as the control cohort 
mentioned in Sections 4.1.2.2 and 4.1.2.3, respectively with additional correlation tests to 
correlate the levels of biomarkers with the plaque and gingival indices scores. 
4.2.3 Results 
The clinical parameters of the subjects enrolled in the present study are shown in Table 4.5. 
Age did not significantly differ between the obese and normal weight groups (p=0.338). 
BMI values of the obese group were significantly higher than those of the normal weight 
group (p<0.0001). 
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Table 4.5 Clinical characteristics of the patients with orthodontic treatment. 
Parameters Normal weight Obese 
Number 19 19 
Age (years): Mean (SD) 24.6 (6.5) 26.6 (6.2) 
Gender: male / female 9 / 10 9 / 10 
BMI (kg/m
2
): Mean (SD) 22.6 (1.6) 32.4 (2.2)* 
SD: standard deviation, BMI: body mass index, *=significantly higher (p<0.0001) using independent t-test. 
 
4.2.3.1 UWMS and GCF flow rate 
Salivary and GCF flow rate can be affected with the presence of orthodontic appliance as 
well as the inflammatory reactions take place during OTM. 
Independent t test showed that in both obese and normal weight groups, UWMS and 
GCF flow rates were comparable (p=0.73, p=0.06), respectively (Table 4.6). 
 
Table 4.6 UWMS and GCF flow rate of patients with orthodontic treatment. 










Number 19 19 19 19 
Mean 0.68 0.65 0.86 0.89 
SD 0.31 0.26 0.17 0.21 
SEM 0.07 0.06 0.04 0.05 
p value 0.73 0.06 
UWMS, unstimulated whole mouth saliva; GCF, gingival crevicular fluid; SD, standard deviation; SEM, 
standard error of mean. 
 
4.2.3.2 Comparison of obesity biomarkers between normal weight and 
obese groups 
The levels of adiponectin were comparable in UWMS, GCF and serum (p=0.795, p=0.258, 
p=0.130) respectively. Leptin levels in UWMS were also comparable in both obese and 
normal weight groups (p=0.116). However, it was significantly higher in GCF (p=0.009) 
and serum (p=0.001) in the obese group in comparison to those of normal weight. No 
differences in resistin levels were observed between the obese and normal weight groups in 
UWMS, GCF and serum (p=0.246, p=0.435, p=0.708), respectively (Figure 4.11, Table 
4.7). 




Figure 4.11 Scatterplots showing the concentrations of obesity biomarkers in unstimulated whole mouth 
saliva (UWMS), gingival crevicular fluid (GCF) and serum of 19 obese and 19 normal weight patients in 
orthodontic treatment cohort (median with 95%CI); **, significant difference (p<0.01). 
 
4.2.3.3 Comparison of tissue remodelling biomarkers between normal 
weight and obese groups 
OTM requires extensive remodelling of the periodontium. MMPs such as MMP8 and 
MMP9 degrade the ECM during remodelling, while their activity is regulated by the tissue 
inhibitors such as TIMP1. 
The levels of MMP8 were comparable in UWMS, GCF and serum (p=0.452, 
p=0.223 and p=0.840), respectively. MMP9 showed comparable levels in UWMS 
(p=0.885) whereas its level was significantly higher in GCF (p=0.020) and serum (p=0.034) 
of the obese group in comparison to normal weight. The levels of the inhibitor, TIMP1, 
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were comparable in UWMS and GCF (p=0.085, p=1.000) respectively; however, in serum 
it was significantly higher in obese group (p=0.002) (Figure 4.12, Table 4.7). 
Since the effect of MMPs is controlled by the inhibitor TIMPs, therefore measuring 
the MMP/TIMP ratio is more objective. No differences were observed in MMP8/TIMP1 
and MMP9/TIMP1 ratios between the obese and normal weight groups in UWMS, GCF 
and serum (MMP8/TIMP1, p=0.751, p=0.603, p=0.212, MMP9/TIMP1, p=1.000, p=0.435, 
p=0.644), respectively (Figure 4.13, Table 4.7). 
 
 
Figure 4.12 Scatterplots showing the concentrations of tissue remodelling biomarkers in unstimulated whole 
mouth saliva (UWMS), gingival crevicular fluid (GCF) and serum of 19 obese and 19 normal weight patients 
in orthodontic treatment cohort (median with 95%CI); MMP8, matrix metalloproteinase-8; MMP9, matrix 
metalloproteinase-9; TIMP1, tissue inhibitor of metalloproteinase 1; *: significant difference (p<0.05); **: 
significant difference (p<0.01). 
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Figure 4.13 Scatterplots showing the levels of MMPs/inhibitor ratios in unstimulated whole mouth saliva 
(UWMS), gingival crevicular fluid (GCF) and serum of 19 obese and 19 normal weight patients in 
orthodontic treatment cohort (median with 95%CI); MMP8, matrix metalloproteinase-8; MMP9, matrix 
metalloproteinase-9; TIMP1, tissue inhibitor of metalloproteinase 1. 
 
4.2.3.4 Comparison of bone remodelling biomarker between normal 
weight and obese groups 
Since the RANKL/RANK pathway is a key for osteoclastogensis and bone resorption, it is 
important to consider levels of RANKL during OTM. 
The levels of RANKL were comparable in UWMS and GCF (p=0.080, p=0.624) in 
both normal weight and obese groups (Figure 4.14, Table 4.7). However, in serum, 
RANKL levels were below the detection limit in all samples of both groups. 
 













































































































Figure 4.14 Scatterplots showing the concentrations of bone remodelling biomarker in unstimulated whole 
mouth saliva (UWMS), gingival crevicular fluid (GCF) and serum of 19 obese and 19 normal weight patients 
in orthodontic treatment cohort (median with 95%CI); RANKL, receptor activator of nuclear factor kappa-B 
ligand. 
 
4.2.3.5 Comparison of inflammation biomarkers between normal weight 
and obese groups 
Forces during orthodontic treatment create acute inflammation in the surrounding 
supporting structure. Certain biomarkers such as CRP and MPO were used for the 
diagnosis and prediction of acute inflammation and tissue damage in many systemic 
diseases. The levels of MPO and CRP were comparable in both obese and normal weight 
groups in UWMS, GCF and serum (MPO: p=0.061, p=0.773, p=0.773; CRP: p=0.191, 
p=0.075, p=0.109), respectively (Figure 4.15, Table 4.7). 
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Figure 4.15 Scatterplots showing the concentrations of inflammation biomarkers in unstimulated whole 
mouth saliva (UWMS), gingival crevicular fluid (GCF) and serum of 19 obese and 19 normal weight patients 
in orthodontic treatment cohort (median with 95%CI); MPO, myeloperoxidase; CRP, C reactive protein. 
 
4.2.3.6 Comparison of biomarkers between saliva, GCF and serum 
The levels of the selected biomarkers were varied in different bio-fluids, the highest levels 
of some biomarkers were observed in serum followed by GCF and the least in UWMS such 
as adiponectin, leptin, MPO and CRP. However, the highest levels of the other biomarkers 
were observed in GCF followed by serum and then UWMS such as resistin, MMP8, MMP9 
and TIMP1. RANKL registered the highest level in GCF followed by UWMS but could not 
be detected in serum in both normal weight and obese groups. These sequences were 
almost the same in both normal weight and obese groups (Table 4.7) 
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Table 4.7 Mean and standard deviations of biomarkers’ levels in UWMS, GCF and serum of 19 normal 
weight and 19 obese patients with orthodontic treatment. 
Biomarkers Sample 
Normal weight Obese 
Mean SD Mean SD 
Adiponectin 
(ng/ml) 
UWMS 6.36 6.48 9.49 13.61 
GCF 6683.80 3224.31 6278.34 5480.16 
serum 30724.40 17961.21 19878.73 6572.60 
Leptin 
(pg/ml) 
UWMS 25.90 10.14 20.94 8.92 
GCF 298.30 81.69 407.77 209.19 
serum 936.33 232.89 2044.38 1691.96 
Resistin 
(ng/ml) 
UWMS 4.29 4.26 4.99 4.80 
GCF 484.14 280.57 552.56 279.73 
serum 16.80 21.73 22.35 27.85 
MMP8 
(ng/ml) 
UWMS 14.78 6.27 17.85 11.15 
GCF 3310.32 775.50 3768.19 1057.75 
serum 15.89 13.92 21.16 21.66 
MMP9 
(ng/ml) 
UWMS 32.27 24.27 36.45 36.73 
GCF 4117.81 1209.17 4787.23 1590.90 
serum 381.29 291.63 643.95 448.42 
TIMP1 
(ng/ml) 
UWMS 13.98 4.84 26.41 5.34 
GCF 103.98 76.43 95.66 59.34 
serum 26.41 11.85 44.21 24.73 
MMP8/ 
TIMP1 
UWMS 0.54 0.36 0.50 0.34 
GCF 20.86 14.00 21.84 10.86 
serum 0.29 0.29 0.20 0.16 
MMP9/ 
TIMP1 
UWMS 0.75 0.79 0.61 0.56 
GCF 15.10 10.46 15.99 7.61 
serum 3.79 3.01 3.78 2.03 
MPO 
(ng/ml) 
UWMS 1.70 0.60 1.37 0.87 
GCF 459.47 319.76 447.57 293.67 
serum 614.62 343.40 641.62 436.81 
CRP 
(ng/ml) 
UWMS 0.20 0.47 0.23 0.32 
GCF 33.02 121.61 249.10 360.31 
serum 825.95 883.40 150.69 1312.66 
RANKL 
(pg/ml) 
UWMS 37.34 69.05 17.13 22.17 
GCF 1040.51 324.95 1343.97 894.56 
serum 0 0 0 0 
SD, standard deviation; UWMS: unstimulated whole mouth saliva; GCF: gingival crevicular fluid; MPO, 
myeloperoxidase; CRP, C reactive protein; MMP8, matrix metalloproteinase-8; MMP9, matrix 
metalloproteinase-9; TIMP1, tissue inhibitor of metalloproteinase 1; RANKL, receptor activator of nuclear 
factor kappa-B ligand. 
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4.2.3.6 Correlation of biomarkers with periodontal health 
Certain biomarkers are produced as a response to local stimuli or inflammation, therefore 
bacterial plaque and inflamed gingivae can potentially influence the levels of these 
biomarkers. 
Both normal weight and obese patients showed comparable values of plaque and 
gingival scores (p=0.662, p=0.302), respectively by independent t-test (Table 4.18). 
 
Table 4.8 Plaque and gingival indices values for normal weight and obese patients with orthodontic 
treatment. 
 Plaque index values Gingival index values 
 normal weight Obese normal weight Obese 
Number 19 19 19 19 
Mean 1.26 1.33 1.94 2.04 
SD 0.42 0.50 0.29 0.28 
SEM 0.10 0.11 0.07 0.06 
p value 0.662 0.302 
SD, standard deviation; SEM, standard error of mean. 
 
In the normal weight group a correlation was observed only between the levels of 
MMP9 and plaque index in UWMS (r=0.51, p=0.027). In the obese group, the correlations 
were found only between the levels of MPO in UWMS with plaque index (r=0.583, 
p=0.009) and with gingival index (r=0.463, p=0.046)  between the levels of CRP in UWMS 
and gingival index (r=0.461, p=0.047) (Table 4.9). 
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Table 4.9 Correlation of analytes in UWMS, GCF and serum with plaque index (PI) and gingival index (GI) 


























UWMS 0.02 0.94 0.12 0.61 0.07 0.79 0.37 0.13 
GCF 0.09 0.73 -0.09 0.72 0.02 0.95 -0.15 0.53 
serum -0.24 0.32 -0.23 0.35 -0.04 0.88 0.15 0.55 
leptin 
UWMS 0.17 0.48 0.07 0.79 0.00 1.00 -0.40 0.09 
GCF -0.30 0.21 -0.24 0.33 0.09 0.73 -0.14 0.57 
serum -0.17 0.49 -0.29 0.24 0.10 0.67 0.14 0.56 
resistin 
UWMS 0.10 0.67 0.11 0.65 0.06 0.80 0.34 0.16 
GCF 0.18 0.45 0.11 0.67 -0.25 0.31 0.00 0.99 
serum 0.09 0.72 -0.30 0.21 0.23 0.34 0.07 0.78 
MMP8 
UWMS -0.14 0.56 0.56 1.00 0.24 0.33 0.09 0.72 
GCF -0.22 0.37 -0.07 0.79 -0.43 0.07 -0.45 0.05 
serum 0.03 0.89 -0.27 0.27 0.20 0.42 0.05 0.85 
MMP9 
UWMS 0.51* 0.03 0.42 0.07 0.09 0.71 0.34 0.16 
GCF -0.33 0.17 -0.30 0.21 -0.06 0.80 -0.22 0.37 
serum 0.02 0.94 -0.30 0.21 0.03 0.90 0.08 0.76 
TIMP1 
UWMS -0.36 0.13 -0.18 0.47 0.10 0.67 -0.12 0.62 
GCF 0.43 0.07 0.00 1.00 -0.06 0.82 0.02 0.95 
serum 0.07 0.78 -0.17 0.49 -0.04 0.86 0.07 0.78 
MPO 
UWMS 0.16 0.51 0.05 0.85 0.58** 0.01 0.46* 0.05 
GCF -0.39 0.10 -0.39 0.10 -0.04 0.89 -0.31 0.20 
serum 0.28 0.25 0.00 0.99 0.16 0.52 -0.02 0.95 
CRP 
UWMS 0.08 0.75 0.02 0.94 0.27 0.27 0.46* 0.05 
GCF 0.12 0.64 0.05 0.83 0.31 0.20 0.24 0.33 
serum -0.28 0.24 -0.03 0.91 -0.23 0.34 0.02 0.94 
RANKL 
UWMS 0.09 0.70 -0.12 0.61 0.15 0.53 -0.01 0.96 
GCF -24.00 0.30 -0.27 0.26 0.09 0.73 -0.14 0.56 
serum a a a a a a a a 
MPO, myeloperoxidase; CRP, C reactive protein; MMP8, matrix metalloproteinase-8; MMP9, matrix 
metalloproteinase-9; TIMP1, tissue inhibitor of metalloproteinase 1; RANKL, receptor activator of nuclear 
factor kappa-B ligand; a: cannot be measured because all values are zero, *,correlation is significant at the 
0.05 level (2-tailed); **, correlation is significant at the 0.01 level (2-tailed). 
  




The main aim of this study was to investigate the effects of obesity on the levels of 
biomarkers in different bio-fluids with and without fixed-appliance orthodontic treatment. 
Both the chronic inflammation associated with obesity and the acute inflammation 
resulting from applied orthodontic forces produce a wide range of pro- and anti-
inflammatory mediators. Therefore, we characterised the biochemical changes resulting 
from obesity alone by comparing the levels of selected biomarkers between normal weight 
and obese adults without orthodontic treatment (control cohort). We then characterised the 
same biomarkers in normal weight and obese adult patients undergoing fixed appliance 
orthodontic treatment with 0.019 x 0.025-inch stainless steel archwires in the upper and 
lower arches (orthodontic treatment cohort) to detect if obesity can modify the 
inflammatory status during orthodontic treatment. Additionally, levels of these biomarkers 
in different bio-fluids were characterised to investigate the local and/or systemic changes. 
In the design of this study, the influence of age and sex were curtailed through the 
selection of volunteers with a minimum age of 18 years and a maximum age of 45 years 
with a matched age and gender, the rationale behind this is that people over 45 years are 
more likely to have artificial prosthesis and/or periodontal diseases that doesn’t fall into the 
criteria of the control cohort, and less likely to undergo orthodontic treatment which doesn’t 
fit the criteria of the orthodontic treatment cohort. 
One of the factors affecting the composition of saliva and GCF is the flow rate. In 
this study, GCF flow rate increased significantly with obesity in control cohort subjects 
who had no orthodontic appliances (Table 4.2). Since there were no clear signs of gingivitis 
and plaque accumulation in all participants, the main reason for higher GCF flow rate could 
be due to subclinical inflammatory effects of obesity on the periodontal tissues, which may 
affect blood vessel permeability and increase GCF flow rate in obese subjects. This has 
been confirmed by previous studies finding that the rate and composition of GCF can be 
altered by inflammation (Kavadia-Tsatala et al., 2001). In the orthodontic treatment cohort, 
a higher GCF flow rate was observed in both normal weight and obese cohorts in 
comparison to control without orthodontic treatment. Such findings could be because 
orthodontic force causes a distortion of the ECM of the PDL and the production of 
molecules; some of which are vasoactive. In addition, the stretching and compression of 
capillaries in the deeper periodontal tissues may alter GCF flow rate and composition. 
Chapter Four  A cross sectional study 
146 
 
However, no significant differences were observed between normal weight and obese 
groups under orthodontic treatment (Table 4.6) which can be explained by increased GCF 
flow rate in both groups in response to orthodontic force exceeding that due to obesity. 
Comparable UWMS flow rates were observed between normal weight and obese groups 
with and without orthodontic treatment, indicating that obesity did not significantly 
influence saliva secretion. These results are in agreement with the findings of previous 
studies measuring salivary flow rate in obese adults (FenolI-Palomares et al., 2004) and 
children (Pannunzio et al., 2010). 
Defensive proteins involved in both the innate and acquired immune system such as 
immunoglobulins can be found in saliva. Secretory immunoglobulin A (sIgA) is an 
important immune regulator at mucosal surfaces, with a secretory component mediating 
anchoring of the polymeric molecule to epithelial surfaces via glycan residues (Phalipon et 
al., 2002). It is mainly produced by the minor salivary and parotid glands (Eliasson et al., 
2006, Sonesson et al., 2011), it is highly concentrated on oral epithelial cells to prevent the 
entry, attachment, replication and colonization of pathological microorganisms, along with 
neutralizing toxins and viruses (Fabian et al., 2008, Gibbins et al., 2014). In addition, it 
down regulates the pro-inflammatory response (Mantis et al., 2011). An absence of sIgA 
therefore increase the likelihood both mucosal infections and those of the respiratory tract 
(Fábián et al., 2007). The control cohort of the present study showed comparable levels of 
sIgA in UWMS of both obese and normal weight groups, which may indicate that obesity 
does not obviously affect the mucosal humeral adaptive immunity in the sample of this 
study (Figure 4.9). 
Given the presence of proteins normally associated with serum in saliva, it is 
evident that there is diffusion of these proteins from serum to saliva, probably via GCF. 
Therefore, this study also measured serum albumin in UWMS to test diffusion of protein 
from serum to saliva via GCF. Comparable levels of salivary albumin were observed in 
both obese and normal weight groups, indicating that diffusion of proteins is similar in both 
groups and is not affected by obesity (Figure 4.8). 
The strengths of the present study include obesity was defined according to widely 
accepted and reliable measures, which makes misclassification unlikely. However, some 
potential limitations include the fact that height and weight measurements were not taken 
before orthodontic treatment and adiposity is not necessarily a static measure. In addition, 
only BMI was used to classify adiposity, which can limit in terms of overestimating body 
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fat in people with unusually large muscle mass, as is frequently the case for trained athletes 
or body builders. These limitations could have been reduced by adding estimates of 
adiposity (body adiposity index), fat distribution (waist-to-height ratio) and estimate 
overweight (skin fold), but could not be done so as to avoid embarrassment of the 
participants. In addition, the salivary flow rate and protein levels are affected by circadian 
rhythm, however it is not ethical to make pressure on the participants to arrange their 
appointments at the same time during the day, and therefore all samples were taken during 
the day in routine clinics between the hours 9:30 am to 3:30 pm. The other limitation was 
that sample collection for the control cohort without orthodontic treatment was performed 
in a sample collection room rather than a dental clinic that inhibits the proper plaque and 
gingival score measurement and was based mainly on a visual assessment. 
4.3.1 Obesity-related biomarkers 
A number of specific proteins are secreted mainly by adipocytes and called adipokines, 
including adiponectin, leptin and resistin. Similar to previous researches, the present study 
confirmed the fact that although adiponectin, leptin and resistin belong to the same family 
of adipokines which are mostly regulated during obesity, they behave differently. In the 
control cohort (without orthodontic treatment), the levels of adiponectin in GCF and serum 
were reduced in obese subjects. These results agree with another study, which demonstrated 
a reduced level of plasma adiponectin and the adiponectin receptors 1 and 2 in obese 
individuals (Kadowaki and Yamauchi, 2005); however, salivary adiponectin was not 
affected by obesity which can confirm our findings of pseudo adiponectin in saliva. These 
findings match data from other studies, where significant correlations between plasma 
adiponectin levels and BMI were reported (Ryo et al., 2004, Galler et al., 2007, Toda et al., 
2007), along with irrelevant correlations between salivary adiponectin levels and BMI 
(Toda et al., 2007, Toda and Morimoto, 2008, Mamali et al., 2012, Nigro et al., 2015). 
Conversely, in the orthodontic treatment cohort the levels of adiponectin in UWMS, GCF 
and serum were comparable in both obese and normal weight groups that can be explained 
by the effects of orthodontic force which are more than obesity result in reduced levels of 
anti-inflammatory protein, adiponectin, in both normal weight and obese groups. 
Another obesity biomarker is leptin, previous researches suggested that leptin 
stimulates pro-inflammatory cytokines production and phagocytosis by macrophages 
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during the host response to infection and inflammatory stimuli (Ahima and Flier, 2000). In 
the present study, the obese subjects without orthodontic treatment showed significantly 
lower levels of salivary leptin in comparison to normal weight that may point to the effect 
of obesity on leptin production by salivary glands. These explanations, based on the 
findings of a previous study, indicated that human salivary glands express leptin at both 
mRNA and protein levels (Randeva et al., 2003). Furthermore, this trend in saliva differs 
from those in GCF and serum may indicate that obesity affects not only the production of 
leptin by salivary gland but also the diffusion of leptin from serum to saliva by changing 
the basement membrane permeability. The findings of this study are further supported by 
other studies found a lower ratio of salivary/plasma leptin in obese subjects in comparison 
to lean subjects (Gr schl et al., 2001). In GCF and serum, comparable levels of leptin were 
observed in both normal weight and obese groups, which disagree with a previous study 
mentioned that the serum levels of leptin correlate with body weight and fat mass as a result 
of a greater amount of leptin being produced by adipocytes (Considine et al., 1996). The 
similar levels of circulating leptin that we identify here might be related to the relatively 
low BMI of the obese subjects participating in this study (mean ± SD; 32.2 ± 2.5). In GCF, 
the comparable levels of leptin could be correlated with healthy periodontal conditions of 
the participants in both groups. These explanations based on the results of a previous study 
undertaken by Karthikeyan and Pradeep to compare levels of leptin in the GCF of 
periodontal healthy and diseased conditions. They found that these levels decreased with 
periodontal disease (Karthikeyan and Pradeep, 2007b). 
Conversely, subjects with orthodontic treatment showed that the levels of leptin 
increased in both GCF and serum of obese group. This could be explained by higher TNF-
α, IL-1β and other cytokines during orthodontic treatment (Uematsu et al., 1996b, Perinetti 
et al., 2002) which consequently increase the production of leptin (Bornstein et al., 1998, 
Wallace et al., 2000). Furthermore, leptin has been reported to have similar structure and 
function of cytokines (Ahima and Flier, 2000) which are significantly increased with 
inflammatory conditions associated with obesity and OTM. Similarly, serum levels of 
leptin have been demonstrated to be increased with higher levels of cytokines such as 
cortisol, TNF-α, IL-6 (Bornstein et al., 1998, Wallace et al., 2000). In contrast to our 
findings, other authors reported reduced levels of leptin in GCF by orthodontic treatment 
(Dilsiz et al., 2010), these incomparable findings could be related to differences in BMI, 
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age and assay used for biochemical analyses. For instance Dilsiz and co-workers used 
ELISA assay to investigate leptin in GCF of normal weight teenagers. 
Although resistin is considered to be an obesity-related biomarker, in this study, its 
highest levels were observed in GCF followed by serum then UWMS with no significant 
differences between the obese and normal weight groups in any of the three samples with 
and without orthodontic treatment. Similarly, a previous study conducted by Patel and Raju 
(2014) comparing resistin levels in GCF and serum from obese and normal individuals with 
and without periodontitis. They found that resistin levels were higher in GCF than serum, 
and elevated with periodontitis with no significant increase with obesity (Patel and Raju, 
2014). The high levels of resistin in GCF can be explained by the main source of resistin 
being neutrophils, macrophages and monocytes with very little expressed in adipocytes in 
human (Patel et al., 2003, Rosen and Spiegelman, 2006). Indeed, this statement is 
corroborated by a previous study reported no association between serum or salivary resistin 
levels with BMI (Mamali et al., 2012). However, another study reported higher serum 
resistin with obesity (Piestrzeniewicz et al., 2008). 
4.3.2 Biomarkers of tissue remodelling 
It has been shown that remodelling of the ECM accompanies the expansion of adipose 
tissue, with enlargement of fat cells affected by MMPs and their endogenous tissue 
inhibitor (TIMPs) (Halberg et al., 2008). These enzymes have also been implicated in the 
bone and connective tissue remodelling during OTM (Nahm et al., 2004, Tiranathanagul et 
al., 2004) and delayed or inhibited by MMP inhibitors (Holmbeck et al., 2004). MMP8 and 
MMP9 are involved in different steps of collagen turnover, catalysing the initial 
degradation of major ECM proteins (Pilcher et al., 1999, Quasnichka et al., 2005). 
In this study, due to the absence of evidence of plaque and signs of gingival 
inflammation or pocket formation in both obese and normal weight groups, we have 
assumed that cells in the periodontium can produce these MMPs; enhanced PDL 
remodelling activity in the obese group results in this overexpression. The levels of 
circulating MMP8 were increased with obesity in subjects without orthodontic treatment, 
due to an increase the neutrophil activation, the main source of MMP8, in obese subjects. 
However, the levels of MMP9 were comparable in UWMS, GCF and serum of the obese 
and normal weight groups (Figure 4.3), which was confirmed by the zymography results 
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observed by the analyses of UWMS of both obese and normal weight groups (Table 4.3, 
Figure 4.5). These findings agree with a previous study conducted to compare the levels of 
circulating MMPs and TIMPs, and their ratios in obese children and adolescents. They 
showed that the levels of MMP8 and MMP8/TIMP1 ratio but not MMP2 and MMP9 were 
increased with childhood obesity (Belo et al., 2009). Thus, obese subjects, at least in part, 
have a high risk for developing cardiovascular diseases, due to high circulating levels of 
MMP8, as several other studies reported high levels of circulating MMP8 associated with 
the presence and severity of cardiovascular diseases (Turu et al., 2006, Souza-Costa et al., 
2007), as well as implicating them in inflammatory disorders such as metabolic syndrome 
(Koh et al., 2005). 
In the cohort with orthodontic treatment, the levels of MMP9 were increased in both 
GCF and serum of the obese group could be associated with the high degradation of elastin 
and collagen IV, V and X (Tayebjee et al., 2004a, Tayebjee et al., 2004b) that may be 
increased during orthodontic treatment and enhanced by inflammatory conditions of 
obesity. However, the same levels of MMP8 in both obese and normal weight groups is 
probably due to a large number of neutrophils recruited and activated with orthodontic 
treatment irrespective of BMI (Figure 4.12). 
Interestingly, the levels of the inhibitor TIMP1 were increased in serum of obese 
individuals with and without orthodontic treatment. Potentially, this is in order to balance 
the effects of MMPs resulting in comparable levels of MMP8/TIMP1 and MMP9/TIMP1 
ratios in both cohorts. The balance between MMPs and TIMPs is a key factor that regulates 
matrix remodelling, and alteration of this equilibrium may contribute to many diseases 
(Goldberg et al., 1992). 
From our data, we can assume that changes in MMP8 are mainly driven by obesity, 
whilst MMP9 is mainly altered during OTM. This might be a reflection of the different 
collagen fibre types targeted by each MMP. 
4.3.3 Biomarker of bone remodelling 
Given the central involvement of bone remodelling/metabolism in orthodontic treatment 
and the impact of obesity on bone metabolism, it is unsurprising that there are changes in 
bone metabolism in our groups. Interestingly, significant differences were found between 
obese and normal weight groups. 
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In the control cohort without orthodontic treatment, the significantly higher levels of 
RANKL (a key of osteoclastogensis and bone resorption) in the GCF and serum of obese 
subjects (Figure 4.6) can be attributed to the effects of pro-inflammatory cytokines such as 
TNF-α, IL-1β and IL-6 that are produced by adipocytes. These findings come in line with 
the results of studies demonstrated that with obesity OPG/RANKL ratio produced by 
osteoblast was reduced, while RANK produced by osteoclast was upregulated that in turn 
stimulate osteoclastogensis (Halade et al., 2011, Xu et al., 2013). Also an in vitro study 
reported that RANKL mRNA was upregulated by the cytokines produced by adipocytes in 
consistence with osteoclasts differentiation results in more osteoclastogensis and bone 
resorption in obese subjects (Goto et al., 2011). 
However, in UWMS the levels of RANKL were reduced in the obese group which 
possibly indicates that obesity might affect the diffusion of RANKL from serum via GCF. 
Also this could be linked to the wide range of cytokines produced by adipocytes, such as 
interleukins, which may induce or inhibit other cytokines in saliva of obese subjects. 
In the orthodontic treatment cohort, although greater bone remodelling takes place, 
circulating RANKL was undetectable in both obese and normal weight groups (Figure 
4.14); this result is surprising as more bone resorption was expected during orthodontic 
treatment. A possible explanation for these results may be that root resorption takes place 
after months of orthodontic treatment. The protective mechanism of root resorption 
involves production of more OPG (pseudo receptors bind with RANKL to prevent 
osteoclastogensis and bone resorption) by cementoblasts and other periodontal tissue to 
protect cementum from resorption. Therefore, the levels of RANKL in this study seems to 
be affected by additional factors and not wholly dependent on BMI. 
Furthermore, the high levels of RANKL in GCF compared to UWMS and serum 
could be related to the expression of RANKL on T and B lymphocytes in human 
periodontal tissues, which confirmed by immunohistochemistry and confocal microscopic 
analyses in a previous study with periodontitis (Taubman et al., 2005). 
4.3.4 Biomarkers of inflammation 
Since the MPO enzyme is stored in neutrophil granules and released with neutrophil 
activation, the significantly higher levels of MPO in the UWMS, GCF and serum of obese 
subjects without orthodontic treatment (Figure 4.7), suggest that neutrophils are activated 
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via inflammatory processes linked with obesity- as confirmed by the findings of Nijhuis et 
al. (2009). However, in subjects with orthodontic treatment comparable levels of MPO 
were observed in UWMS, GCF and serum of both obese and normal weight groups, 
suggesting that greater numbers of neutrophils are activated as a result of increased 
inflammatory process associated with OTM, irrespective to BMI (Figure 4.15). 
Additionally, the highest level of MPO in control cohort was observed in GCF, whilst in 
the group with orthodontic treatment the peak was in serum. This is probably due to the 
inflammation associated with long time orthodontic treatment (as the sample was collected 
at the final alignment stage of the treatment) which may influence the circulating levels of 
MPO. 
The other inflammatory biomarker we analysed was CRP. Notably, in our study 
there is an absence of any statistically significant difference of CRP levels in UWMS and 
GCF between the normal weight and obese subjects with and without orthodontic 
treatment. This could be related to the healthy gingival and periodontal status of the 
participants show similarly low levels of CRP in GCF and UWMS in both obese and 
normal weight groups. These finding are confirmed by previous studies found a correlation 
between CRP in saliva with the severity of periodontitis (Pederson et al., 1995) and clinical 
attachment loss (Aurer et al., 2005). The systemic origin and low level of CRP in GCF 
(when compared to serum) may go some way in explaining its low levels in UWMS in this 
study. 
The circulating CRP in control cohort without orthodontic treatment is significantly 
increased in obese group compared to normal weight (Figure 4.7). These findings match the 
results of previous studies conducted to find out the differences between obese and non-
obese participants. They found higher CRP levels in serum of obese subjects due to the 
inflammatory conditions linked to obesity (Ellulu et al., 2016) and increased levels of pro-
inflammatory cytokines, such as IL-6 (Jaye and Waites, 1997, Du Clos, 2000). 
Furthermore, a significant correlation between IL-6 and CRP with BMI was outlined by 
Khaodhiar et al. (2004). The close association of these factors can be explained by the 
observation that increases in IL-6 stimulate the production of CRP by the liver (Berg and 
Scherer, 2005). Previous studies have also found significantly higher serum CRP in 
diseased groups when compared to healthy groups (Sibraa et al., 1991, Tüter et al., 2007). 
In the orthodontic treatment cohort, the levels of circulating CRP were comparable 
in both obese and normal weight groups (Figure 4.15). This can be explained as the 
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orthodontic forces increase the production of pro-inflammatory cytokines in particular IL-6 
in both groups, which have the potential to in turn enhance production of CRP from liver 
(Berg and Scherer, 2005, Ide et al., 2004, Gabay, 2006, Nibali et al., 2007). Therefore, after 
a long time with orthodontic treatment the levels of CRP in serum of both normal weight 
and obese patients can be increased independent to body weight. 
4.3.5 Clinical implications 
Statistical implication is used to test the null hypothesis at a selected level of significance. 
Accordingly, the levels of some biomarkers in some bio-fluids were statistically different 
between normal weight and obese participants in both control and orthodontic treatment 
cohorts. However, although these significant differences provide evidence about the 
biochemical changes to be taken into consideration in the long term, they give no clear 
indication of the magnitude or clinical importance of the difference. For instance, the 
significantly increased GCF flow rate in participants of our study was still within the 
normal range between 0.5-1 µl as reported by Lamster et al. (1985). Also our results of 
salivary and GCF levels of biomarkers associated with obesity and/or orthodontic treatment 
were incomparable to the previously published reports for the same  biomarkers under  
pathological conditions such as periodontitis (Kinney et al., 2014). 
4.4 Conclusion 
This cross sectional study investigated the effect of obesity on inflammation, tissue and 
bone remodelling, and obesity-related biomarkers in UWMS, GCF and serum of normal 
weight and obese 18-45 years old subjects of two cohorts. The first cohort was a cohort 
without orthodontic treatment and the second cohort was orthodontic treatment patients 
having 0.019 x 0.025-inch stainless steel rectangular archwires in upper and lower fixed 
orthodontic appliance during the final alignment stage. This study concluded: 
1- In the absence of orthodontic treatment, obesity affects markers in bio-fluids. 
However, orthodontic treatment produces larger effects; 
2- Obesity increases the risk of inflammation and bone resorption by suppressing anti-
inflammatory (adiponectin) and enhancing pro-inflammatory (MPO, CRP, 
RANKL) mediators. However, with good plaque and gingival control, obesity alone 
Chapter Four  A cross sectional study 
154 
 
is insufficient to alter the local tissue remodelling biomarkers MMP8, MMP9 and 
TIMP1; 
3- After months of orthodontic treatment with fixed appliances, the effects of 
orthodontic forces are more significant than those of obesity on biomarker levels; 
4- Obesity may affect the diffusion of biomarkers from serum to saliva through GCF, 
such as leptin and RANKL; and 
5- Saliva cannot substitute GCF or serum for investigation of changes in biomarker 
with obesity and/or orthodontic treatment. 
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Chapter 5 Clinical and biochemical effects of 
obesity on OTM: a prospective cohort study 
5.1 The clinical impact of obesity on orthodontic alignment 
in adolescents 
5.1.1 Introduction 
OTM takes place as a direct consequence of tissue and bone remodelling following the 
application of external mechanical force (Meikle, 2006). It is initially represented by simple 
mechanical displacement of the tooth and bone-bending within the socket, which occurs 
due to compression of the PDL following the application of orthodontic force. However, 
over the longer-term tooth movement occurs as a direct consequence of connective tissue 
remodelling within the periodontium and alveolar bone mediated through a localised 
inflammatory response. This triggers the release of biochemical mediators that are essential 
for this process to occur and are often detectable within GCF (Kapoor et al., 2014). In 
particular, RANKL, MMPs and TIMPs (Grant et al., 2013). 
Obesity is also known to influence systemic bone metabolism through complex 
mechanical, hormonal, and inflammatory interactions (López-Gómez et al., 2016) with 
associations between obesity and reduced bone remodelling (Ivaska et al., 2016) and 
increased bone mineral density (Salamat et al., 2016). 
The potential implications of adolescent obesity for orthodontic treatment have been 
highlighted (Neeley and Gonzales, 2007) with increased BMI being a risk factor for less 
cooperation and longer treatment duration with fixed appliances (von Bremen et al., 2015). 
In addition, there is some evidence of variation in the levels of adipokines in the GCF of 
obese and normal weight individuals with periodontal disease, particularly up-regulation of 
pro-inflammatory adipokines (Zimmermann et al., 2013, Duzagac et al., 2015, Gonçalves et 
al., 2015, Suresh et al., 2016). However, despite known associations between raised BMI 
and chronic inflammatory changes within the periodontium, there have been no prospective 
investigations of OTM in obese patients. 
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5.1.1.1 Aims and objectives 
The main aim of this prospective cohort study was to investigate the effect of obesity on 
OTM in adolescent patients during routine treatment with fixed-appliances; specifically, the 
time taken to complete tooth alignment and variation in clinical parameters, including GCF 
biomarkers. 
The following measurements were carried out in both normal weight and obese 
groups: 
1- Time taken to complete tooth alignment; 
2- Rates of tooth movement; 
3- Variation in clinical parameters, including plaque and gingival indices, and GCF 
flow rate; and 
4- Biochemical analyses of GCF. 
The null hypothesis was that there is no difference in the time to orthodontic tooth 
alignment between normal weight and obese patients. 
5.1.2 Methods 
5.1.2.1 Ethical approval 
Ethical approval was obtained by the United Kingdom National Research Ethics Service, 
NRES Committee foundation (14/LO/0769, October 2014), and written informed consent 
was received from all parents, guardians and children. We report and present data 
according to the STROBE statement (Von Elm et al., 2008). 
5.1.2.1 Inclusion Criteria 
Eligibility included the following criteria: (1) patients undergoing routine fixed-appliance 
treatment with or without teeth extraction; (2) 12-18 years old at treatment-start; (3) no 
medical contraindications or regular medication (including antibiotic-therapy in previous 
three-months); (4) non-smokers; (5) permanent dentition; (6) mandibular arch incisor 
irregularity index of 4-12 mm; and (7) normal weight (BMI-centile 2-91) and obese (BMI-
centile >98) classification. Those classified as underweight (BMI-centile <2) and 
overweight (BMI-centile 91-98) were excluded, respectively. 
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5.1.2.2 Exclusion Criteria 
Patients with a complete bite that could interfere with fixed appliance placement during the 
early stages of treatment; those who needed expansion with or without interdental stripping; 
and those who have any history of juvenile periodontal disease were excluded from the 
study. 
5.1.2.3 Participants 
Participants fulfilling the inclusion criteria were recruited as described in Section 2.4 
number 3, between January 2015 and January 2016. Follow-up took place between January 
2015 and June 2016 and covered periods from baseline records, appliance placement to 
completion of tooth alignment (0.019 x 0.025-inch stainless steel rectangular archwire in 
the lower arch). 
Following informed consent, BMI-centile was measured as described in Section 
2.2.2. All measurements were taken by a single-trained operator (HFS) using the same 
equipment. Subjects were classified as normal weight (BMI-centile 2-91) and obese (BMI-
centile >98). Those classified as underweight (BMI-centile <2) and overweight (BMI-
centile 91-98) were excluded, respectively. 
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5.1.2.4 Data collection 
Data were collected at four time-points as follow: 
 
 
5.1.2.5 Periodontal health 
Periodontal health was measured clinically using established validated gingival and plaque 
indices (Silness and Löe, 1964, Löe and Silness, 1963) as described in Section 2.3. 
5.1.2.6 Impression taking 
Alginate impressions of the lower arch were taken at T1, T3 and T4 in order to monitor 
tooth movement. The impression was then disinfected and moved to the laboratory for 
model casting and scanning using three-dimensional scanner (3Shape R700 laboratory 
scanner, Copenhagen, Denmark). 
• Periodontal health indices 
• Unstimulated whole mouth saliva sample 
• Gingival crevicular fluid sample 
• Peripheral blood sample 
• Dental study cast for lower arch 
T1 
 ( Prior to 
treatment) 
• Unstimulated whole mouth saliva sample 
• Gingival crevicular fluid sample 
• Peripheral blood sample 
T2 
 (1 hour post 
appliance 
placement) 
• Periodontal health indices 
• Unstimulated whole mouth saliva sample 
• Gingival crevicular fluid sample 
• Peripheral blood sample 
• Dental study cast for lower arch 
T3 
 ( 1 week post 
appliance 
placement) 
• Periodontal health indices 
• Unstimulated whole mouth saliva sample 
• Gingival crevicular fluid sample 
• Peripheral blood sample 
• Dental study cast for lower arch 
T4 
 (End of the 
alignment) 
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5.2.2.7 Alignment and rate of tooth movement 
Tooth alignment was calculated from scanned dental stone casts using an irregularity-index, 
which measures the horizontal linear contact-point displacement of each mandibular incisor 
from the adjacent tooth and therefore, represents the sum of the five individual 
displacements (Little, 1975) (Figure 5.1). 
 
 
Figure 5.1 Little’s Irregularity Index to calculate teeth irregularity by measuring the liner distances (1-5) 
between the contact points of lower anterior teeth. Adapted from (Little, 1975). 
 
5.1.2.8 Sample collection 
GCF was collected as described in Section 2.4 and flow rate of GCF was measured as 
mentioned in Section 2.6.2. 
5.1.2.9 Biochemical analyses 
GCF was analysed by magnetic Luminex screening assay using a commercially available 
kit (R&D Systems, Bio-Techne, Abingdon, UK) as mentioned in Section 2.13 for detection 
of the selected biomarkers (in pg/ml), including the adipokines adiponectin, leptin and 
resistin; the inflammation biomarkers MPO and CRP; the tissue remodelling biomarkers 
MMP8 and MMP9, TIMP1, MMP8/TIMP1, MMP9/TIMP1; and bone remodelling 
biomarker RANKL. 
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5.1.2.10 Appliance placement 
Fixed-appliances and bonding method were standardized between groups (3M Victory-
APC 0.022-inch brackets, MBT prescription, 3M-Unitek, Monrovia, USA). After bracket 
bonding, a 0.014-inch nickel-titanium archwire was tied in and ligated using conventional 
elastomerics. The archwire was cut distal to the first molar teeth and not cinched. No bite 
planes, auxiliary-arches, inter-maxillary elastics, headgears or temporary anchorage devices 
were used during the investigation. 
All appliances were placed by postgraduate orthodontic trainees under direct 
supervision of a consultant orthodontist. This was a pragmatic study undertaken in a 
clinical department. Patients were seen at approximately 6 week intervals for appliance 
adjustment and archwire progression took place as deemed clinically appropriate by the 
treating clinicians. 
The primary outcome was time to achieve tooth alignment in the lower arch. 
Secondary outcomes included rate of tooth movement, changes in clinical parameters and 
GCF biomarkers during treatment. There were no changes to outcomes following study 
commencement. 
All primary data were coded so that the outcome assessor (HFS) and statistician 
(SNP) were blinded to subject classification. Data-coding was broken after the end of the 
analysis and no blinding breaches were identified. 
5.1.2.11 Reliability of the measurement 
To examine measurement reliability and agreement, 36-pairs of models from baseline (T1) 
and 1 week (T3) were selected and re-measured after 2 weeks. The Concordance 
Correlation Coefficient (CCC) (Lawrence and Lin, 1989) and Bland-Altman method (Bland 
and Altman, 1986) were used to test intra-examiner reliability and agreement. 
5.1.2.12 Study size 
The sample size was based upon previous randomised prospective data on time to 
completion of alignment with fixed-appliances, which found a mean time-to-alignment of 
200.7 days with standard deviation (SD) 73.6 days in the presence of 8.9 mm incisor 
irregularity (Woodhouse et al., 2015a). A total of 50 patients were required to detect with 
an unpaired t-test a hypothesized 30% reduction (Schulz and Grimes, 2005) in alignment 
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time with a common SD across groups to yield 80% power at p=0.05. Five additional 
patients were recruited to account for possible drop-outs. 
5.1.2.13 Statistical analysis 
Descriptive statistics were calculated after checking for normal distribution. All biomarker 
data were Log10 transformed for normalization. Initial crude differences in baseline and 
outcome data were calculated with independent t-tests, chi-square tests or Mann-Whitney U 
tests, where needed. 
The effect of obesity was investigated using univariable (crude) and multivariable 
generalized estimation equation regression models with robust standard errors to take into 
account correlation between repeated measurements for each patient through the follow-up 
period (baseline, 1-hour, 1- week, and completion of alignment), adjusted for the 
confounding effect of baseline data (sex, age, and baseline-irregularity). Results are 
reported as unstandardized coefficients or Odds Ratios (ORs) for continuous and binary 
outcomes, respectively. The effect modification of obesity on the progress of tooth 
alignment was tested by introducing interaction terms, which were ultimately dropped from 
the model if not significant. Analysis of residuals was conducted to confirm the regression 
assumptions. As patients within the study had initial irregularity ranging from 4-12 mm, 
sensitivity analyses were conducted to include only those with severe (≥7 mm) or moderate 
(4-7 mm) baseline-irregularity. All analyses were carried out using Stata 12.0 (Statacorp 
College Station, Texas, USA). A 2-tailed p-value of 0.05 was considered statistically 
significant with a 95% confidence interval (CI) for all tests. 
5.1.3 Results 
5.1.3.1 Participants 
The 82 patients who fulfilled the inclusion criteria were enrolled in this study, 19 patients 
were excluded because of changes in treatment plan, such as starting the treatment of upper 
arch only or add accessories for the appliance; and 8 patients were declined to participate. 
Therefore, this prospective cohort study included 55 patients (27 male, 28 female) with a 
mean age of 15.1 (SD 1.7) years and mean irregularity index of 7.6 (SD 2.4; 95% CI 6.9-
8.2) mm. Mean BMI centile of the cohort was 24.7 (SD 6.2) kg/m
2
. From the original 55 
patients recruited, 7 were excluded at 1-week (T3) due to missed appointments, but all 55 
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were included at completion of alignment (T4). Missingness at 1-week (T3) was judged as 
random (Table 5.1). The reliability and agreement of repeated measurements was excellent 
(CCC: 0.99 with 95% CI: 0.98 to 0.99; average difference 0.06 with 95% limits of 
agreement: -0.68 to 0.79). Patient-flow through the study is shown in Figure 5.2. 
Table 5.2 shows demographics and GCF parameters for the two cohorts at baseline 
(T1). The mean BMI was 19.4 (2.2) kg/m
2
 in the normal weight group and 30.2 (3.5) kg/m
2
 
in the obese group. Apart from BMI, there were no statistically significant differences in 
demographics among groups at baseline; however, the obese group did have 1.2 mm more 
irregularity (p=0.061). In contrast, significant differences were present between normal 
weight and obese groups for a number of GCF biomarkers at baseline (Table 5.2; p<0.05) 
including increased GCF flow-rate, increased leptin, resistin, MPO, MMP8, TIMP1, 
RANKL, and reduced MMP9/TIMP1 levels in obese patients. 
 
 
Figure 5.2 Patient-flow through the investigation. 
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Obese P value 
Recruited sample (data for baseline, 
completion of alignment)    
 
Patients 55 28 27  
Male - n (%) 27 (49%) 15 (54%) 12 (44%) 0.498* 
Age - mean (SD) 15.1 (1.7) 15.1 (1.6) 15.1 (1.9) 0.991
#
 
Irregularity - mean (SD) 7.6 (2.4) 7.0 (2.3) 8.2 (2.4) 0.061
#
 
BMI - mean (SD) 24.7 (6.2) 19.4 (2.2) 30.2 (3.5) <0.001
#
 
Sample with drop-outs (data for one 
week) 
    
Patients 48 24 24  
Male - n (%) 24 (50%) 13 (54%) 11 (46%) 0.564* 
Age - mean (SD) 15.3 (1.7) 15.2 (1.6) 15.3 (1.8) 0.737
#
 
Irregularity - mean (SD) 7.7 (2.4) 7.2 (2.3) 8.2 (2.5) 0.156
#
 
BMI - mean (SD) 24.7 (6.2) 19.3 (2.2) 30.2 (3.6) <0.001
#
 
SD, standard deviation; BMI, body mass index; * from chi-square test; # from independent t-test. 
  










Obese P value 
Demographics 
   
 
 Patients (n) 55 28 27  
 Male / female (n) 27/28 15/13 12/15 0.498* 
 Age - mean (SD) 15.1 (1.7) 15.1 (1.6) 15.1 (1.9) 0.991
#
 
 Caucasian – n (%) 29 (61) 17 (61) 12 (44) 0.516* 
 Asian – n (%) 4 (7) 2 (7) 2 (7)  
 African – n (%) 5 (9) 1 (4) 4 (15)  
 Mixed – n (%) 8 (15) 3 (11) 5 (19)  
 Others – n (%) 9 (16) 5 (18) 4 (15)  
 BMI - mean (SD) 24.7 (6.2) 19.4 (2.2) 30.2 (3.5) <0.001
#
 
 Plaque index (SD) 0.56 (0.32) 0.57 (0.32) 0.54 (0.31) 0.745
#
 
 Gingival index (SD) 0.74 (0.39) 0.74 (0.40) 0.73 (0.38) 0.934
#
 





 – n (%) 31 (56%) 13 (46%) 18 (67%) 0.130* 
 Tooth extraction – n (%) 8 (15%) 4 (14%) 4 (15%) 0.956* 
GCF parameters 
(Log10 transformed) 
    
 GCF flow-rate
 † 
(l/min) -0.29 (0.14) -0.33 (0.12) -0.25 (0.12) 0.011
£
 





(pg/ml) 13.91 (22.64) 6.40 (14.65) 19.15 (24.45) 0.031
£
 
 Resistin (pg/ml) 5.61 (0.56) 5.30 (0.55) 5.92 (0.36) <0.001
#
 





(pg/ml) 2.50 (0.51) 2.47 (0.27) 2.65 (0.87) 0.827
#
 





(pg/ml) 6.23 (0.30) 6.18 (0.59) 6.27 (0.15) 0.245
#
 
 TIMP1 (pg/ml) 5.00 (0.48) 4.72 (0.38) 5.28 (0.40) <0.001
#
 
 MMP8/TIMP1 (pg/ml) 0.96 (0.64) 0.93 (0.62) 0.99 (0.68) 0.699
#
 





(pg/ml) 3.54 (0.33) 3.39 (0.25) 3.65 (0.27) <0.001
£
 
SD, standard deviation; BMI, body mass index; GCF, gingival crevicular fluid; MPO, myeloperoxidase; CRP, 
C reactive protein; MMP8, matrix metalloproteinase-8; MMP9, matrix metalloproteinase-9; TIMP1, tissue 
inhibitor of metalloproteinase 1; RANKL, receptor activator of nuclear factor kappa-B ligand.* from chi-
square test. # from independent t-test. £ from Mann-Whitney test. ¥ according to Little (1975). †Log10 
transformation improved the skewness of the data, but the Shapiro-Wilk test indicated that transformed data 
were still not normally distributed. Therefore, the median (interquartile range) is presented instead of mean 
(SD) and the Mann-Whitney test is used on the transformed data instead of the unpaired t-test. ‡ Square root 
transformation used instead of log10, as several null values were included. Therefore, the median 
(interquartile range) is presented instead of mean (SD) and the Mann-Whitney test is used on the transformed 
data instead of the unpaired t-test. 
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5.1.3.2 Primary outcome 
The results of both crude and adjusted regression analyses indicated only a small difference 
in time to achieve alignment between obese and normal weight patients. Overall, obese 
patients needed a mean 23.0 days less than normal weight to reach final alignment (Figure 
5.3 A), but this was not statistically significant (Table 5.3, p>0.05). 
5.1.3.3 Secondary outcomes 
A number of significant differences were observed between obese and normal-weight 
patients in the clinical response to orthodontic force. The rate of mechanical tooth 
displacement within week-1 was statistically significantly increased in the obese group 
(p<0.001); whilst overall rate of alignment from baseline to completion-of-alignment was 
also increased (p=0.05) (Table 5.4). However, tooth alignment rate from week-1 to 
completion-of-alignment was not significantly different between groups (Table 5.4; 
p=0.119). After taking into account all confounders in the adjusted analysis, obese patients 
were associated with a significantly increased rate of tooth movement throughout the whole 
study duration compared to normal weight patients (0.017 mm/day; 95% CI: 0.008, 0.025 
mm/day). Additionally, a significant association was found between rate of tooth 
movement and initial tooth irregularity (0.007 mm/day increase per mm irregularity) (Table 
5.3, Figure 5.3 B). Sensitivity analyses for patients with either severe or moderate 
irregularity were consistent in direction with the main analyses (Table 5.5 and 5.6 
respectively) with an expected loss of power due to the division of the study sample, and a 
higher difference in alignment rate between obese and normal weight patients in the severe 
irregularity group. 
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Table 5.3 Regression analyses on primary outcome, time to completion of tooth alignment in days, and 
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Ref   
b, unstandardized regression coefficient; CI confidence interval; BMI, body mass index; Ref, reference; NT, 
not tested; *Interaction of obesity with time found to be non-significant (p=0.112) and was dropped from the 
model. 
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Tooth alignment rate: baseline to completion of 








Tooth alignment rate: baseline to week one 








Tooth alignment rate: week one to completion of 








d, days; SD, standard deviation; CI, confidence interval. * from independent t-test. 
†
Due to 7 patient drop-outs at one week, 48/55 patients (24 obese and 24 control patients) are included in 
these two measurements. The measurement of time-to-alignment and alignment rate: baseline to completion 




Figure 5.3 Box plots of measured values in normal weight and obese patients for (A) primary (time to 
completion of alignment in days) and (B) secondary (tooth alignment rate from start of treatment to 
completion of alignment in mm/day) outcomes. Plotted boxes with horizontal lines indicate interquartile 
ranges with medians. Vertical whiskers and points indicate upper and lower adjacent values and outliers. 
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Table 5.5 Sensitivity analysis: regression analysis on the primary (time to completion of alignment in days) 
and secondary outcome (rate of tooth movement in mm/day) for the category of patients with severe initial 
crowding (≥7 mm; n=31). 
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Ref   
b, unstandardized regression coefficient; CI, confidence interval; Ref, reference. 
*Interaction of obesity with time found to be non-significant (p=0.171) and was dropped from the model. 
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Table 5.6 Sensitivity analysis: regression analysis on the primary (time to completion of alignment in days) 
and secondary outcome (rate of tooth movement in mm/day) for the category of patients with moderate initial 
crowding (<7mm; n=24). 
   
  



































































































































































Ref   Ref   


























Ref   





each phase start 















Ref   
b, unstandardized regression coefficient; CI, confidence interval; Ref, reference. 
*Interaction of obesity with time found to be non-significant (p=0.171) and was dropped from the model. 
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Plaque and gingival indices deteriorated significantly (Table 5.7), but there were no 
differences between groups for any of these parameters. GCF flow-rate increased during 
orthodontic treatment for both groups, but significantly more in obese patients. 
 
Table 5.7 Results of regression models assessing the effect of obesity and time-variation during orthodontic 
treatment on the levels of clinical indices and GCF biomarkers. Explorative interactions between obesity and 
time were tested in each case, but were dropped from the model if they were not statistically significant. 
Biomarker transformation Factor 
 
b 95% CI 
P  
value 
Plaque index Obese  
0.03 -0.05,0.12 0.460 







T3 0.16 0.07,0.26 0.001 
 
 
T4 0.34 0.27,0.41 <0.001 
 
Interaction 
   
0.353 
Gingival index Obese  
0.04 -0.05,0.12 0.391 







T3 0.14 0.06,0.21 0.001 
 
 
T4 0.30 0.24,0.36 <0.001 
 
Interaction 
   
0.206 
GCF flow-rate Obese  
0.08 0.04,0.13 <0.001 
Log10 transformed Time T1 Ref   
   
T2 0.10 0.05,0.15 <0.001 
   
T3 0.10 0.06,0.14 <0.001 
   
T4 0.09 0.04,0.13 <0.001 
  Interaction    
0.282 
Adiponectin Obese  
0.08 -0.12,0.28 0.417 
Log10 transformed Time T1 Ref   
 
 
T2 0.15 0.04,0.26 0.010 
 
 
T3 0.23 0.10,0.36 <0.001 
 
 




-0.07 -0.13,-0.01 0.027 
Leptin Obese  
6.41 1.71,11.10 0.007 
Square-root transformed Time T1 Ref   
   
T2 -2.44 -5.18,0.29 0.080 
   
T3 -1.21 -1.85,4.27 0.439 
   
T4 -4.44 -8.50,-0.38 0.032 
  Interaction    
0.556 
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Continue Table 5.7 
Biomarker transformation Factor 
 
b 95% CI 
P  
value 
Resistin Obese  
0.60 0.44,0.76 <0.001 
Log10 transformed Time T1 Ref   
 
 
T2 0.13 -0.04,0.30 0.124 
 
 
T3 0.03 -0.16,0.21 0.757 
 
 
T4 -0.05 -0.18,0.09 0.519 
 
Interaction 
   
0.975 
MPO Obese  
1.36 1.11,1.62 <0.001 
Log10 transformed Time T1 Ref   
 
 
T2 0.36 0.13,0.59 0.003 
 
 
T3 0.56 0.39,0.74 <0.001 
 
 
T4 0.69 0.52,0.87 <0.001 
 
Interaction 
   
0.994 
CRP Obese  
-0.02 -0.24,0.20 0.860 
Log10 transformed Time T1 Ref   
 
 
T2 0.10 -0.04,0.23 0.149 
 
 
T3 0.27 0.09,0.46 0.004 
 
 
T4 0.26 0.07,0.44 0.006 
 
Interaction 
   
0.192 
MMP8 Obese  
0.62 0.32,0.93 <0.001 
Log10 transformed Time T1 Ref   
 
 
T2 0.16 0.05,0.28 0.007 
 
 
T3 0.12 0.01,0.23 0.037 
 
 
T4 0.05 -0.07,0.17 0.446 
 
Interaction 
   
0.995 
MMP9 Obese  
0.06 -0.02,0.15 0.149 
Log10 transformed Time T1 Ref   
 
 
T2 0.38 0.28,0.49 <0.001 
 
 
T3 0.35 0.25,0.44 <0.001 
 
 
T4 0.08 -0.03,0.19 0.181 
 
Interaction 
   
0.388 
TIMP1 Obese  
0.61 0.38,0.84 <0.001 
Log10 transformed Time T1 Ref   
 
 
T2 -0.04 -0.20,0.13 0.668 
 
 
T3 0.25 0.07,0.42 0.005 
 
 




-0.08 -0.15,-0.00 0.040 
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Continue Table 5.7 
Biomarker transformation Factor 
 
b 95% CI 
P 
 value 
MMP8/TIMP1 Obese  
0.20 -0.14,0.54 0.254 
Log10 transformed Time T1 Ref   
 
 
T2 0.24 0.03,0.45 0.027 
 
 
T3 -0.05 -0.22,0.13 0.600 
 
 
T4 -0.25 -0.42,-0.08 0.003 
 
Interaction 
   
0.166 
MMP9/TIMP1 Obese  
-0.34 -0.57,-0.11 0.004 
Log10 transformed      
 




T2 0.46 0.33,0.59 <0.001 
 
 
T3 0.18 0.02,0.34 0.024 
 
 
T4 -0.23 -0.35,-0.10 <0.001 
 
Interaction 
   
0.239 
RANKL Obese  
0.38 0.28,0.48 <0.001 
Log10 transformed Time T1 Ref   
 
 
T2 0.01 -0.06,0.09 0.733 
 
 
T3 0.03 -0.06,0.12 0.532 
 
 
T4 0.37 0.27,0.47 <0.001 
 
Interaction 
   
0.089 
T1, baseline; T2, 1 hour; T3, 1 week; T4, completion of alignment; b, unstandardized regression coefficient; 
CI, confidence interval; Ref, reference; GCF, gingival crevicular fluid; MPO, myeloperoxidase; CRP, C 
reactive protein; MMP8, matrix metalloproteinase-8; MMP9, matrix metalloproteinase-9; TIMP1, tissue 
inhibitor of metalloproteinase 1; RANKL, receptor activator of nuclear factor kappa-B ligand. 
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In order to further understand the biochemical basis of observed differences in rates 
of tooth movement, explorative regression analyses were undertaken (Table 5.8). GCF flow 
rate and levels of leptin, resistin, MPO, MMP8, TIMP1, MMP9/TIMP1 and RANKL were 
significantly different between obese and normal weight patients at baseline (Table 5.2) and 
during subsequent assays (Table 5.7). 
When the grounds for a possible inter-relation between these biomarkers and rate of 
tooth movement were investigated, it was found that GCF levels of leptin, resistin, MPO 
and RANKL were significantly associated with the amount of tooth movement for each 
patient (Table 5.9). Therefore, from an epidemiological basis, these would be the best 
candidates to explain the clinical performance difference between obese and normal weight 
patients during fixed-appliance orthodontic alignment. 
 
Table 5.8 Summary of exploratory analyses on the secondary outcome: GCF biomarker levels. 
  
Different in obese 
and normal weight 
at baseline 
(Table 5.2) 
Different in obese 
and normal weight 
during treatment  
( Table 5.7 ) 
Associated with 
alignment rate 





Plaque index No No - 
 
Gingival index No No - 
 




Adiponectin No No - 
 
Leptin Yes Yes Yes 
 
Resistin Yes Yes Yes 
 
MPO Yes Yes Yes 
 
CRP No No - 
 
MMP8 Yes Yes No 
 
MMP9 No No - 
 
TIMP1 Yes Yes No 
 
MMP8/TIMP1 No No - 
 
MMP9/TIMP1 Yes Yes No 
 
RANKL Yes Yes Yes 
MPO, myeloperoxidase; CRP, C reactive protein; MMP8, matrix metalloproteinase-8; MMP9, matrix 
metalloproteinase-9; TIMP1, tissue inhibitor of metalloproteinase 1; RANKL, receptor activator of nuclear 
factor kappa-B ligand; b, unstandardised regression coefficient. 
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Table 5.9 Results of regression models assessing the association of time-variation during orthodontic 
treatment, baseline irregularity, and biomarker levels with tooth alignment rate in mm/day. 
Biomarker 
transformation 
Factor b 95% CI P value 




0.007 0.005,0.010 <0.001 
 Leptin 0.001 0.000,0.001 0.006 




0.007 0.005,0.010 <0.001 
 
Resistin 0.013 0.006,0.020 0.001 




0.007 0.005,0.009 <0.001 
 
MPO 0.010 0.004,0.014 <0.001 




0.007 0.005,0.010 <0.001 
 
MMP8 0.003 -0.004,0.010 0.415 




0.007 0.005,0.010 <0.001 
 
TIMP1 0.004 -0.004,0.012 0.335 




0.007 0.005,0.009 <0.001 
 
MMP9/TIMP1 -0.003 -0.012,0.007 0.592 




0.007 0.005,0.010 <0.001 
 
RANKL 0.011 0.000,0.022 0.040 
MPO, myeloperoxidase; MMP8, matrix metalloproteinase-8; TIMP1, tissue inhibitor of metalloproteinase 1; 
RANKL, receptor activator of nuclear factor kappa-B ligand. 




This prospective study followed a cohort of obese and normal-weight adolescent patients 
during the alignment phase of fixed-appliance orthodontic treatment. Obese patients needed 
less time to achieve alignment but this was not significant. However, obese patients 
demonstrated significantly increased rates of tooth movement during the whole observation 
period; this apparent discrepancy might be explained by a number of factors. Firstly, the 
obese group had a significantly increased initial mechanical displacement of the teeth 
during the first week following the application of orthodontic force (T1-T3), then decreased 
until the two groups showed comparable movement between the first week and the end of 
alignment (T3-T4). At the end of alignment, the obese group displayed a significantly 
higher rate of overall tooth movement (T1-T4) with comparable duration of teeth 
alignment. Also there may have been possible between-group variation in attendance 
during routine appointments. Evidence exists from a similar experimental model that initial 
alignment can increase by 0.01 mm per day whilst overall alignment increases by 0.004 
mm per day every millimetre of initial irregularity (Woodhouse et al., 2015a). It is 
important to remember that statistical and clinical significance are not the same. A 
randomized controlled trial conducted to investigate the effect of bracket–ligature 
combination on the amount of orthodontic space closure over 3 months demonstrated a 
non-significant difference in the amount of space closure (1 mm per 28 days) between three 
different bracket/archwire combinations (Wong et al., 2013). Thus, the results of our study 
with a statistical significant difference of 0.017 mm per day (0.5 mm per month) would be 
clinically insignificant. 
Significant differences were also found in the GCF biochemical profile between 
obese and normal weight patients and to our knowledge, this represents the first prospective 
data to suggest that obese patients may respond differently to those with normal weight 
during routine orthodontic treatment. 
Appliance variation has little or no effect on rate of OTM (Woodhouse et al., 2015a, 
Scott et al., 2008a). Interestingly, we found that obesity does influence tooth movement, as 
obese patients had increased rates when compared to normal weight. Statistical modelling 
of alignment rate and its change through time (Table 5.3) demonstrated that obesity and 
initial irregularity at each phase explained part of the variation seen in alignment. Given the 
absence of a significant interaction between obesity and time, the difference in alignment 
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rate between obese and normal weight patients was consistently present through the 
alignment process and independent of confounders. 
Importantly, the groups in this investigation were not different in terms of baseline 
demographics, including plaque/gingival indices and irregularity, with BMI representing 
the only significant difference. However, a number of differences existed in baseline GCF 
parameters between groups, including GCF flow-rate and the levels of several biomarkers. 
The pro-inflammatory adipokines leptin and resistin were both elevated in the GCF of 
obese patients (Suresh et al., 2016), suggestive of a baseline pro-inflammatory state within 
the periodontium of these individuals. It is also consistent with the significantly increased 
levels of MPO, which represents an established marker for inflammation in the GCF 
(Marcaccini et al., 2010, Navarro-Palacios et al., 2014). Interestingly, the levels of several 
biochemical mediators of tissue and bone remodelling were also increased at baseline in the 
obese group, including MMP8, TIMP1 and RANKL, providing evidence of an altered 
inflammatory biochemical profile in the GCF of obese patients. 
Amongst the GCF biomarkers assayed, leptin, resistin, MPO, and RANKL most 
predictably accounted for the observed differences in rates of tooth movement. The levels 
of these biomarkers differed significantly between obese and normal weight patients both 
before and during treatment; whilst at the same time, being significantly associated with the 
amount of tooth movement observed. 
The higher levels of leptin and resistin in GCF of obese patients may enhance the 
pro-inflammatory condition of those patients during orthodontic treatment. However, these 
biomarkers did not remarkably change at different time points of orthodontic alignment in 
both normal weight and obese patients, indicating that orthodontic force did not influence 
the levels of these adipokines in GCF. This result disagrees with a previous study, which 
reported reduced levels of GCF leptin during orthodontic treatment (Dilsiz et al., 2010). 
This inconsistency could be related to differences in BMI, age and assay used for 
biochemical analyses. For instance, Dilsiz and co-workers used ELISA assay to investigate 
leptin in GCF of normal weight teenagers. Resistin, like leptin, is up-regulated in inflamed 
gingival tissue as compared to healthy (Suresh et al., 2016), but the relationship between 
GCF resistin and OTM has not previously been investigated. 
The levels of MPO increased significantly after fixed orthodontic appliance 
placement and continued until the end of alignment, with statistically significantly higher 
levels in obese patients at all-time points (T1-T4). These results reflect the greater 
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neutrophil activation in the periodontal tissues of obese patients, for whom obesity-related 
inflammation was exacerbated by orthodontic treatment. The increased levels of MPO with 
orthodontic treatment confirmed by previous studies reported that MPO levels were 
increased 2 hours after appliance placement (Marcaccini et al., 2010) with no differences 
between severe and moderate crowding (Navarro-Palacios et al., 2014). The high levels of 
MPO associated with obesity were also confirmed by recent studies reporting a significant 
increase in MPO levels in obese children compared to control groups (Marcovecchio et al., 
2016, Varma et al., 2016). 
The higher levels of RANKL in obese patients before and throughout the 
orthodontic alignment (T1-T4) could be related to higher pro-inflammatory cytokines 
produced by adipocytes such as TNF-α, IL-1β and IL-6, which stimulate RANKL/RANK 
pathway and result in more osteoclastogensis and bone resorption with obesity (Khosla, 
2001, Pfeilschifter et al., 2002). 
The other biomarker, MMP8, is mainly produced by neutrophils, demonstrated 
significantly higher levels in GCF of obese patients throughout the whole alignment stage. 
This indicates that neutrophils are highly activated by obesity, leading to higher levels of 
MMP8 in obese patients. Similarly, the higher levels of the inhibitor (TIMP1) in obese 
patients before and throughout the alignment period could be considered as an attempt to 
counterpart the increase in the levels of MMP8 and balance the ECM destruction by MMPs 
during remodelling. 
The results of this study did not show any significant association between plaque 
and gingival indices and the levels of biomarkers at all-time points. This indicates that the 
variation in the levels of biomarkers in GCF resulted from the response of periodontal 
tissues to the applied orthodontic force rather than bacterial plaque or gingivitis. 
The strengths of the present study include its prospective design (Papageorgiou et 
al., 2015b), baseline comparability between experimental groups, absence of drop-outs at 
study completion and use of measurement-blinding. Moreover, obesity was defined 
according to widely accepted and reliable measures, which makes misclassification 
unlikely. Collectively, this means that the respective risk for selection, attrition and 
detection bias is low. The study sample was based on a conservative a priori power 
calculation, and planned dropouts did not occur. However, some potential limitations 
include the fact that height and weight measurements were only taken at baseline and 
adiposity is not necessarily a static measure. Indeed, in an adolescent population underlying 
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growth might have influenced BMI during the course of the investigation, although with a 
mean observation of 158 days and mean patient age of 15.1 years, this effect may have 
even been negligible. In addition, only BMI was used to classify adiposity, which can limit 
the identification of overweight and could have been reduced by adding estimates of 
adiposity (body adiposity index) and fat distribution (waist-to-height ratio) (del Mar 
Bibiloni et al., 2013). Moreover, in order to widen the inclusion criteria of participants, the 
need for teeth extraction was not considered as an exclusive criterion which may have an 
impact on the rate of tooth movement. Also in a cohort undergoing routine orthodontic 
treatment with fixed appliances it is not practical to see each patient at exactly the same 
time-point for archwire adjustments or identify the absolute first time-point that alignment 
is complete for every single patient. For these reasons, the increased rates of tooth 
movement that were identified in the obese group may not have resulted in a clinically 
significant reduction in time to final alignment. In addition, it is worth mentioning that 
there is another statistical method for analysing the medical research data collected serially 
on subjects, which takes the form of a two stage method that uses summary measures 
(Matthews et al., 1990). 
In addition, whilst the observed differences in rates of tooth movement are tangible 
effects with obvious potential clinical relevance, the underlying biological mechanisms are 
likely to be complex. The measured differences in GCF biomarkers may be associated with 
the inter-relationship between obesity and tooth movement, but this study provides no 
conclusive evidence. Further investigation will be required to elucidate the precise role of 
each biomarker in mediating OTM. However, this investigation provides evidence that 
informs clinical practice both in orthodontics and wider healthcare. The results are 
applicable to obese and normal weight patients, although it should be remembered that 
adipose tissue can behave differently according to age group in other body systems (Palmer 
and Kirkland, 2016). A pro-inflammatory obese state can influence OTM, with significant 
associations between levels of specific biomarkers within the GCF of obese patients. These 
results highlight potential implications for orthodontic treatment in obese subjects and one 
area for future research would be a comparison of post-orthodontic stability in obese and 
normal weight patients. 




This prospective clinical study investigated tooth alignment in obese and normal weight 
patients undergoing fixed-appliance orthodontic treatment. Obese and normal weight 
patients needed the same time to achieve tooth alignment. After adjusting for confounders, 
the rate of OTM was significantly higher in obese patients compared to normal weight. 
Additionally, explorative analyses indicated GCF-levels of leptin, resistin, MPO and 
RANKL were significantly different between obese and normal weight patients and 
associated with observed rates of OTM. This is the first prospective data to show a different 
orthodontic treatment response in obese patients. These differences have potential clinical 
implications for treatment over both the short and long-term. 
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5.2 Time-related changes in biomarker levels during 
orthodontic alignment in normal weight and obese patients 
5.2.1 Introduction 
Biological reaction in the teeth and supporting tissue during OTM is a subject of interest 
(Meikle, 2006, Davidovitch and Krishnan, 2009). When orthodontic mechanical stimuli 
transfer to the teeth, blood vessels dilate and inflammatory cells are recruited to the 
periodontal space and produce mediators as biological response. The local micro-
environmental status of the supporting tissue during orthodontic treatment can therefore be 
reflected by these mediators (Kook et al., 2011, Zainal Ariffin et al., 2011, Salla et al., 
2012). 
While it is clear that both OTM and obesity mediate the biomarkers in the PDL 
space, there has been a lack of analysis of biochemical changes with orthodontic treatment 
of obese subjects. This study investigates obesity-related biomarkers, alongside tissue and 
bone remodelling biomarkers and inflammation biomarkers, in three human bio-fluids 
(UWMS, GCF and serum). This is the first comprehensive analysis of biomarker changes 
during the orthodontic alignment stage of both obese and normal weight patients. 
5.2.1.1 Aims and objectives 
The aim of this prospective cohort study was to investigate the effects of obesity on the 
level of biomarkers during the alignment stage of orthodontic treatment in obese and 
normal weight adolescent patients. 
To address this aim, the following steps were taken: 
1. Biochemical analysis of inflammation, tissue and bone remodelling and obesity-
related biomarkers in UWMS, GCF and serum. This analysis was conducted for 
both normal weight and obese patients, in order to assess which fluid best presents 
the local biological changes that occur during OTM; 
2. Assessment of the effect of orthodontic treatment on the concentrations of selected 
biomarkers by measuring their levels before the placement of the fixed orthodontic 
appliance and at three points during their treatment; and 
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3. Assessment of the effect of obesity on the concentrations of the selected biomarkers 
by comparing the levels of selected biomarkers between obese and normal weight 
patients at each time point. 
The null hypotheses were that obesity does not modify the biochemical changes that 
take place during OTM and that there is no difference between UWMS, GCF and serum in 
the biochemical analysis. 
5.2.2 Methods 
5.2.2.1 Sample collection for biochemical analyses 
Of the 55 patients recruited for the prospective study, 28 were of normal weight and 27 
were obese. UWMS, GCF and serum were collected at four time points, as described in 
Section 2.4: (T1) start of treatment; (T2) 1 hour following appliance placement; (T3) 1 
week following appliance placement; and (T4) end of alignment stage (0.019 x 0.025-inch 
stainless steel rectangular archwire in the lower arch). For all participants, plaque levels and 
gingival health were measured at T1, T3 and T4, as mentioned in Section 2.3. UWMS and 
GCF flow rate were measured at T1, T2, T3 and T4 as described in Section 2.6. 
Since biochemical changes were more likely to be observed in GCF during OTM, 
GCF was analysed for all 55 patients (28 normal weight and 27 obese); whilst UWMS and 
serum were assayed for a random selection of 20 patients (10 normal weight and 10 obese). 
UWMS, GCF and serum were analyzed by magnetic Luminex screening assay, 
using a commercially available kit (R&D systems, Bio-Techne, Abingdon, UK) as 
mentioned in Section 2.13. The screening was conducted to detect (in pg/ml): adipokines 
(adiponectin, leptin and resistin), inflammatory mediators (MPO and CRP), the bone 
remodelling biomarker (RANKL), and tissue remodelling biomarkers (MMP8, MMP9, 
TIMP1, and their ratios MMP8/TIMP1, MMP9/TIMP1). 
5.2.2.2 Statistical analysis 
Descriptive statistics were used to summarise the outcome variables. Parametric and non-
parametric analyses were carried out after checking for the normality distribution using 
Shapiro-Wilk test of normality. The Friedman test was used to measure the difference in 
the levels of the not normally distributed data of biomarkers over time for both normal 
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weight and obese groups. The Mann Whitney U test was used to compare the not normally 
distributed data of biomarkers’ concentrations in normal weight and obese groups at each 
time point. All statistical analyses were done using SPSS (BM Corp. Released 2013. IBM 
SPSS Statistics for Windows, Version 23; Armonk; New York; IBM;Corp). 
5.2.3 Results 
5.2.3.1 Participants 
The clinical parameters of the subjects enrolled in the present study are shown in Table 
5.10. Age did not significantly differ between the obese and normal weight groups 
(p>0.05). The BMI was significantly higher in obese group compared to normal weight 
(p<0.00001). 
 
Table 5.10 Demographics and clinical characteristics of the patients participated in prospective cohort study. 
Sample Parameters Normal weight Obese 
GCF 
Number 28 27 
Age (years): Mean (SD) 15.1 (1.6) 15.1 (1.9)  
Gender: male / female 15 / 13 12 / 15 
BMI (kg/m
2




Number 10 10 
Age (years): Mean (SD) 14.9 (1.6) 15.9 (2.1) 
Gender: male / female 5 / 5 3 / 7 
BMI (kg/m
2
): Mean (SD) 19.6 (2.3) 29.7 (2.3) * 
UWMS, unstimulated whole mouth saliva; GCF, gingival crevicular fluid; SD, standard deviation; BMI, body 
mass index; *,significantly higher (p<0.00001) using independent t-test. 
 
5.2.3.2 UWMS and GCF flow rate 
Both the mechanical stimuli of the orthodontic appliance, and the inflammatory reactions 
that take place during OTM, may affect the salivary and GCF flow rate. 
The Friedman test followed by the Bonferroni correction showed that UWMS and 
GCF flow rate increased significantly at all-time points (T2-T4) in comparison to the 
baseline (T1) in both normal weight and obese patients.  
Comparing the flow rate between normal weight and obese patients at each time 
point, the Mann Whitney U test showed that GCF flow rate was significantly higher in 
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obese patients than in normal weight patients before and throughout the orthodontic 
alignment, whereas there was no significant difference in UWMS flow rate at any time 
point (Figure 5.4). 
 
 
Figure 5.4 Box plots showing the UWMS, unstimulated whole mouth saliva (A) and GCF, gingival 
crevicular fluid (B) flow rate of normal weight (n=28) and obese (n=27) patients at four time points. T1, 
baseline (before placement of orthodontic appliance); T2, 1 hour after placement of orthodontic appliance; 
T3, 1 week after placement of orthodontic appliance (n=24 in each group); T4, end of the alignment (0.019 x 
0.025-inch stainless steel rectangular archwire in the lower arch); *, significant difference between normal 
weight and obese (p<0.05) by Mann Whitney U test; (a), significant difference with T1 by Friedman test 
followed by Bonferroni correction (p<0.0125) for normal weight group; (b), significant difference with T1 by 
Friedman test followed by Bonferroni correction (p<0.0125) for obese group, vertical whiskers indicate 
minimum to maximum values. 
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5.2.3.3 Periodontal health assessment 
As bacterial plaque and inflamed gingivae can influence the levels of biomarkers in GCF, a 
periodontal health measurement is required. The Friedman test, followed by the Bonferroni 
correction, showed that the plaque index increased significantly in both normal weight and 
obese patients at the end of alignment (T4), compared with the baseline measurement (T1). 
However, gingival index significantly increased at T4 in normal weight patients and after 1 
week (T3) in obese patients, continuing until the end of alignment. The Mann-Whitney U 
test showed comparable plaque and gingival scores between the normal weight and obese 
groups at all-time points (Figure 5.5). 
 




Figure 5.5 Box plots showing the plaque index (A) and the gingival index (B) of normal weight (n=28) and 
obese (n=27) patients at four time points. T1, baseline (before placement of orthodontic appliance); T3, 1 
week after placement of orthodontic appliance (n=24 in each group); T4, end of the alignment (0.019 x 0.025-
inch stainless steel rectangular archwire in the lower arch); (a), significant difference with T1 using Friedman 
test followed by Bonferroni correction (p<0.0166) for normal weight group; (b), significant difference with 
T1 using Friedman test followed by Bonferroni correction (p<0.0166) for obese group, vertical whiskers 
indicate minimum to maximum values. 
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5.2.3.4 Biochemical analyses of UWMS 
The biochemical analyses of UWMS collected at four time points from 10 normal weight 
and 10 obese patients showed very few significant changes (Figures 5.6 - 5.10). 
Between time points, the only significant biochemical changes in UWMS were 
observed in the levels of MPO, the biomarker of inflammation (Figure 5.9). MPO levels 
were significantly increased in obese patients 1 hour after appliance placement (T2) and in 
normal weight patients after 1 week (T3), compared with baseline levels and continue until 
the end of alignment. No other biomarkers showed changes over time in UWMS; however, 
several biomarkers showed significantly higher levels in obese patients compared to normal 
weight patients at certain time points, including MPO levels at T2 and T3, resistin levels at 
T2, and TIMP1 at T4 (end of the alignment); whilst, RANKL levels were significantly 
lower in obese compared to normal weight group at T4. 




Figure 5.6 Graphs showing the levels of obesity biomarkers in unstimulated whole mouth saliva (UWMS) of 
normal weight and obese patients at four time points. T1, baseline (before placement of orthodontic 
appliance) (n=10); T2, 1 hour after placement of orthodontic appliance (n=10); T3, 1 week after placement of 
orthodontic appliance (n=8); T4, end of the alignment (0.019 x 0.025-inch stainless steel rectangular archwire 
in the lower arch) (n=10); *, significant difference between normal weight and obese (p<0.05) by Mann 
Whitney U test. 




Figure 5.7 Graphs showing the levels of tissue remodelling biomarkers in unstimulated whole mouth saliva 
(UWMS) of normal weight and obese patients at four time points. T1, baseline (before placement of 
orthodontic appliance) (n=10); T2, 1 hour after placement of orthodontic appliance (n=10); T3, 1 week after 
placement of orthodontic appliance (n=8); T4, end of the alignment (0.019 x 0.025-inch stainless steel 
rectangular archwire in the lower arch) (n=10); MMP8, matrix metalloproteinase-8; MMP9, matrix 
metalloproteinase-9; TIMP1, tissue inhibitor of metalloproteinase 1; *, significant difference between normal 
weight and obese (p<0.05) by Mann Whitney U test. 




Figure 5.8 Graphs showing the levels of MMP8/TIMP1 and MMP9/TIMP1 ratios in unstimulated whole 
mouth saliva (UWMS) of normal weight and obese patients at four time points. T1, baseline (before 
placement of orthodontic appliance) (n=10); T2, 1 hour after placement of orthodontic appliance (n=10); T3, 
1 week after placement of orthodontic appliance (n=8); T4, end of the alignment (0.019 x 0.025-inch stainless 
steel rectangular archwire in the lower arch) (n=10); MMP8, matrix metalloproteinase-8; MMP9, matrix 
metalloproteinase-9; TIMP1, tissue inhibitor of metalloproteinase 1. 




Figure 5.9 Graphs showing the levels of inflammation biomarkers in unstimulated whole mouth saliva 
(UWMS) of normal weight and obese patients at four time points. T1, baseline (before placement of 
orthodontic appliance) (n=10); T2, 1 hour after placement of orthodontic appliance (n=10); T3, 1 week after 
placement of orthodontic appliance (n=8); T4, end of the alignment (0.019 x 0.025-inch stainless steel 
rectangular archwire in the lower arch) (n=10); MPO, myeloperoxidase; CRP, C reactive protein; (s), 
significant difference with T1 by Friedman test followed by Bonferroni correction (p<0.0125); *, significant 
difference between normal weight and obese (p<0.05) by Mann Whitney U test. 




Figure 5.10 Graph showing the levels of bone remodelling biomarkers (RANKL) in unstimulated whole 
mouth saliva (UWMS) of normal weight and obese patients at four time points. T1, baseline (before 
placement of orthodontic appliance) (n=10); T2, 1 hour after placement of orthodontic appliance (n=10); T3, 
1 week after placement of orthodontic appliance (n=8); T4, end of the alignment (0.019 x 0.025-inch stainless 
steel rectangular archwire in the lower arch) (n=10); RANKL, receptor activator of nuclear factor kappa-B 
ligand;*, significant difference between normal weight and obese (p<0.05) by Mann Whitney U test. 
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5.2.3.5 Biochemical analyses of serum 
The biochemical analyses of serum collected at four time points from 10 normal weight and 
10 obese patients showed no changes in the level of inflammatory biomarkers (MPO and 
CRP) during the orthodontic alignment (Figure 5.11). Only the levels of adiponectin among 
the obesity biomarkers were significantly reduced in both normal weight and obese patients 
at the end of alignment (T4) (Figure 5.12). In contrast, the levels of RANKL (bone 
remodelling biomarkers) were significantly increased at T4 in both normal weight and 
obese groups (Figure 5.13). Among the tissue remodelling biomarkers, the levels of MMP8 
significantly increased, while TIMP1 levels significantly reduced by the end of alignment 
(T4) in obese patients only (Figure 5.14). Such changes result in significant increase in the 
MMP8/TIMP1 ratio in the same group over time (T2-T4) (Figure 5.15). 
Comparing the levels of circulating biomarkers between normal weight and obese 
patients at each time point showed that, among the inflammatory biomarkers (MPO and 
CRP), comparable levels of MPO were observed between the two groups. However, the 
levels of circulating CRP were significantly higher in obese patients before and throughout 
the orthodontic alignment (Figure 5.11). The same findings were observed for leptin 
(obesity biomarker) levels, which were higher in obese than in normal weight patients, 
from the baseline until the end of alignment (T1-T4). Conversely, the circulating levels of 
the other obesity biomarker, adiponectin, were significantly reduced in obese patients at the 
baseline (T1) and at the end of alignment (T4). The levels of the third obesity biomarker, 
resistin, did not significantly change at all time points in both groups (Figure 5.12). The 
levels of RANKL (bone remodelling biomarker) were significantly increased in the serum 
of obese patients compared to normal weight patients at the end of alignment (T4) (Figure 
5.13). Similarly, the tissue remodelling biomarkers showed minor changes at the end of the 
alignment (T4), including higher levels of circulating MMP8 and lower levels of TIMP1 in 
obese patients (Figure 5.14). Therefore, a significantly higher MMP8/TIMP1 ratio was 
observed in obese patients at T4, in comparison with normal weight patients (Figure 5.15). 




Figure 5.11 Graphs showing the levels of inflammation biomarkers in serum of normal weight and obese 
patients at four time points. T1, baseline (before placement of orthodontic appliance) (n=10); T2, 1 hour after 
placement of orthodontic appliance (n=10); T3, 1 week after placement of orthodontic appliance (n=8); T4, 
end of the alignment (0.019 x 0.025-inch stainless steel rectangular archwire in the lower arch) (n=10); MPO, 
myeloperoxidase; CRP, C reactive protein; *, significant difference between normal weight and obese 
(p<0.05) by Mann Whitney U test; ***, significant difference between normal weight and obese (p<0.001) by 
Mann Whitney U test. 




Figure 5.12 Graphs showing the levels of obesity biomarkers in serum of normal weight and obese patients at 
four time points. T1, baseline (before placement of orthodontic appliance) (n=10); T2, 1 hour after placement 
of orthodontic appliance (n=10); T3, 1 week after placement of orthodontic appliance (n=8); T4, end of the 
alignment (0.019 x 0.025-inch stainless steel rectangular archwire in the lower arch (n=10); (s), significant 
difference with T1 by Friedman test followed by Bonferroni correction (p<0.0125);*, significant difference 
between normal weight and obese (p<0.05) by Mann Whitney U test; **, significant difference between 
normal weight and obese (p<0.01) by Mann Whitney U test; ***, significant difference between normal 
weight and obese (p<0.001) by Mann Whitney U test. 




Figure 5.13 Graph showing the levels of bone remodelling biomarkers (RANKL) in serum of normal weight 
and obese patients at four time points. T1, baseline (before placement of orthodontic appliance) (n=10); T2, 1 
hour after placement of orthodontic appliance (n=10); T3, 1 week after placement of orthodontic appliance 
(n=8); T4, end of the alignment (0.019 x 0.025-inch stainless steel rectangular archwire in the lower arch) 
(n=10); RANKL, receptor activator of nuclear factor kappa-B ligand; (s), significant difference with T1 by 
Friedman test followed by Bonferroni correction (p<0.0125); **, significant difference between normal 
weight and obese (p<0.01) by Mann Whitney U test. 




Figure 5.14 Graphs showing the levels of tissue remodelling biomarkers in serum of normal weight and obese 
patients at four time points. T1, baseline (before placement of orthodontic appliance) (n=10); T2, 1 hour after 
placement of orthodontic appliance (n=10); T3, 1 week after placement of orthodontic appliance (n=8); T4, 
end of the alignment (0.019 x 0.025-inch stainless steel rectangular archwire in the lower arch (n=10); 
MMP8, matrix metalloproteinase-8; MMP9, matrix metalloproteinase-9; TIMP1, tissue inhibitor of 
metalloproteinase 1; (s), significant difference with T1 by Friedman test followed by Bonferroni correction 
(p<0.0125); **, significant difference between normal weight and obese (p<0.01) by Mann Whitney U test. 




Figure 5.15 Graphs showing the levels of MMP8/TIMP1 and MMP9/TIMP1 ratios in serum at four time 
points of normal weight and obese patients. T1, baseline (before placement of orthodontic appliance) (n=10); 
T2, 1 hour after placement of orthodontic appliance (n=10); T3, 1 week after placement of orthodontic 
appliance (n=8); T4, end of the alignment (0.019 x 0.025-inch stainless steel rectangular archwire in the lower 
arch) (n=10); MMP8, matrix metalloproteinase-8; MMP9, matrix metalloproteinase-9; TIMP1, tissue 
inhibitor of metalloproteinase 1; (s), significant difference with T1 by Friedman test followed by Bonferroni 
correction (p<0.0125); **, significant difference between normal weight and obese (p<0.05) by Mann 
Whitney U test. 
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5.2.3.6 Biochemical analyses of GCF 
The results of our cross-sectional study, alongside the findings from the literature review, 
demonstrate that GCF is more likely to be changed by the biological reactions that take 
place in the periodontal tissues during OTM. GCF from all 55 patients was therefore 
analysed in this prospective study. The biochemical analyses of GCF collected from 28 
normal weight and 27 obese patients at four time points showed more changes than those 
seen in UWMS and serum during the orthodontic alignment stage. 
No change in the level of obesity biomarkers (adiponectin, leptin and resistin) was 
observed at all-time points of orthodontic alignment (Figure 5.16). 
Tissue remodelling biomarkers (MMP8, MMP9, and TIMP1) showed that MMP8 
and TIMP1 levels increased only in the normal weight group. MMP8 increased after 1 hour 
(T2), whereas TIMP1 increased after 1 week until the end of the alignment (T3-T4). 
Conversely, the levels of MMP9 were significantly increased at T2 and T3 in both normal 
weight and obese groups, then returned to the baseline level at T4 (Figure 5.17). The ratios 
of MMP8/TIMP1 and MMP9/TIMP1 therefore changed accordingly. The MMP8/TIMP1 
ratio increased at T4 in the normal weight group, while the MMP9/TIMP1 ratio increased 
at T2 and T4 in the normal weight group and at T2 in obese patients (Figure 5.18). 
Analysis of the inflammatory biomarkers (MPO and CRP) showed that the levels of 
MPO were significantly increased 1 hour after appliance placement (T2) in obese patients 
and after 1 week (T3) in normal weight patients until the end of alignment. CRP levels 
showed no changes in GCF during the orthodontic alignment in both groups (Figure 5.19). 
The levels of bone remodelling biomarker (RANKL) were significantly increased at 
the end of the alignment (T4) in both normal weight and obese patients (Figure 5.20). 
Comparing the levels of biomarkers between normal weight and obese patients at 
each time point showed that the levels of some biomarkers were significantly higher in the 
obese group at baseline (T1) and continued to remain higher throughout the study period 
such as MMP8, TIMP1, RANKL, MPO, leptin and resistin. Other biomarkers, such as 
adiponectin, showed comparable levels in both normal weight and obese groups from 
baseline to the end of the alignment stage (T1-T4). MMP9 levels were higher in obese 
patients after 1 hour of appliance placement (T2), then returned to the same levels as for 
normal weight patients at T3 and T4, whereas CRP levels were higher in obese patients 
after 1 week of appliance placement (T3) and continued until the end of alignment (T4). 




Figure 5.16 Graphs showing the levels of obesity biomarkers in gingival crevicular fluid (GCF) of normal 
weight and obese patients at four time points. T1, baseline (before placement of orthodontic appliance) (n=28 
normal weight and 27 obese); T2, 1 hour after placement of orthodontic appliance (n=28 normal weight and 
27 obese); T3, 1 week after placement of orthodontic appliance (n=24 normal weight and 24 obese); T4, end 
of the alignment (0.019 x 0.025-inch stainless steel rectangular archwire in the lower arch) (n=28 normal 
weight and 27 obese); *, significant difference between normal weight and obese (p<0.05) by Mann Whitney 
U test; **, significant difference between normal weight and obese (p<0.01) by Mann Whitney U test, ***: 
significant difference between normal weight and obese (p<0.001) by Mann Whitney U test. 




Figure 5.17 Graphs showing the levels of tissue remodelling biomarkers in gingival crevicular fluid (GCF) of 
normal weight and obese patients at four time points. T1, baseline (before placement of orthodontic 
appliance) (n=28 normal weight and 27 obese); T2, 1 hour after placement of orthodontic appliance (n=28 
normal weight and 27 obese); T3, 1 week after placement of orthodontic appliance (n=24 normal weight and 
24 obese); T4, end of the alignment (0.019 x 0.025-inch stainless steel rectangular archwire in the lower arch) 
(n=28 normal weight and 27 obese); MMP8, matrix metalloproteinase-8; MMP9, matrix metalloproteinase-9; 
TIMP1, tissue inhibitor of metalloproteinase 1; (s), significant difference with T1 by Friedman test followed 
by Bonferroni correction (p<0.0125);*, significant difference between normal weight and obese (p<0.05) by 
Mann Whitney U test; **, significant difference between normal weight and obese (p<0.01) by Mann 
Whitney U test; ***, significant difference between normal weight and obese (p<0.001) by Mann Whitney U 
test. 




Figure 5.18 Graphs showing the levels of MMP8/TIMP1 and MMP9/TIMP1 ratios in gingival crevicular 
fluid (GCF) of normal weight and obese patients at four time points. T1, baseline (before placement of 
orthodontic appliance) (n=28 normal weight and 27 obese); T2, 1 hour after placement of orthodontic 
appliance (n=28 normal weight and 27 obese); T3, 1 week after placement of orthodontic appliance (n=24 
normal weight and 24 obese); T4, end of the alignment (0.019 x 0.025-inch stainless steel rectangular 
archwire in the lower arch) (n=28 normal weight and 27 obese); MMP8, matrix metalloproteinase-8; MMP9, 
matrix metalloproteinase-9; TIMP1, tissue inhibitor of metalloproteinase 1; (s), significant difference with T1 
by Friedman test followed by Bonferroni correction (p<0.0125);*, significant difference between normal 
weight and obese (p<0.05) by Mann Whitney U test; **, significant difference between normal weight and 
obese (p<0.01) by Mann Whitney U test; ***, significant difference between normal weight and obese 
(p<0.001) by Mann Whitney U test. 




Figure 5.19 Graphs showing the levels of inflammation biomarkers in gingival crevicular fluid (GCF) of 
normal weight and obese patients at four time points. T1, baseline (before placement of orthodontic 
appliance) (n=28 normal weight and 27 obese); T2, 1 hour after placement of orthodontic appliance (n=28 
normal weight and 27 obese); T3, 1 week after placement of orthodontic appliance (n=24 normal weight and 
24 obese); T4, end of the alignment (0.019 x 0.025-inch stainless steel rectangular archwire in the lower arch) 
(n=28 normal weight and 27 obese); MPO, myeloperoxidase; CRP, C reactive protein; (s), significant 
difference with T1 by Friedman test followed by Bonferroni correction (p<0.0125);*, significant difference 
between normal weight and obese (p<0.05) by Mann Whitney U test.; ***, significant difference between 
normal weight and obese (p<0.001) by Mann Whitney U test. 




Figure 5.20 Graph showing the levels of bone remodelling biomarkers (RANKL) in gingival crevicular fluid 
(GCF) of normal weight and obese patients at four time points. T1, baseline (before placement of orthodontic 
appliance) (n=28 normal weight and 27 obese); T2, 1 hour after placement of orthodontic appliance (n=28 
normal weight and 27 obese); T3, 1 week after placement of orthodontic appliance (n=24 normal weight and 
24 obese); T4, end of the alignment (0.019 x 0.025-inch stainless steel rectangular archwire in the lower arch) 
(n=28 normal weight and 27 obese); RANKL, receptor activator of nuclear factor kappa-B ligand; (s), 
significant difference with T1 by Friedman test followed by Bonferroni correction (p<0.0125); ***, 
significant difference between normal weight and obese (p<0.001) by Mann Whitney U test. 
 
5.2.3.7 Correlation of biomarkers with periodontal health 
Since bacterial plaque and inflamed gingivae can potentially influence the GCF flow rate 
and the production of some biomarkers, regression analysis was performed of the outcome 
(the GCF flow rate and biomarker levels), the explorative factor (plaque index or gingival 
index) and the variation through time points. The results showed that there was no 
significant correlation between the GCF flow rate and the levels of biomarkers with plaque 
and gingival indices (Table 5.11). 
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Table 5.11 Results of regression models assessing the effect of PI and GI on the levels of biomarkers in 
prospective cohort study. 
 PI (transformed) GI (transformed) 




































































































PI, plaque index; GI, gingival index; GCF, gingival crevicular fluid; MPO, myeloperoxidase; CRP, C reactive 
protein; MMP8, matrix metalloproteinase-8; MMP9, matrix metalloproteinase-9; TIMP1, tissue inhibitor of 
metalloproteinase 1; RANKL, receptor activator of nuclear factor kappa-B ligand. †Log10 transformation 
improved the skewness of the data, but the Shapiro-Wilk test indicated that transformed data were still not 
normally distributed. Therefore, the median (interquartile range) is presented instead of mean (SD) and the 
Mann-Whitney test is used on the transformed data instead of the unpaired t-test. ‡ Square root transformation 
used instead of log10, as several null values were included. Therefore, the median (interquartile range) is 
presented instead of mean (SD) and the Mann-Whitney test is used on the transformed data instead of the 
unpaired t-test. 
  




In OTM, the periodontium endures an aseptic inflammation, in which various cytokines are 
released by the effect of mechanical forces (Salla et al., 2012). This study was designed to 
assess the effect of obesity on the level of inflammation, tissue and bone remodelling, and 
obesity-related biomarkers in UWMS, GCF and serum before and during the alignment 
stage of fixed appliance orthodontic treatment. Four time points were chosen in an attempt 
to take into account the different biological mechanisms characterizing the initial, lag and 
postlag phases of OTM. The study evaluated the levels of biomarkers compared with the 
baseline measurement (T1) and described the difference in the levels of selected biomarkers 
between normal weight and obese patients at each of the four time points. 
5.2.4.1 UWMS and GCF flow rate 
The UWMS flow rate increased significantly after the placement of the fixed orthodontic 
appliance, with no significant differences between normal weight and obese groups, both 
before and throughout the orthodontic alignment. This indicates that the cause of more 
saliva production is the mechanical stimulation by orthodontic appliance, rather than patient 
BMI. The findings are in agreement with data collected in previous salivary flow rate 
studies, indicating no difference between obese and healthy controls (Powers et al., 1981, 
Epstein et al., 1996). On the contrary, reduced whole saliva was observed in adults aged 
<50 years with BMI>25 (Flink et al., 2008). Reduced stimulated whole saliva is also an 
observation from childhood obesity studies (Modéer et al., 2010). They attribute the 
reduced salivary flow to the storage of adipocytesin in the parotid gland, in addition to 
increased pro-inflammatory cytokines that may affect the function of the salivary glands. 
These controversial findings may result from differences in sample size, patient age, and 
the method and time of sample collection. The limitation of our study is that samples were 
collected at various times during the day and therefore, to some extent, the salivary flow 
rate results may be influenced by circadian rhythms (Flink et al., 2008). 
Previous studies have suggested that GCF flow reflects changes in deeper 
periodontal tissues, such as the alveolar bone and the PDL of the teeth, while under the 
influence of orthodontic treatment (Grieve et al., 1994, Heasman et al., 1996, Iwasaki et al., 
2005, Iwasaki et al., 2001, Tuncer et al., 2005, Krishnan and Davidovitch, 2006b, Masella 
and Meister, 2006). Since there was no association between GCF flow rates and plaque and 
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gingival scores, the increased GCF flow rate resulted from the influence of both obesity and 
fixed appliance orthodontic treatment. The effect of obesity can be seen in the higher GCF 
flow rate in obese patients before and throughout all time points of orthodontic alignment. 
This may be related to the inflammatory effects of obesity on the periodontal tissues that 
impacts on the permeability of blood vessels and GCF flow rate in obese subjects. This has 
been confirmed by previous studies highlighted that inflammation can modify the rate and 
composition of GCF (Kavadia-Tsatala et al., 2001). 
The significant increase of GCF flow rate after orthodontic appliance placement 
may indicate the effect of orthodontic treatment. These findings are confirmed by previous 
studies that demonstrate the impact of orthodontic forces on the volume of GCF (Basaran et 
al., 2006, Karacay et al., 2007); however, these findings are not consistent, as some studies 
did not demonstrate a significant influence of mechanical stress on GCF flow (Apajalahti et 
al., 2003, Ingman et al., 2005, Bildt et al., 2009). One explanation for this difference might 
derive from the different methods used for GCF collection. 
GCF volume is not necessarily influenced by OTM, but instead is influenced by 
inflammation of the periodontal tissue (Nishijima et al., 2006, Perinetti et al., 2002). Our 
results confirm this, as the GCF flow rate was higher as a consequence of both obesity-
related inflammation and the inflammation that occurs as a result of orthodontic treatment. 
5.2.4.1 Biochemical analyses of UWMS 
Significant changes in salivary biomarker levels were restricted to the inflammatory 
mediator, MPO. The MPO levels in UWMS reflect, to a certain extent, the levels of MPO 
in GCF, indicating an increase in the number of PMNs in the periodontal tissue due to 
inflammation from the orthodontic treatment. These findings are in agreement with the 
results of a previous study, showing a significant increase of MPO in UWMS and GCF 2 
hours after orthodontic force application (Marcaccini et al., 2010). The same results were 
observed in another study using different amount of force (Navarro-Palacios et al., 2014). 
In our study, however, MPO levels were significantly increased after force application at 1 
hour (T2) in obese patients and 1 week (T3) in normal weight patients. The differences 
between the two groups could be related to the increased recruitment and activation of 
PMNs in consistence with the inflammatory status associated with obesity. 
The significantly higher MPO levels in obese patients, compared with normal 
weight patients, at T2 and T3 time points, indicate that obesity influences the immune 
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system and increases PMNs in periodontal tissues which represent one of the most innate 
immune system components, displaying potent phagocytic and antimicrobial activity 
(Nijhuis et al., 2009). 
5.2.4.2 Biochemical analyses of serum 
Significant changes in the level of biomarkers in serum were limited to adiponectin, 
RANKL, MMP8 and TIMP1 at the end of alignment (T4). 
The reduction of adiponectin levels in both normal weight and obese patients may 
reflect the increased inflammation accompanied with tissue and bone metabolism during 
orthodontic treatment, irrespective of obesity. This can be confirmed by the findings of 
studies that report reduced serum adiponectin with inflammation such as periodontitis, 
independent of BMI (Saito et al., 2008, Furugen et al., 2008, Zimmermann et al., 2013); 
however, there is no previous studies that measure the levels of adiponectin during 
orthodontic treatment to provide a direct comparison. Conversely, serum RANKL levels 
were increased in both normal weight and obese groups at the end of the alignment (T4), 
which mostly reflects the postlag phase of OTM, in which higher bone remodelling takes 
place for more tooth movement. This reduction in adiponectin and increase in RANKL 
levels were significantly greater in obese patients than normal weight, indicating greater 
inflammation and bone resorption in obese patients comparing to normal weight. The 
possible reason behind this is the high pro-inflammatory cytokines produced by adipocytes, 
which suppress the anti-inflammatory function of adiponectin and stimulate the 
RANKL/RANK pathway, the key to osteoclastogensis and bone resorption. These findings 
partly agreed with a previous study that measured the levels of OPG, RANKL and 
adiponectin in the serum of obese and lean subjects, which confirmed reduced levels of 
adiponectin and unchanged RANKL levels in the serum of obese subjects (Ashley et al., 
2011). 
The significant increase in MMP8 and decrease in TIMP1 at the end of alignment 
(T4) in obese patients resulted in a significant increase of the MMP8/TIMP1 ratio at (T2, 
T3, and T4), without any significant changes in the levels of MMP9. The exact reason for 
this is unclear, but it possibly relates to higher neutrophil activation (the main source of 
MMP8) that occurs with obesity. These results are confirmed by a study conducted by Belo 
and co-workers that demonstrated higher MMP8 (but not MMP9) and lower TIMP1 in 
obese groups, compared to non-obese children and adolescents (Belo et al., 2009). 
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The circulating levels of other biomarkers, such as MPO and resistin, did not show 
any significant changes in both normal weight and obese groups. Others, such as leptin and 
CRP, did not change with orthodontic treatment, although their levels were already 
significantly higher in obese patients before and throughout the alignment stage. These 
findings can be related to the role of leptin in the host defence mechanism against infection 
(Liu et al., 2005) and in response to pro-inflammatory stimuli such as LPS and TNF-α, 
which increase with obesity (Karthikeyan and Pradeep, 2007a, Shimada et al., 2010). 
Similarly, high levels of CRP are associated with the inflammatory conditions of obesity 
(Ellulu et al., 2016) and higher production of IL-6 by adipocytes that influence the 
production of CRP by hepatocytes to blood (Berg and Scherer, 2005, Nibali et al., 2007). 
Furthermore, the comparable levels of leptin and CRP at all-time points comparing to 
baseline indicate that orthodontic treatment results in more local, rather than systemic, 
inflammation. 
5.2.4.3 Biochemical analyses of GCF 
The results from the regression models did not demonstrate any significant association 
between plaque and gingival indices and the levels of biomarkers at all-time points. This 
indicates that the variation in the levels of biomarkers in GCF should result from the 
response of periodontal tissues to the applied orthodontic force. 
This study outlined that obesity-related biomarkers, with both anti-inflammatory 
(adiponectin) and pro-inflammatory (leptin and resistin) effects, did not significantly 
change in GCF during orthodontic treatment for both normal weight and obese patients. 
These findings indicated that orthodontic force did not influence the levels of adipokines in 
GCF. This result disagrees with a previous study, which reported reduced levels of GCF 
leptin during orthodontic treatment (Dilsiz et al., 2010); however, the relationship between 
GCF resistin and adiponectin with OTM has not previously been investigated. In relation to 
periodontitis, existing literature reports reduced levels of leptin in GCF with periodontal 
diseases (Karthikeyan and Pradeep, 2007a), whilst the GCF resistin levels were reduced 
(Zimmermann et al., 2013) or increased with periodontitis (Patel and Raju, 2014) and/or 
obesity (Suresh et al., 2016). Moreover, in this study, leptin and resistin proteins were 
higher in GCF of obese patients than in normal weight patients before the placement of the 
orthodontic appliance and throughout the whole orthodontic alignment. This can be 
confirmed by a correlation between leptin (Considine et al., 1996) and resistin (Patel and 
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Raju, 2014) with BMI, and may explain the correlation between leptin and resistin with the 
high rate of OTM in obese patients, as mentioned in Section 5.1 of this study. The high 
levels of leptin and resistin associated with obesity may result from the increased size and 
number of adipocytes, in addition to the release of these proteins by peripheral 
mononuclear cells and macrophages in response to hyper-production of IL-6 (Ouchi et al., 
2011). 
Orthodontic treatment leads to change in the periodontium; foremost of these 
changes is the induction of inflammation. Measuring the levels of inflammation markers 
during OTM is therefore required. As MPO is an enzyme stored in granules of neutrophils, 
the level of MPO activity is directly linked to the number of PMNs in the tissue (Cao and 
Smith, 1989). In this study, the levels of MPO increased significantly after 1 hour (T2) in 
GCF of obese patients, and after 1 week (T3) in normal weight patients and continued until 
the end of alignment, with significantly higher levels in obese patients at all-time points 
(T1-T4). These results reflect the greater neutrophil activation in the periodontal tissues of 
obese patients, for whom obesity-related inflammation was exacerbated by orthodontic 
treatment. Previous studies that measured the levels of MPO in GCF of orthodontic patients 
reported that MPO levels were increased 2 hours after application, and then returned to the 
baseline level at the 7 and 14-day measurement points in both saliva and GCF (Marcaccini 
et al., 2010). This inconsistency could be related to different selection criteria, sample size, 
the assay used to analyse the samples and the effects of other additional variables. The high 
levels of MPO associated with obesity were also confirmed by recent studies reporting a 
significant increase in MPO levels in obese children compared to control groups 
(Marcovecchio et al., 2016, Varma et al., 2016). 
The other inflammatory marker is CRP, produced by hepatocytes during 
inflammation. In this study, the levels of CRP were not changed in GCF during orthodontic 
alignment in both normal weight and obese patients. However, the levels steadily increased 
and became significantly higher in obese compared to normal weight patients after 1 week 
of appliance placement (T3) and at the end of orthodontic alignment (T4). These elevations 
can be explained by the effects of cytokines such as IL-1, IL-6 and TNF-α, produced as a 
response to orthodontic stimuli, which intensified with obesity (Khanna and Mali, 2010). 
These pro-inflammatory cytokines are produced at the sites of inflammation before being 
carried to the liver via systemic circulation, resulting ultimately in the increased secretion 
of acute inflammatory reactants such as CRP (Ide et al., 2004, Nibali et al., 2007). 
Chapter Five  A prospective cohort study 
210 
 
The RANKL/RANK/OPG pathway relates to the bone metabolism; the 
concentrations of RANKL in GCF during OTM therefore need to be evaluated. The levels 
of RANKL were higher in obese patients than normal weight patients before and 
throughout the orthodontic alignment (T1-T4). This could be related to higher pro-
inflammatory cytokines produced by adipocytes such as TNF-α, IL-1β and IL-6. During the 
alignment stage, the levels of RANKL were significantly increased at the end of alignment 
(T4) in both normal weight and obese groups, leading to higher osteoclastogensis and bone 
resorption at T4 – a reflection of the high bone remodelling in the postlag phase of OTM. 
As confirmed by previous study noticed a dramatic increase in osteoclastic activity during 
the transition from lag to postlag phase (Rody et al., 2001). Interestingly, this increase was 
significantly higher in obese patients, indicating that more bone resorption takes place with 
obesity, which explains the correlation between RANKL levels and the high rate of OTM 
in obese patients in our study. Increased RANKL levels also confirmed by previous studies 
that measured the levels of RANKL in GCF with OTM, demonstrating that RANKL levels 
were increased after 24 hours (Kawasaki et al., 2006) and after 42 days (Grant et al., 2013). 
The MMPs play a key role in regulating various biological processes including PDL 
remodelling in both physiological and pathological conditions. The results of this study 
demonstrated a sharp increase in the levels of MMP9, 1 hour after appliance placement in 
both groups, with significantly higher increases in obese patients. This gradually reduced 
through the first week, but was still significantly higher than baseline levels at T3. It finally 
returned to baseline levels at T4. Such changes indicate that the levels of MMP9 were 
highly influenced by orthodontic force, which enhances the recruitment and activation of 
MMP9-producing cells, such as fibroblasts, monocytes and macrophages, in the first week 
of orthodontic force application. However, MMP8, which is mainly produced by 
neutrophils, demonstrated significantly higher levels in GCF of obese patients in 
comparison to normal weight patients, even before starting the orthodontic treatment and 
throughout the whole alignment stage. The only significant change between time points 
was observed after 1 hour of appliance placement (T2) in the normal weight group, after 
which it returned to baseline levels. This indicates that neutrophils are highly activated by 
obesity, leading to higher levels of MMP8 in obese patients. These changes were not 
significantly affected by the inflammatory conditions associated with orthodontic treatment. 
The inhibitor TIMP1 reduces the damage done by MMPs to the ECM. In this study, 
the levels of TIMP1 were significantly higher in obese patients before and throughout the 
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entire alignment period. Between different time points, TIMP1 levels were significantly 
increased in GCF of normal weight patients from the first week (T3) forward. This could be 
an attempt to counter the increase in the levels of MMP9 and balance the ECM destruction 
by MMPs during remodelling. The findings of our study are in line with a previous study 
that measured MMPs and TIMPs in GCF with OTM and registered a significant increase in 
MMP9 and TIMPs 1 and 2 across all of the time points used in the study following force 
application (Grant et al., 2013). These changes also confirm the results of our cross-
sectional study, in which MMP9 levels were significantly changed by orthodontic 
treatment, whereas MMP8 levels were significantly influenced by obesity. 
The MMPs/TIMPs ratio is also important in assessing and monitoring the balance 
of ECM destruction and inhibition during OTM. Since the levels of TIMP1 were 
significantly higher in the obese group, this leads to reduced MMP9/TIMP1 and 
MMP8/TIMP1 ratios in obese group. As MMP9 showed more significant differences 
between time points of orthodontic alignment, more significant differences were also seen 
in the MMP9/TIMP1 ratio between time points and between normal and obese patients. 
5.2.5 Conclusion 
This prospective study investigated the levels of biomarkers in UWMS, GCF and serum 
before and during the orthodontic alignment stage in a cohort of obese and normal weight 
adolescent patients, undergoing fixed-appliance orthodontic treatment concluded that:  
1- Salivary MPO levels reflect GCF MPO during the orthodontic alignment stage; 
2- Bone remodelling marker RANKL levels were increased at the end of the alignment 
in GCF and serum; 
3- Changes in inflammation, tissue and bone remodelling biomarkers during 
orthodontic alignment were mainly seen in GCF; and 
4- The levels of tissue remodelling biomarkers, inhibitors, bone remodelling 
biomarkers, inflammation, and pro-inflammatory obesity biomarkers were higher in 
obese patients than in normal weight patients. 
From the above findings, the null hypotheses were rejected, as obesity intensified 
some biochemical changes that take place during orthodontic alignment and GCF is more 
likely to express the biochemical changes associated with OTM. 
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5.3 The effect of obesity on orofacial pain following fixed-
appliance placement 
5.3.1 Introduction 
Obesity in children and young adults has also been associated with poor mental health and 
psychosocial problems, including depression, anxiety and low self-esteem (Dreber et al., 
2015, French et al., 1995). Collectively, these psychological factors can contribute to low 
quality-of-life indices for obese subjects (Buttitta et al., 2014, Heo et al., 2003), which can 
be improved with weight loss (Kaukua et al., 2003). There is an established relationship 
between obesity and chronic musculoskeletal pain, which can also manifest from childhood 
(Smith et al., 2014); however, there are also suggestions that obesity can influence 
peripheral pain perception and be a contributory factor for increased pain thresholds 
(Torensma et al., 2016, Price et al., 2013, Zahorska-Markiewicz et al., 1988, Zahorska-
Markiewicz et al., 1983). 
Orofacial pain is a common adverse effect of orthodontic treatment with fixed-
appliances (Scheurer et al., 1996, Johal et al., 2014), particularly during the first few days 
after orthodontic appliance placement (Jones and Chan, 1992, Scott et al., 2008b, 
Woodhouse et al., 2015b, Scheurer et al., 1996, Johal et al., 2014, Otasevic et al., 2006, 
Rahman et al., 2015, Pringle et al., 2009). Archwire progression during treatment often 
produces further episodes of pain, which can collectively affect eating and sleeping, and 
impact on day-to-day activities (Brown and Moerenhout, 1991, Johal et al., 2014). 
The experience of discomfort was registered in about 95% of orthodontic patients 
(Kvam et al., 1987, Scheurer et al., 1996), ranged from separator placement and band fitting 
(Ngan et al., 1989, Bergius et al., 2002, Bondemark et al., 2004), archwire placement and 
activations (Ngan et al., 1989, Scheurer et al., 1996, Firestone et al., 1999, Erdinç and 
Dinçer, 2004, Jones, 1984, Polat et al., 2005) that create tension and compression sites in 
the PDL space resulting in a painful sensation for the patients. Many factors can affect the 
pain sensation such as age (Ngan et al., 1989, Brown and Moerenhout, 1991, Jones and 
Chan, 1992, Scheurer et al., 1996, Fernandes et al., 1998, Jones and Richmond, 1985, Scott 
et al., 2008b), gender (Erdinç and Dinçer, 2004, Krishnan, 2007, Ngan et al., 1989, Scott et 
al., 2008b), cultural differences (Bergius et al., 2000, Krishnan, 2007), psychological 
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wellbeing (Brown and Moerenhout, 1991, Sergl et al., 1998), the emotional status and 
stress (Andreasen et al., 1997) and previous pain experience (Okeson, 2005). 
Orthodontic force magnitude was considered the most effective factor, the lighter 
force, the more efficient and less traumatic during OTM (Reitan, 1956). Therefore, pain 
intensity may be directly correlated with the severity of crowding and the amount of the 
applied force. 
The literature has widely documented that the pain caused by orthodontic 
appliances can be a primary factor affecting patient compliance (Brown and Moerenhout, 
1991, Sergl et al., 1998, O'Connor, 2000), and a discontinuation of treatment or its early 
termination was reported mainly due to pain, functional, and aesthetic impairment caused 
by the appliances (Patel, 1989). 
A number of studies have investigated the effect of different fixed-appliance 
systems on orthodontic pain, including bracket design (Papageorgiou et al., 2014a, 
Papageorgiou et al., 2016, Scott et al., 2008b, Bertl et al., 2012, Fleming et al., 2009, 
Rahman et al., 2015, Riley and Bearn, 2009, Pringle et al., 2009) and archwire composition, 
but there is little evidence to suggest that any particular appliance combination is associated 
with less pain than any other (Papageorgiou et al., 2014a, Riley and Bearn, 2009). 
However, orthodontic pain during the first week following the placement of fixed-
appliances has been shown to have a consistent and reproducible pain profile, increasing 
during the first 24-72 hours and then reducing to baseline levels after a week (Woodhouse 
et al., 2015b, Fleming et al., 2009, Pringle et al., 2009), which provides a useful 
experimental model to investigate orofacial pain experience in different subjects. 
5.3.1.1 Aims and objectives 
The main aim of this study was to investigate the effect of obesity on orthodontic pain in 
subjects undertaking routine orthodontic treatment with fixed appliances. Specifically, this 
prospective cohort study compared orthodontic pain experience during the first week of 
fixed-appliance therapy in two groups of adolescents aged between 12-18 years and 
classified as normal weight and obese based upon BMI. 
To address this aim the following steps were undertaken: 
1. Measure the maximum pain intensity using a self-reported 100 millimetre (mm) 
visual-analogue scale (VAS), immediately after (Ta) and at 4, 24, 72-hours and 1-
week (Tb-Te, respectively) following appliance placement. 
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2. Measure the secondary outcomes included mean pain intensities, frequency and 
amount of oral analgesia taken during the observation period. 
The null hypothesis was that there is no difference in the pain intensity during the initial 
phase of orthodontic alignment between normal weight and obese patients. 
5.3.2 Methods 
5.3.2.1 Participants 
The 55 patients (28 normal weight and 27 obese) recruited for the prospective study were 
provided with a pain diary to complete over the week following placement of the fixed 
appliance. The diary recorded orthodontic pain immediately after appliance placement (Ta), 
at 4 hours (Tb), 24 hours (Tc), 72 hours (Td) and 1 week (Te) following the appointment, 
by means of a 100-mm VAS using the terms ―Very comfortable‖ and ―Very 
uncomfortable‖ as peripheral weightings (Seymour, 1982). The VAS score is the distance 
from the left end of the line to the point of the patients’ mark, measured to the nearest mm. 
Each VAS score was measured on two separate occasions by the same operator (HFS); with 
the mean of the two measurements taken as the representative value. In addition to the VAS 
score, patients noted the consumption of oral analgesics that will later be expressed as 
logistic data in percentage and dosage that will be measured as amount of oral analgesics 
taken in milligram (mg). Each patient was free to take non-prescription oral analgesia as 
required. The pain diary was completed by the patient and returned at the following 
appointment (Figure 5.21). 




Figure 5.21 Pain score diary supplied to the patients at fixed appliance placement appointment. 
 
Pain diaries were coded appropriately so that both outcome assessor (HFS) and 
statistician were blinded to subject classification. The coding of data was broken after the 
end of the analysis and no breach of blinding was identified. A previous study showed 
through the intra-class correlation coefficient that the repeatability of measurements for 
VAS scores is almost perfect (Woodhouse et al., 2015b). 
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5.3.2.2 Study size 
Study size calculation for this investigation was based upon the outcome of initial rate of 
orthodontic tooth alignment, which gave a required sample of 23 per group and has been 
described previously (Scott et al., 2008a). A post hoc power analysis was performed to 
assess, if this study had sufficient sample to identify a set 30% difference in maximum pain 
in obese compared to normal weight patients. Baseline maximum pain (74.63 mm) and 
common standard deviation (SD) for both groups (21.95 mm) originated from a previous 
study in the same clinical setting (Woodhouse et al., 2015b), while alpha for the 
independent t-test was set at 5%. The results of the power analysis indicated that the present 
study has 96% power to identify the specified effect on the primary outcome of maximum-
pain experience. 
5.3.2.3 Statistical analysis 
Descriptive statistics were calculated to characterize the experimental groups, including 
means and standard deviations for continuous variables and frequencies for binary 
outcomes, after checking for normal distribution. Initial crude differences in baseline and 
outcome data were calculated with independent t-tests and chi-square tests. 
The effect of obesity on the primary outcome (maximum-pain experienced during 
alignment) and all secondary outcomes was investigated using univariable (crude) and 
multivariable generalized estimation equation regression models with robust standard 
errors, adjusted for the confounding effect of baseline data (sex, age, baseline-irregularity, 
baseline-pain, plaque and gingival indices) and co-interventions (previous tooth extraction 
and use of analgesia during alignment). 
Results are reported as unstandardized coefficients or Odds Ratios (ORs) for 
continuous and binary outcomes (the consumption of oral analgesics), respectively. In the 
analysis of mean pain across time-points, the model accounted for within-patient and time-
point correlations. 
Analysis of residuals was conducted to confirm no violation of the linear regression 
assumptions. All analyses were carried out using Stata 12.0 (Statacorp, College Station, 
TX, USA). A 2-tailed p-value of 0.05 was considered statistically significant with a 95% 
confidence interval (CI) for all tests. 





This prospective cohort study included 55 participants (27 males and 28 females) with a 
mean age of 15.1 (SD, 1.7) years and mean irregularity index of 7.6 (SD 2.4; 95% CI 6.9-
8.2) mm. No patient drop-outs existed during the study period and all distributed pain 
diaries were collected and analysed. Mean overall BMI centile of the cohort was 24.7 (SD, 
6.2) kg/m
2
. Table 5.12 shows the baseline demographics and clinical characteristics of the 
two cohorts at start of treatment. The normal weight group had a mean BMI of 19.4 (SD, 
2.2) whilst the obese group had a mean BMI of 30.2 (SD, 3.5) kg/m
2
. Apart from BMI, 
there were no significant differences among groups for baseline characteristics. 
 





Obese P value 
Patients 55 28 27  
Male / female - n 27/28 15/13 12/15 0.498* 
Age - mean (SD) 15.1 (1.7) 15.1 (1.6) 15.1 (1.9) 0.991
#
 
Plaque Index (SD) 0.56 (0.32) 0.57 (0.32) 0.54 (0.31) 0.745 
Gingival Index (SD) 0.74 (0.39) 0.74 (0.40) 0.73 (0.38) 0.934 
Crowding - mean (SD) 7.6 (2.4) 7.0 (2.3) 8.2 (2.4) 0.061
#
 
BMI - mean (SD) 24.7 (6.2) 19.4 (2.2) 30.2 (3.5) <0.001
#
 
Tooth extraction – n (%) 8 (15%) 4 (14%) 4 (15%) 0.956* 
SD, standard deviation; BMI, body mass index; * from chi-square test; 
#
 from independent t-test. 
 
5.3.3.2 Primary outcome (maximum pain intensity during alignment) 
Maximum-pain intensity across all time-points for the total sample was 73.7 mm (SD 14.8; 
95% CI 69.8-77.7) with no significant differences among groups (Figure 5.22; Table 5.13; 
p=0.247). Moreover, at every single time point, the maximum-pain intensity was higher for 
the obese group compared to normal weight with a statistically significant difference at Td 
(p=0.034) (Table 5.13). A greater percentage of the obese group reported taking oral 
analgesia when compared to normal weight (74 versus 57 per cent), but this difference was 
not significant (p=0.187). 




Figure 5.22 Box plot showing the maximum pain during the whole alignment period (mm in VAS) from the 
multivariable regression analysis. 
 




Obese P value 
Maximum pain in mm – mean 
(SD) 
73.7 (14.8) 71.5 (15.9) 76.1 (13.4) 0.247* 
VAS in mm Ta – mean (SD) 18.5 (22.5) 19.4 (23.8) 17.6 (21.6) 0.765* 
VAS in mm Tb – mean (SD) 47.3 (22.3) 46.2 (22.6) 48.4 (22.4) 0.715* 
VAS in mm Tc – mean (SD) 70.3 (18.0) 66.9 (20.2) 74.0 (15.0) 0.146* 
VAS in mm Td – mean (SD) 46.1 (19.4) 40.6 (19.5) 51.7 (18.0) 0.034* 
VAS in mm Te – mean (SD) 12.5 (14.0) 10.9 (13.5) 14.2 (14.6) 0.388* 
Reported use of oral analgesia 
– n (%) 
36 (65) 16 (57) 20 (74) 0.187
#
 
Overall oral analgesia used in 
mg – mean (SD) 




SD, standard deviation; VAS, visual analogue scale; *from independent t-test; 
#
from chi square test. 
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Multivariable regression analysis indicated that there were no significant differences 
between normal weight and obese groups in terms of maximum reported pain during initial 
tooth alignment for a number of factors, including subject age, gender, irregularity, baseline 
reported pain, reported use of oral analgesia, and baseline plaque index (Table 5.14). 
However, there were significant differences between groups in terms of previous history of 
extractions (p=0.045) and baseline gingival index (p=0.010). Patients taking oral analgesics 
also reported slightly higher maximum pain compared to those who did not (represented by 
a difference of 5.98 mm in VAS scores), but this was not statistically significant (p=0.163). 
 
Table 5.14 Regression analyses on the outcome of maximum reported pain during the alignment period (Ta-








Coefficient 95% CI P value 









Age (per year increase) 





Gender (Ref: female) 





Irregularity at start 





Tooth extraction (Ref: 





Baseline pain (per VAS 





Use of oral analgesia 





Plaque index at Ta 





Gingival index at Ta 





VAS, visual analogues scale; CI, confidence interval; Ref, reference; Ta, immediately after appliance 
placement. 
Chapter Five  A prospective cohort study 
220 
 
5.3.3.3 Secondary outcomes (mean pain at each time point and 
consumption of analgesics) 
Figure 5.23 illustrates the mean-pain intensity of normal weight and obese groups at all 
time-points. Crude multivariable linear regression for mean pain at each time point 
indicated that the only significant predictors for pain intensity were time (Ta-Te) and 
reported baseline-pain (Figure 5.24; Table 5.15). However, after adjusting for confounders, 
obesity was associated with slightly higher (+4.42 mm in the VAS) mean pain at each time-
point, which was statistically significant (p=0.017). Additionally, the interaction between 
obesity and time was not statistically significant (p=0.416), which indicates that although 
obese patients reported slightly higher pain than normal-weight patients at all time-points, 
the pain variation across time-points per se was similar in both groups. 
Analysis of the consumption of oral analgesics (as a binary outcome) revealed no 
statistically significant association in either the univariable or the multivariable (adjusted) 
analyses (Table 5.16). Analysis of the total amount of analgesics consumed (as a 
continuous outcome) revealed statistically significant associations with obesity for both 
univariable and multivariable (adjusted) analyses (+601.20 mg, p=0.035 and +646.38 mg, 
p=0.023, respectively). There was also a significant association with age in the 
multivariable analysis, with older patients taking smaller amounts of analgesics (p=0.018). 
Also after accounting for confounders, obese patients were associated with higher overall 
amount of consumed oral analgesics (difference=646.38 mg) (Table 5.17). 




Figure 5.23 Box plots showing the mean pain at each time-point Ta-Te (min to max). Ta, immediately after 
appliance placement; Tb, 4 hours; Tc, 24 hours; Td, 72 hours; and Te, 1 week following the placement of 
fixed orthodontic appliance appointment, vertical whiskers indicate minimum to maximum values. 
 
 
Figure 5.24 Graph showing the mean pain at each time-point Ta-Te (mm in VAS) from the multivariable 
regression analysis. Ta, immediately after appliance placement; Tb, 4 hours; Tc, 24 hours; Td, 72 hours; and 
Te, 1 week following the placement of fixed orthodontic appliance appointment. 
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Table 5.15 Regression analyses on the outcome of reported pain at each time-point in mm in VAS scale. 
 
Multivariable model 1 Multivariable model 2 
Factor Coefficient 95% CI P value Coefficient 95% CI P value 










      
Ta Ref 





























Age (per year 





Gender (Ref: male) 





Crowding (per mm 













Baseline pain (per 





Use of oral 





Plaque index at Ta 





Gingival index at 





*Interaction of obesity with time found to be non-significant (p=0.416) and was dropped from the model. 
CI, confidence interval; Ref, reference; VAS, visual analogues scale; Ta, immediately after appliance 
placement; Tb, 4 hours; Tc, 24 hours; Td, 72 hours; and Te, 1 week following the placement of fixed 
orthodontic appliance appointment. 
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Factor OR 95% CI P value OR 95% CI P value 









Age (per year increase) 





Gender (Ref: female) 





Crowding (per mm increase) 





Tooth extraction (Ref: non-





Baseline pain (per VAS mm 





Plaque index at Ta 





Gingival index at Ta 









Table 5.17 Regression analyses on the outcome of overall dose of oral analgesia taken during the alignment 
phase (Ta-Te) in mg. 
 
Univariable Multivariable 
Factor Coefficient 95% CI 
P 
value 
Coefficient 95% CI 
P 
value 









Age (per year 





Gender (Ref: female) 





Crowding (per mm 





Tooth extraction (Ref: 





Baseline pain (per 





Co, Coefficient; CI, confidence interval; Ref, reference; VAS, visual analogue scale. 
 




The commonality of obesity in Western society means that the implications of this 
condition are likely to affect increasing areas of modern healthcare and therefore, it is 
important that clinicians from all specialties understand potential issues associated with the 
care of obese patients. 
During orthodontic treatment the perception of pain was correlated with various 
substances released as a result of change in blood flow caused by orthodontic force, such as 
substance P, histamine, enkephalin, dopamine, serotonin, glycine, glutamate, gamma-
aminobutyric acid, PGs, leukotrienes, and cytokines (Davidovitch et al., 1988, Alhashimi et 
al., 2001, Yamasaki et al., 1984). 
In the present study, we have investigated orthodontic pain during the first week 
following the placement of fixed orthodontic appliances in normal-weight and obese 
adolescents. We found that maximum reported pain across the first week was not 
significantly different between the two groups. However, mean pain was higher in the 
obese group when compared to normal-weight group at all individual time-points. This 
general trend for higher pain at each time-point and the fact that obesity did not have a 
modifying effect on the progression of pain through the study period (interaction p>0.05) 
suggests that obese patients reported generally higher pain levels than normal weight 
patients. Other psychological issues including depression, low self-esteem and anxiety are 
also correlated with pain experience during orthodontic treatment (Bergius et al., 2008, 
Ireland et al., 2017); however, these parameters have not been tested in this study. In 
addition, the higher amount of total analgesia taken by obese group may have no clinical 
importance. The effectiveness of analgesia is more likely related to the type of analgesic 
and  mode of action (Bradley et al., 2007). For instance, acetaminophen inhibits the third 
isoform of cyclooxygenase enzyme (COX3) that does not or slightly inhibits the formation 
of prostaglandins, whilst ibuprofen, piroxicam, aspirin and naproxen sodium inhibit COX1 
and COX2 which control pain sensation through blocking the production of prostaglandins 
(Dionne and Berthold, 2001). Also it should be noted that the pain is a subjective sensation 
which can be influenced by cultural background, previous traumatic experience, sex and 
age (Brown and Moerenhout, 1991, Scheurer et al., 1996, Patel et al., 2011). 
We found a pattern of orofacial pain intensity experienced during the week 
following placement of fixed-appliances that was similar to that seen in previous 
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investigations (Woodhouse et al., 2015b, Scott et al., 2008b, Pringle et al., 2009). This 
reinforces the consistency of pain response that is seen amongst individuals following 
placement of fixed orthodontic appliances and makes this a useful experimental model to 
investigate orofacial pain (Scott et al., 2008b, Woodhouse et al., 2015b, Fleming et al., 
2009, Pringle et al., 2009). The prospective design (Papageorgiou et al., 2015b) and 
comparability of the experimental groups at baseline can also be considered strengths of the 
present study. Moreover, obesity was defined according to widely-accepted and reliable 
measures, which makes misclassification unlikely. Additionally, as the patients in the obese 
and normal-weight groups were similar apart from their BMI, no drop-outs were seen as we 
kept reminding the participants by phone, and even if the patient did not show up after 1 
week, the diary was collected at the next appointment. The VAS measurement blinding was 
implemented, the respective risk for selection, attrition, and detection bias is low. Although 
we did not investigate orthodontic pain in the longer-term, there is evidence to indicate that 
there is consistency in the pattern during subsequent archwire changes (Woodhouse et al., 
2015b, Scott et al., 2008b, Pringle et al., 2009). Although the VAS was explained clearly to 
the patients, there are some potential limitations, including the fact that the results depend 
mainly on the participants’ reports, with the possibility of confusion between pain and 
discomfort, in addition to the accurate dose of analgesic components included in the taken 
tablets. In addition, it is worth mentioning that there is another statistical method for 
analysing the medical research data collected serially on subjects, which takes the form of a 
two stage method that uses summary measures (Matthews et al., 1990). 
The relationship between obesity and oral disease is complex, but there are 
associations with reduced tooth number and irregular dental visits (Ostberg et al., 2012), 
periodontal disease (Suvan et al., 2011, Chaffee and Weston, 2010) dental caries status 
(Kantovitz et al., 2006) and increased risk of dental erosion (Tong et al., 2014). Moreover, 
the presence of oral disease seems to have a greater negative impact on quality-of-life in the 
morbidly obese when compared to normal weight subjects (Yamashita et al., 2015). 
Although the implications of obesity for orthodontic therapy are less clear, a number of 
potential associated factors have been discussed that may impact on treatment, which 
include psychosocial well-being, altered craniofacial growth, overall tissue turnover, and 
bone metabolism (Neeley and Gonzales, 2007, Mack et al., 2013, Giuca et al., 2012, 
Sadeghianrizi et al., 2005). In this study a number of associated factors were investigated 
such as sex, age, baseline-irregularity, baseline-pain, previous tooth extraction and use of 
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analgesia during alignment which may affect the pain sensation of individuals; also plaque 
and gingival inflammation, may induce some biochemical changes such as, IL-1β which is 
one of the inflammatory chemical mediators induce the secretion of pain-producing 
substances that have an impact on pain perception (Davidovitch et al., 1989). 
The results of this investigation suggest that there are differences in the pain 
response between obese and normal-weight subjects during orthodontic treatment over the 
short-term with corresponding differences in the consumption of analgesics. This is in 
agreement with previous studies, which report that obesity can influence peripheral pain 
perception and be a contributory factor for increased pain thresholds (Price et al., 2013, 
Torensma et al., 2016, Zahorska-Markiewicz et al., 1983, Zahorska-Markiewicz et al., 
1988). Possible explanations for this relationship include amongst others, peripheral factors 
such as skin thickness and innervation density (Shir et al., 2001), a possible nociceptive 
modulation through leptin (Kutlu et al., 2003) or interaction of ghrelin with central opioid 
mechanisms, which seems to have an anti-nociceptive effect on endogenous opioids 
(Guneli et al., 2010). In any case, prolonged orthodontic pain has been shown to have 
potential negative consequences on compliance (Sergl et al., 2000) and treatment 
completion (Sergl et al., 1998, Doll et al., 2000). As oral analgesics are effective in 
reducing orthodontic pain (Sandhu et al., 2016) it would seem prudent for clinicians to 
ensure that obese patients are provided with the necessary information and measures to 
ensure appropriate pain relief following the placement of fixed-appliances. 
This is the first prospective study to investigate orthodontic pain in association with 
variation in body weight and provides evidence that informs clinical practice, both in 
orthodontics and other areas of medicine and dentistry. The results of this study are widely 
generalizable and applicable to the majority of obese and normal-weight adolescents aged 
between 12-18 years. 
5.3.5 Conclusion 
Based on the results of this prospective cohort study on pain experience during alignment in 
obese and normal-weight children with moderate to severe mandibular incisor irregularity, 
the following can be concluded: 
1. The maximum-pain experienced during alignment was comparable in both normal 
weight and obese patients; 
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2. Obese patients experience statistically higher mean pain than normal weight patients at 
each time point during the first week after appliance placement; and 
3. This was accompanied by a corresponding statistically significant higher consumption 
of pain medication. 
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Chapter 6 General discussion 
6.1 General discussion 
The term obesity refers to an excess accumulation of body fat produced by adipocyte cells. 
Together, these cells form layers of adipose tissue, an endocrine organ responsible for the 
dysregulation of immune responses through the secretion of bioactive molecules called 
adipocytokines (Ouchi et al., 2011). Obesity increases the risk of chronic health problems 
and leads to serious comorbid conditions, clustered behavioural risk factors and, ultimately, 
high mortality rates. Recent meta-analyses have demonstrated a positive association 
between obesity and periodontitis (Suresh et al., 2016, Suvan et al., 2011, Keller et al., 
2015), which appears to be more severe and more common in obese individuals than in 
normal weight individuals (Suvan et al., 2011). Since OTM mainly depends on periodontal 
tissues and alveolar bone remodelling, obesity can potentially affect orthodontic therapy, 
particularly the inflammatory mediators secreted in the periodontal sulcus. 
Previous evidence concerning the relationship between obesity and orthodontics 
was limited to the implications of obesity for orthodontic diagnosis and treatment (Neeley 
and Gonzales, 2007) with recent evidence suggesting that increased BMI can be a risk 
factor for reduced cooperation, longer treatment duration and increased health-related 
problems during fixed appliance treatment (von Bremen et al., 2015). Currently no data 
exists in relation to OTM in obese patients. The main aim of this study was to examine the 
influence of obesity on OTM, from both clinical and biochemical perspectives, by studying 
the biochemical analysis of biomarkers for inflammation, tissue and bone remodelling and 
obesity, in different bio-fluids (UWMS, GCF and serum), alongside measurement of the 
rate of tooth movement and pain experience in both normal weight and obese subjects. For 
this purpose, the following hypotheses were tested: 
 First hypothesis: Obesity does not change the levels of selected biomarkers. 
This was disproved and the null hypothesis was rejected as there were significant changes 
in the profile of several biomarkers in some bio-fluids, such as adiponectin, leptin, MMP8, 
TIMP1, RANKL, MPO and CRP, with obesity. 
 Second hypothesis: Obesity does not change the levels of selected biomarkers in patients 
undergoing fixed appliance orthodontic treatment. 
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This was proved and the null hypothesis was accepted because although obesity affects 
markers in bio-fluids, orthodontic treatment drives even bigger effects. 
 Third hypothesis: There is no difference between UWMS, GCF and serum in the 
biochemical analysis with OTM. 
This was disproved and the null hypothesis was rejected because changes in inflammation, 
tissue and bone remodelling biomarkers during orthodontic alignment were mainly seen in 
GCF. 
 Fourth hypothesis: There is no difference in the orthodontic tooth alignment between 
normal weight and obese patients. 
This was disproved and the null hypothesis was rejected because obese patients showed a 
significantly higher rate of tooth movement compared with normal weight patients, 
although there was no significant reduction in the time required for the orthodontic 
alignment of obese patients. 
 Fifth hypothesis: There is no difference in the pain intensity felt during the initial phase of 
orthodontic alignment between normal weight and obese patients. 
This was disproved and the null hypothesis was rejected because obese patients 
experienced higher mean pain than normal weight patients in the first week after appliance 
placement, accompanied by a concomitant consumption of analgesics that was also higher. 
6.1.1 Rate of OTM 
The measurement time points in this study were: T1 (before treatment); T2 (1 hour after 
appliance placement); T3 (1 week after); and T4 (end of orthodontic alignment). These 
points were selected in an attempt to follow the different biological changes underlying 
tooth movement. Based on human studies, it has been widely accepted that OTM follows a 
specific pattern in time with three phases (King et al., 1991, Rody et al., 2001): an initial 
phase, 1 - 2 days after force application, representing either rapid displacement of the tooth 
in the PDL space (Burstone, 1962) or bending of the alveolar bone (Baumrind, 1969); a lag 
phase, lasting 4 - 20 days, with relatively low or no displacement as a result of hyalinization 
of the PDL in areas of compression; and an acceleration postlag phase during which the 
rate of OTM reassumes after the removal of hyalinised tissue formed during the second 
phase (Burstone, 1962). Each phase is determined by specific reactions involving the 
recruitment of bone-resorbing and bone-forming precursors, as well as the extravasation 
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and chemotaxis of inflammatory cells (Krishnan and Davidovitch, 2006b). The activity of 
these cells can be measured biochemically by certain markers of inflammation and of tissue 
and bone metabolism. 
In this study, significant association was found between the rate of tooth movement 
and the amount of initial tooth irregularity. This could be due to the fact that the same wire 
applies more force on teeth that are more crowded, resulting in greater displacement during 
the initial phase of tooth movement. This rate of tooth movement was significantly higher 
in obese patients after 1 week of archwire placement and at the end of alignment, largely 
due to the bone texture of obese subjects. 
Existing information about the effect of body mass on bone texture varies. Some 
authors describe a positive effect of body mass on bone mineral density, as an adaptation to 
the increased load carried on the bone (Leonard et al., 2004, Clark et al., 2006); however, if 
this were also true for the bones surrounding the teeth, it would mean a slower OTM in 
obese patients. Other authors found that the change in hormones caused by obesity 
negatively affects bone quality, which could imply easier OTM (Janicka et al., 2007, Rhie 
et al., 2010, Viljakainen et al., 2011). This is verified by animal studies that reported a 
decrease in bone mineral density, bone mineral content and total skeleton area in rats fed on 
a high fat diet compared with those given a standard diet (Lac et al., 2008). 
Rates of tooth movement were significantly higher in obese patients compared to 
normal weight patients during the first week (T1-T3; p<0.001), then decreased until the two 
groups showed comparable movement (p=0.119) between T3 (1 week) and T4 (the end of 
alignment). At the end of alignment, the obese group had displayed a significantly higher 
rate of overall tooth movement (T1-T4; p=0.05). One possible explanation is that the bone 
texture of obese subjects allows greater tooth displacement in the supporting bone, resulting 
in significantly faster tooth movement in the first week. In contrast, the bone remodelling 
process was less efficient in obese patients due to higher levels of leptin and pro-
inflammatory cytokines that modulate bone metabolism (Krysiak et al., 2012, Carbone et 
al., 2012). These higher levels may lead to slower bone turnover, resulting in decelerated 
tooth movement. Taken together, these two parallel processes – one causing greater OTM 
and the other less efficient OTM – may explain why the orthodontic alignment period for 
obese patients remains comparable with that of normal weight patients. 
It is worth noting that obesity and bone metabolism are interrelated, as both bone-
forming cells (osteoblasts) and adipocytes are derived from a common multi-potential 
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mesenchymal stem cell (Greqoir et al., 1998); agents inhibiting adipogenesis therefore 
stimulate osteoblast differentiation (Gimble et al., 1996, David et al., 2007b, Sen et al., 
2008) and vice versa (Beresford et al., 1992). Obesity affects bone metabolism through the 
upregulation of pro-inflammatory cytokines, such as IL-6 and TNF-α, that may increase 
bone resorption by stimulating osteoclast activity through the regulation of the 
RANKL/RANK/OPG pathway (Pfeilschifter et al., 2002). Furthermore, it provokes an 
increase in adipocyte-derived leptin (Canavan et al., 2005, Van Dielen et al., 2001) and a 
decrease in adiponectin, which stimulate macrophage transportation, accumulation and 
adhesion to endothelial cells (Maeda et al., 2002, Sierra-Honigmann et al., 1998). 
Additionally, the excess fatty acids found in a high-fat diet form unabsorbable, insoluble 
calcium soaps that interfere with proper calcium absorption in the intestine (Nelson et al., 
1998, Carnielli et al., 1996, Lucas et al., 1997). 
6.1.2 Biochemical analysis 
Most human studies concerning the biology of OTM have focused on the analysis of 
different mediators involved in periodontal tissue and alveolar bone remodelling. 
Knowledge of biomarkers during OTM has clinical value when applied to considering 
aspects of orthodontic treatment such as the use of mechanical force to improve and shorten 
treatment time with minimal side effects (Kumar et al., 2015). 
The next stage of investigation concerns how these biomarkers are produced. 
During orthodontic treatment, the applied forces affect the ECM of the PDL, resulting in 
cellular alteration, cytoskeletal configuration and temporary bioelectric signals that change 
the membrane polarity and ion channel activities. Such events lead to the production of 
neuropeptides, released from afferent nerve endings, as well as the vasodilatation of blood 
vessels in the PDL space, which causes the migration of leucocytes into the gingival sulcus. 
This migration creates a wide range of inflammatory mediators. The overall result of this 
interaction is the production of tissue-degrading enzymes and acids that induce cellular 
proliferation and differentiation, and promote wound healing and tissue remodelling. All of 
these biochemical changes take place across all stages (earlier and later) of active 
orthodontic treatment and even during the retention period following orthodontic therapy 
(Hill and Orth, 1998, Davidovitch, 1995, Sandy et al., 1993). The status of the tissue 
around the teeth during OTM can be examined by analysing the GCF in the surrounding 
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sulcus to assess and modify the orthodontic treatment procedure. A major limitation of 
GCF studies is the small sample volume for analysis (typically less than 0.5 µl) that is 
obtained from healthy sites (Canavarro et al., 2013). The small volume of GCF limits the 
number of analytes that can be conveniently studied by traditional ELISA; however, the 
introduction of the multianalyte microsphere assay allows the simultaneous quantification 
of several targets in a single assay. The multiplex, magnetic bead-based Luminex assay was 
used in this study to detect multiple biomarkers in UWMS, GCF and serum. 
Data from the study showed that there was no correlation between biomarker levels 
and plaque and gingival scores. Changes of biomarkers can therefore be attributed to 
inflammation taking place during OTM, rather than bacterial plaque or gingivitis. 
Obesity biomarkers (adiponectin, leptin and resistin) showed that the levels of 
adiponectin and leptin, which are mainly produced by adipocytes, were higher in serum 
than in GCF and were lowest in UWMS, thus indicating their systemic secretion from 
adipocytes directly into circulation. In contrast, the highest levels of resistin were found in 
GCF, followed by serum and finally UWMS. This is due to the fact that, although it is an 
obesity biomarker, it is mainly produced by neutrophils, macrophages with very little 
presence in adipocytes in humans (Patel et al., 2003, Rosen and Spiegelman, 2006). These 
findings are in agreement with previous studies that reported higher levels of resistin in 
GCF than serum (Patel and Raju, 2014). 
In this study, the levels of adiponectin were lower, whereas the levels of leptin and 
resistin were higher in obese subjects compared with normal weight subjects. These results 
are in agreement with other studies that report a decrease in the levels of adiponectin 
(Ouchi et al., 1999, Joseph et al., 2002, Kadowaki and Yamauchi, 2005, Ashley et al., 
2011) and an increase in the levels of leptin (Considine et al., 1996) and resistin 
(Piestrzeniewicz et al., 2008) with obesity; however, another study reported no association 
between resistin levels with BMI (Mamali et al., 2012), which confirms the findings of the 
cross-sectional study. The reason for this inconsistency is unclear, but it could be related to 
differences in patient age and stage of orthodontic treatment. 
The prospective study highlighted that, during orthodontic alignment, the only 
significant change in adipokine levels was the reduction of adiponectin levels in serum at 
the end of the alignment (T4), with significantly greater reduction in the obese group than 
the normal weight group. While the overall levels of these adipokines during orthodontic 
alignment were comparable to those before treatment, they still showed higher leptin and 
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resistin, and lower adiponectin levels in obese patients. The remarkably higher levels of 
leptin and resistin in GCF of obese patients can explain the association between these 
proteins and the higher rate of tooth movement in obese patients. 
The other group of biomarkers is the tissue remodelling biomarkers such as MMP8, 
MMP9 and their inhibitor TIMP1. These biomarkers have been chosen for this study 
because they are involved in collagen turnover and catalyse the initial degradation of the 
major ECM proteins in PDL remodelling during OTM, which can also be delayed or 
inhibited with TIMPs (Holmbeck et al., 2004). 
Data from cross-sectional and prospective studies showed that MMP8 mostly 
changed with obesity, MMP9 mostly changed with OTM, and TIMP1 changed with both. 
MMP8, mainly produced by the PMNs (Mäntylä et al., 2003, Ingman et al., 2005), cleaves 
the interstitial collagens I, II, and III (Raffetto and Khalil, 2008). MMP9, mainly secreted 
by fibroblasts, monocyte and macrophages, (Bourboulia and Stetler-Stevenson, 2010) 
cleaves elastin and collagen IV, V and X (Tayebjee et al., 2004a, Tayebjee et al., 2004b). 
TIMPs inhibit MMPs by developing 1:1 enzyme-inhibitor complexes (Gomez et al., 1997). 
In the gingival sulcus, where the local effects of orthodontic forces take place, GCF 
showed an increase in MMP9 levels within the first week of orthodontic treatment in both 
normal weight and obese groups, without marked differences between the two groups. On 
the contrary, MMP8 and TIMP1 levels were significantly higher in the obese group before 
and throughout the orthodontic alignment, with limited changes between time points during 
the orthodontic treatment. These findings confirm the results of GCF analysis in the cross-
sectional study, in which only MMP9 (but not MMP8 or TIMP1) increased significantly in 
the GCF of obese patients with orthodontic appliances. These results could be due to the 
impact of MMP9 on the degradation of elastin and different types of collagen, such as IV, 
V, and X (Tayebjee et al., 2004a, Tayebjee et al., 2004b) that may be increased during 
orthodontic treatment and enhanced by the inflammatory conditions of obesity. 
Additionally, MMP9 plays a role, not only in the degradation of collagen matrices, but also 
in the migration of osteoclast precursors to sites of bone resorption (Ishibashi et al., 2006). 
This may explain the elevation in the levels of MMP9, but not MMP8, at 1 hour after the 
placement of the fixed orthodontic appliance and throughout the first week, affecting the 
MMP9/TIMP1 ratio. 
Circulating MMP8, MMP9 and TIMP1 showed comparable levels in obese and 
normal weight patients in the prospective study; however, at the end of alignment (T4), the 
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levels of MMP8 and MMP8/TIMP1 ratio were significantly higher in obese patients. 
Furthermore, although circulating MMP8 levels were not significantly higher in obese 
patients with fixed orthodontic appliances in the cross-sectional study; the MMP9 levels 
were significantly increased. Such events may indicate the possible systemic effects of 
fixed appliance orthodontic treatment in obese patients and increase the risk of systemic 
diseases, such as cardiovascular diseases and metabolic syndromes associated with high 
levels of MMP8 in the blood (Turu et al., 2006, Souza-Costa et al., 2007, Koh et al., 2005). 
The other biomarkers investigated in this study were the inflammation biomarkers 
including MPO and CRP. Levels of MPO increased with obesity and with orthodontic 
treatment, indicating a greater number of neutrophils in response to the inflammatory 
condition triggered by obesity or orthodontic therapy or both. The changes in the levels of 
MPO can be clearly seen in saliva and GCF, in agreement with the findings of previous 
studies (Marcaccini et al., 2010, Navarro-Palacios et al., 2014). The regression analysis 
demonstrated that the association between this enzyme and the rate of tooth movement can 
be explained by the high levels of MPO in GCF with obesity and significant changes in 
orthodontic treatment. 
CRP, which acts as a diagnostic marker for inflammation, tissue damage and low-
grade systemic inflammation (Ridker and Silvertown, 2008, Paraskevas et al., 2008), was 
elevated in the obese group and mainly detected in serum. During orthodontic treatment, 
the prospective study explored whether there were any significant changes in the levels of 
CRP at all-time points in the three tested bio-fluids. However, the significantly higher 
levels of circulating CRP in obese subjects, before and through the whole orthodontic 
alignment, was reflected in the GCF of those patients, resulting in significantly higher 
levels of CRP in GCF of obese patients compared to normal weight patients after 1 week of 
fixed orthodontic appliance placement. This may indicate that the orthodontic treatment of 
obese subjects has a systemic effect, as a result of the hyper-production of IL-1, IL-6 and 
TNF-α in the gingival sulcus, combined with an orthodontic force that stimulates the 
hepatocyte to produce more CRP in the serum (Ide et al., 2004, Nibali et al., 2007) that then 
diffuses to GCF. 
The last biomarker measured in this study is the bone remodelling cytokine 
RANKL, the key to osteoclastogensis and bone resorption. Produced mainly by osteoblasts, 
it is highly influenced by pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6. The 
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highest levels of RANKL were therefore found in GCF and were significantly greater in 
obese subjects (Halade et al., 2011, Xu et al., 2013). 
Interestingly, the data of this study demonstrated that the levels of RANKL in GCF 
and serum were significantly increased at the end of alignment (T4), which reflects the 
postlag phase in which a higher rate of bone resorption take place. These findings are in 
agreement with a previous study (Grant et al., 2013). In relation to obesity, RANKL levels 
in GCF and serum were remarkably higher in obese than normal weight patients, both 
before and throughout the alignment stage. However, salivary RANKL showed a different 
pattern than GCF and serum, with reduced levels in obese subjects compared with the 
normal weight group. Although these differences were not significant enough during the 
first week, it appeared significant at the end of alignment (T4). This is supported by the 
significant reduction of salivary RANKL levels with obesity in the control cohort of our 
cross-sectional study. The reason behind such variation is possibly related to the effect of 
obesity on the diffusion of RANKL from serum and GCF to saliva, rather than the salivary 
glands themselves. This can be supported by previous studies, reporting that salivary 
RANKL originates from GCF rather than salivary glands (Sakellari et al., 2008, Buduneli 
et al., 2009, Tang et al., 2009). 
6.1.3 The levels of biomarkers in different bio-fluids 
Alongside advances in biology, interest in the potential use of oral biomarkers in 
periodontal diagnostics and prognostics has soared. Saliva has been proposed as the most 
useful sample to use for periodontal monitoring, due to the fact that it is unlike serum or 
GCF in terms of easy, rapid, safe and non-invasive collection; a cost-efficient method of 
disease screening, without the need for highly trained professionals. Simple processing and 
analysis is required; and salivary analytes are very stable, which makes it feasible for 
patients to produce the sample at home and post it to the laboratory. Investigating GCF 
analytes in relation to OTM is also an easy, non-invasive process. It is more reflective of 
the site-specific view, rather than the overall oral status of an individual supplied by saliva 
alone. This is due to the fact that the supracrestal gingival collagen fibres are not 
completely resorbed or degraded during OTM; rather, they are compressed or retracted 
during tooth dislocation (Redlich et al., 1996). This mechanism may be important in the 
maintenance of a healthy periodontium during orthodontic movement. The constant 
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presence of supracrestal collagen during tooth movement might restrict the diffusion of 
mediators from the PDL to the gingival margin. Serum analysis in obesity research is also 
required in this study, as adipocytes produce adipokines and cytokines directly into 
circulation. 
The data of this study showed that some biomarkers are systemically produced, 
such as adiponectin, leptin and CRP, which are directly secreted from adipocytes and 
hepatic cells into the circulation. These had the highest levels in serum, followed by GCF, 
and the least in UWMS. Other biomarkers such as resistin, MMPs and their inhibitor 
TIMPs, MPO, and RANKL showed their highest levels in GCF, which may indicate local 
production, as well as their diffusion from blood. Biomarkers that are locally produced are 
able to play a role in the biological mechanisms that take place in the PDL under normal 
conditions, such as tooth eruption and physiological tooth movement. They also potentially 
constitute a response to mechanical stimuli, such as OTM, and inflammatory conditions 
such as periodontitis. Furthermore, in this study, it was noticed that obesity may affect the 
diffusion of some mediators from blood to saliva, as the different patterns of RANKL and 
leptin in saliva were observed in comparison to those in GCF and serum. 
6.1.4 UWMS and GCF flow rate 
Since the concentration of biomarkers is highly influenced by flow rate, the UWMS and 
GCF flow rate were measured in this study. From these results, it can be seen that UWMS 
flow rate was not affected by obesity, as a comparable UWMS flow rate was observed in 
normal weight and obese adults aged 18 to 45 without orthodontic treatment (control cohort 
in cross-sectional study), and at baseline (T1) before the placement of orthodontic 
appliances for patients aged 12 to 18 (in the prospective study). These findings are in 
agreement with previous studies measuring the salivary flow rate in obese adults (FenolI-
Palomares et al., 2004)  and children (Pannunzio et al., 2010). However, UWMS flow rate 
was influenced by OTM, regardless of BMI, and significantly increased in both normal 
weight and obese patients after 1 hour of fixed orthodontic appliances placement, as seen at 
T2-T4 in the prospective study. Such modifications can be considered as a physiological 
response to the mechanical stimulation of fixed orthodontic appliance components such as 
bands, tubes, brackets and wires that can influence the UWMS flow rate. This was 
previously reported by other researchers (Li et al., 2009) and might affect the salivary 
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constituents (Edgar, 1992). This explanation is based on the phenomenon that the 
placement of a foreign body in the mouth stimulates saliva secretion and increases the flow 
rate (Forsberg et al., 1992); that the salivary parameters become stable after 6 months of 
fixed orthodontic appliance placement can be seen as a form of adaptation (Li et al., 2009), 
which can explain a comparable UWMS flow rate in normal weight and obese adults aged 
18 to 45 with orthodontic treatment (orthodontic treatment cohort in cross-sectional study). 
Conversely, the GCF flow rate increased with both obesity and with orthodontic 
treatment, as was clearly seen in the prospective study in which GCF flow rate had a higher 
starting point in obese patients than in normal weight patients before the treatment. This 
then significantly increased in both groups 1 hour after fixed orthodontic appliance 
placement, with remarkably greater levels in the obese group until the end of the 
orthodontic alignment (T1-T4). The cross-sectional study also showed increased GCF flow 
rate with obesity in the control cohort, without orthodontic treatment, while the cohort 
undergoing orthodontic treatment showed comparable GCF flow rates in obese and normal 
weight patients. Such diversity could be related to the age of patients and the stage of the 
orthodontic treatment, as the prospective study was started before, and continued during, 
the orthodontic alignment of patients aged 12 to 18, while the cross-sectional study was 
undertaken at the final alignment stage of fixed appliance orthodontic treatment of patients 
aged 18 to 45. These explanations are based on the findings of previous studies highlight 
that the GCF flow rate increased with inflammation (Goodson, 2003), showed greater 
quantity in adolescents than adults regardless of the presence of any stimuli (Ren et al., 
2002) and its constitutes were affected by local and systemic conditions (Ebersole, 2003). 
Interestingly, the increase in GCF flow rate with orthodontic treatment could be attributed 
to the effect of orthodontic force on blood vessels, rather than biochemical changes in the 
ECM (Baldwin et al., 1999). The data of this study confirms previous studies (Basaran et 
al., 2006, Karacay et al., 2007); however, other investigations reported that the mechanical 
stress of orthodontic appliance has no impact on GCF flow rate during OTM (Uematsu et 
al., 1996b, Miyajima et al., 1990). 
6.1.5 Pain during orthodontic treatment 
The pain experienced during orthodontic treatment is an inflammatory pain that results 
from vascular changes, recruitment and differentiation of inflammatory and immune cells, 
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and the production of neurogenic and inflammatory mediators in response to the 
mechanical stimuli by the orthodontic appliance. It has been reported that OTM and pain 
are two dependent and interrelated biological events, incorporating local inflammation and 
the production of various mediators that act on sensory nerve endings to incite painful 
sensations (Sacerdote and Levrini, 2012, Nimeri et al., 2013). Therefore, the mechanisms 
underlying orthodontic pain lie in the interaction of vascular, cellular and chemical 
components of periodontal inflammatory responses, induced by orthodontic forces. Pain 
signals pass through the periodontal sensory nerve endings to the pain perception areas of 
the brain’s sensory cortex (Long et al., 2016). 
In relation to obesity, there is evidence that the increased production of 
inflammatory mediators, by the macrophage accumulated in adipose tissues, plays a role in 
pain modulation (Wellen and Hotamisligil, 2003). The mechanism behind this could be 
related to the elevated levels of pro-inflammatory mediators, TNF-α, IL-6 and CRP, and 
decreased anti-inflammatory mediators like adiponectin in blood, leading to systemic 
inflammation (Blüher et al., 2005). This consequently affects the peripheral and central 
pain transmission system and results in hyperalgesia (Bastard et al., 2006). 
In relation to biochemical analysis, studies have focused on the correlation between 
GCF biochemical mediators and pain intensity during orthodontic treatment. The intensity 
of pain 1 hour after the separator placement was associated with prostaglandin E2 levels, 
and after 24 hours, it was associated with IL-1β levels (Giannopoulou et al., 2006). Others 
found the correlation of pain intensity with prostaglandin E2 levels extends to 12, 24 and 
72 hours after the application of labial orthodontic force (Yao et al., 2003). Substance P 
was also recognized as a mediator that initiates dental pain and inflammation, which 
remarkably increased in patients undergoing orthodontic treatment (Sacerdote and Levrini, 
2012). 
From the above, it has been postulated that increased levels of cytokines influence 
and contribute to the sensation of pain by increasing the sensitization of nociceptors 
(Srikanth Babu et al., 2012, Stürmer et al., 2005). This can explain the higher mean of pain 
in the obese group at all-time points, which in turn leads to a higher quantity of oral 
analgesic intake by obese subjects. Pain-related cytokines were not included in the 
biomarkers selected in this study, but the outcome was clearly similar to the findings of 
previous investigations of pain with orthodontic treatment (Scott et al., 2008b, Woodhouse 
et al., 2015b, Pringle et al., 2009). 




The results of this thesis suggest there are clinical and biochemical implications of obesity 
for orthodontic treatment. 
6.2.1 The clinical implications 
During orthodontic alignment, the rate of OTM was higher in obese patients, particularly in 
the first week, due to the hyper-production of pro-inflammatory biomarkers that modify 
bone texture with obesity. This leads to initial faster displacement of teeth in the 
surrounding bone, and then slows down; ending with an insignificant difference in the time 
required for the orthodontic alignment compared with normal weight patients. 
Obese patients experience higher mean pain than normal weight patients, 
accompanied by higher consumption of analgesics; therefore, obese patients need to be 
provided with the necessary information and measures to ensure appropriate pain relief 
following the placement of fixed-appliances. 
6.2.2 The biochemical implications 
GCF analysis is more likely to express the biochemical changes during OTM in both 
normal weight and obese subjects, although some changes were expressed in serum and 
saliva. Thus, the biochemical analysis of GCF can be used clinically to monitor and predict 
the outcome of orthodontic treatment. For instance, the optimum force can be determined to 
achieve the most rapid tooth movement with minimal side effects, optimize the required 
retention period, and minimize the chance of relapse when these changes have disappeared. 
The adipokines leptin and resistin, the inflammatory-marker myeloperoxidase, and 
the bone remodelling cytokine RANKL, were significantly different in the GCF of obese 
and normal weight patients. As these biomarkers are associated with observed rates of tooth 
movement, further investigation of these biomarkers is recommended with OTM. 
Sequentially, both obesity and orthodontic force influence the levels of some 
biomarkers in some bio-fluids. At the early stage of fixed appliance orthodontic treatment, 
the effect of obesity was greater on the level of these biomarkers; however, by the advanced 
stage, the orthodontic treatment itself had bigger effects. 
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Obesity, to some extent, can reduce the levels of salivary leptin and RANKL by 
affecting their diffusion from serum and GCF, which showed higher levels of leptin and 
RANKL in obese subjects. 
Salivary MPO levels can reflect the levels of MPO in GCF of normal weight and 
obese subjects both with and without orthodontic treatment; therefore, the recommendation 
is to measure MPO non-invasively in UWMS. 
Salivary adiponectin has a small contribution from serum, but there also appears to 
be a contaminating protein that reacts with several antibodies in Western blots and ELISA, 
which is unlikely to be adiponectin. 
6.3 Future work 
The outcomes of this thesis suggest the need for further clinical and biochemical 
investigations. 
Clinically, the data of this thesis highlights potential implications for orthodontic 
treatment in obese subjects during the alignment stage of fixed appliance orthodontic 
therapy. Additional avenues of study also exist to compare the stability of teeth following 
the orthodontic treatment in obese and normal weight patients. 
Additionally, the thesis showed that the rate of tooth movement was comparable in 
normal weight and obese patients between the end of the first week and the end of 
alignment (T3-T4). Therefore, it would be interesting to also measure the rate of tooth 
movement at every follow up visit, to assess closely the difference in the speed of tooth 
movement between the two groups. 
Biochemically, from the data presented in this thesis, the bone remodelling cytokine 
RANKL a key for osteoclastogensis, was significantly different between obese and normal 
weight patients and is associated with OTM. Previous literature reported that the 
RANKL/OPG balancing system is crucial in the regulation of osteoclastogenesis (Trouvin 
and Goeb, 2010, Bae et al., 2011). It would be valuable to measure the inhibitor OPG and 
RANKL/OPG ratio with obesity. This was not possible in this study, because OPG could 
not be included in the same base panel of the Luminex kit. 
The other finding of this thesis and previous investigations (Junior et al., 2011, 
Almeida et al., 2015) was the significant changes in the levels of MMPs, starting within 
hours of orthodontic appliance placement, then shortly returning to baseline levels. It would 
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be interesting to investigate these enzymes multiple times within the first day and on a daily 
basis within the first week to monitor the fluctuating changes in their levels. 
Finally, the data presented in this thesis provides evidence that salivary adiponectin 
has a small contribution from serum, but there also appears to be a contaminating protein 
that reacts with several antibodies in Western blots and ELISA, which is unlikely to be 
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Appendix 3 List of proteins detected by mass spectrometry in positive bands of serum sample 
 
1 Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2
2 Alpha-amylase 1 OS=Homo sapiens GN=AMY1A PE=1 SV=2
3 Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3
4 Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2
5 Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2
6 Complement factor B OS=Homo sapiens GN=CFB PE=1 SV=2
7 Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2
8 Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 SV=1
9 Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2
10 Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2
11 Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=1
12 Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens GN=ITIH2 PE=1 SV=2
13 Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1
14 Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2
15 Transitional endoplasmic reticulum ATPase OS=Homo sapiens GN=VCP PE=1 SV=4
16 Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1
17 Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3
18 Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3
19 Ig gamma-3 chain C region OS=Homo sapiens GN=IGHG3 PE=1 SV=2
20 Catalase OS=Homo sapiens GN=CAT PE=1 SV=3
21 Ig lambda-2 chain C regions OS=Homo sapiens GN=IGLC2 PE=1 SV=1
22 Annexin A2 OS=Homo sapiens GN=ANXA2 PE=1 SV=2
23 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2
24 Protein AMBP OS=Homo sapiens GN=AMBP PE=1 SV=1
25 Cathepsin D OS=Homo sapiens GN=CTSD PE=1 SV=1
26 Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=2
27 Carbonic anhydrase 2 OS=Homo sapiens GN=CA2 PE=1 SV=2
28 Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1 SV=4
29 Ubiquitin-60S ribosomal protein L40 OS=Homo sapiens GN=UBA52 PE=1 SV=2
30 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2
31 Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=2
32 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3
33 Caspase-14 OS=Homo sapiens GN=CASP14 PE=1 SV=2
34 Complement component C7 OS=Homo sapiens GN=C7 PE=1 SV=2
35 Calmodulin-like protein 5 OS=Homo sapiens GN=CALML5 PE=1 SV=2
36 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2
37 Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1
38 Prolactin-inducible protein OS=Homo sapiens GN=PIP PE=1 SV=1
39 Apolipoprotein D OS=Homo sapiens GN=APOD PE=1 SV=1
40 Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1
41 Complement C2 OS=Homo sapiens GN=C2 PE=1 SV=2
42 Cystatin-A OS=Homo sapiens GN=CSTA PE=1 SV=1
43 Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 SV=3
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45 Protein S100-A7 OS=Homo sapiens GN=S100A7 PE=1 SV=4
46 Complement component C6 OS=Homo sapiens GN=C6 PE=1 SV=3
47 Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens GN=ITIH1 PE=1 SV=3
48 Inter-alpha-trypsin inhibitor heavy chain H3 OS=Homo sapiens GN=ITIH3 PE=1 SV=2
49 Prelamin-A/C OS=Homo sapiens GN=LMNA PE=1 SV=1
50 Ubiquitin carboxyl-terminal hydrolase 5 OS=Homo sapiens GN=USP5 PE=1 SV=2
51 Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2 PE=1 SV=2
52 Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4
53 Galectin-7 OS=Homo sapiens GN=LGALS7 PE=1 SV=2
54 Protein S100-A9 OS=Homo sapiens GN=S100A9 PE=1 SV=1
55 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1
56 Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4
57 Annexin A1 OS=Homo sapiens GN=ANXA1 PE=1 SV=2
58 Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2
59 Cathepsin B OS=Homo sapiens GN=CTSB PE=1 SV=3
60 Ezrin OS=Homo sapiens GN=EZR PE=1 SV=4
61 Plectin OS=Homo sapiens GN=PLEC PE=1 SV=3
62 Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1
63 Ig heavy chain V-III region TIL OS=Homo sapiens PE=1 SV=1
64 Desmocollin-1 OS=Homo sapiens GN=DSC1 PE=1 SV=2
65 Calmodulin-like protein 3 OS=Homo sapiens GN=CALML3 PE=1 SV=2
66 Gamma-glutamylcyclotransferase OS=Homo sapiens GN=GGCT PE=1 SV=1
67 Gasdermin-A OS=Homo sapiens GN=GSDMA PE=2 SV=4
68 Plasma protease C1 inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=2
69 Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1 SV=5
70 Serpin B3 OS=Homo sapiens GN=SERPINB3 PE=1 SV=2
71 Ig gamma-4 chain C region OS=Homo sapiens GN=IGHG4 PE=1 SV=1
72 Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1
73 Tropomyosin alpha-3 chain OS=Homo sapiens GN=TPM3 PE=1 SV=1
74 14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1
75 Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1
76 Ubiquitin-like modifier-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 SV=3
77 L-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB PE=1 SV=2
78 78 kDa glucose-regulated protein OS=Homo sapiens GN=HSPA5 PE=1 SV=2
79 Ganglioside GM2 activator OS=Homo sapiens GN=GM2A PE=1 SV=4
80 Cathepsin L2 OS=Homo sapiens GN=CTSL2 PE=1 SV=2
81 Histidine-rich glycoprotein OS=Homo sapiens GN=HRG PE=1 SV=1
82 Vinculin OS=Homo sapiens GN=VCL PE=1 SV=4
83 Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3
84 Filaggrin OS=Homo sapiens GN=FLG PE=1 SV=3
85 Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=1 SV=2
86 Malate dehydrogenase, cytoplasmic OS=Homo sapiens GN=MDH1 PE=1 SV=4
87 Adiponectin OS=Homo sapiens GN=ADIPOQ PE=1 SV=1




Appendix 4 List of proteins detected by mass spectrometry in positive band of saliva sample 
 
1 Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2
2 Alpha-amylase 1 OS=Homo sapiens GN=AMY1A PE=1 SV=2
3 Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2
4 Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 SV=1
5 Myeloperoxidase OS=Homo sapiens GN=MPO PE=1 SV=1
6 Protein disulfide-isomerase OS=Homo sapiens GN=P4HB PE=1 SV=3
7 Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2
8 Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=1
9 Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM PE=1 SV=4
10 Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1
11 Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2
12 Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1
13 Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3
14 Ig gamma-3 chain C region OS=Homo sapiens GN=IGHG3 PE=1 SV=2
15 Moesin OS=Homo sapiens GN=MSN PE=1 SV=3
16 Catalase OS=Homo sapiens GN=CAT PE=1 SV=3
17 Ig lambda-2 chain C regions OS=Homo sapiens GN=IGLC2 PE=1 SV=1
18 Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2 PE=1 SV=3
19 Coronin-1A OS=Homo sapiens GN=CORO1A PE=1 SV=4
20 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2
21 Cystatin-S OS=Homo sapiens GN=CST4 PE=1 SV=3
22 Nucleobindin-2 OS=Homo sapiens GN=NUCB2 PE=1 SV=2
23 Ubiquitin-60S ribosomal protein L40 OS=Homo sapiens GN=UBA52 PE=1 SV=2
24 Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=2
25 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3
26 Caspase-14 OS=Homo sapiens GN=CASP14 PE=1 SV=2
27 Adenylyl cyclase-associated protein 1 OS=Homo sapiens GN=CAP1 PE=1 SV=5
28 Brain acid soluble protein 1 OS=Homo sapiens GN=BASP1 PE=1 SV=2
29 Lactotransferrin OS=Homo sapiens GN=LTF PE=1 SV=6
30 Prolactin-inducible protein OS=Homo sapiens GN=PIP PE=1 SV=1
31 Calreticulin OS=Homo sapiens GN=CALR PE=1 SV=1
32 SPARC-like protein 1 OS=Homo sapiens GN=SPARCL1 PE=1 SV=2
33 DnaJ homolog subfamily C member 3 OS=Homo sapiens GN=DNAJC3 PE=1 SV=1
34 Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2 PE=1 SV=2
35 Annexin A11 OS=Homo sapiens GN=ANXA11 PE=1 SV=1
36 Leukocyte elastase inhibitor OS=Homo sapiens GN=SERPINB1 PE=1 SV=1
37 Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR PE=1 SV=4
38 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1
39 Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4
40 Glucose-6-phosphate isomerase OS=Homo sapiens GN=GPI PE=1 SV=4
41 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform OS=Homo sapiens GN=PPP2R1A PE=1 SV=4
42 Annexin A1 OS=Homo sapiens GN=ANXA1 PE=1 SV=2
43 Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2
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45 Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1
46 Basic salivary proline-rich protein 1 OS=Homo sapiens GN=PRB1 PE=1 SV=2
47 Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1
48 Ig heavy chain V-III region TIL OS=Homo sapiens PE=1 SV=1
49 IgGFc-binding protein OS=Homo sapiens GN=FCGBP PE=1 SV=3
50 Kallikrein-1 OS=Homo sapiens GN=KLK1 PE=1 SV=2
51 Mucin-5B OS=Homo sapiens GN=MUC5B PE=1 SV=3
52 Carbonic anhydrase 6 OS=Homo sapiens GN=CA6 PE=1 SV=3
53 Plastin-2 OS=Homo sapiens GN=LCP1 PE=1 SV=6
54 Ig gamma-4 chain C region OS=Homo sapiens GN=IGHG4 PE=1 SV=1
55 Tropomyosin alpha-3 chain OS=Homo sapiens GN=TPM3 PE=1 SV=1
56 BPI fold-containing family B member 1 OS=Homo sapiens GN=BPIFB1 PE=2 SV=1
57 Cystatin-SN OS=Homo sapiens GN=CST1 PE=1 SV=3
58 Glucose-6-phosphate 1-dehydrogenase OS=Homo sapiens GN=G6PD PE=1 SV=4
59 Nicotinamide phosphoribosyltransferase OS=Homo sapiens GN=NAMPT PE=1 SV=1
60 EH domain-containing protein 1 OS=Homo sapiens GN=EHD1 PE=1 SV=2
61 Nucleobindin-1 OS=Homo sapiens GN=NUCB1 PE=1 SV=4
62 Immunoglobulin J chain OS=Homo sapiens GN=IGJ PE=1 SV=4
63 Protein disulfide-isomerase A3 OS=Homo sapiens GN=PDIA3 PE=1 SV=4
64 Cytochrome b-245 heavy chain OS=Homo sapiens GN=CYBB PE=1 SV=2
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Obesity levels have been rising among children and adults in 
Western societies over the past few decades (Ng et al. 2014). This 
represents a major health care challenge because of the known 
associations between raised body mass index (BMI) and multiple 
chronic diseases, including insulin-resistant diabetes, cardiovas-
cular disease, and cancer (Deng et al. 2016). It is recognized that 
obesity represents a state of chronic subclinical inflammation 
mediated through excess adipose tissue (Hotamisligil 2006). 
Adipocytes produce a host of metabolically active proteins or 
adipokines that influence metabolic function and inflammatory 
responses (Ouchi et al. 2011) and include proinflammatory leptin 
(Zhang et al. 1994) and resistin (Steppan et al. 2001) and anti-
inflammatory adiponectin (Scherer et al. 1995).
Adipose tissue can influence the intensity and resolution of 
inflammatory responses in multiple tissues (Issa and Griffin 
2012; Pierpont et al. 2014). Indeed, an increased risk of chronic 
periodontitis (Suvan et al. 2011; Keller et al. 2015) and variation 
in inflammatory and metabolic markers exist in obese subjects 
affected by periodontal disease compared with normal-weight 
subjects (Papageorgiou, Reichert, et al. 2015). The systemic 
induction of inflammatory markers may provide a link between 
obesity and periodontitis, with current focus on C-reactive 
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Abstract
Obesity is a widespread chronic inflammatory disorder characterized by an increased overall disease burden and significant association 
with periodontitis. The aim of this prospective clinical cohort study was to investigate the effect of obesity on orthodontic tooth 
movement. Fifty-five adolescent patients (27 males, 28 females) with a mean (SD) age of 15.1 (1.7) years and mean (SD) body mass index 
(BMI) of 30.2 (3.5) kg/m2 in obese and 19.4 (2.2) kg/m2 in normal-weight groups were followed from start of treatment to completion 
of tooth alignment with fixed orthodontic appliances. Primary outcome was time taken to complete tooth alignment, while secondary 
outcomes included rate of tooth movement and change in clinical parameters (plaque/gingival indices, unstimulated whole-mouth salivary 
flow rate, gingival crevicular fluid biomarkers). Data collection took place at baseline (start of treatment: appliance placement), 1 h and 
1 wk following appliance placement, and completion of alignment. Results were analyzed by descriptive statistics followed by generalized 
estimating equation regression modeling. There were no significant differences between groups in time taken to achieve tooth alignment 
(mean [SD] 158.7 [75.3] d; P = 0.486). However, at 1 wk, initial tooth displacement was significantly increased in the obese group (P < 
0.001), and after adjusting for confounders, obese patients had a significantly higher rate of tooth movement compared with normal-
weight patients (+0.017 mm/d; 95% confidence interval, 0.008–0.025; P < 0.001) over the period of alignment. Explorative analyses 
indicated that levels of the adipokines leptin and resistin, the inflammatory marker myeloperoxidase (MPO), and the cytokine receptor 
for nuclear factor kappa-B ligand (RANKL) were significantly different between obese- and normal-weight patients and associated with 
observed rates of tooth movement. This represents the first prospective data demonstrating a different response in obese patients 
compared with normal-weight patients during early orthodontic treatment. These differences in the response of periodontal tissues to 
orthodontic force in the presence of obesity have potential short- and long-term clinical implications.
Keywords: biomarkers, BMI, inflammation, MMPs, RANKL, saliva
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protein (CRP) as an important potential mediator (Pradeep et al. 
2012).
Orthodontic tooth movement is initially represented by sim-
ple mechanical displacement of the tooth and bone bending 
within the socket, which occurs due to compression of the peri-
odontal ligament following the application of external force. 
However, over the longer term, tooth movement occurs as a 
direct consequence of connective tissue remodeling within the 
periodontium and alveolar bone mediated through a localized 
inflammatory response. This triggers the release of essential 
biochemical mediators, which are often detectable within gin-
gival crevicular fluid (GCF) (Kapoor et al. 2014)—in particu-
lar, the tissue-modulating factors receptor for nuclear factor 
kappa-B ligand (RANKL), matrix metalloproteinases (MMPs), 
and tissue inhibitors of MMPs (TIMPs) (Grant et al. 2013). 
Obesity is also known to influence systemic bone metabolism 
through complex mechanical, hormonal, and inflammatory 
interactions (López-Gómez et al. 2016) with associations 
between obesity and reduced bone remodeling (Ivaska et al. 
2016) and increased bone mineral density (Salamat et al. 
2016). Although there are little data relating obesity to changes 
in alveolar bone composition within the healthy periodontium, 
longitudinal data have shown a significant association with 
increased rates of tooth eruption (Must et al. 2012).
The potential implications of adolescent obesity for orth-
odontic treatment have been highlighted (Neeley and Gonzales 
2007), with increased BMI a risk factor for less cooperation and 
longer treatment duration with fixed appliances (von Bremen et al. 
2016). However, despite known associations between raised 
BMI and chronic inflammatory changes within the periodon-
tium, there have been no prospective investigations of orth-
odontic tooth movement in obese patients. The aim of this study 
was to investigate the effect of obesity on orthodontic tooth 
movement during routine treatment with fixed appliances—
specifically, time taken to complete tooth alignment and varia-
tion in clinical parameters, including GCF biomarkers.
Materials and Methods
Study Design
This prospective cohort study compared the effects of obesity on 
tooth alignment with fixed appliances. Ethical approval was 
obtained from the United Kingdom National Research Ethics 
Service (UK NRES) (14/LO/0769). Written informed consent was 
received from all parents, guardians, and children. We report and 
present data according to STROBE (Strengthening the Reporting 
of Observational Studies in Epidemiology; von Elm et al. 2008).
Setting
Participants fulfilling the inclusion criteria were recruited con-
secutively from orthodontic treatment clinics at King’s College 
London Dental Institute (Guy’s Hospital) between January 
2015 and January 2016. Follow-up occurred to June 2016 and 
covered appliance placement to completion of alignment.
Participants
Inclusion criteria included the following: 1) fixed-appliance 
treatment, 2) aged 12 to 18 y at treatment start, 3) no medical 
contraindications or regular medication (including antibiotic 
therapy) in the last 6 mo, 4) nonsmokers, 5) permanent denti-
tion, 6) mandibular arch incisor irregularity index of 4 to 12 mm, 
and 7) normal-weight (BMI-centile 2–91) and obese (BMI-
centile >98) classification. Those classified as underweight 
(BMI-centile <2) and overweight (BMI-centile 91–98) were 
excluded, respectively.
Subject body weight was measured to the nearest 0.1 kg 
using a calibrated scale and height measured to the nearest cen-
timeter using a wall-mounted rule. BMI was calculated as mass 
(kg) divided by height in meters squared (kg/m2). United 
Kingdom Royal College of Pediatrics and Child Health World 
Health Organization growth charts were used to calculate and 
classify BMI-centile in relation to age and sex (World Health 
Organization/Royal College of Paediatrics and Child Health 
2016). All measurements were taken by a single-trained opera-
tor (H.F.S.) using the same equipment.
Variables
Tooth alignment was calculated from scanned (3Shape-R700) 
stone dental casts using an irregularity index (Little 1975).
Unstimulated whole mouth salivary flow rate (uWMS) was 
calculated as milliliter per minute from saliva obtained from 
relaxed patients spitting into a plastic tube for 5 min. 
Periodontal health was measured clinically using established 
validated plaque and gingival indices (Loe and Silness 1963; 
Silness and Loe 1964). GCF was collected from the distal side 
of the lower 6 anterior teeth and pooled. Following isolation, 
teeth were gently dried using an air syringe and Periopaper fil-
ter strips (OraFlow) placed 1 mm into the gingival crevice for 
30 s. If there was any contamination of the strip with saliva or 
blood, it was discarded. The volume of collected fluid was 
measured directly using a Periotron-8000 electronic micro-
moisture meter (OraFlow) with readings converted to an actual 
volume by reference to the standard curve and flow rate calcu-
lated (per minute). GCF was retrieved from filter strips with 
the addition of 20 µL phosphate-buffered saline (PBS) and cen-
trifugation for 5 min at 9,200 × g. Samples were stored at 
−80°C for subsequent analysis. GCF was analyzed by a 
Luminex bead-based multiplex assay using a commercially 
available kit (R&D Systems) for detection (pg/mL) of adipo-
nectin, leptin, and resistin; inflammatory mediators myeloper-
oxidase (MPO) and CRP; and tissue-remodeling biomarkers 
MMP8, MMP9, TIMP1, MMP8/TIMP1, MMP9/TIMP1, and 
RANKL (Appendix Table 1).
Fixed appliances and bonding method were standardized 
(3M Victory-APC 0.022-inch brackets, MBT prescription; 
3M-Unitek). After bracket bonding, a 0.014-inch nickel- 
titanium archwire was tied in and ligated using conventional 
elastomerics. The archwire was cut distal to the first molar 
teeth and not cinched. No bite planes, auxiliary arches, inter-
maxillary elastics, headgears, or temporary anchorage devices 
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were used during the investigation. All appliances were placed 
by postgraduate orthodontic trainees under direct supervision 
of a consultant orthodontist.
Sample collection took place during routine appointments 
between 9:30 a.m. and 3:30 p.m. at baseline (start of treatment: 
appliance placement) (irregularity index, uWMS, plaque and 
gingival indices, GCF flow rate, biomarker analysis), 1 h fol-
lowing appliance placement (GCF flow rate, biomarker analy-
sis), 1 wk following appliance placement (irregularity index, 
uWMS, plaque and gingival indices, GCF flow rate, biomarker 
analysis), and completion of tooth alignment (0.019 × 0.025-
inch stainless steel archwire) (irregularity index, uWMS, 
plaque and gingival indices, GCF flow rate, biomarker analy-
sis). This was a pragmatic study undertaken in a clinical depart-
ment. Patients were seen at approximate 6-wk intervals for 
appliance adjustment, and archwire progression took place as 
deemed clinically appropriate by treating clinicians. Patient 
flow through the study is shown in the Appendix Figure.
Primary outcome was time to achieve tooth alignment in 
the lower arch. Secondary outcomes included rate of tooth 
movement, changes in clinical parameters, and GCF biomark-
ers during treatment. There were no changes to outcomes fol-
lowing study commencement.
Sample Size
Sample size was based on previous randomized prospective 
data on time to completion of alignment with fixed appliances, 
which found a mean (SD) time to alignment of 200.7 (73.6) d 
in the presence of an 8.9-mm incisor irregularity (Woodhouse 
et al. 2015). A total of 50 patients were required to detect with 
an unpaired t test a hypothesized 30% reduction (Schulz and 
Grimes 2005) in alignment time with a common SD across 
groups to yield 80% power (P = 0.05). Five additional patients 
were recruited to account for possible dropouts.
Statistical Methods
Descriptive statistics were calculated after checking for normal 
distribution. All biomarker data were log
10
 transformed for 
normalization. Initial crude differences in baseline and out-
come data were calculated with independent t tests, χ2 tests, or 
Mann-Whitney tests, where needed.
The effect of obesity was investigated using univariable 
(crude) and multivariable generalized estimation equation 
regression models with robust standard errors to take into 
account correlation between repeated measurements for each 
patient through the follow-up period (baseline, 1 h, 1 wk, and 
completion of alignment), adjusted for the confounding effect 
of baseline data (sex, age, baseline irregularity). Results are 
reported as unstandardized coefficients or odds ratios for con-
tinuous and binary outcomes, respectively. The effect modifi-
cation of obesity on the progress of tooth alignment was tested 
by introducing interaction terms, which were ultimately 
dropped from the model, if not significant. Analysis of residu-
als was conducted to confirm the regression assumptions. As 
patients within the study had initial irregularity ranging from 4 
to 12 mm, sensitivity analyses were conducted to include only 
those with severe (≥7 mm) or moderate (4–7 mm) baseline 
irregularity. All analyses were carried out using Stata 12.0 
(StataCorp LP). A 2-tailed P value of 0.05 was considered sta-
tistically significant with a 95% confidence interval (CI) for all 
tests.
All primary data were coded so that the outcome assessor 
(H.F.S.) and statistician (S.N.P.) were blinded to subject clas-
sification. Data coding was broken following analysis, and no 
blinding breaches were identified. To examine measurement 
reliability and agreement, 36 pairs of models from baseline and 
1 wk were selected and remeasured after 2 wk. The concor-
dance correlation coefficient (CCC) (Lin 1989) and Bland-
Altman method (Bland and Altman 1986) were used to test 
intraexaminer reliability and agreement.
Results
Participants
This study included 55 patients (27 male, 28 female) with a 
mean (SD) age of 15.1 (1.7) years and a mean (SD) irregularity 
index of 7.6 (2.4) mm. Mean (SD) BMI of the cohort was 24.7 
(6.2) kg/m2. From the original 55 patients recruited, 7 were 
excluded at 1 wk due to missed appointments, but all 55 were 
included at completion of alignment. Missingness at 1 wk was 
judged as random (Appendix Table 2). The reliability and 
agreement of repeated measurements were excellent (CCC = 
0.99 with 95% CI, 0.98–0.99; average difference of 0.06 with 
95% limits of agreement, –0.68 to 0.79). Table 1 shows demo-
graphics and GCF parameters for the 2 cohorts at baseline. 
Mean (SD) BMI was 19.4 (2.2) in the normal-weight group 
and 30.2 (3.5) kg/m2 in the obese group. Apart from BMI, there 
were no statistically significant differences in demographics 
among groups at baseline; however, the obese group did have 
1.2 mm more irregularity (P = 0.061). In contrast, significant 
differences were present between normal-weight and obese 
groups for a number of GCF biomarkers at baseline (Table 1; 
P < 0.05), including increased GCF flow rate; increased leptin, 
resistin, MPO, MMP8, TIMP1, and RANKL; and reduced 
MMP9/TIMP1 levels in obese patients.
Primary Outcome
The results of both crude and adjusted regression analyses 
indicated a small difference in time required to achieve tooth 
alignment between obese and normal-weight patients. Overall, 
obese patients needed a mean 23.0 d less than normal-weight 
patients to reach final alignment (Fig. A), but this was not sta-
tistically significant (Table 2, P > 0.05).
Secondary Outcomes
A number of significant differences were observed between 
obese and normal-weight patients in the clinical response to 
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orthodontic force. The rate of mechanical tooth 
displacement within week 1 was significantly 
increased in the obese group (P < 0.001), while 
overall rate of alignment from baseline to com-
pletion of alignment was also increased (P = 
0.05) (Table 3). However, tooth alignment rate 
from week 1 to completion of alignment was 
not significantly different between groups 
(Table 3; P = 0.119). After taking into account 
all confounders in the adjusted analysis, obese 
patients were associated with a significantly 
increased rate of tooth movement throughout 
the whole study duration compared with normal-
weight patients (0.017 mm/d; 95% CI, 0.008–
0.025 mm/d; P < 0.001) (Fig. B). In addition, a 
significant association was found between rate of tooth 
movement and initial irregularity (0.007mm/d 
increase per millimeter of irregularity). Sensitivity 
Figure. Box plots of measured values in normal-weight and obese patients for (A) 
primary (time to completion of alignment in days; left panel) and (B) secondary (tooth 
alignment rate from start of treatment to completion of alignment in mm/d; right panel) 
outcomes. Plotted boxes with horizontal lines indicate interquartile ranges with medians. 
Vertical whiskers and points indicate upper and lower adjacent values and outliers.
Table 1. Demographics and GCF Parameters of Patients at Baseline.
Overall Normal Weight Obese P Value
Demographics  
 Patients (n) 55 28 27  
 Male/female (n) 27/28 15/13 12/15 0.498a
 Age, y 15.1 (1.7) 15.1 (1.6) 15.1 (1.9) 0.991b
 Race, n (%)  
  Caucasian 29 (53) 17 (61) 12 (44) 0.516a
  Asian 4 (7) 2 (7) 2 (7)  
  African 5 (9) 1 (4) 4 (15)  
  Mixed 8 (15) 3 (11) 5 (19)  
  Other 9 (16) 5 (18) 4 (15)  
 BMI, kg/m2 24.7 (6.2) 19.4 (2.2) 30.2 (3.5) <0.001b
 uWMS, mL/min 0.61 (0.32) 0.64 (0.34) 0.58 (0.29) 0.480b
 Plaque index 0.56 (0.32) 0.57 (0.32) 0.54 (0.31) 0.745b
 Gingival index 0.74 (0.39) 0.74 (0.40) 0.73 (0.38) 0.934b
 Irregularity index, mm 7.6 (2.4) 7.0 (2.3) 8.2 (2.4) 0.061b
 Severe irregularity, n (%) 31 (56) 13 (46) 18 (67) 0.130a
 Tooth extraction, n (%) 8 (15) 4 (14) 4 (15) 0.956a
GCF biomarkers, pg/mL(log
10
 transformedc)  
 GCF flow rate, µL/min –0.29 (0.14) –0.33 (0.12) –0.25 (0.12) 0.011d
 Adiponectin 6.60 (0.34) 6.55 (0.42) 6.66 (0.23) 0.237b
 Leptine 13.91 (22.64) 6.40 (14.65) 19.15 (24.45) 0.031d
 Resistin 5.61 (0.56) 5.30 (0.55) 5.92 (0.36) <0.001b
 MPO 5.05 (0.85) 4.44 (0.64) 5.69 (0.52) <0.001b
 CRP 2.50 (0.51) 2.47 (0.27) 2.65 (0.87) 0.827b
 MMP8 6.32 (0.64) 6.01 (0.48) 6.64 (0.64) <0.001b
 MMP9 6.23 (0.30) 6.18 (0.59) 6.27 (0.15) 0.245b
 TIMP1 5.00 (0.48) 4.72 (0.38) 5.28 (0.40) <0.001b
 MMP8/TIMP1 0.96 (0.64) 0.93 (0.62) 0.99 (0.68) 0.699b
 MMP9/TIMP1 0.54 (0.54) 0.75 (0.54) 0.32 (0.47) 0.002b
 RANKL 3.54 (0.33) 3.39 (0.25) 3.65 (0.27) <0.001d
For demographics: values are mean (SD) unless otherwise indicated. For GCF parameters: values are pg/mL unless otherwise indicated. Significant 
results are indicated in bold. BMI, body mass index; CRP, C-reactive protein; GCF, gingival crevicular fluid; MMP8, matrix metalloproteinase 8; 
MMP9, matrix metalloproteinase 9; MPO, myeloperoxidase; RANKL, receptor activator of nuclear factor kappa-B ligand; TIMP1, tissue inhibitor of 
metalloproteinase 1; uWMS, unstimulated whole-mouth salivary flow rate.
aFrom χ2 test.
bFrom independent t test.
cLog
10
 transformation improved the skewness of the data, but the Shapiro-Wilk test indicated that transformed data were still not normally distributed. 
Therefore, the median (interquartile range) is presented instead of mean (SD) and the Mann-Whitney test is used on the transformed data instead of 
the unpaired t test.
dFrom Mann-Whitney test.
eSquare root transformation was used instead of log
10
, as several null values were included. Therefore, the median (interquartile range) is presented 
instead of mean (SD) and the Mann-Whitney test is used on the transformed data instead of the unpaired t test.
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analyses for patients with either severe or moderate irregularity 
were consistent in direction with the main analysis (Appendix 
Tables 3 and 4, respectively), with an expected loss of power 
due to the division of the study sample and a higher difference 
in alignment rate between obese and normal-weight patients in 
the severe irregularity group.
uWMS increased during treatment, while plaque and gingi-
val indices deteriorated significantly (Appendix Table 5), but 
there were no differences between groups for either of these 
parameters. GCF flow rate increased during orthodontic treat-
ment for both groups, but significantly more in obese patients.
To further understand the biochemical basis of observed dif-
ferences in rates of tooth movement, explorative regression 
analyses were undertaken (Table 4). GCF levels of leptin, resis-
tin, MPO, MMP8, TIMP1, MMP9/TIMP1, and RANKL were 
significantly different between obese and normal-weight patients 
at baseline and during subsequent assays (Appendix Table 5). 
When a possible interrelation between these biomarkers and rate 
of tooth movement was investigated, it was found that leptin, 
resistin, MPO, and RANKL were significantly associated with 
the amount of tooth movement for each patient (Appendix Table 
6). Therefore, from an epidemiological basis, these biomarkers 
are the best candidates to explain the clinical performance differ-
ence between obese and normal-weight patients during orth-
odontic tooth alignment with fixed appliances.
Discussion
This prospective study followed a cohort of obese and normal-
weight adolescent patients during the alignment phase of 
fixed-appliance orthodontic treatment. Obese patients demon-
strated significantly increased rates of tooth movement during 
the whole observation period, although there were no signifi-
cant differences in time taken to achieve alignment. This 
apparent discrepancy might be explained by a number of fac-
tors. First, the obese group had a significantly increased initial 
mechanical displacement of the teeth during the first week fol-
lowing the application of orthodontic force, there was also a 
slightly increased (albeit statistically nonsignificant) baseline 
irregularity present in the obese group, and there may have been 
possible between-group variation in attendance during routine 
appointments. Evidence exists from a similar experimental 
Table 2. Regression Analysis on Primary Outcome (Time to Completion of Alignment in Days) and Secondary Outcome (Rate of Orthodontic Tooth 
Movement in mm/d).
Crude Model Adjusted Model
Factor b 95% CI P Value b 95% CI P Value
Primary outcome (time to completion of tooth alignment)
 BMI group  
  Obese –14.3 –54.3 to 25.7 0.483 –23.0 –66.1 to 20.1 0.295
  Control Reference  
 Age  
  Per year NT –3.2 –15.6 to 9.1 0.608
 Sex  
  Male NT –6.6 –48.4 to 35.2 0.756
  Female NT  
 Ethnicity NT –0.2 –13.4 to 13.0 0.974
 Extraction  
  Yes NT –15.3 –76.0 to 45.5 0.623
  No NT  
 Baseline irregularity, per mm NT 6.9 –2.5 to 16.3 0.151
Secondary outcome (rate of orthodontic tooth movement: baseline to completion of alignment)
 BMI group  
  Obese 0.023 0.011 to 0.035 <0.001 0.017 0.008 to 0.025 <0.001
  Control Reference Reference  
 Time  
  1 wk Reference Reference  
  Complete alignment –0.025 –0.036 to 0.015 <0.001 –0.021 –0.032 to −0.010 <0.001
 Age, per year NT 0.001 –0.002 to 0.003 0.609
 Sex  
  Male NT 0.001 –0.008 to 0.011 0.768
  Female NT Reference  
 Ethnicity NT –0.001 –0.003 to 0.002 0.643
 Irregularity at each phase start, per mm NT 0.007 0.005 to 0.009 <0.001
 Extraction  
  Yes NT –0.004 –0.014 to 0.006 0.415
  No NT Reference  
Interaction of obesity with time found to be nonsignificant (P = 0.112) and was dropped from the model. Significant results are indicated in bold. b, 
unstandardized regression coefficient; CI, confidence interval; BMI, body mass index; NT, not tested.
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model that initial alignment can increase by 0.01 mm/d while 
overall alignment increases by 0.004 mm/d for every millime-
ter of initial irregularity (Woodhouse et al. 2015). However, 
significant differences were also found in the GCF biochemi-
cal profile between obese and normal-weight patients, and to 
our knowledge, this represents the first prospective data to sug-
gest that obese patients may respond differently to those with 
normal weight during routine orthodontic treatment.
Appliance variation has little or no effect on rate of orth-
odontic tooth movement (Scott et al. 2008; Woodhouse et al. 
2015). Interestingly, we found that obesity does influence tooth 
movement, as obese patients had increased movement rates 
compared with normal-weight patients. Statistical modeling of 
alignment rate and its change through time (see Table 2) dem-
onstrated that obesity and initial irregularity at each phase 
explained part of the variation seen in alignment. Given the 
absence of a significant interaction between obesity and time, 
the difference in alignment rate between obese and normal-
weight patients was consistently present through the alignment 
process and independent of confounders.
Importantly, the groups in this investigation were not differ-
ent in terms of baseline demographics, including plaque/gingi-
val indices and irregularity, with BMI representing the only 
significant difference. However, a number of differences 
existed in baseline GCF parameters between groups, including 
GCF flow rate and levels of several biomarkers. The proin-
flammatory adipokines leptin and resistin were both elevated 
in the GCF of obese patients (Suresh et al. 2016), suggestive of 
a baseline proinflammatory state within the periodontium of 
these individuals. It is also consistent with the significantly 
increased levels of MPO, an established marker for inflamma-
tion in the GCF (Marcaccini et al. 2010; Navarro-Palacios et al. 
2014). Interestingly, the levels of several biochemical media-
tors of tissue remodeling were also increased at baseline in the 
obese group, including MMP8, TIMP1, MMP9/TIMP1, and 
RANKL, providing evidence of an altered inflammatory bio-
chemical profile in the GCF of obese patients.
Among the GCF biomarkers assayed, leptin, resistin, MPO, 
and RANKL most predictably accounted for the observed dif-
ferences in rate of tooth movement. The levels of these bio-
markers differed significantly between obese and normal-weight 
patients both before and during treatment while being signifi-
cantly associated with the amount of tooth movement observed. 
Previous studies have reported that orthodontic tooth move-
ment is followed by a decrease in GCF leptin (Dilsiz et al. 
2010) and an increase in both MPO (Marcaccini et al. 2010; 
Navarro-Palacios et al. 2014) and RANKL (Grant et al. 2013). 
Resistin, like leptin, is upregulated in inflamed gingival tissue 
compared with healthy tissue (Suresh et al. 2016), but the rela-
tionship between GCF resistin and orthodontic tooth move-
ment has not been investigated previously. Variation in the 
levels of proinflammatory adipokines has been identified in the 
GCF of obese and normal-weight individuals with periodontal 
disease (Zimmermann et al. 2013; Gonçalves et al. 2015; 
Duzagac et al. 2016; Suresh et al. 2016), but data relating to 
adipokines during orthodontic tooth movement are sparse 
(Dilsiz et al. 2010).
The strengths of the present study include its prospective 
design (Papageorgiou, Xavier, et al. 2015), baseline compara-
bility between experimental groups, absence of dropouts at 
completion, and use of measurement blinding. Moreover, obe-
sity was defined according to widely accepted and reliable 
Table 3. Rate of Tooth Movement (mm/d) during the Study Period.
Outcome
Overall (n = 55),  
Mean (SD)
Normal Weight  
(n = 28), Mean (SD)
Obese (n = 27),  
Mean (SD) P Value
Time to completion of alignment (d) 158.7 (75.3) 165.8 (72.5) 151.4 (78.7) 0.486
Tooth alignment rate: baseline to completion of alignment (mm/d) 0.057 (0.029) 0.050 (0.025) 0.065 (0.031) 0.050a
Initial tooth displacement rate: baseline to week 1 (mm/d)b 0.081 (0.031) 0.065 (0.025) 0.097 (0.028) <0.001a
Tooth alignment rate: week 1 to completion of alignment (mm/d)b 0.056 (0.031) 0.049 (0.027) 0.063 (0.033) 0.119a
CI, confidence interval; SD, standard deviation.
aFrom independent t test.
bDue to 7 patient dropouts at 1 wk, 48 of 55 patients (24 obese and 24 control patients) are included in these 2 measurements. The measurement of 
time to completion of alignment and alignment rate: baseline to completion of alignment pertain to the whole sample of 55 patients.
Table 4. Summary of Exploratory Analyses on the Secondary 














Clinical indices  
 Plaque index No No –
 Gingival index No No –
 uWMS No No –
 GCF volume Yes Yes No
GCF biomarkers  
 Adiponectin No No –
 Leptin Yes Yes Yes
 Resistin Yes Yes Yes
 MPO Yes Yes Yes
 CRP No No –
 MMP8 Yes Yes No
 MMP9 No No –
 TIMP1 Yes Yes No
 MMP8/TIMP1 No No –
 MMP9/TIMP1 Yes Yes No
 RANKL Yes Yes Yes
CRP, C-reactive protein; GCF, gingival crevicular fluid; MMP8, matrix 
metalloproteinase 8; MMP9, matrix metalloproteinase 9; MPO, 
myeloperoxidase; RANKL, receptor activator of nuclear factor 
kappa-B ligand; TIMP1, tissue inhibitor of metalloproteinase 1; uWMS, 
unstimulated whole-mouth salivary flow rate.
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international measures. Collectively, this means that the 
respective risk for selection, attrition, and detection bias is low. 
The study sample was based on a conservative a priori power 
calculation, and planned dropouts did not occur. However, 
some potential limitations include the fact that height and 
weight measurements were only taken at baseline and adipos-
ity is not necessarily a static measure. Indeed, in an adolescent 
population, underlying growth might have influenced BMI 
during the course of the investigation, although with a mean 
observation of 158 d and mean patient age of 15.1 y, this effect 
may have been negligible. In addition, only BMI was used to 
classify adiposity, which can limit the identification of over-
weight and could have been reduced by adding estimates of 
adiposity (fat mass index) and fat distribution (waist-to-height 
ratio) (Bibiloni Mdel et al. 2013). Moreover, in a cohort under-
going routine orthodontic treatment with fixed appliances, it is 
not practical to see each patient at exactly the same time point 
for each adjustment or identify the absolute first time point that 
alignment is complete for every patient. For these reasons, the 
increased rates of tooth movement identified in the obese 
group may not have resulted in a clinically significant reduc-
tion in time to final alignment. In addition, while observed dif-
ferences in rates of tooth movement are tangible effects with 
obvious potential clinical relevance, the underlying biological 
mechanisms are likely to be complex. The measured differ-
ences in GCF biomarkers may be associated with the interrela-
tionship between obesity and tooth movement, but this study 
provides no conclusive evidence. Further investigation will be 
required to elucidate the precise role of each biomarker in 
mediating tooth movement. However, this investigation pro-
vides evidence that informs clinical practice in orthodontics 
and wider health care. The results are applicable to obese and 
normal-weight adolescent patients, although it should be 
remembered that adipose tissue can behave differently accord-
ing to age group in other body systems (Palmer and Kirkland 
2016). A proinflammatory obese state can influence orthodon-
tic tooth movement, with significant associations between lev-
els of specific biomarkers within the GCF of obese patients. 
These results highlight potential implications for orthodontic 
treatment in obese subjects, and one area for future research 
would be a comparison of postorthodontic stability.
This prospective clinical study investigated tooth alignment in 
obese and normal-weight patients undergoing fixed-appliance 
orthodontic treatment. Obese patients needed less time to achieve 
tooth alignment compared with normal-weight patients, but this 
was nonsignificant. After adjusting for confounders, rate of orth-
odontic tooth movement was significantly higher in obese patients 
compared with normal-weight patients. Explorative analyses indi-
cated GCF levels of leptin, resistin, MPO, and RANKL were sig-
nificantly different between obese and normal-weight patients and 
associated with observed rates of tooth movement.
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Periodontal parameters of a self-ligating bracket
The concept of a self-ligating bracket (SLB) is not a new
one in orthodontics, but continued research and develop-
ment in the design and manufacturing of these brackets
has meant that a wide range of mechanically reliable
SLBs are now commercially available. Although there
have been many claims regarding the theoretical clinical
advantages of these brackets to both the patient and
orthodontist, much of the current clinical evidence
suggests that they perform within similar parameters to
conventional brackets. However, an undeniable differ-
ence between all SLBs and their conventional counter-
parts is the lack of an elastomeric to keep the archwire
in place. This presents some obvious potential advan-
tages, not least in terms of maintaining oral hygiene and
promoting both gingival and periodontal health during
treatment. However, the opening and closing mechanism
associated with SLBs may itself have some impact on
plaque retention, depending upon the design, but currently
there is very little data relating to how SLBs perform in
relation to these parameters.
There is certainly some diversity in the results of investi-
gations that have compared the influence of SLBs and
conventional brackets on plaque accumulation, gingival
and periodontal health. However, two recently published
systematic reviews have gone some way to showing that
SLBs do not seem to perform any better than conventional
brackets in terms of these variables (Arnold et al. 2016;
Yang et al. 2016). The Arnold study carried out a systema-
tic evaluation of adolescent populations over the short (4–
6 weeks) and slightly longer-term (3–6 months) and
showed only ‘scarce’ evidence of a greater plaque index
for conventional brackets at 3–6 months of treatment.
However, gingival index and pocket depth pooled esti-
mates revealed no significant differences between SLBs
and conventional brackets at either time-point (Arnold
et al. 2016). The Yang study just compared plaque
indices associated with passive SLBs and conventional
brackets and found no significant differences. This data
was derived from four studies with high heterogeneity
and in the case of two of them, very wide confidence inter-
vals and therefore should be treated with some caution
(Yang et al. 2016). However, the best current evidence
would suggest that SLBs should not be offered to patients
on the basis that they help to keep the teeth cleaner and
healthier, but as is the case in much orthodontic research,
this best current evidence could be of better quality.
In this issue of the Journal of Orthodontics Bergamo
and co-workers have investigated gingival crevicular
fluid (GCF) volume and a number of periodontal par-
ameters in a prospective cohort of subjects bonded with
different bracket types in the upper labial segment
(Bergamo et al. 2016). Interestingly, they find significant
differences in plaque index and GCF volume associated
with SmartClip brackets at 60 days following appliance
placement. This suggests that other variables, such as
GCF volume may be influenced by bracket design and
should be followed up with more definitive prospective
data. Some attention should be given to the detail of
the methodology. The GCF was collected by inserting
paper strips into the gingival sulcus until resistance was
felt and this method can increase local trauma, poten-
tially affecting GCF volume (Chapple et al. 1996).
However, these points notwithstanding, this investigation
suggests a need for more data in relation to this subject.
Indeed, the assay of GCF provides a relatively non-inva-
sive means of evaluating multiple changes within the per-
iodontium at the biochemical level and it would seem
appropriate to extend some of these studies into this
area of bracket-based research. There is some low-level
evidence that levels of the substance P neuropeptide are
lower in the GCF of teeth bonded with Damon SLBs
in comparison to conventional over the short-term
(Yamaguchi et al. 2009) although this does not seem to
correlate with any differences in pain perception at the
clinical level (Yang et al. 2016).
This is inevitably an area of great potential complexity
and whilst variation in isolated biological and biochemi-
cal parameters associated with SLBs and conventional
brackets are likely to be found, whether this has a funda-
mental influence on clinical performance is more difficult
to predict. Certainly, the evidence to date would suggest
that for virtually all the clinical variables that have been
FOCUS Journal of Orthodontics, Vol. 43, 2016, 253–254
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tested, an orthodontic bracket will perform in a similar
manner whether it is a SLB or not.
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